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Abstract 
Clostridioides difficile is the major cause of infectious antibiotic-associated 
diarrhoea, imparting a substantial clinical and financial burden on healthcare 
facilities. Resistance development, particularly to fluoroquinolones, has been 
implicated in major, international epidemics, predominantly associated with the 
hyper-virulent ribotype 027. The development of multiple antimicrobial 
resistance may contribute significantly to the considerable clinical challenges 
associated with this organism.  
In this study, optimised germination environments, antimicrobial susceptibility 
testing and next generation sequencing were utilised in the recovery and 
characterisation of an historical C. difficile collection (1980-86). Epidemiological 
comparisons of ribotype distribution and susceptibility patterns with modern 
surveillance data (2012-2016) sought to reveal antimicrobial resistance 
variance between two distinct periods. By correlating phenotypic resistance and 
genetic determinants, the dissemination of resistance genes was evaluated. 
Contributions of bacterial mutability to resistance propagation were 
investigated in response to fluoroquinolone exposure amongst seven prevalent, 
clinical ribotypes; (n=44). Through in vitro batch and continuous co-culture 
modelling, the impact of resistance-conferring gyrA and gyrB mutations on the 
fitness of ribotype 027 (n=7) was assessed. 
The majority of test antimicrobials (n=8/9) were less active against modern vs 
historical isolates. This is potentially due to increased antimicrobial exposure 
and subsequent selection/expansion of resistant strains. Moxifloxacin testing 
demonstrated the largest increase in resistant populations, reinforcing the 
notion of reduced susceptibility to modern fluoroquinolones as a potential 
contributory factor in disease. Phylogenetic analyses highlighted the complexity 
of molecular clock predictions, with 69% of historical genomes correlating with 
a 95% prediction interval.  
Elevated mutability was observed amongst ribotype 027, suggesting greater 
propensity for resistance evolution in this type. Common fluoroquinolone 
resistance-conferring substitutions revealed advantages to bacterial fitness. 
Continuous, competitive co-culture modelling of a Thr82>Ile mutant, 027 strain 
- vi - 
emphasised the fitness benefits of this polymorphism, retained in the absence of 
fluoroquinolone pressure. These findings indicate a potential contribution to the 
success of this ribotype. 
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Chapter 1 Introduction 
1.1 Clostridioides difficile 
Clostridioides difficile is a Gram-positive, spore bearing, obligate anaerobe. This 
highly motile, rod-like bacterium is ubiquitous in nature, often found in soil and 
aquatic environments (1, 2). The existence of C. difficile spores in both hospital (3, 4) 
and community cohorts (5) demonstrates the abundance of this organism, whilst 
asymptomatic colonisation (6-8) and zoonotic carriage (9, 10) further facilitate 
transmission. Pathogenicity is toxin-mediated and directly related to antibiotic-
associated microbiota depletion and the creation of colonic niches (11). 
1.2 History 
Though the importance was not appreciated at the time, the first recorded 
isolation of this significant pathogen was published by Hall and Toole in 1935 
(12). They reported the isolation of this bacterium from the stool of a healthy 
infant, originally giving it the name Bacillus difficilis, due to difficulties associated 
with its culture. A dearth of research followed this discovery, with no significant 
literature published until the 1960s, by 1970 the organism was renamed 
Clostridium difficile (13). Evidence of human infections soon followed (14).  
Pseudomembranous colitis (PMC) was first discovered by an American surgeon, 
John Finney in 1893 (15). He identified complications arising with a post-
operative patient, whom developed haemorrhagic diarrhoea after gastro-enteric 
surgery. Nonetheless, associations between C. difficile and this severe outcome 
were not made until much later (16, 17). 
By 1973 the first links between PMC and antibiotic exposure were made, 
through a study connecting seven out of eight PMC patients with prior 
lincomycin use (18). Clindamycin use was first associated with PMC in 1973 (19, 20), 
with a plethora of cases reported in the following years (21-24). By 1974 the initial 
discovery of a cytopathic toxin associated with clinical manifestations of PMC 
was made, as described in guinea pig stools (25).   
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Hamster models proved significant in initiating further breakthroughs in the 
understanding of the disease. C. difficile was established as the aetiological agent 
of PMC in 1978, when it was isolated from the caecal contents of diseased 
animals, and the presence of neutralisable toxins were demonstrated (26-28). 
Work by Bartlett and colleagues was crucial in demonstrating the link between 
C. difficile and PMC, suggesting a cross-reactivity with clostridial anti-toxins (16, 
17). Subsequently antibiotics were identified as specific risk factors, with 
clindamycin and cephalosporins deemed the agents of highest risk and the main 
antimicrobial classes associated with infection (20, 29). The awareness of C. difficile 
infection (CDI) risk associated with quinolone compounds rapidly followed their 
introduction and wide spread usage (30).  
Recently, the classification of C. difficile has been under review, with 
phylogenetic analyses first suggesting a proximity to the Peptostreptococcaceae 
family (31). However, further research assessing phenotypic behaviour in 
conjunction with phylogenomics has led to a reclassification into a novel genus, 
and should be officially referred to as Clostridiodes difficile (32). Nonetheless, this 
bacterium is still commonly referred to a C. difficile and will herein be referred to 
by that name. 
1.3 Clostridioides difficile infection 
C. difficile is the leading cause of antimicrobial-associated diarrhoea in hospital, 
and increasingly, community settings (33). CDI primarily affects the elderly, with 
incidences and mortality dramatically increasing at >50 years and risk further 
escalating at >65 years (34). C. difficile produces resilient spores that can remain 
dormant in the environment for prolonged periods, before potentially being 
ingested by a host. Subsequent exposure to broad-spectrum antibiotics has a 
deleterious effect on the host gut flora, depleting colonisation resistance; a 
mechanism where the resident gut bacteria inhibit invading pathogens from 
colonising (35). This subsequently allows C. difficile to proliferate, release toxin 
and initiate infection (11). Most recent UK figures from 2012 indicated that 1,646 
deaths were attributable to C. difficile (36), with an estimated potential healthcare 
cost of up to £8,542 per CDI patient (37). Financial impact on healthcare 
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providers is significant, with annual healthcare costs have been estimated as 
more than five billion US dollars, in North American alone (38).  
1.4 Clinical manifestations 
CDI is characterised by a wide range of clinical symptoms, from mild, self-
limiting antibiotic-associated diarrhoea to colitis, PMC and toxic megacolon (39). 
Diarrhoea is often watery, voluminous and commonly emanates a distinctive 
odour (40), whilst additional clinical markers include fever, low serum albumin 
levels (<3 g/dL), raised leukocyte count (>15,000 cells/µL) and high serum 
creatinine levels (41, 42). Severe cases resulting in PMC and toxic megacolon are 
often associated with abdominal cramping, distention, vomiting, lethargy, 
nausea and white blood cell counts as high as 50,000 cells/µL (40, 43, 44). PMC is 
characterised by necrosis of the epithelial lining, producing lesions that can 
erupt exudate, effecting further necrosis (45). Other complications associated 
with CDI are tachycardia, hypotension and extensive dehydration leading to 
renal failure (40). Fulminant disease is reported in <5% of CDI patients, where 
toxic megacolon can result in bowel perforation and death (40), with fulminant 
CDI associated with an all-cause, 30 day mortality rate as high as 36% (46).  
 
1.4.1 Recurrence of infection 
Post symptomatic CDI resolution, 13-35% of patients suffer recurrent episodes 
of infection (47-50). Of these cases 45-65% experience further episodes of relapse 
or reinfection (51, 52), with extrapolated rates reported in the United States of 
83,000 recurrent infections in 2011 (53). Retention of C. difficile spores or the 
reintroduction of new strains into a sustained diminished colonic environment 
can result in germination, proliferation and disease. Several studies have 
reported an increased risk of mortality associated with recurrent CDI, with 9.3% 
and 16.4% of cases resulting in death after 30 and 365 days, respectively (54-56). 
Many of the common risk factors associated with primary instances of CDI are 
further correlated with recurrent infections, including advancing age, use of 
antacids and prolonged antibiotic treatments (57-60). Immune response is 
important in the prevention of recurring infections, with poor IgG antibody 
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responses to C. difficile toxins associated with elevated primary and recurrent 
CDI risk (61, 62).  
Recurrent episodes of CDI can be differentiated into relapses of disease with the 
same strain, and reinfections with a different strain from the environment. 
Figueroa et al. reported higher proportions of relapse over reinfection in early 
(0-14 days) compared to late (15-31 days) recurrences, 86.7% and 76.7% 
respectively (63). Ribotype 027 cases were significantly more likely to result in 
relapses (93%), than non-027 strains (75%), indicating further challenges 
associated with this hyper-virulent ribotype. In support of these findings, data 
from molecular surveillance of 102 patients revealed that 88% of secondary 
episodes occurring within 8 weeks were a result of a relapse, whilst only 65% of 
episodes recurring after 8 weeks were attributed to the same strains (64). This 
suggests that retained spores may be the most likely aetiology of recurrent 
infection in the majority of instances, even two months after initial disease 
resolution.  
Secondary to the clinical implications, the cost of recurrent infections is a major 
burden to healthcare providers, and has been estimated as $2.8 billion per 
annum in the USA alone (65). Spiralling costs are predominantly attributable to 
increased lengths of hospital stay and additional intensive care admissions (58), 
with one study reporting 68% of cost associated with increased hospitalisation, 
20% with surgeries and 8% constituted of additional drug expenditures (65). The 
true cost of recurrent CDI is difficult to calculate, due to many confounders, such 
as associations with co-morbidities. However, a large scale, retrospective 
observational study by Zhang et al. proposed an estimated average cost of 
$49,456/£37,289 per case, $10,580/£7,977 more than a primary CDI instance 
(58). 
Antimicrobial resistance is not thought to be a factor in CDI recurrence (66), and 
recommended therapies often involved repeat courses of either metronidazole 
or vancomycin, although efficacy of this approach was observed in only 50% of 
cases (67). Therefore, recent guidelines focus on treatment with vancomycin, 
administered via a tapered or pulsed regimen (68). These alternative dosing 
regimens were reported as significantly improved over standard therapies, with 
recurrence reported in 44.8%, 31.0% and 14.3% of cases, for repeat, tapered 
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and pulsed vancomycin treatments respectively (69). Due to the evident success 
of fidaxomicin in clinical trials (50, 70), current recommendations also suggest the 
use of this narrow spectrum antimicrobial, however this remains a far more 
costly drug (71). In cases of multiple recurrences, the use of faecal microbiota 
transplants has demonstrated superior efficacy (72-74). 
 
1.4.2 CDI risk factors 
Identification and understanding of the risk factors associated with CDI 
acquisition and severity are crucial to the effective diagnosis and management of 
potential patients. Several important patient characteristics have been linked 
with increased incidence and severity of CDI. 
1.4.2.1 Increased age 
The most commonly reported risk factor for CDI is increased age (34, 75-80). As 
outlined in the Society for Healthcare Epidemiology of America (SHEA) 
guidelines, incidence of CDI is highest in patients aged over 65 (68). One 
prospective study encapsulating over 4,000 patients across six Canadian 
hospitals, further outlined this risk, demonstrating a 2% increase in risk for 
every additional year beyond 18 years of age (34). The same research group 
further delineated their findings, indicating an elevated incidence amongst a 
population of over 50 years of age, whilst mortality rates correlated significantly 
with those over the age of 60 (78). Whilst age demographics strongly correlate 
with CDI rates, the association with disease severity is less clear. A recent 
retrospective chart review revealed significant correlation between advanced 
age (>70), severe CDI and all-cause mortality (81). Nonetheless, other studies 
have found no links to outcome severity (82-85). The plethora of confounding 
factors that are associated with age further complicate this picture. Increased 
contact with healthcare settings, greater exposure to antimicrobial treatments, 
additional co-morbidities and potential physiological alterations impairing 
immune response efficacy, may all contribute to an overall risk (80, 86, 87). Changes 
in microbial diversity of the gut have been observed in aging populations (88, 89), 
with Rea et al. identifying a distinct reduction in Bacteroidetes and Clostridium 
species amongst this population (88). Ultimately, these alterations to the gut 
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microbiota may affect the level of colonisation resistance and susceptibility to 
CDI onset.  
1.4.2.2 Predisposing antimicrobials 
Understanding the complex relationship between antimicrobial usage and CDI is 
critical to reducing incidence of this disease. The majority of antimicrobial 
classes have previously been linked with predisposition to CDI (90), however, 
early research implicated particular broad-spectrum antimicrobials as CDI 
inducing agents, including clindamycin, ampicillin and cephalosporins (29). 
Further studies supported these findings, indicating those compounds with 
greater anti-anaerobic activity were associated with greater CDI risk (91, 92). 
Conversely, several antibiotic classes, including ureidopenicillins and 
tetracyclines have been associated with a lower risk (93). Exposures to both 
prolonged therapies and multiple, concurrent antimicrobials have also been 
correlated with an increased risk of severe CDI (80, 94, 95), undoubtedly due to the 
severe deleterious effect on intestinal microbiota. 
1.4.2.2.1 Clindamycin 
This broad spectrum lincosamide has a range of indications for use, including 
respiratory, soft skin, bone and joint infections (96). Clindamycin has long been 
established as a risk for the onset of antibiotic-associated diarrhoea (20), with 
many subsequent studies confirming the high level of risk related to use of this 
antimicrobial (28, 80, 95, 97-99). Three large scale meta-analyses comprising of 
almost 50,000 subjects (100-102) all determined clindamycin as one of the primary 
risk factors for CDI (with odds ratios as high as 20.4), whether in hospital or 
community environments. As awareness of this association increased, 
restrictions on this antibiotic have led to decreased incidence of CDI, attributable 
to more considered prescribing, as opposed to declining resistance development 
(97, 103, 104). Consequently, current UK guidelines recommend the avoidance of 
clindamycin in elderly patients (105). High-level resistance development to this 
agent has been reported as characteristic of epidemic strains and may be 





Cephalosporins, particularly second and third generation compounds, have 
demonstrated some of the strongest associations with CDI risk (100-102). 
Increasingly reported in the aftermath of clindamycin restriction (29), these 
agents were regularly described as significant risk factors for C. difficile disease 
in both hospital and community settings (78, 80, 95, 98, 106, 107). A systematic review 
revealed cephalosporins as, by far, the class of antibiotics with the greatest risk 
of CDI, more than four-fold higher than clindamycin (80). One prospective study 
of Canadian cohorts indicated cephalosporins as a risk of disease (OR 3.8; 95% 
CI 2.2-6.6) even after adjustment for confounders, such as age and co-
morbidities (34). The high degree of CDI risk associated with cephalosporin use 
may partly be due to their low-level of activity against C. difficile (108-110). This 
intrinsic resistance to many agents in this class, may exacerbate the associated 
risk, by enabling the bacteria to survive and proliferate where other gut flora do 
not. 
1.4.2.2.3 Fluoroquinolones 
Fluoroquinolones were previously considered as low risk antibiotics with 
regards to CDI development (111). However, more recent work has revealed an 
increasing risk association (34, 92, 99). Crucially, the emergence of the hyper-
virulent, PCR ribotype 027 as a major cause of epidemic disease at the beginning 
of the century was strongly attributed to the development of fluoroquinolone 
resistance (34, 112). In the context of this outbreak situation, Loo et al. observed a 
strong, independent correlation between prior fluoroquinolone exposure and C. 
difficile-associated diarrhoea (OR 3.9, 95% CI 2.3-6.6) (34). Pepin et al. 
demonstrated that one quarter of CDI patients received fluoroquinolones prior 
to onset, with over a third of these featuring a quinolone as contributory to the 
onset of infection (99). Gaynes et al. reported associations amongst a long-term 
care facility cohort, where prescribing policies changed from levofloxacin to a 
predominance of gatifloxacin (91). This shift in third generation fluoroquinolone 
was correlated significantly with CDI acquisition (p<0.0001), as 30% of patients 
receiving gatifloxacin developed CDI. Equally, prolonged treatment was 
associated with significant increases in CDI risk, with those developing disease 
averaging a length of fluoroquinolone exposure of 13.5 days vs 6.9 in the non-
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CDI cohort. The distinct difference in risk may be explained by the markedly 
improved activity of gatifloxacin against anaerobic bacteria (113), potentially 
conveying considerable deleterious effects against the gut microbiota. In support 
of these data, another study demonstrated similar findings (114), with Gaynes et 
al. further demonstrating significance with a reversion in the formulary back to 
levofloxacin. This resulted in a considerable decrease in CDI cases, although 
other factors, such as differing illness severity amongst the cohorts and potential 
ascertainment bias from clinicians are possibly involved (91). Conversely, one 
North American study revealing fluoroquinolone use as the only significant risk, 
demonstrated vastly more levofloxacin use (60%) than gatifloxacin (15%) (115), 
further indicating the complexity of drug-microbiota interactions. 
Interestingly, work by Cain and O’Connor indicated that the infection risk 
increased, where the resident C. difficile strain displayed existing resistance to 
the administered drug (111). With rates of asymptomatic carriage described as 
high as 51% within certain populations (116), it may be proposed that 
administration of fluoroquinolones could have greater implications if resistance 
increased in colonising strains. Intriguingly, Saxton’s research determined that a 
combination of ribotype 027 and moxifloxacin in an in vitro model of the human 
gut, indicated toxin production prior to notable germination and the generation 
of fluoroquinolone resistant colonies (117). This may be due to a pre-existing sub-
population of resistant colonies connected with the hyper-virulent strain. The 
risk is not always straight forward; in the aforementioned in vitro models, 
levofloxacin displayed a reduced impact on gut flora, although spore 
germination still occurred. These data highlight the potential involvement of 
additional factors in disease onset, such as direct stimulatory effects of antibiotic 
molecules or the relevance of elimination of specific metabolites (117) 
Although fluoroquinolones were attributed to CDI risk to a lesser extent than 
clindamycin and cephalosporin in a large meta-analysis, the association was 
described in more studies than any other antibiotic class (100). With the increased 
prevalence of fluoroquinolone resistant strains (118), the risk associated with this 
broad spectrum class of antimicrobials is considerable. 
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1.4.2.2.4 Other CDI eliciting compounds 
In the 1980s broad spectrum penicillins, such as amoxicillin, were the second 
highest antibiotic CDI risk factor behind clindamycin (29, 119, 120), largely due to 
the extent of usage. Current opinions reflected in several meta-analyses, report 
them as moderate risk (OR 1.45), above macrolides and 
sulphonamides/trimethoprim (100-102), whilst carbapenem use has also been 
reported as a significant risk factor (79). A further review suggested the length of 
exposure as more important in penicillin risk, with treatments prolonged over 
one week carrying a significant risk (Relative Risk 3.62; 95% CI 1.28-8.42) (121). 
In contrast, a recent analysis of randomised-controlled trials demonstrated 
penicillins and fluoroquinolones as involved in equal numbers of CDI cases (122).  
1.4.2.2.5 Low risk antimicrobials 
There does not appear to a simple relationship between broad-spectrum 
compounds and onset of disease. Antimicrobial combinations, such as 
piperacillin/tazobactam have demonstrated relatively low CDI risk compared to 
other antibiotic classes (101, 123, 124). A large meta-analysis of clinical CDI risk 
factors recently identified an odds ratio of 1.45 (1.05-2.02) associated with 
penicillins (100). Interestingly, in an in vitro model of the human gut, 
piperacillin/tazobactam combination therapy effected a major deleterious 
influence on gut microbiota populations, yet C. difficile spores remained dormant 
(125). Nonetheless, the literature does correlate strongly for some antimicrobial 
classes. All three large scale meta-analyses of healthcare and community settings 
concurred in the observation of no significant CDI risk increase relating to 
tetracyclines treatment, whilst assessment of aminoglycosides also 
demonstrated no elevation of risk (100, 101, 126). 
1.4.2.3 Length of hospitalisation 
Length of hospital stay has regularly been associated with an increased risk of 
CDI acquisition (76, 80, 82, 107, 127). This may be as anticipated, as prior exposure to 
healthcare settings often serves as a proxy for an increased period of potential 
contact with spores in the clinical environment, raising the chance of 
colonisation. Equally, patients suffering extended hospitalisation are often 
burdened with co-morbidities and are exposed to further risk factors, such as 
multiple antibiotic treatments. Length of hospital stay is not only associated with 
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increased incidence of CDI, but an elevated severity. Dudukgian et al. reported 
significance associated with mortality, observing a prior hospitalisation of 12 
days vs. 6 days in deceased and living CDI patients; respectively (82). Ultimately, 
this risk is difficult to separate from other risk factors, but demonstrates a 
compounding effect of several high risk characteristics. 
1.4.2.4 Proton pump inhibitor use 
One area of considerable debate is the impact of proton pump inhibitors (PPI) 
on CDI acquisition. Several studies have reported gastric acid suppressants as 
significantly associated with CDI (128-130), while others have found no correlation 
(131, 132). These widely consumed gastric acid supressing drugs, used in the 
treatment of ulcerations and gastroesophageal reflux disease (133) were first 
independently associated with C. difficile colonisation risk by Dial et al. in 2004 
(128). This study of a large scale Canadian cohort also revealed an increasing risk 
associated with prolonged PPI use. The mechanism behind this elevation in risk 
is likely to revolve around an increased potential for ingested spores to reach 
the lower gastrointestinal tract intact. Research has demonstrated that the 
reduction of gastric acid production associated with these agents has been 
demonstrated to lead to overgrowth of bacteria in the gastrointestinal tract (134), 
with considerable microbiome alterations reported with prolonged PPI use (135, 
136). Nonetheless, not all studies have observed an increased risk associated with 
PPIs (99, 131). 
1.4.2.5 Nasogastric intubation 
The association between nasogastric tube feeding and CDI has been well 
documented (80, 137, 138). This relationship is generally attributed to the extra 
involvement of clinical staff during insertion (137, 139), in addition to the risk of 
feed contamination (140). A recent large scale meta-analysis demonstrated a 1.8-
fold increase in risk associated with enteral feeding tubes, although no 
significance was linked to recurrence (138). Bliss et al. observed a significant risk 
of nasogastric tubes, with involvement reported in 20% of colonisation cases vs. 
8% of the control (137). Disease was established in 9% of intubated patients in 
comparison with only 1% of control cases. Again, the literature is not always 
consistent, with an increased severity of disease reportedly associated with 
enteral feeding in some studies (85, 139), whilst others observed no significant link 
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(76, 81, 94). Nonetheless, Bignari’s major systematic review did report an overall 
significance associated with this clinical practice (80). 
1.4.2.6 Additional risk factors 
The severity of underlying disease and additional comorbidities, including 
inflammatory bowel disease, renal failure, cardiac disease, diabetes and 
hematologic cancer have all been correlated with CDI risk (49, 141, 142). Host factors 
such as immune response have also been linked to C. difficile colonisation and 
disease. Loo et al. reported a link between the level of toxin B antibodies and 
healthcare-associated colonisation (78). This association has been supported by 
recent findings of trials of monoclonal antibodies to C. difficile toxins, where 
antibody response to toxin B was deemed as protective to recurrent CDI (143). 
 
1.4.1 Diagnosis of CDI 
Diagnostic algorithms for CDI vary across country, study and even hospital (144). 
Although recommendations of “gold standard” methodologies have been 
outlined (145, 146), not every institution can access the finance or expertise 
required for best practice. This variation impacts on infection rate surveillance 
(147) and could lead to falsely reported CDI cases, due to the use of sub-optimal 
testing algorithms. 
1.4.1.1 Detection of clinical manifestations 
The foundation of any diagnostic assay is the accurate determination of clinically 
relevant symptoms. Since, the primary indicator of CDI is diarrhoeal stools, 
reliable and consistent definitions of what constitutes diarrhoea are necessary. 
Current SHEA and Infectious Diseases Society of America (IDSA) guidelines 
recommend that more than three episodes of loose stools in 24 hours, which 
take the shape of the container, should be further tested for the presence of C. 
difficile, unless explained by an underlying reason (68). Confirmation of disease 
should then be sought through histopathological evidence of PMC or subsequent 
laboratory testing. The absence of correct diarrhoeal diagnosis may result in 
wasted financial and time resources. 
Two methodologies have been considered as the “gold standard” for the 
identification of toxigenicity; cell cytotoxicity neutralisation assays (CCNA) and 
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cytotoxigenic culture (68, 146, 148). CCNAs rely on the identification of a cytopathic 
effect on a cell culture line, associated with the action of C. difficile toxin. 
Confirmation of cell death can be attributed to C. difficile toxins, through the 
simultaneous demonstration of the neutralising effect of Clostridium sordellii 
anti-toxin. While this method is highly specific and sensitive (148-150), it is not 
ideal for rapid clinical diagnosis, as it is time consuming and requires constant 
maintenance of cell lines. Cytotoxigenic culture involves an initial culture step on 
selective agar, and subsequent CCNA of broth culture to identify the presence of 
a toxin producing strain (151). Where the latter has been demonstrated as more 
sensitive (152), questions are raised as to the validity of this method, as it only 
tests the potential for the colonising strain to produce toxin and not the actual 
presence of toxin in faeces (148). Therefore, since these tests identify different 
targets, they demonstrate differing sensitivities and specificities (148, 153, 154). 
1.4.1.2 Glutamate dehydrogenase and toxin screening  
Many commercially available kits exist for the detection of glutamate 
dehydrogenase (GDH) and C. difficile toxin (151, 155). Based on enzyme 
immunoassay (EIA), lateral flow (immunochromagraphic) and PCR techniques, 
these kits enable the simple and rapid detection of surface enzymes, free toxin or 
the presence of the tcdB gene in stool. The detection of C. difficile in faeces is 
routinely carried out with an EIA, which detects the GDH enzyme present on the 
outer surface of all C. difficile cells (156). Although this method is unable to 
distinguish between toxigenic and non-toxigenic strains, it acts as a highly 
sensitive screening method for C. difficile detection (155-159). Interestingly, GDH 
sensitivity has been demonstrated as strain dependent, with significantly lower 
sensitivities observed for PCR ribotypes 002, 027 and 106 (160, 161). Due to the 
low specificity of GDH assays and the lack of direct association with disease (162), 
positive GDH specimens must be subjected to subsequent toxin testing to 
diagnose CDI (68, 146).  
With the increasing prevalence of CDI associated with toxin A negative, toxin B 
positive strains (163-165), EIA is now widely used for the detection of both toxins A 
and B. Where commercially available toxin detection kits provide a rapid result 
and reduce the level of expertise required, they have been demonstrated to 
exhibit extensive variability and, in some cases, suboptimal 
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sensitivities/specificities (151, 155). In one large scale comparison of nine toxin 
detection kits, sensitivity ranged from 66.7 to 91.7%, whilst specificity ranged 
between 90.9 to 98.8%, with the Premier toxin A+B and Techlab toxin A/B kits 
amongst the most sensitive EIAs (155). Both of the membrane assays 
demonstrated greater specificity than the EIAs tested, with highest positive 
predictive values (PPVs) observed for these kits. Nonetheless, PPVs for 
commercial kits are generally reported as low, with a systematic review by 
Planche et al. suggesting that due to poor results, single assay kits were 
insufficient as independent diagnostic tests (151). 
1.4.1.3 Nucleic acid amplification testing 
The advent of PCR based, nucleic acid amplification testing (NAATs) methods, 
has led to a reconsideration of recommended testing algorithms (68, 146). There 
are multiple different commercial testing platforms available for these molecular 
tests, which are used to identify the presence of tcdA and/or tcdB genes in a 
specimen, but none are able to differentiate between expression of toxin and 
toxigenic potential (166). PCR techniques have been demonstrated as far more 
sensitive than CCNA approaches (167), with Berry et al. reporting sensitivity of 
99.1% vs 81.0%; respectively (168). However, since asymptomatic carriage of 
toxigenic strains has been reported as approximately 6% (169), the use of NAATs 
could potentially over diagnose CDI (166, 170) and a multiple step algorithm may 
be necessary for accurate diagnosis (166, 171). Therefore, both the European and 
North American guidelines recommend a two-step algorithm of GDH and toxin 
detection or toxin detection and PCR identification, never NAATs alone (68, 146). 
 
1.4.2 CDI treatment 
There are several therapeutic options for the treatment of CDI, with antibiotic 
administration often the primary response (68, 146). Nonetheless, this paradox of 
treating an antibiotic-associated disease with further antimicrobial therapies 
has led to the consideration of other approaches, including faecal microbiota 





Metronidazole has been used to treat anaerobic infections for over fifty years 
(172), with a range of diseases, including respiratory, bone and joint, intra-
abdominal, oral and skin and skin structure infections treatable with this 
antimicrobial (173). This nitroimidazole agent has demonstrated good activity 
against a variety of anaerobes, with a spectrum covering Gram positive and 
negative bacteria (174, 175). Metronidazole is well-absorbed and can be given 
intravenously and topically, but since the CDI target is in the gastrointestinal 
tract, oral administration is most common (173). Alongside vancomycin, 
metronidazole is a primary treatment for CDI, previously considered as the 
antibiotic of choice (176, 177), due to the low cost (178) and perceived non-
inferiority to vancomycin (179-181). A ten year surveillance program revealed oral 
metronidazole clinical cure rates of CDI as superior to vancomycin (91% vs 
88%), with only 7% recurrence associated with the former (181). However, 
considerably more patients were treated with this antibiotic, potentially 
skewing the data. Another study by Wenisch et al. revealed comparable rates of 
clinical cure and recurrence with vancomycin (180).  
Recently the efficacy of metronidazole has come into question, with several 
studies indicating treatment failures and inferior outcomes compared to those 
with vancomycin (84, 122, 182, 183). A study by Musher et al. revealed only 50% of 
207 patients treated with metronidazole were cured, with 22% demonstrating 
no symptomatic relief at all (182). They also reported significantly higher 
mortality rates associated with those demonstrating minimal treatment 
response, compared to cure (33% vs 21%; p<0.05). In a randomised-controlled 
study by Zar et al. clinical cure was observed as 90% and 98%, for 
metronidazole and vancomycin respectively (183), while others found failure 
rates as high as 22% (84). Whilst seemingly efficacious in the treatment of mild to 
moderate CDI, metronidazole has demonstrated poor success in cases of severe 
disease (183-185). A retrospective cohort of almost 50,000 patients showed that 
treatment of CDI with metronidazole was significantly more likely to result in 
death than if vancomycin was used (184). Recurrence rates associated with 
metronidazole treatment have also been reported as elevated above other 
therapeutic options (84, 182, 185, 186); in some instances recurrent infection was 
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described in as many as 25% of patients (84, 186). Although resistance to 
metronidazole is scarce, isolates with reduced susceptibility have been reported 
(187, 188). Whilst resistance is rare, since faecal concentrations are relatively low 
(189), any small reduction in susceptibility may contribute towards treatment 
failures. The true reasons behind metronidazole treatment failures are likely to 
be multifaceted, with some suggesting correlations between increased age, 
severity of underlying disease (141, 190), broad spectrum antimicrobials (191), 
resistance development (not primarily to metronidazole) (91, 115, 191) and the 
emergence of hyper-virulent epidemic clones (112, 192). Taken together these 
results have led to a consideration of a shift in CDI treatments away from 
metronidazole.   
1.4.2.2 Vancomycin 
Vancomycin is a widely used antibacterial agent, particularly in cases of severe 
Gram positive infections, often where resistance to other frontline antibiotics is 
encountered (193). Due to the poor absorption of vancomycin, high faecal 
concentrations are achieved (>1,000 mg/L) (194), which are ideal for the 
treatment of gastrointestinal diseases. As one of the recommended primary 
treatments for mild to moderate cases of CDI (68, 146), vancomycin has 
demonstrated significant superiority of clinical cure rates, over metronidazole 
(183, 195, 196). Equally, for severe CDI, significant differences (p=0.02) in cure rates 
were observed for vancomycin (97%) compared to metronidazole (76%) (183). 
However, these differences are not always observed. Several early studies have 
exhibited comparable efficacies of vancomycin and metronidazole (179, 180), and 
since the latter agent is considerably less expensive (178), it is still used as a 
frontline treatment. Recurrence of CDI is comparable between vancomycin and 
metronidazole (183, 184), with approximately 16% of cases resulting in further 
episodes. However, although the study was not powered for the investigation of 
recurrence, Johnson et al. identified vancomycin superiority amongst the total 
study population, including 20% with recurrent infections (195). 
Although vancomycin resistance is uncommon in C. difficile (118, 197, 198), instances 
of resistant isolates are gradually being reported (199-201). Whilst these are 
unlikely to contribute to treatment failures, due to high colonic concentrations, it 
demonstrates the potential for resistance acquisition. Furthermore, the selective 
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potential on concomitant bacteria must be considered, as the emergence of 
vancomycin-resistant enterococci (VRE) has been associated with use of the 
compound (202). Evidence of co-existing VREs and C. difficile populations has 
been reported (203, 204) and both correlate with many of the same risk factors (190).  
1.4.2.3 Fidaxomicin 
Fidaxomicin is a macrocyclic antibiotic demonstrating strong activity against C. 
difficile (118, 205, 206), with high concentrations of the compound accumulating in 
the faeces (>1,000 µg/g) (207). Exhibiting a narrow spectrum of activity, focussed 
on Gram positive anaerobic bacteria (208), fidaxomicin has a lower deleterious 
effect on the concomitant gut microbiota than vancomycin. After phase III 
clinical trials revealed its safety and a non-inferiority to vancomycin (50, 70), 
fidaxomicin was introduced to the European market in 2012 for the treatment of 
severe CDI (50). Clinical cure rates have been demonstrated as 88%-92%, 
compared to 86-91% for vancomycin (50, 195). Fidaxomicin demonstrates 
superiority over other antimicrobials, with reduced incidence of recurrent 
episodes of CDI reported. Clinical trial evidence revealed that fidaxomicin 
reduced the risk of recurrence, with only 15% of cases relapsing, compared to 
25% with vancomycin (50, 70). Nonetheless, the significant impact on recurrence 
rate was only observed in non-ribotype 027 strains (50). One proposed 
mechanism contributing to the reduction in recurrent infections is the 
adherence of the compound, via electrostatic interactions, to spore surfaces (209). 
This could mean that vegetative forms emerging after spore germination are 
rapidly met with direct antibiotic action. 
The main drawback of fidaxomicin use is expense (71), however, the clinical 
benefits of reduced recurrent infections and hospital stay can result in cost 
savings (210, 211). Whilst this compound may not currently be routinely used as a 
first line treatment, it may be beneficial in the treatment of the first episode of 
recurrence. Until recently, fidaxomicin resistant isolates have not been reported 
in clinical specimens (188, 206, 212), but laboratory mutants have demonstrated the 
potential for resistance development (213). However, a contemporary study of 
Floridian isolates has identified one of the first clinical strains, resistant to up to 
16 mg/L fidaxomicin (214), whilst a single French isolate demonstrated a 
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fidaxomicin MIC of >8 mg/L, amongst >3,000 susceptible surveillance strains 
(215).   
1.4.2.4 Faecal microbiota transplant 
Failure of antimicrobial therapies and recurrent infections often require 
alternative approaches to treatment. Since dysbiosis of the gut microbiota is 
essential to the onset of CDI, replenishment of a healthy and diverse colonic 
microbial population is considered as a novel preventative method for chronic 
relapses of infection. The instillation of healthy faeces directly into the gut 
through a naso-gastric tube, colonoscopy or even via the ingestion of frozen 
faecal capsules (216) act to redress the balance of micro-organisms in the colon. 
Thus, restoring the benefits associated with a healthy gut microbiome, including 
“colonisation resistance” and a proficient metabolic environment (217). 
The first randomised, controlled clinical trial to investigate the efficacy of faecal 
microbiota transplants (FMT) in the resolution of CDI symptoms was performed 
in the Netherlands, between 2008 and 2012 (72). Van Nood et al. randomly 
assigned each of 43 CDI patients to one of three treatment regimen; vancomycin 
alone, vancomycin followed by bowel lavage, or vancomycin, bowel lavage and 
subsequent FMT instillation through naso-duodenal tube. With a primary 
endpoint of diarrhoeal resolution and no recurrent infection for up to ten weeks, 
13 out of 16 FMT patients (81%) demonstrated clinical cure and a further two 
patients achieved symptomatic resolution with a second instillation. Results 
were significantly superior to vancomycin treatment, which achieved only 31% 
cure rate (p<0.0001). Importantly, no significant differences in adverse events 
were observed. Furthermore, one major systematic review of FMT studies 
identified a treatment resolution of over 90% (74).  
Although the success of faecal bacteriotherapy is not wholly understood, 
associations have been observed with increased microbial diversity in the gut, 
particularly with elevated populations of Bacteroidetes and Clostridium clusters 
IV and XIVa (72, 73, 218). The search for the combination of fundamental species 
necessary to prevent C. difficile proliferating in the human gut continues through 
the use of modern metagenomic techniques, such as 16S sequencing (219). 
Although a successful treatment option, it is not without limitations and 
controversy. There may be a stigma associated with the nature of this treatment, 
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with 41% and 24% of patients reportedly concerned about safety and 
cleanliness, respectively (220). Crucially, there are no studies demonstrating the 
longitudinal outcomes of FMT, and whilst there are suggestions of potential links 
between intestinal microbiota composition and diseases such as obesity and 
diabetes (221, 222), the National Institute for Health and Care Excellence (NICE) 
guidelines advise caution (223).  
1.4.2.5 Novel therapeutics 
The search for new anti-CDI antibiotics is ongoing, with several compounds 
reaching clinical trial stages. Equally, attempts to circumvent the treatment 
paradox of using antimicrobial therapies to treat an antibiotic elicited disease 
have generated several novel approaches to CDI. 
1.4.2.5.1 Novel antimicrobials 
Ridinilazole is a novel, bactericidal antimicrobial demonstrating potent activity 
against C. difficile (224, 225). Although its mechanism of action is unknown, it has 
been demonstrated to effect cell division and septum formation (226). Due to its 
narrow spectrum of activity (227-229), demonstrating superior retention of gut 
microbial diversity than fidaxomicin (228), the gut microbiota is spared any major 
deleterious effects, potentially preserving colonisation resistance (228). During 
phase II clinical trials ridinilazole demonstrated a non-inferiority to vancomycin 
treatments in rates of sustained clinical cure over 30 days (66% vs. 42.4%; 
p=0.0004) (230). The strong potential of the agent was further outlined by the 
indication of statistical superiority over vancomycin in the primary analysis 
population (230). Furthermore, Snydman et al. revealed a lessened risk of VRE 
acquisition, compared to vancomycin (23.7% vs. 29.7%), although this was not 
significant (231).  
Another promising anti-C. difficile compound was the oxazolidinone, cadazolid. 
This protein synthesis inhibitor demonstrated potent activity against C. difficile, 
preventing toxin and spore formation (232, 233). Phase II clinical trials revealed 
increased rates of diarrhoeal resolution compared to vancomycin (60.0% vs. 
33.3%), with marked reductions in recurrent infections (50% vs. 25%) (234). 
Unfortunately, following mixed phase III trial results, development was 
discontinued (235). 
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An alternative approach to reducing the impact of antimicrobial therapies is 
employed by ribaxamase. This oral β-lactamase is administered concurrently 
with intravenous β-lactams antibiotics (236). Ribaxamase administration is aimed 
at reducing the impact on gut microbes by degrading excess β-lactam compound 
reaching the gastrointestinal tract, thus reducing the risk of CDI development 
(236). Ribaxamase has performed well in phase II clinical trials, demonstrating 
both significant reductions in relative CDI risk (p=0.045) and VRE acquisition 
(p=0.0002) (236, 237). 
1.4.2.5.2 Microbiota therapeutics 
Based on the perceived success of faecal transplantations in the treatment of 
recurrent CDI (72), probiotic capsules derived from faecal microbiota are under 
clinical testing as a potentially more accessible treatment option. SER-109, 
created by Seres Therapeutics, Inc. is a formulation of purified spores 
(predominantly Firmicutes) from healthy faecal donors, promoted as an anti-CDI 
recurrence treatment. Initial clinical trials demonstrated safety and clinical 
success, with 86.7% of patients sustaining resolution of diarrhoea for 8 weeks 
(238). Significant increases in microbial diversity were observed and deemed 
important to the success of this formulation, however, no placebo control cohort 
was used in this study. Disappointingly, the phase II, randomised, placebo 
controlled trial results failed to meet primary efficacy end points (239), but 
further analyses suggested that higher dosages may improve the results (240). 
Phase III trialling of SER-109 is currently underway (241). 
A similar microbial formulation, designed for the treatment of recurrent CDI is 
RBX-2660. Phase II clinical trials revealed 87-89% success in prevention of 
recurrent infection (242, 243), with comparable efficacy to FMT treatments (72). 
Nonetheless, the most recent trial did not meet the primary end point, as the 
efficacy of two doses was not significant, with only single doses demonstrating 
significance over placebo (242). This serves to highlight the complexity of 
microbiota suspension treatments, with further trialling necessary. As with FMT, 
the long term consequences of microbiota alterations are yet to be determined 
and therefore caution must be taken with these approaches. 
Knowledge of the role of both primary and secondary bile acids in C. difficile 
spore germination (244) has also led to proposed novel therapies, such as those 
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altering the bile acid milieu, either through instillation with probiotic, bile acid 
metabolising microbiota (245) or synthetic bile acid analogues (246). Other 
approaches include the controversial targeted colonisation with non-toxigenic 
strains (247), and largely unsuccessful toxin-sequestering adjunctive compounds 
such as tolevamer (195). 
1.4.2.5.3 Immunotherapeutics 
A considerably elevated risk of developing severe CDI has been associated with 
low IgG levels in the serum (86). Therefore, to counteract this lack of antibody 
response, artificially increasing immunoglobulin concentrations is one approach 
to reduce the risk of CDI recurrence. The intravenous administration of 
immunoglobulins, containing anti-toxin antibodies against C. difficile has 
demonstrated efficacy in preventing infection relapse (248-251). Nonetheless, 
mixed results have been observed with these passive immunotherapies. In a 
retrospective review of immunoglobulin treatments, McPherson et al. reported 
sustained resolution of disease in 64% of cases (252), and Abougergi et al. 
indicated that beneficial effects were achieved in four non-controlled trials (253). 
However, the only controlled study reported, revealed no significant differences 
in all-cause mortality rates associated with post-antibiotic immunotherapy (254). 
One promising monoclonal antibody therapy is Bezlotoxumab. Targeting the 
clostridial toxins A and B, Bezlotoxumab inhibits the binding of toxin to host cell, 
neutralising the threat and conferring host immunity. Phase III clinical trials 
have revealed a significant reduction in recurrent CDI episodes associated with 
this treatment (7% compared to 25%) (255). Interestingly, further analysis by 
Gerding et al. revealed that the largest reduction in CDI recurrence associated 
with Bezlotoxumab use was observed in patients with more than three risk 
factors (256). 
 
1.4.3 Asymptomatic colonisation 
Highly discriminatory molecular techniques, such as next genome sequencing 
have been utilised to map nosocomial transmissions of C. difficile (257-259). Due to 
large proportions of unexplained transmissions in these studies, the role of 
asymptomatic carriers has become a focus of recent infection control 
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considerations (6, 8). Where C. difficile spores are ingested by subjects with 
healthy gut microbiomes, the organism can either colonise asymptomatically or 
transiently pass through the gut (8). Although these carriers have no direct 
clinical concerns, they can potentially act as transmission sources for CDI (257, 
258). Reported colonisation rates differ extensively and seem dependant on the 
study setting. Asymptomatic colonisation rates range from 3-21% amongst 
hospitalised patients (4, 78, 259-261) and 4-15% in healthy adults (262-264), with 
highest rates observed in long term healthcare facility cohorts, (4-51%) (88, 265-
267). Nonetheless, instances of colonisation are difficult to separate from CDI 
cases, with testing algorithms important to differentiation (8). These issues could 
be reflected in the wide range of colonisation rates described. The lowest rates 
of colonisation are reported by some of the largest studies (78, 259), however, Kong 
et al. suggest that this may be due to the high prevalence of epidemic strains 
within these study populations (268). Nonetheless, there is evidence suggesting 
that asymptomatic carriage may act as a potential transmission source for C. 
difficile and the value of additional screening at hospital admission should be 
considered. 
 
1.4.4 C. difficile in the community 
CDI is traditionally regarded as a hospital-acquired infection, associated with 
well-defined risk factors, such as antibiotic and healthcare exposure. However, 
increasing numbers of case reports of community acquisition and onset of 
disease associated with individuals not previously deemed at risk, have been 
reported (269). This has highlighted the importance of these cases and is currently 
considered essential to the holistic understanding of epidemiology and infection 
prevention. Community-acquired (CA)-CDI is generally defined as symptomatic 
onset within 48 hours of admission or more than 12 weeks post discharge (270) 
(Figure 1), although as highlighted by Wilcox et al. (271), many authors use 
varying definitions further complicating the determination of true acquisition 
rates. Rates of CA-CDI vary extensively, with ranges reportedly between 2-46% 
of CDI cases (53, 77, 271-273). Whilst these cases are generally considered to elicit 
less severe clinical outcomes with fewer reported instances of recurrent 
infections (41, 272), CA-CDI has been associated with a greater severity of early 
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symptoms (274), likely due to late diagnoses. Although still primarily a 
nosocomial disease, the incidence of community onset infections remains high, 
whilst strict adherence to classical risk factors may result in a significant 
proportion of CA-CDI cases being overlooked (271). Interestingly, in the UK 
ribotype prevalence varies between hospital and community settings, with the 
latter dominated by the toxigenic 002 type (275). 
 
 
Figure 1: Definitions of hospital vs community onset of CDI. CO-community 
onset, HO – hospital onset, CA-HCFA – Community acquired healthcare facility 
associated. Adapted from McDonald (2007) (270).  
 
1.5 Virulence factors 
Symptoms of CDI are elicited by the action of up to three distinct, 
proinflammatory toxin molecules, toxin A (enterotoxin), toxin B (cytotoxin) and 
binary toxin (CDT) (276). 
1.5.1  Large clostridial cytotoxins A and B 
The main virulence components of C. difficile, toxin A (TcdA) and toxin B (TcdB) 
are large clostridial cytotoxins, 308 kDa and 270 kDa in size, respectively (276). 
TcdA weakens the junction between epithelial cells, whilst TcdB further disrupts 
the actin cytoskeleton (277). These toxins, encoded by genes within the 
pathogenicity locus (PaLoc), act by glycosylating Rho GTPases, inhibiting 
essential transcription proteins and disrupting cell integrity. Subsequently, 
membrane permeability is increased and characteristic diarrhoea is instigated 
(278). TcdA was initially considered as the key virulence factor, demonstrating 
direct causation of mucosal damage in rats in the absence of TcdB, whereas TcdB 
alone had no effect (279). This stance has recently become more ambiguous, with 
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evidence of disease-causing, TcdA negative TcdB positive strains (280) and work 
from Riegler and colleagues indicating TcdB as ten times more potent, with 
increased electrophysiological and permeability alterations in Ussing chamber 
experiments (281). Furthermore, Lyras et al. were able to demonstrate the 
necessity of TcdB through the production of isogenic C. difficile strains with tcdA 
and tcdB gene knockouts (282). Interestingly, Warny et al. identified a greater 
proportion of TcdB production in hyper-virulent ribotype 027, demonstrating 
toxin production as 23 times higher when compared to twelve other types (283). 
Nonetheless, the results of this experiment should be treated with caution, as the 
findings were only representative of batch culture experiments, lacking the 
complexities of immune response in vivo. Strains lacking the tcdA and tcdB genes 
are deemed as non-toxigenic (280).  
 
1.5.2 Pathogenicity Locus 
The pathogenicity locus is a well characterised, 19.6 kb section of the C. difficile 
genome, which encodes the TcdA/B elements of the organism. The absence of 
the PaLoc is also well documented in non-toxigenic isolates, where it is replaced 
with a 115-bp fragment (284). The PaLoc consists of tcdA and tcdB genes, 
corresponding to the toxins of the same name and additional accessory genes, 
tcdC, tcdD, and tcdE (285, 286). Hundsberger and colleagues analysed the 
transcriptional pattern of the PaLoc and determined that tcdD and tcdC are 
positive and negative transcriptional regulators for tcdA and tcdB, respectively 
(285). By determining high levels of tcdC expression during the exponential 
growth phase and its depletion at stationary phase, in correlation with toxin 
production, they were able to indicate the impact of this negative regulatory 
gene. Whilst the PaLoc is highly stable and conserved (287), variation in the small 
open reading frames (ORFs), containing the accessory genes, have been reported 
(288). Interestingly, Spigaglia and Mastrantonio demonstrated 25% PaLoc 
divergence, with all strains variant in tcdC, offering further support for this 




1.5.3 Binary toxin 
The first binary toxin was identified by Popoff et al. in 1988, who discovered the 
production of a novel ADP-ribosyltransferase in the hyper-virulent C. difficile 
strain, CD196 (289). Subsequent studies have identified an association with 
hyper-virulence in selected ribotypes (34, 290). As an ADP-ribosyltransferase, it 
blocks actin polymerisation (276) and has been linked to increased pathogenicity 
due to greater cell adherence capabilities, enabling a more efficient delivery of 
its inhibitory elements (278). CDT is unrelated to the large clostridial toxin group 
and consists of two independent protein chains, CDTa and CDTb (289). Encoded 
by cdtA and cdtB, which demonstrate >80% sequence identity with the iota toxin 
produced by other clostridia (291), these components are required in combination 
for functionality. The larger, binding component enables the translocation of the 
enzymatic component, preventing polymerisation and effecting modifications to 
the cytoskeleton (292). The expression of CDT genes is reportedly controlled by a 
regulator, cdtR, demonstrating influence on CDT production with the insertion 
and deletion of this putative gene (293). CDT prevalence amongst C. difficile 
isolates has been reported as around 6%, but variable rates have been 
demonstrated (1.6-34.7%), depending on sample size and outbreak context (283, 
294-297).  
The precise relevance of the binary toxin to C. difficile virulence remains unclear. 
Case-control studies have exhibited a significant increase in diarrhoeal severity 
(76.9% liquid stools compared to 59.5% in non-CDT producing strains) and 
mortality associated with binary toxin strains (28% deaths within 30 days of 
infection vs 17% in binary toxin negative strains) (298, 299). Nonetheless, 
differentiating between the impact of TcdA/B and binary toxin has proven 
difficult, since they are often expressed concomitantly (296). The demonstration 
of a TcdA/B negative, CDT positive toxinotype XI failing to cause disease in a 
hamster model, suggests that the role of binary toxin may be more 
interconnected, exhibiting an additive effect (300, 301).  
 
1.5.4 C. difficile Spores 
The ability of this anaerobic bacterium to sporulate, allows survival in aerobic 
atmospheres, extreme temperatures and chemical pressures (302). This 
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environmental persistence through resilient C. difficile spores ensures an 
effective pathway for onward transmission of this successful pathogen. 
Importantly, spores in isolation are unable to cause disease and therefore must 
germinate in order to reach a vegetative state, where they can produce the 
toxins essential to elicit disease (11). 
1.5.4.1  Structure 
The ultrastructure of C. difficile endospores has been elucidated through 
transmission electron microscopy. Similar in structure to other well 
characterised species, such as Bacillus subtilis and Clostridium perfringens, they 
consist of an inner peptidoglycan core containing dipicolonic acid, germ cell wall 
(which forms the outer wall of the nascent vegetative cell), thick spore cortex 
and a spore coat (303). Further to these classical spore components, C. difficile 
spores exhibit an additional surface layer, the exosporium (303, 304). Although less 
than 25% of C. difficile spore coat proteins demonstrate homology to B. subtilis, 
research has suggested their similar roles in protection from external stressors 
and potential links to virulence (305, 306). 
1.5.4.2  Sporulation 
The fundamental dogma of C. difficile transmission is its ability to sporulate and 
repeat the cycle of infection. Although not fully defined, its sporulation pathway 
shows many similarities to other Bacilli (304, 307). SpoOA is reported as the master 
regulator for sporulation, and is activated by a sequence of phosphorylation in B. 
subtilis (308, 309). While there is a distinct lack of homologous phosphorelay 
transferases, research suggests direct kinase activation of SpoOA as the initiating 
factor for C. difficile sporulation (307, 310). A collection of key sigma factors activate 
specific transcriptional pathways leading to endospore formation (307, 311). As 
outlined in other species, sporulation commences with asymmetrical division of 
the mother cell with septum formation, creating a large mother cell and smaller 
forespore compartment. This division is influenced by sigF- and sigE- (307). Under 
the influence of sigG- and sigK-, the mother cell then engulfs the forespore by a 
process akin to phagocytosis, forming membrane and outer coat layers. Finally, 
mother cell autolysis releases the endospore into the environment (307). Whilst 
these pathways are relatively conserved in C. difficile, Pereira and colleagues 
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reported variant sigma factor pathways, indicating that the order of sigma factor 
expression may not be crucial (311). 
1.5.4.3  Germination 
Proliferation and outgrowth of quiescent C. difficile spores requires reactivation 
of this form to a metabolically active state. This complex process of germination 
is necessary to initiate the outgrowth of the toxin producing, vegetative cell 
form.  
1.5.4.3.1 Mechanisms 
Germination pathways for C. difficile are not as well defined as in other spore-
forming organisms, where mechanisms are highly conserved. In the model 
organism, B. subtilis, germination triggers (which are species dependant) signal 
ger receptors to initiate the germination process. Briefly, nutrient germinants, ʟ-
alanine, ʟ-valine and ʟ-asparagine bind to ger receptor, protein complexes in the 
inner-membrane, leading to a change in permeability and the release of Ca2+DPA 
(dipicolonic acid) through SpoVA channels. This triggers cortex lysis enzymes to 
hydrolyse the spore cortex, allowing rehydration, activation of cell metabolism 
and eventual outgrowth (312). However, through analysis of the complete C. 
difficile 630 genomic sequence, Sebaihia and colleagues discovered a marked 
lack of germinant receptor homologues, as described in Bacillus and other 
clostridial species (313, 314). This absence of the tricistronic ger operon is 
indicative of a novel response mechanism to external germination stimuli 
utilised by C. difficile. 
Since ingested C. difficile spores inhabit the gastrointestinal tract, the key to 
germination initiation can also be discovered there. A combination of the 
primary bile acid, taurocholate and glycine (co-germinant) has been identified as 
an important germinant trigger in C. difficile (244, 315, 316). Bile secreted by the gall 
bladder, to assist with digestion and absorption of fat and cholesterol, consists of 
cholate and deoxycholate molecules conjugated with taurine or glycine. 
Metabolism of these complexes by the indigenous gut flora releases potential C. 
difficile germinants into the ileum. Also, bile salt hydrolases produced by the gut 
flora alter glycine conjugates as they passes through the lower gastrointestinal 
tract, releasing free glycine for germination interactions (317). Adding to the 
complexity of the germination mechanics, other primary bile acids have been 
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implicated in the direct inhibition of C. difficile germination, with 
chenodeoxycholate demonstrated as inhibitory by Sorg and Sonenshein (318). In 
the aforementioned study they observed direct competition for receptor sites 
between primary bile acids, with chenodeoxycholate exhibiting a greater affinity 
than taurocholate. This correlated convincingly with the knowledge of a 
reduction in chenodeoxycholate concentration in the colon (319), enabling 
directed germination in the anaerobic environment of the lower intestine. The 
availability of both taurocholate and amino acid co-germinants allow 
interactions with inhabiting C. difficile spores and the initiation of the complex 
germination process. Interestingly, Buffie et al recently discovered the 
significance of the bile acid 7α-hydroxylating action of Clostridium scindens to an 
enhanced protective effect to CDI (320). This was deemed to be due to the 
generation of inhibitory secondary bile acids and could be considered as a novel 
pre-treatment. Nonetheless, as with any therapy affecting the balance of gut 
microflora, caution would be advised when considering this mechanism as a 
potential method of prophylaxis, as high levels of bile acids have been linked 
with several cancers (321). 
Detailed mechanisms for these interactions are only gradually being elucidated. 
The current working model (Figure 2) implicates CspC, a pseudoprotease, as the 
initial receptor for cholic acid derivatives. This interaction stimulates a protease, 
CspB (322), to activate SleC via cleavage of a small prodomain, leading to lysis of 
the spore cortex. Ca2+DPA is released and the germination process proceeds as 
in other organisms (323-325). Further work on this model suggested that CspC, 
although essential in signalling CspB, actually inhibits the core lysis enzyme (323).  
How the nutrient signal of glycine presence interacts with this model remains 
unclear. Since several other amino acids have also been implicated as effective 
germinants for C. difficile spores, including ʟ-alanine, ʟ-phenylalanine, ʟ-arginine 
and serine (326-328), further mechanistic elucidation is required. Interestingly, 
Shrestha and Sorg highlighted the importance of lower-level temperature 
differences in germinant potential, indicating a series of amino acids previously 
considered as ineffective at 25°C, as germination stimulating at 37°C (327). This 
broad spectrum of potential germinants is suggestive of either the presence of 
multiple specific receptor sites or a more complex, pliable interaction at a single 
site.  
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Other factors must also be considered in this complex process, as additional 
elements have been implicated in C. difficile germination response. Intriguingly, 
Kochan and colleagues reported the influence of Ca2+ ions on the C. difficile 
germination process (329). By demonstrating a 90% germination reduction in 
murine models with depleted ileal calcium levels, they related this deficiency to 
the use of proton pump inhibitors, a known CDI risk factor (130). They postulated 
that the presence of glycine triggers the release of endogenous calcium, 
stimulating the germination cascade. 
Research is ongoing to complete the understanding of C. difficile germination 
pathways, with modern molecular techniques such as forward and reverse 
genetics demonstrating vast potential in the elucidation of all the relevant 
proteins involved (330). Whilst determination of the intricacies of the C. difficile 
germination pathway is valuable, identification of optimal germination 
conditions is of importance in the practical and diagnostic implications of this 
knowledge. Since the factors affecting germination are multifaceted and often 
appear contradictory in the literature, further investigation is necessary to 





Figure 2: Proposed C. difficile germination model by Francis et al. (324, 325), additional calcium involvement reported by Kochan et al. (329) 
(Orange circle). Diagram adapted from Kochan et al. (329). 1. Taurocholate (TC) and glycine (G) from bile acid interact with CspC, 2. Enabling 
glycine and Ca2+ transport through the spore coat. 3. Glycine binds to an unknown receptor, 4. Releasing Ca2+ from the core, which interacts with 





1.5.4.3.2 In vitro germination 
To increase the efficacy of C. difficile diagnostics and research, careful selection 
of culture environment is essential to the optimisation of germination and 
outgrowth of spores. Comparisons of agar and broth media, along with potential 
germination enhancing supplements have previously been investigated, with 
varied results (244, 331-335). 
Supplementation of taurocholate into solid agar has been shown to improve 
recovery rates of C. difficile spores, with addition to cycloserine-cefoxitin-
fructose agar (CCFA) consistently demonstrating improved recovery (332). 
Nonetheless, the concentration of cholate utilised in culture media is important 
to the efficacy of C. difficile germination. Studies have indicated that although a 
0.1 mmol/L taurocholate concentration is the minimum requirement for 
germination, a greater concentration of 1-10 mmol/L produces a more complete 
recovery of spore populations (244, 331). The latter concentration is comparable to 
the physiological concentrations found in the jejunum (1.2 mmol/L) (336) and 
duodenum (6.9 mmol/L) (337), suggesting an evolutionary, clinical relevance. 
Conversely, there are reports in the literature suggesting that lesser 
concentrations produce comparable levels of recovery, with 0.05% taurocholate 
recommended as an equally effective, cheaper alternative (338). Nevertheless, 
variable strain responses are often observed with bile acid supplementation 
(339), so it may not be achievable to identify a C. difficile culture media, optimised 
for recovery of all strains. 
The germination process appears to be more convoluted, with Sorg and 
Sonenshein suggesting exposure period impacts on bacterial propagation (244). 
They determined that prolonged exposure to low levels of taurocholate, coupled 
with the co-factor glycine, acted as a more efficient germinant combination than 
high concentrations over a short exposure period. Exposure to 10% sodium 
taurocholate for a ten minute period led to germination of only 60% of the 
spores recovered through continuous exposure at 0.1% concentration. This 
would suggest that a prolonged exposure to the bile salt provides a more 
suitable environment for efficient spore germination and recovery than a 




bacterial spores have been demonstrated to commit to germination (340), 
suggesting that prolonged exposure to germinant signals is unnecessary. 
The purity of taurocholate is also considered as a potential factor affecting C. 
difficile germination. Earlier studies reported inefficiencies with some crude 
reagents lacking purity (315, 341). However, manufacturing processes have vastly 
improved in recent times and synthetic analogues are likely to negate this 
variance.  
Lysozyme has also been associated with increased C. difficile spore germination 
and recovery from environmental samples (342). Deemed an artificial germinant, 
lysozyme acts to digest the spore cortex releasing Ca2+DPA and initiating 
germination, as opposed to interacting with species specific germination 
receptors (312, 343).  
As with many core functions, strain variability inevitably affects germination, 
with research indicating significant divergence in the germination efficiency 
between C. difficile ribotypes (304). Interestingly, Kamiya’s work identified 
distinct differences between toxigenic and non-toxigenic C. difficile strains, with 
the latter demonstrating lesser germination efficiency (341). 
 
1.5.5 Biofilms 
Biofilms are ubiquitous in nature and the clinical environment is no different. 
Formation on medical devices and prosthetic implants can be a serious 
challenge to clinicians, and their presence in dental and gastrointestinal niches 
are universal (344-346). C. difficile has been demonstrated to form biofilms in the 
gut environment (347, 348), offering protection from external stressors and 
survival assistance in a hostile environment. Biofilms often consist of multiple, 
co-existing species prompting symbiotic relationships. C. difficile has been 
reported in these integrated bacterial communities (349, 350). Formation and 
arrangement of planktonic cells into sessile structures is a multifactorial 
process, which is not fully understood in C. difficile. The influence of quorum 
sensing on biofilm formation is often reported (351, 352), with evidence of a luxS 
homologue implicated in cell assembly (352, 353). Surface layer proteins have 




pili have been shown to mediate cell surface adhesion (354). Flagella have been 
implicated in maintenance of mature biofilms, with fliC deficient mutants 
demonstrating decrease efficacy (353). The production of extra-cellular matrix 
contributes large portions of biofilm structure (353, 355), whilst acting as a physical 
buffer for the sessile cells within (356). Implicated in recurrent infections, biofilms 
are of extreme importance when considering antimicrobial susceptibility. 
Phenotypes of cells within biofilms have been reported as divergent from 
planktonic populations(350), with reports of up to 1000-fold increase in 
resistance levels (356). Dapa and colleagues demonstrated resistance to higher 
concentrations of vancomycin in C. difficile sessile populations (353), whilst in 
silico modelling predicted treatment failures after a growth density threshold 
was reached (357).  
1.6 C. difficile epidemiology 
1.6.1 Typing methods 
Molecular typing of C. difficile is essential to epidemiological investigation and 
the identification and control of potential hyper-virulent, epidemic strains. 
Numerous typing methods have been utilised globally, with geographic 
preferences highly apparent (358-361). Different methodologies present distinctive 
nomenclature, making direct comparisons challenging (E.g. PCR ribotype 027 is 
also referred to as North American pulsed-field gel electrophoresis type 1 
(NAP1) and restriction endonuclease analysis group BI).  
Restriction endonuclease analysis (REA) utilises the HindIII enzyme to digest the 
entire bacterial genome, with fragments resolved via gel electrophoresis (362). 
Pulsed-field gel electrophoresis (PFGE) is similar to REA, but exploits the SmaI 
enzyme to generate larger fragments and specialist equipment to apply pulsed-
field separation for greater fragment resolution. Whilst PFGE was historically 
considered as the gold standard for outbreak investigation, these gel-based 
methods are time consuming, require technical expertise and are limited by the 
inter-laboratory comparability of profiles (358). 
PCR ribotyping is the most widely applied method throughout Europe (360, 361), 
implemented as the technique of choice by the UK’s national surveillance 




demonstrates significantly greater variability in the 16S - 23S intergenic spacer 
regions than other organisms (364), ribotyping takes advantage from this 
variability to discriminate between strains. Demonstrating strong concordance 
with PFGE types, this methodology provides highly accurate and reproducible 
groupings (365). Originally developed in conjunction with gel electrophoresis (366-
368), the profile comparability was improved by the addition of fluorescently 
labelled primers and the use of capillary electrophoresis resolution (369). This 
development enabled direct transferability of ribotype profiles across 
laboratories with searchable databases allowing rapid and reproducible 
comparisons.  
More discriminatory methods such as multi-locus variable number tandem 
repeat analysis (MLVA), fragment DNA based on the highly variable number of 
non-coding tandem repeats. Due to its high discriminatory power, MLVA has 
applications in sub-typing (370) and outbreak investigations (371). Nonetheless, it 
cannot be used to infer ribotype and is not used routinely in the UK, due to its 
requirements in cost and expertise (359, 361). 
Several other techniques provide typing of C. difficile strains into distinct groups 
aligned by a specific phenotype. Toxinotyping amplifies and digests specific 
regions of the PaLoc, identifying variability in toxin genes. Currently 34 
toxinotypes have been identified outlining strains’ toxigenic potentials, although 
they are less discriminatory than other methods and binary toxin identification 
cannot be determined (13, 372). Serotyping methods rely on bacterial surface layer 
proteins and the variation amongst the antigens present. Initially relying on 
immunoassay techniques, they were proven as reliable and reproducible in 
grouping C. difficile isolates (373). Modern surface layer protein (SLP) gene 
analysis methods have largely superseded these (374). However, this typing 
method is uncommon and SLP types differ within ribotypes, presenting 
comparability challenges (358).  
Multi-locus sequence typing (MLST) utilises sequence differences in seven or 
more housekeeping genes, assigned to distinct alleles to designate sequence 
types (ST). This allows some phylogenetic relationships to be identified, as well 
as accurate translatability between testing laboratories (375). Single nucleotide 




also expensive (360). Nonetheless, the viability of typing by sequencing common 
genes through next generation sequencing (NGS) has already been 
demonstrated effectively (257, 376). The advent of high-throughput sequencing 
technologies and sequencing by synthesis methods is generating greater access 
to bacterial genomes. Where previous typing methods utilise a select number of 
genes to calculate sequence type, NGS allows for a considerably greater number 
of target genes or even the whole genetic sequence to be assessed in typing 
algorithms (377). Providing far superior resolution, NGS typing is able to 
distinguish between previously indistinct sub-groups (377), as well as predict 
antimicrobial resistance (378, 379).  
 
1.6.2 C. difficile epidemiology in the United Kingdom 
Prior to the emergence of hyper-virulent ribotype 027, C. difficile epidemiology 
in the UK was dominated by ribotype 001 (367, 380, 381). As the first reported 
epidemic strain, ribotype 001 was implicated in 55% of all UK CDI cases (380), 
and 93% of all UK outbreaks (382). Other prevalent UK ribotypes prior to the 
twenty-first century were 010, 014, 106, 012 and 020 (367). The first UK outbreak 
of CDI caused by the PCR ribotype 027 strain, epidemic in North America (34, 112), 
occurred between 2003 and 2004 at Stoke Mandeville hospital, where it was 
involved in 174 cases and 19 deaths (383). As this hyper-virulent strain spread 
through the country, the number of deaths associated with CDI rose sharply, 
from 2238 in 2004 to 8324 in 2007 (105). By 2008 ribotype 027 was implicated in 
55% of all UK incidences of CDI (384). In 2007, the introduction of a national 
surveillance service, the CDRN, alongside mandatory cases reporting (105), 
enabled a valuable insight into the epidemiology of C. difficile in the UK (363). 
With ribotyping data for more than two-thirds of reported cases, this national 
service acts as a vital tool in outbreak assessment and control, allowing a greater 
understanding of UK epidemiology and the ability to track ribotype prevalence 
longitudinally.  
Two recent, large scale studies reported CDI incidences in the UK of 3.7 and 10.6 
cases per 10,000 patient days (154, 385). Bauer et al. reported clustering of 
ribotype 106 in the UK (13 isolates), whilst it was not detected in any of the 




data from the USA and UK revealed a considerably lower rate in the latter (115.1 
vs 19.3 cases per 100,000 population; p<0.0001) (386). These vast differences 
were reflective of, and potentially attributed to, the introduction of CDI 
management policies in the UK (105), resulting in a reduction of pre-disposing 
antibiotic use. This finding was supported by Dingle et al., who used national C. 
difficile data in conjunction with NGS to report a decrease in CDI cases caused by 
fluoroquinolone resistant strains in Oxfordshire. Correlating with a reduction of 
fluoroquinolone use, CDI rates from resistant strains declined from 67% in 
2006, to 3% in 2013 (387).  
A major pan-European study into C. difficile epidemiology and antimicrobial 
resistance revealed that in 2014 the most prevalent UK ribotypes were 014, 106, 
015, 020, 078 and 002 (188). Ribotype 027 only constituted 3% of all UK CDI 
reported in the study. The latest CDRN report (2013-15) confirmed similar 
results as the large European studies (154, 188), identifying emergent ribotypes as 
078, 002, 005, 014 and 015 (363). The longitudinal data also indicated 
considerable decreases in UK epidemic strains, 027, 001 and 106, correlating 
with decreased usage of high CDI risk antibiotics, cephalosporins and 
fluoroquinolones (384). Compensatory increases in sporadic strain types led to a 
more heterogeneous spread of ribotypes (363), potentially reflecting improved 
infection control and antimicrobial stewardship.  
 
1.6.3 C. difficile epidemiology in Europe 
The emergence of PCR ribotype 027 in North America at the beginning of the 
twenty-first century resulted in rapid dissemination into Europe. As observed in 
the UK (383), by 2005-06 outbreaks were being reported across several European 
countries (388-392). In the Netherlands, considerable increases in CDI between 
2004 and 2005 were attributed to the emergence of ribotype 027, with 
incidence rising from 4 to 83 cases per 10,000 patient admissions (390). To 
combat this rise, restrictions of cephalosporins and a ban on fluoroquinolone 
use were instated. In conjunction with increased infection control procedures 





In 2003, Barbut and colleagues reported a mean incidence of CDI in one pan-
European study, as 11 cases per 10,000 patient days (144). This rate was 
considerably lower when reported from 97 hospitals across 34 European 
countries in 2008, where a mean incidence of 4.1 per 10,000 patient days was 
observed (385). However, this rate varied widely between individual countries 
and hospitals, with Turkey and Poland demonstrating polarised incidence of 0.0 
and 36.3 per 10,000 patient days, respectively. Two large scale studies reported 
comparable numbers of ribotypes amongst European populations, with 66 
reported in 2007 and 65 in 2008 (385, 394). In 2007 Barbut et al. reported a distinct 
lack of diversity, with a predominance of 12 ribotypes (mostly 001, 014, 027, 
020, and 017) constituting over 65% of the total (394). All of the ribotype 027 
isolates demonstrated resistance to modern fluoroquinolones, but were 
clustered in only three hospitals. Bauer reported similar ribotype prevalence, 
with 014 (16%), 001 (9%), 078 (8%) and 027 (5%) the most abundant (385). 
Instances of ribotypes 106 and 078 were increased over early findings (144), 
reflecting the emergence of these ribotypes in other countries (290, 395), with the 
latter potentially implicating the role of zoonotic transmission (10). In support of 
Barbut’s findings, ribotype 027 demonstrated clustering in certain countries, 
only being detected in six out of 34 nations. This may be a result of improved 
management and infection control practices in response to major outbreaks of 
previous years. Potential outbreaks of other ribotypes were reported by Barbut 
et al., with ribotype 017 observed in up to 80% of cases from Poland and Ireland 
(394). Equally, ribotype 001 was detected in 73% of CDIs across three hospitals in 
Madrid. 
More recent, large scale pan-European surveillance reported that PCR ribotypes 
027, 001, 078 and 014 were prominent, comprising of over one third of all 
infections (118, 188). Ribotype 027 prevalence remained stable between 2011-14, 
constituting between 11.8% and 12.6% of all CDI cases. Nonetheless, these 
instances were highly country dependant, and were particularly abundant in 
Denmark, Hungary, Italy and Poland. This reinforced the findings of the earlier, 
European, multicentre, prospective, biannual, point-prevalence study of CDI in 
hospitalised patients with diarrhoea (EUCLID) study, which reported similar 
prevalence rates, with the noticeable lesser frequency of ribotype 078 (154). In 




again these were isolated primarily in four countries, with isolates from 
Germany, Hungary, Poland and Romania comprising 88% of total cases. 
Considerably more ribotypes were reported in these recent studies than those of 
Barbut and Bauer et al., with 144 and 138 reported in the ClosER and EUCLID 
studies respectively (118, 154). The ClosER study also revealed the presence of 
ribotypes 198 and 356 emerging in Italy and Hungary, respectively; potentially 
due to further diversification of CDI strains (118). Nonetheless, as highlighted by 
Davies et al., only 32% of hospitals involved in the EUCLID study utilised optimal 
diagnostic methods (154). It was conservatively projected that this could lead to 
more than 40,000 missed instances of CDI per year, representing a vast potential 
impact on CDI rates. Through the sequencing of the EUCLID isolates, Eyre et al. 
suggested that there were two distinct patterns of C. difficile dissemination 
across Europe, one health care transmitted (027 and 001) and one diverse 
lineage, widely spread group (002, 014, 020) (396).  
 
1.6.4 C. difficile epidemiology in North America and the rest of the 
world 
Historical CDI outbreaks in the USA, were attributed to a PCR ribotype 001, 
clindamycin resistant “J-strain”, which was implicated in multiple cases across 
four hospitals, between 1989 and 1992 (97). CDI rates rapidly increased at the 
turn of the century, with the emergence of the hyper-virulent ribotype 027, 
implicated in several outbreaks across Canada and North America (34, 112, 397). The 
first 027 reports from the multi-institution, case-controlled study by Loo et al. 
revealed 22.5 CDI cases per 1,000 admissions (34), whilst rates in the USA more 
than doubled between 1997 and 2001, due to of clonal expansion of this 
epidemic strain (92, 398). A review of Canadian cases by Pépin et al. indicated a 
four-fold increase in CDI incidence between 1991 and 2003, with a ten-fold 
increase observed in the population of over 65 year olds (397). In support of these 
findings, a multi-centre study comprising eight American institutions revealed 
the presence of the BI/NAP1/027 type in 51% of CDI cases (112). The success of 
these isolates was attributed, in part to a resistance to modern fluoroquinolones 




Adjusted estimates of CDI cases in ten geographical distinct regions of the USA 
indicated 453,000 instances and approximately 29,000 deaths in 2011 (53). 
Increasing community cases (53), in addition to reports of disease onset in 
previously low risk populations, such as paediatrics (399) and peri-partum 
women (400) all contributed to this large burden of disease. A recent, nationwide 
database review including ten years of CDI case data from the USA (2005-2014), 
revealed an annual increase in infections of 3.3%, with a larger proportional 
increase in community acquired disease (401). Although rates continued 
increasing, mortality rates decreased from 9.7% in 2005 to 6.8% in 2014; 
(p<0.0001). This may be attributable to improved awareness of antimicrobial 
restriction and infection control requirements, as observed by Evans et al. (402). 
The aforementioned study of CDI in veteran affairs long-term care facilities in 
the USA demonstrated a 36% decrease in CDI following the introduction of a CDI 
prevention initiative in 2014 (402). 
The clonal expansion of the epidemic ribotype 027 has reached beyond Europe 
and North America. Although this ribotype is not as prevalent in the rest of the 
world, cases have been reported across Asia (403-405) and into Australia (406). 
Nonetheless, in a collection of 474 Australian isolates typed by Knight et al., 37 
different ribotypes were detected, but none were ribotype 027 (407). Historically, 
high levels of CDI in Western Australia were attributed to widespread use of 
third generation cephalosporins in the 1980s (408). Rates decreased as the usage 
of this high risk class of antimicrobials lessened, with 2-3 cases per 1,000 
discharges reported in 1993-98, compared to 0.87 in 1999. A five year study of 
Japanese cases revealed an epidemiological shift from a predominance of 
ribotype a in 2000 (45%), to domination by ribotype f/smz in 2004 (409). Meta-
analysis of 51 studies of Asian C. difficile infections revealed similar instances to 
Europe and the USA, 5.3 cases per 10,000 patient days (410). CDI was highest in 
East Asia (19.5%), with the Middle Eastern and South Asian regions 
demonstrating rates of 11.1% and 10.9%, respectively. There is a paucity of 
epidemiological data from Latin America, with data from Argentina suggesting 
an increase in CDI from 37 cases per 10,000 admissions in 2000, to 84 in 2005 
(411), and one review suggesting a 4% mortality rate, lower than more developed 
countries (412). However, caution must be taken as these results may be 




Where global epidemiology often reflects divergent patterns of strain 
prevalence, comparisons are made more challenging due to the lack of 
consensus on typing methods (413). Geographic isolation, diverse infection 
control measures and varied prescribing regulations can lead to differing strain 
dominance (186, 198, 201, 407, 414-416). 
   
1.6.5 PCR ribotype 027 
As previously mentioned, hyper-virulent ribotype 027 emerged as an epidemic 
strain in North America in 2004 and has been implicated in multiple 
international outbreaks since first reported (34, 112). The discovery of the 027 
strain correlated with a 400% increase in CDI cases in Canada alone, with 82% 
of Canadian cases attributed to this hyper-virulent strain. Ribotype 027 emerged 
as a cause of CDI outbreaks in the UK shortly thereafter (383), followed by a 
dramatic increase in C. difficile associated deaths (417). This important ribotype 
has also been linked to increased rates of recurrent disease (418, 419), although 
other risk factors such as increasing age and antibiotic use may be stronger 
predictors of recurrence. (420). 
The success of this particular strain has been linked to superior toxin production 
(283), although not all evidence supports this finding (421). Initially assumed to be 
caused by an 18bp deletion in a putative toxin regulator gene, tcdC, (112, 283), 
Matamouros et al. demonstrated no detriment to TcdC harbouring the 18bp 
deletion (422). A single base pair deletion at the 117 position of the tcdC gene, 
resulting in truncation of the negative regulator protein, has also been 
implicated in the elevated production of TcdA and TcdB (422, 423). However, there 
may be other factors involved in hyper-virulence, as Curry et al. observed other 
distantly related, non-hyper-virulent C. difficile strains exhibiting the same 1bp 
tcdC deletion (423).  
Although generally described as hyper-virulent, there are reports demonstrating 
no correlation between 027 isolates and superior toxin levels or disease severity 
(424-426), whilst not all ribotype 027 strains have demonstrated equivalent 
behaviour (424, 427). A study of Swedish ribotype 027 isolates discovered several 
genotypically distinct strains containing the wild-type tcdC gene, revealing a 13-




demonstrated the increased rate of spore production in hyper-virulent vs non-
hyper-virulent strains, with considerable intra-ribotype variation observed 
amongst 027 isolates (421, 427). Akerlund et al. demonstrated sporulation rates 
ranging between 25% and 45% of C. difficile cells after 48 hours of in vitro 
culture (427). Conversely, Burns et al. observed no significant association between 
increased sporulation and ribotype 027, reporting wide variation within the 
population (428). These phenotypic differences could be factors in differing 
disease severity and recurrence potential. 
Other potential explanations for the success of ribotype 027 have been 
proposed. Stabler et al. reported instances of novel tcdB variants, suggesting 
putative N-terminal domain alterations were impacting the binding potential of 
the toxin molecule (429). Merrigan and colleagues suggested that excess toxin 
production may be attributed to RNA polymerase sigma factor, tcdR, and 
polymorphisms in the ribosomal binding site, leading to potential 
transcriptional read-through of tcdA and tcdB (421).  
Robinson et al., used in vivo murine modelling to observe the ability of ribotype 
027 strains to outcompete non-027 isolates in the gut (430), suggesting this 
competitive advantage as a potential contributor to its success. Recent work 
using stochastic simulations of infection models tested several healthy, 
colonised and diseased states for the probability of an invading C. difficile strain 
to proliferate amongst established intestinal microbiota (431). Here they observed 
a propensity for more infectious/virulent strains to supersede other resident 
microbes.  
Nonetheless, increased resistance to antibiotics, particularly fluoroquinolones 
remains strongly linked to the success of this ribotype, which has become 
synonymous with a gyrA, Thr82>Ile mutation (34, 99, 112). Resistance to these 
widely used, broad spectrum antimicrobials can result in C. difficile survival in 
severely diminished gut microbial environments and a high risk of disease onset. 
Nevertheless, recent increased awareness and infection control governance, 
along with the implementation of national surveillance systems has led to a 





1.7 Antimicrobial resistance in C. difficile 
In order to fully comprehend the effects of both direct and ancillary antibiotic 
exposures on the evolution of C. difficile strains, the mechanisms of action and 
resistance must be fully understood. Whilst resistance to CDI treatment drugs is 
minimal, the development of reduced susceptibilities to other antimicrobial 
classes is of high importance to the onset of disease. 
1.7.1 Quinolones 
1.7.1.1 Mechanism of action 
Quinolones are a class of synthetic, broad spectrum antibiotics that have been 
widely used for over 50 years. Their extensive spectrum of activity allows for an 
abundance of clinical applications in the treatment of skin and soft tissue, 
respiratory, sexually transmitted and urinary tract infections (432). 
Fluoroquinolones are modern generation quinolone derivatives containing an 
additional fluorine atom at position C-6. This modification provides increased 
efficacy of DNA gyrase sub-unit A binding, interfering with the DNA cutting and 
resealing process (433). 
The mechanism of action employed by quinolones involves the inhibition of two 
essential bacterial DNA enzymes, DNA gyrase and topoisomerase IV. By 
targeting specific regions of both these enzymes, antibiotic-enzyme complexes 
form and binding elicits conformational changes, enzymatic inactivation and 
eventual DNA replication inhibition (434). The impact on these key elements of 
the DNA replication process enables quinolones to effect bactericidal properties 
(435).  
DNA gyrase and topoisomerase IV are the two type II topoisomerase enzymes 
involved in the essential processes of bacterial DNA replication. The DNA gyrase 
molecule consists of two sub-units, A and B (436). Hydrolysed adenosine 
triphosphate (ATP) binds to the molecule, effecting a conformational change, 
which allows the gyrase enzyme to begin a process of negative supercoiling. The 
enzyme binds to positively supercoiled bacterial DNA enabling a transient break 
of the double-strand (a process carried out by sub-unit A) and a negative 




Topoisomerase IV is the essential affiliated enzyme to DNA gyrase for DNA 
replication in most bacteria. Similar in structure to gyrase, it contains 2 ParC and 
2 ParE sub-units. Its primary function is to allow the separation of interlinked 
daughter chromosomes in the final stages of DNA replication. A secondary 
function is to enable the positive supercoil to relax in preparation for gyrase 
enzymes to carry out negative superhelical twisting of the DNA. An absence of 
topoisomerase IV genes has been outlined in the C. difficile genome and 
therefore eliminates it as a quinolone target in this organism (438). 
1.7.1.2 Mechanism of resistance 
Resistance to the quinolone class of antimicrobials is commonly mediated by 
mutations in the targeted, DNA gyrase genes (gyrA & gyrB). Located within the 
quinolone resistance determining region (QRDR) (439), mutations of the gyrA 
coding region reduce the binding affinity of the transcribed gyrase molecule to 
quinolone molecules, whilst chromosomal changes in the gyrB region often 
exacerbate binding affinity reductions (440). If the quinolone molecule cannot 
bind to its target effectively, its efficacy will reduce and the organism will benefit 
from reductions in susceptibility.  
Mutational hotspots (regions of high mutational frequency (441)) have been 
implicated in resistance to fluoroquinolones. Cambau and Gutmann highlighted 
the clustering of substitutions around the Ser-83 codon of the gyrA gene in E.coli 
as a predisposition for quinolone resistance (442). Due to phylogenetic closeness, 
mutations in this region can also be associated with quinolone resistance in C. 
difficile isolates.  
Ackermann and colleagues identified moxifloxacin resistance in 19 out of 72 
(26%) clinical C. difficile isolates, with 14 harbouring single point mutations in 
codon 82 (equivalent to E. coli numbering 83) (443). Single point mutations were 
demonstrated in 13 of these isolates, ACT (Thr) to ATT (Ile). The remaining 
resistant isolate displayed two base changes, GTT, leading to the expression of 
valine. All susceptible strains exhibited the same, wild type sequence, 
reinforcing the significance of these mutational substitutions. Data from 
Spigaglia et al. supported this finding; by determining 73 of 82 multidrug 
resistant isolates exhibited the same single point mutation in the gyrA gene, in 




Spigaglia’s study indicated quinolone resistance in five isolates without 
modification in this region of the genome. This sustains the comprehension that 
quinolone resistance can be multifaceted with additional mechanisms, such as 
mutations in gyrB genes or an increase in drug efflux being influential.  
Mutations in the gyrB gene have also been implicated in quinolone resistant C. 
difficile strains, with the critical importance of the Asp-426 codon reported in E. 
coli and S. aureus (432). Drudy et al. demonstrated a comparable mutation 
repeatedly occurring in gyrB across all fluoroquinolone resistant C. difficile 
isolates in one study (445). This group hypothesised that the relationship of 
mutations in codon 426, from aspartic acid to valine, and fluoroquinolone 
resistance is potentially due to a physical hindrance of the binding process. As 
valine is a branched chain amino acid, this additional bulk in the binding pocket 
region could partially inhibit the antimicrobial molecule forming the necessary 
complex with the organism. Dridi and colleagues identified mutations in the 
same Asp-426 codon in five isolates with moxifloxacin minimum inhibitory 
concentrations (MICs) of 8-16 mg/L (438). However, unlike in previous studies, 
these isolates reflected a mutation into an asparagine amino acid, as opposed to 
valine. This may indicate the influence of charge on the binding complex, as 
Asp426>Asn reflects a replacement of a negatively charged amino acid with an 
uncharged residue. The same alteration in charge would apply to the valine 
mutation in Drudy’s work. 
Barrett et al. suggested that quinolones bind to a pocket created by a complex of 
the QRDR of gyrase sub-unit A and a similarly influential region of sub-unit B 
(446). One proposed model of this binding pocket implicated Asp-426 and Lys-
447 of gyrB as key regions, demonstrating interactions with both the phosphate 
backbone of DNA and the C-7 group of ciprofloxacin (447). This proposal 
suggested that the antibiotic molecule acts as an intercalating agent, inhibiting 
the enzyme. Therefore, any mutations at the gyrB encoding region leading to 
structural changes, may affect the solidity of the complex and the activity of the 
quinolone molecule. Although this provides a detailed insight into the 
ciprofloxacin-gyrase interface, there is a requirement for this proposed 




between an array of fluoroquinolone compounds, greater confidence in these 
defined complexes can be established. 
 
1.7.2 Nitroimidazoles 
1.7.2.1 Mechanism of action 
Metronidazole is a low molecular weight compound which diffuses across the 
cell membrane and imparts bactericidal effects via intracellular reduction within 
anaerobic organisms (448). Reduction occurs through interactions with the nitro-
group of metronidazole and Pyruvate-Ferredoxin oxidoreductase (PFOR) 
creating toxic derivatives that covalently bond to DNA. This disrupts the helix, 
inhibiting DNA synthesis and instigating cell death (449).  
1.7.2.2 Mechanism of resistance 
Since sensitivity to metronidazole is dependent on PFOR activity, primary 
resistance mechanisms have been identified as involving the alteration of 
enzyme efficiency and reductase pathways. In Bacteroides spp. the involvement 
of nim genes has been identified in the reduction of the nitro-group of 
nitroimidazoles and the creation of an inefficiently active amine group (450), 
leading to the conversion of nitroimidazoles into non-toxic derivatives (448). Gal 
& Brazier discovered 24% carriage of nim genes amongst Bacteroides spp., with 
11.6% displaying resistance above therapeutic levels (>16 mg/L) (451). However, 
they did also indicate that seven isolates not carrying the nim genes were 
resistant to 5 mg/L, suggesting alternative mechanisms, such as decreased 
uptake or increased efflux.  
Nitroimidazole resistance is multifaceted, and since analysis of metronidazole 
resistance in C. difficile presented no evidence of nim genes (452, 453), other 
mechanisms must be considered. In C. difficile, Lynch et al. identified mutations 
in the nifJ, fur and rsbW genes, encoding for part of the PFOR pathway, 
regulation of ferric uptake and an anti-sigma factor, respectively (454). These are 
involved in bacterial stress reactions, potentially reducing oxidative stress and 
nitroimidazole activation (455). Disruption of electron transport pathways (456), 




all been implicated in reduced susceptibility to metronidazole in other 
organisms, although these are yet to be reported in C. difficile. 
A recent series of work from Wu & Hurdle et al. suggested a strong correlation 
between stable metronidazole resistance and presence of heme in C. difficile 
cultures (459). They demonstrated resistance instability by reducing 
metronidazole MICs from ≥8 mg/L to between 1-2 mg/L, via simple passage (460). 
The addition of heme maintained the resistant phenotype in vitro. Not only this, 
but the group were able to demonstrate the association, both through a 
reduction in MIC with the exclusion of hemin from growth media and the 
dramatic increase in MIC in its presence. Ribotype 027 strains were specifically 
influenced by hemin inclusion in culture media, with 4-10-fold increases in 
metronidazole MIC observed (459). The group went on to test hemin metabolite 
action on metronidazole MIC, indicating no correlation between resistance and 
the presence of hemin breakdown products (Biliverdin, Protoporphyrin IX, 
Bilirubin and FE3+), only evidencing a correlation with the complete hemin 
molecule. One hypothesis is that hemin may be acting as a co-factor for an 
unknown enzyme. Further work is required in this area to identify the potential 
involvement of iron regulatory genes, nifJ, feoB and Iscr (460). Emerging research 
from Smits et al. has implemented in silico analyses to find a correlation between 
the presence of a pCD630 plasmid and a metronidazole resistant phenotype (461). 
 
1.7.3 Glycopeptides 
1.7.3.1 Mechanism of action 
As a primary treatment option for CDI, vancomycin is the key glycopeptide of 
interest when considering resistance in C. difficile. Its mechanism of action 
involves interfering with the process of cell wall biosynthesis via the binding of 
this bulky molecule to ᴅ-Ala-ᴅ-Ala peptidoglycan precursors, physically blocking 
the transpeptidation process (462). Without this cross-linked formation the 
nascent cell’s rigidity is absent and it cannot survive intra cellular pressures. 
1.7.3.2 Mechanism of resistance 
The high specificity of the glycopeptide class of antimicrobials allows for a 




resistance acquisition is difficult. Vancomycin does not directly target the cell 
wall biosynthesis enzymes, its efficacy comes from effecting the substrate 
specificity of peptidoglycan precursors synthesising enzymes (463). Therefore, 
resistance to this class is determined by gene clusters working to simultaneously 
synthesise modified precursors and eliminate pre-existing high-affinity peptides 
(464). A VanH dehydrogenase enzyme, usually located on a Tn1546 transposon, 
reduces pyruvate to ᴅ-Lac, while VanA ligates this to ᴅ-Ala to generate the 
modified precursor (464). Different configurations of van genes have been 
identified among other genera (465-467), where similar mechanisms generate 
variant precursors containing ᴅ-Ser or ᴅ-Ala components. Simultaneous activity 
of a ᴅ-ᴅ-dipeptidase encoded by vanXY genes results in the removal of usual 
precursors, subsequent uptake of modified peptides and an intermediate 
resistant phenotype. 
In C. difficile a vanG-like cluster was identified in the 630 reference genome, 
containing five open reading frames, vanR, vanS, vanG, vanXY and vanT (314). 
However, no resistant phenotype was observed. Later Amman et al. 
demonstrated the functionality of this operon, identifying the presence of 
modified precursors (468). Whilst it is unclear why these do not lead to 
phenotypic expression, the lack of regulatory genes may be contributory.  
 
1.7.4 Rifamycins 
1.7.4.1 Mechanism of action 
The rifamycins class originates from the fermentation product of Amycolatopsis 
mediterranei, rifamycin B (469). Rifampicin and rifaximin are semi-synthetic 
derivatives of this natural product with increased antimicrobial activity. The 
mechanism of action they employ involves inhibition of RNA synthesis through 
allosteric hindrance of polymerase activity. Physical binding to the β sub-unit of 
RNA polymerase blocks phosphodiester bonding early in the elongation process 
of the RNA back-bone, effectively inhibiting the synthesis of essential bacterial 






1.7.4.2 Mechanism of resistance 
As with fluoroquinolones, rifamycin resistance generally arises from mutational 
events reducing the binding affinity of the antimicrobial agent and target 
molecule, RNA polymerase (471). Several studies have reported over 20 SNP 
variations in the 350bp rpoB gene of C. difficile, in direct correlation with 
rifamycin resistance (444, 474-477). Studies by Huhulescu et al., Curry et al. and 
Pecavar et al. all identified Arg505>Lys as the predominant sequence variant, in 
74%, 48% and 46% of resistant strains, respectively (475-477). Combinations of 
multiple SNPs in the rpoB gene were also reported by these groups, with the 
majority located within a “hot spot” region of rpoB (477). The mechanism was 
further delineated through the use of X-ray crystallography, which identified the 
proximity of key RpoB amino acids and the rifamycin binding pocket (473).  
Since the presence or absence of an rpoB mutation directly affect susceptibility 
phenotype, the distribution of susceptibilities to this class of antibiotics is 
generally reported as bimodal (478, 479). Whilst geographic bias impacts resistance 
epidemiology, due to over-use of rifamycins in certain countries (480), often 
epidemic ribotypes reveal rifampicin resistance (474, 475).  
C. difficile research identifies a strong correlation between resistance to 
rifampicin and rifaximin, once considered for its potential as an alternative CDI 
treatment option (474, 476). One in vivo study reported the rapid development of 
rifaximin resistant C. difficile in a patient exposed to rifampicin (481). 
Furthermore, a rifampicin resistant, ribotype 046 clone has also been implicated 
in an outbreak amongst tuberculosis patients in Poland (482). Interestingly, seven 
out of eight patients exposed to a rifamycin in one North American study 
harboured resistant strains (475). 
 
1.7.5 Tetracyclines 
1.7.5.1 Mechanism of action 
Antimicrobials of the tetracycline class function via protein synthesis inhibition. 
By binding to a single, high affinity site of the 30S ribosomal subunit, they 





1.7.5.2 Mechanism of resistance 
The mechanism of resistance to tetracyclines revolves around ribosomal 
protection. Resistant determinants were first discovered in Streptococci spp. 
(now E. faecalis), indicating that tetM genes express a soluble protein, which 
protects the ribosome, preventing translation interference and protein synthesis 
inhibition (484). The majority of tetracycline resistance determinants have been 
demonstrated to reside on mobile elements (485). 
Tetracycline resistance in C. difficile is usually mediated by tetM genes found on 
conjugative transposons (486-488). The most prevalent of these mobilisable 
elements is Tn916 (487, 488). Nonetheless, reports of tetM positive isolates that are 
susceptible to tetracycline suggest a more complex relationship between genes 
and phenotype (201, 489). Interestingly, Spigaglia et al. identified confluent 
resistance in strains containing the Tn5397-like determinant, whilst those 
harbouring Tn916 exhibited a spectrum of susceptibilities. Wang et al provided 
the first reported instance of a clinical C. difficile strain containing the Tn916 
insertion (490). The discovery of this transposon in S. aureus, Enterococcus spp. 
and Streptoccocus spp. suggests that transfer is highly likely to occur between a 
range of organisms, widening the potential sources for clostridial acquisition 
(491).  
The use of cryo-electron microscopy to study the detailed interactions of 
tetracyclines and TetM, ribosomal protection proteins indicated potential 
interactions between the C-terminal of the TetM protein and 70S ribosomal 
subunit (492). Further interactions with the 16S rRNA binding site, leading to 
conformational changes and eventual drug release from the active site were 
observed. Contemporary research furthered this work by imaging the complex 
during translation (493), reporting no alteration of nucleotide C1054, as 
previously proposed (492).  
 
1.7.6 Resistance to other antimicrobial classes 
Resistance to chloramphenicols in C. difficile is often mediated by a catD gene, 
encoding for a chloramphenicol acetyltransferase (494). Carried on a Tn4435a or 




molecules, effectively inhibiting its complex formation with the ribosome (495). 
This gene has been found in combination with other mobile genetic elements, 
such as ermB and tetM, and is typically lineage associated (496). 
β-Lactam compounds such as agents in the cephalosporin class, act upon the 
penicillin binding proteins during cell wall synthesis. Resistance to this action is 
associated with the production of β-Lactamases, which hydrolyse the β-Lactam 
ring and degrade the antibiotic (497). Several putative β-Lactamase genes have 
been identified in C. difficile, but at present no functional activity has been 
determined (498). 
 
1.7.7 Antimicrobial susceptibility testing methodologies 
In vitro susceptibility testing provides a valuable prediction of bacterial 
response to antimicrobial compounds in clinical settings. MIC data can be used 
as an indicator of novel agent efficacy or as essential surveillance to track the 
intrinsic levels of susceptibility of an organism. Although the Clinical and 
Laboratory Standards Institute (CLSI) recommend the agar dilution technique 
for anaerobes (499), there are multiple methodologies in use across clinical and 
research settings. Whilst considered as the “gold standard” method, agar 
dilution is laborious and time consuming, making it unsuitable for routine 
analysis of clinical specimens (500). Nonetheless, comparisons of more rapid 
methods, such as Etest and disk diffusion, have identified discrepancies between 
MIC findings. In support of previous findings (501), a recent comparative study 
demonstrated a negative bias for MIC data generated using a broth 
microdilution method, as opposed to agar dilution (500), also observing poor 
reproducibility of the former technique. Conversely, Igawa et al. demonstrated 
concordance between the methods, when testing a panel of Japanese isolates 
(502). This serves to highlight the ambiguity of method accuracies. Whilst 
discrepant disk diffusion and Etest results have incited debate as to where the 
resistant breakpoints should lie, due to the subjective nature of zone boundaries 
(503), research has demonstrated their inferiority to agar dilution methods (187, 
504). Despite the fact that comparisons largely favour the guideline method, there 
remains a debate as to which is the optimal agar for C. difficile testing. Baines et 




(187), whilst others have supported the notion of differing media constitution 
affecting growth density and the generation of variable results (503, 505). Use of 
Wilkins Chalgren agar has been demonstrated to display greater reproducibility 
over Brucella agar (187), and has been used successfully in a major European 
surveillance study (188). 
 
1.7.8 Multidrug resistance 
1.7.8.1 Epidemiology 
A consortium, comprising of experts from both the European Centre for Disease 
Prevention and Control (ECDC) and the Center for Disease Control and 
Prevention (CDC) outlined standardised definitions of multidrug resistance (506). 
In these guidelines the development and acquisition of resistance to three or 
more antimicrobial classes was defined as multidrug resistance (MDR). 
Resistant organisms were further delineated as extensively drug-resistant 
(XDR), where resistance is demonstrated to all but two antimicrobial classes and 
pan drug-resistant (PDR), where non-susceptibility to all of the agents tested is 
observed. (506).  
Large scale surveillance studies have begun to highlight the extent of the 
problem in C. difficile (188, 444). The Clostridium difficile European Resistance 
(ClosER) study indicated the predominant MDR strains as PCR ribotype 001, 
017, 012 and 027, in agreement with Spigaglia’s research demonstrating the 
former three types as 39%, 18% & 12% of all MDR isolates, respectively. 
However, no ribotype 027 isolates were reported in the latter work, possibly 
due to a small collection period in this prospective study. The ClosER study also 
highlighted regional prevalence, with high levels of MDR linked to the related 
ribotype 018 and emergent ribotype 356 strains in Italy. Further work by 
Freeman and colleagues expanded the antibiotic test panel of the ClosER study, 
indicating that ribotypes previously linked to MDR (including ribotype 027) also 
displayed resistance to linezolid and/or ceftriaxone (225). Adding additional 
concern, these already MDR ribotypes demonstrated the highest MICs for 
fidaxomicin and a novel treatment compound (SMT19969). This strengthens the 
suggestion of the presence in specific ribotypes of determinants that are able to 




Where Spigaglia’s surveillance reported almost 50% of 316 European clinical C. 
difficile isolates as resistant to at least one antibiotic, 54 isolates displayed 
resistance to two antimicrobials, whilst 82 were resistant to three or more (444). 
Of these, 39 (12% of total) showed resistance to four different classes, 
lincosamides, macrolides, fluoroquinolones and rifamycins. A recent review of 
12 studies encapsulating 370 MDR isolates, indicated class prevalence in these 
strains, with combined clindamycin, erythromycin and fluoroquinolone 
resistance comprising almost 30% of all MDR (507).  
Recent large scale, retrospective surveillance across >7,000 inpatients indicated 
C. difficile as the most frequently reported MDR pathogen (1.66%) (508). As the 
principal aetiological agent of antibiotic-associated diarrhoea, development of 
MDR in C. difficile has important implications with regards to the instigation of 
infection. However, resistance to multiple classes of antimicrobials implicates 
complex mutational and transposable mechanisms, many of which remain 
unidentified.  
1.7.8.2 Mechanisms 
The factors involved in expressing resistance are multifaceted (Figure 3), with 
numerous elements often working in synergy. Conformational changes in a 
drug’s target site, along with antibiotic structure altering enzymes, often work in 
combination with mutable influx and efflux determinants (509). Although not fully 
understood, several of these multiple resistance mechanisms have been 






Figure 3: Antibiotic resistance mechanisms overview. Created by J. Vernon 
 
1.7.8.2.1 Erythromycin resistance methylase (erm) genes 
The primary determinants implicated in the cross-resistance of the macrolide-
lincosamide-streptogramin B (MLSB) classes of antibiotics are the erythromycin 
resistance methylase genes; erm (444, 489, 510). Whilst most Erm determinants are 
genus specific, ermB is widespread throughout bacterial genera and are 
reported extensively in C. difficile populations (511, 512). Ribosomal RNA 
methyltransferases encoded by erm genes, methylate the adenine residue at 
position 2058 of the 23S rRNA molecule, part of the 50S ribosomal unit (513-515). 
This effectively blocks antibiotic binding complexes forming and allows DNA 
synthesis to proceed as normal. Since the active sites for MLSB antimicrobials 
overlap, resistance can develop simultaneously for multiple agents (514).  
Surveillance studies have reported ermB frequencies of 28% and 19% in 
European and American C. difficile isolates, respectively (444, 510). With all isolates 
demonstrating the cross-resistant phenotype to erythromycin and clindamycin 
(444). The widespread distribution of these resistance determining elements 
suggests that genetic transfer is rife amongst C. difficile populations. Early work 




Tn5398, demonstrating the capability for bi-directional genetic transfer, but 
lacking the excision and integration genes necessary for independent 
conjugation (516, 517). Nonetheless, Wasels and colleagues later successfully 
implemented conjugation assays with these mobilisable elements, 
demonstrating the potential of genetic transfer in the absence of plasmid DNA 
(518). Furthermore, one recently identified arrangement of ermB determinant, 
Tn6215, has been demonstrated as bacteriophage mediated (519). Interestingly, 
transconjugants have been demonstrated to suffer from a fitness cost associated 
with the insertion of ermB carrying transposons (518). Those strains harbouring 
the transduced DNA exhibited significant growth deficiencies, although it cannot 
be discounted that this was due to insertional site disruption. 
Seventeen genetic variants of the ermB arrangement have been reported to date, 
termed E1 – E17 (444, 489, 517). The most prevalent ermB variant is reportedly 
transferred on the Tn6194 conjugative transposon (444, 520). Interestingly, the 
MLSB resistant, CD630 genome contains two copies of the ermB gene on a 
Tn5398 transposon, a novel arrangement proposed to be the product of 
homologous recombination (517). Whilst no direct correlation between genetic 
arrangement and PCR ribotype have been identified (444), the E2 arrangement 
demonstrated resistance to a lesser extent (489).  
Although ErmB elements appear to drive the majority of MLSB resistance in C. 
difficile, repeated findings of erythromycin and clindamycin resistant strains in 
the absence of erm elements are apparent (444, 521-523). These underline the 
potential contribution of other mechanisms in the expression of this resistance 
phenotype, such as efflux and mutation of the 23S rDNA target (521, 524).  
1.7.8.2.2 Chloramphenicol-florfenicol resistance gene 
Resistance to the phenicols, lincosamides, oxazolidinones, pleuromutilins and 
streptogramin A (PhLOPSA) group of antimicrobials is associated with the 
presence of a chloramphenicol-florfenicol resistance gene, cfr (525, 526). First 
observed in Staphylococcus scuiri (525), this MDR determinant expresses a 
methyltransferase, leading to the methylation of the A2503 residue of the 23S 
rRNA sub unit. Since the target of these antimicrobial classes overlap, a simple 
methylation interferes with drug binding and allows synthesis to proceed (527). 




C. difficile, with direct associations with a concurrent linezolid and 
chloramphenicol resistant phenotype (528-530). 
Whilst oxazolidinone insusceptibility is rare in C. difficile, resistant strains have 
been reported (225, 444, 531). Marin’s study of Spanish strains revealed seven of the 
nine linezolid, clindamycin and chloramphenicol resistant strains harboured a 
cfr-like gene (528), with findings reinforced by the absence of a cfr gene in ten 
susceptible strains. This gene indicated 89% sequence identity with cfr elements 
from Bacillus amyloliquefaciens, suggesting a similar epigenomic modification in 
clostridia. Equally, the absence of point mutations/deletions in the 23S rRNA sub 
unit, indicated that, although linezolid resistance is often caused by this, 
additional mechanisms, such as cfr genes must be involved.  
Later designated as Tn6218, due to its mobilisable characteristics, cfr 
demonstrated a concrete relationship with the PhLOPSA resistant phenotype 
through its expression in E. coli and insertion/deletion in a C. difficile genome 
(529, 532). Confirmation of the cfr homologue’s expressed function was indicated 
through significantly elevated MICs and the indication of both methylation at 
A2503 and reduction at the Cm2498 stop codon. 
Contemporary research has indicated the presence of a novel cfr-like gene, 
cfr(C), and a direct correlation with PhLOPSA resistance (530). Whilst ten percent 
of C. difficile isolates and seven percent of genomes analysed in silico harboured 
this gene, it is primarily found in other commensal gut bacteria (533). Ultimately, 
these plasmid mediated cfr genes demonstrate high potential for dissemination 
and the expansion of problematic MDR strains (534). 
1.7.8.2.3 Efflux pumps 
Efflux pumps are active transporters, requiring chemical energy to transport 
toxic compounds including antibiotics across the cell membrane and out of the 
cell. These transmembrane pumps are grouped into two main categories, 
primary ATP-binding cassettes (ABC) and secondary multidrug transporters. 
The former rely on the hydrolysis of ATP to provide energy for transport, whilst 
the latter generate a difference in electrochemical potential by pumping ions in 




electrochemical gradient, either out (uniporters/symporters) or in and out 
simultaneously (antiporters) (536, 537). 
Efflux pumps are a major factor associated with MDR in prokaryotic cells (537). 
Where some transporters mediate the extrusion of a specific class of drug, 
others are able to efflux multiple, structurally unrelated compounds. Therefore, 
these multidrug transporters are of major interest in the identification and 
treatment of MDR infection.  
It is not only the presence of efflux encoding genes that must be considered. 
Mutations in these sequences have been demonstrated to reduce antimicrobial 
susceptibility in other organisms (538, 539), whilst adaptation to environmental 
stimuli, such as pH and iron availability have been reported to affect expression 
regulation (540, 541). 
1.7.8.2.3.1 Major facilitator superfamily (MFS) 
The major facilitator superfamily group consists of several subgroups, including 
the multi antimicrobial extrusion protein superfamily (MATE), small multidrug 
resistance family (SMR) and resistance nodulation cell division superfamily 
(RND) (536). To date, there is no evidence of the latter two subgroups in C. difficile 
reported in the literature. 
All MFS efflux pumps consist of membrane proteins involved in uniport, symport 
and antiport. These efflux processes are divided into two main categories, those 
with 12 transmembrane segments (TMS) and those with 14. Within the 12-TMS 
cluster, the S. aureus protein NorA has been implicated in resistance to 
hydrophilic compounds, such as antimicrobials from the fluoroquinolone and 
methicillin classes (542, 543). Further work by Neyfakh et al. suggested that NorA 
mediates resistance to a range of structurally diverse drugs in S. aureus with 
structural homologues identified in other species, including B. subtilis (544, 545).  
Lebel et al. observed five ORFs in C. difficile with homology to NorA 
determinants, transforming the cme gene into E. faecalis to demonstrate a link 
between its expression and erythromycin resistance (546). Equally, the use of 
reserpine, an efflux pump inhibitor, facilitated enhanced resistance to ethidium 




the cme gene in one draft C. difficile genome was putatively identified as the 
cause of erythromycin resistance (548). 
1.7.8.2.3.2 Multi antimicrobial extrusion protein superfamily 
The first multidrug transporter determinant reported in C. difficile was cdeA (509). 
Dridi et al. determined that this gene encoded a protein with homology to 
known proteins from the MATE family of efflux pumps present in other 
organisms. Through PCR detection methods, this work highlighted that cdeA is 
present in the majority of C. difficile strains (509).  
Research has indicated that MATE family proteins are Na+ coupled efflux pumps, 
dependent on the presence of sodium for transportation (549, 550). Dridi’s group 
confirmed this with CdeA, by observing weak efflux activity in the absence of Na+ 
and an eight-fold increase in its presence (509). Although cdeA harbouring strains 
demonstrated high levels of efflux for ethidium bromide, the extrusion of 
ciprofloxacin and norfloxacin remained low. However, by overexpressing the 
protein with the Plac promotor driving the transcription, resistance to 
ciprofloxacin and norfloxacin increased. Therefore, mutations in the cdeA 
regulatory gene have the potential to markedly increase resistance to 
fluoroquinolones.  
Further mechanisms have been determined in other organisms. The norM gene 
of Vibrio parahaemolyticus has been identified, along with its homologue in E.coli 
(ydhE), as encoding an energy dependent efflux system (551). These mediate 
resistance to hydrophilic fluoroquinolones and aminoglycosides. Nonetheless, 
although NorM has 12 transmembrane segments, which would generally classify 
it as part of the major facilitator superfamily, no other similarities in sequence to 
this family were determined. 
1.7.8.2.3.3 Multiple antibiotic resistance (mar) gene 
Although not clearly defined in C. difficile, the mar regulon, consisting of 
transcriptional regulators, influences resistance to a plethora of compositionally 
diverse compounds, including antimicrobials, organic solvents and disinfectants 
(552). Associations have been determined between the mar locus in E.coli and 




chloramphenicol, cephalosporins, rifamycins, tetracyclines, fluoroquinolones 
and penicillins (553).  
The sequence of this multiple antibiotic resistance locus has revealed the 
involvement of a series of fundamental regulatory genes in both E. coli and 
Salmonella typhimunium (554). Martin & Rosner first described the involvement of 
MarR, a repressor that binds to the operator, MarO (555). This down regulates 
expression of the repressor itself and MarA, a regulator in efflux mechanisms 
and outer membrane proteins. Therefore, mutations in the repressor gene, 
marR, result in inactivation and subsequent expression of marA. The multiple 
resistance phenotype occurs due to marA up-regulation of a series of genes 
involved in the activation of the AcrAB efflux pump, coupled with the down 
regulation of outer membrane protein F (556, 557). 
Cohen et al. indicated a propensity for E. coli strains containing mutations in the 
mar loci to have a lower susceptibility to fluoroquinolones (558). By identifying a 
4-8-fold decrease in fluoroquinolone susceptibility in mar mutants, when 
compared to an OmpF only mutant, they highlighted the involvement of other 
resistance mechanisms. Underlining the impact of non-gyrase or topoisomerase 
gene mutations on fluoroquinolone resistance, Kerr and colleagues described up 
to a ten-fold decrease in fluoroquinolone susceptibility in strains containing 
both gyrA and mar mutations in E. coli (559). This highlights the potential for the 
mar gene to impact heavily on multiple antimicrobial resistance, compounding 
existing prevalent mechanisms. 
There is a paucity of data available relating to mar genes in C. difficile, but the 
presence of MarR encoding genes have been identified in the 630 genome (560).  
Although the C. difficile marR gene has reported low sequence similarities with E. 
coli and S. aureus marR genes, investigation of its crystal structure identified 
highly similar dimer structures (560). One recent investigation into fidaxomicin 
resistance in the organism, through in vitro induction by serial passage, 
identified a mutation in a marR homologue (213). Discovered in a laboratory 
mutant displaying a 64-fold increase in fidaxomicin MIC, the homologue 
exhibited a deletion in CD22120 resulting in a frame shift after amino acid 117 
of the mar loci. This significant finding implies the presence of non-RNA 




phenotype. Nevertheless, no direct evidence of resistance to other antimicrobial 
classes was reported to correlate with the mutation at CD22120. 
1.7.8.2.3.4 ATP-binding cassette superfamily (ABC) 
There are currently no reports of ABC transporters present in C. difficile, but 
work by Harnvoravongchai and colleagues suggested that expression of E. coli 
primary transporter genes in C. difficile reduced susceptibility to several 
compounds (535). 
1.8 C. difficile evolution 
1.8.1 Evolutionary analysis methodologies 
Epidemiological distributions and C. difficile strain transmission are routinely 
investigated using several well defined genotyping methods; PFGE, REA and PCR 
ribotyping (360). Where further strain differentiation is required, more advanced 
genomic techniques, such as MLVA prove valuable (371, 561). However, since the 
rapid progression of NGS technologies, high throughput apparatus has brought 
affordability and widespread accessibility to near complete genomic sequences. 
Subsequently, analysis of species phylogeny has enabled a greater 
understanding of bacterial evolutionary lineages (562-564). 
 
1.8.2 Phylogeny 
Comparative analysis of the C. difficile genome has demonstrated the existence 
of at least eight phylogenetic clades (2, 375, 564, 565). Clade 1 represents a highly 
heterogeneous collection of clinically relevant strains; clade 2 includes the 
hyper-virulent PCR ribotype 027 as well as closely related ribotypes 176, 198 
and 244 (566), clade 3 includes RT023, whilst clade 4 comprises the atypical toxin 
B only type, RT017 (564). Reported by Griffiths and colleagues (375), the fifth clade 
includes the genetically distinct, binary toxin producing, RT078, which has been 
linked to zoonotic transmission (567). The final clades, C-I, C-II and C-III consist of 
rare, environmental, often non-toxigenic strains of even greater genetic 
distinction than clade 5, potentially considered as novel subspecies of C. difficile 




Evolution occurs through mutational or transposable alterations to a genome 
that do not significantly disrupt the core survival processes of the mutant. Since 
mutation rates for the C. difficile genome have been determined to lie between 
0.74 and 1.4 SNPs per genome, per year (257, 569), it is apparent that major 
genomic evolution is likely to be driven by transfer of large coding sequences. 
A study of 75 representative strains covering clades 1-4 demonstrated that only 
19.7% of genes were homologous throughout all C. difficile isolates, comprising 
those responsible for essential cell processes, such as metabolism and 
replication (564). Since around 11% of the comprehensively annotated 630 
genome consists of mobile genetic elements, indicative of longitudinal 
interactions with gut microbiota (314), it can be concluded that the C. difficile 
genome is highly adaptable to change. With a genome over 40% larger than 
closely related clostridia (up to 4.3kb) and variability amongst core coding 
sequences (570), it is highly suited to adaptation and species survival (571, 572). In 
support of this notion, the C. difficile pan-genome has been conservatively 
estimated to contain 9,640 coding DNA sequences (573), suggesting ultra-low 
levels of conservation.  
Such diversity in the C. difficile gene pool suggests an abundance of horizontal 
gene transfer, affecting evolutionary change. Whilst investigating the 
evolutionary dynamics of C. difficile, He and colleagues identified large coding 
regions distinctly unrelated to C. difficile origins, as well as determining that the 
majority of SNPs were limited to distinct areas of the genome. These findings 
potentially signified large fragments of homologous recombination, up to 300kb 
(563). In assessing the relative ratio of recombination and mutation, they 
determined a moderately high ratio, supporting the concept of homologous 
recombination asserting a substantial effect on genome expansion. Analysis of 
the PaLoc of 1,693 C. difficile isolates strongly supported this hypothesis, 
highlighting 26 independent evolutionary events of acquisition or loss of full loci 
and the involvement of homologous recombination in this species’ evolution 
(565). The actions of bacteriophages are likely to contribute to extensive 





1.8.3 PaLoc evolution 
Investigation of the PaLoc indicated high conservation of this operon, essential 
to disease potential (565). Similar phylogeny of this region across PCR ribotypes 
indicated evolution post-clade divergence, strongly suggesting the involvement 
of homologous recombination between clades. Similarly, evidence of related 
tcdA and tcdB genes in other clostridia suggests the strong probability of the 
contribution of inter-species transfer on the C. difficile pangenome (574). 
 
1.8.4 Molecular clock 
The determination of a theoretical rate of evolution is essential to the 
phylogenetic analyses of any organism. Approximations of the number of 
mutational events per genome, per year allow lineages to be approximately 
dated and transmission events to be linked through microevolutionary analyses. 
Based on Bayesian phylogenetics, for C. difficile the number of SNPs has been 
estimated at between 0.74 and 1.4 per genome, per year (257, 562, 569, 575). This 
figure correlates strongly with other bacterial species (576).  
A key factor potentially affecting the accuracy of C. difficile molecular clock 
calculations is the time spent in the quiescent spore form (569). This state of 
evolutionary suspension is difficult to assess, potentially impacting the mutation 
rate, leading to a substantial underestimation. Nonetheless, the rate applied in 
any given investigation must be carefully considered, as several factors could 
impact on the analysis. Short term estimates of the molecular clock, calculated 
through the sequencing of serial samples, have demonstrated rates elevated 
above historical approximations (563, 576, 577). Whilst short-term rates are useful 
for microevolutionary analysis of transmission, extrapolations of these 
estimates may lead to inaccurate long-term rates. Also, the emergence of 
recombination events must be considered, so not to vastly overestimate the SNP 
rates (569). Software algorithms are available to include variable elements, such 







1.8.5 PCR ribotype 027 evolution 
The evolution of PCR ribotype 027 is of acute interest to enable a greater 
understanding of the important genetic alterations that have led to the 
emergence of hyper-virulence. Phylogenetic analysis has suggested that this 
ribotype experienced a population expansion period around the turn of the 
century, with evidence of horizontal gene transfer across multiple points of 
phylogeny (563). This was demonstrated through evidence identifying 
complementary SNPs between isolates with large evolutionary distances. 
Comparisons of whole genome sequences between modern, epidemic and 
“historic”, non-epidemic 027 strains have indicated five large genomic regions of 
difference, suggesting recent acquisitions in evolutionary terms (579). However, 
no genetic differences were identified in the PaLoc between 027 isolates from 
pre or post outbreak eruption of 2003 (562). This lends greater weight to the 
argument that excess fluoroquinolone use and subsequent resistance in this 
ribotype was the major influential factor driving its emergence (99, 417). He’s study 
utilised maximum-likelihood models and Bayesian statistics to strongly indicate 
the presence of two main lineages for PCR ribotype 027, both acquiring 
Thr82>Ile mutations through separate evolutionary events, leading to 
fluoroquinolone resistance. Offering the nomenclature of FQR1 and FQR2, He 
and colleagues discovered that FQR1 originated in North-East USA, whereas 
FQR2 was more widespread across Canada and North America, and was the 
source of international dissemination of the original outbreak. Similar patterns 
of lineage divergence have recently been determined in the toxin B only 
ribotype, 017 (580).  
Additionally, transcriptomic analysis of different strains in a murine model of 
infection has highlighted the differential expression of C. difficile genes (581). The 
well characterised 027 strain, R20291 demonstrated upregulation of different 
genes to CD630 (PCR ribotype 012), including many proteins of unknown 
function, which may have involvement in the success of this strain. This finding 
correlates with the previous discovery of several point mutations upstream of 
coding sequences in ribotype 027 isolates (564). All of these findings further 





1.8.6 C. difficile mutation 
1.8.6.1 Spontaneous mutation 
Mutations are spontaneously occurring, permanent modifications in the 
nucleotide sequence of DNA. Any mutational event has the potential to alter the 
translational output of amino acid chains and result in divergent phenotypes. 
This capacity for the generation of genetic variation is crucial for bacterial 
populations to survive changeable environments and exogenous stresses. As 
conventional DNA replication occurs, errors will arise in the base pairings 
created by DNA polymerase enzymes. Internal DNA repair systems ordinarily 
correct these mistakes, but not with 100% efficiency (582). Spontaneous 
mutagenesis is understood to be a product of leakage through the error repair 
pathways resulting in these errors being permanently incorporated into the 
bacterial genome. (583)  
The fundamentals of evolution dictate that under stable conditions, bacterial 
genomes will spontaneously mutate at a given rate, which is generally accepted 
to lie between 10-9 and 10-10 mutations per genome, per generation (584). The 
natural variation in mutagenesis rate is dependent on a multiplicity of factors, 
including organism and environment (585). In the in vivo experiments by Giraud 
et al., population dynamics within a murine model were shown to affect the 
mutation frequency (585). When the environment remained stable and bacterial 
populations thrived, mutation frequencies were low. In contrast, the presence of 
exogenous stressors or environmental pressures elevated mutant generation 
rates. Since spontaneous genomic mutations are considered to be stochastic, 
with no bias toward advantageous changes (586), increased mutagenesis in stable 
populations has the potential to disadvantage the population through increased 
risk of introducing deleterious effects. Conversely, where populations are under 
threat, an increased mutation rate presents the opportunity to generate 
beneficial adaptations and survive the “selective bottleneck” (585, 587, 588). 
One key external stressor implicated in increased formation of bacterial 
mutations that has been well reported in the literature, is exposure to 





1.8.6.2 Mechanisms (DNA SOS, mut genes, mismatch repair) 
Bacterial SOS response was first outlined over 40 years ago, with further 
elucidations of precise mechanisms following (592). LexA and RecA have long 
since been recognised as the key proteins involved in bacterial SOS response, 
protecting the stability of the genome (593). LexA is a transcriptional regulator, 
which binds to DNA sequences near gene promotor regions, obstructing RNA 
polymerase and the transcription of SOS response genes. RecA acts as the 
inducer protein, cleaving LexA and enabling cell survival responses, such as 
increased mutagenesis. These genes are ubiquitous in the bacterial kingdom, 
with homologues identified across most species (594). Whilst studies have 
reported mechanisms in other clostridia (595, 596), minimal evidence has been 
reported in C. difficile. Walter and colleagues have undertaken comprehensive 
analyses of this mechanism, identifying its role in a host of crucial pathways, 
including sporulation, biofilm formation and sensitivity to antibiotics (597, 598). 
They discovered amino acid substitutions amongst a collection of strains, but 
none were associated with the active site. Interestingly, they determined that 
LexA disassociation from recA genes was twenty times slower in C. difficile than 
that of E. coli equivalents. This indication of late expression of key SOS genes was 
deemed suggestive of C. difficile potentially prioritising upregulation of other 
stress response genes, located on the same regulon, such as those involved with 
transporters and sporulation (598).  
The bacterial methyl-directed mismatch repair (MMR) system is also 
understudied in C. difficile, but mutS/mutL operon knockouts have 
demonstrated an increased mutability in other clostridial strains (599). One C. 
difficile focussed study discovered high conservation of the MMR genes across 
genomes (573), whilst Eyre and colleagues discovered comparable data (600). 
Nonetheless, any evidence of genomic differences in these loci may lead to 
reduced stability of the genome and high rates of mutation, as observed in other 
genera (582, 589, 601). 
The hfq gene is pleiotropic in nature, demonstrating effects on multiple core 
processes, including sporulation, growth rate and stress response (602). Its 
involvement in the unification of small RNAs and mRNA targets has 




other organisms has provided evidence of differing stress responses and 
therefore may have involvement in mutation propensity (603). 
1.8.6.3 Antimicrobial mutagenesis 
The principal mechanisms of antibiotic resistance are the presence of 
endogenous mutations in active target sites, drug uptake/efflux systems and 
exogenous horizontal gene transfer of resistant determinants (604, 605). Since 
hypermutable strains demonstrate inefficiencies in DNA repair systems and 
increased capacities for inter-species gene transfer (588, 606), the potential for 
these phenotypes to promote MDR is vast. Consequently, the study of these 
hypermutable strains can be extremely valuable in researching worst case 
scenarios for resistance acquisition. 
Ground-breaking work by Mao et al. demonstrated the potential of mutagenesis 
associated with a single selection stage, with mutator proportions elevated from 
0.001% to 0.5% (607). Miller et al. demonstrated large increases in mutant E. coli 
generation with independent exposure to both rifampicin and ciprofloxacin (608). 
Since development of resistance to both of these compounds require only a 
single point-mutation in either rpoB or gyrA respectively; mutant phenotypes 
are likely to occur. Nonetheless, they also indicated that resistance to 
antimicrobials requiring mutations in multiple target regions (cefotaxime & D-
cycloserine) were more prevalent in mutator strains than normomutators. 
Although resistance to fluoroquinolones can be demonstrated with single 
mutations, multiple DNA gyrase mutations have been linked to further 
reductions in susceptibilities to this class of antibiotic.  
Studies have shown that increased mutation frequencies of fluoroquinolone 
resistance in other genera are associated with pressure from compounds such as 
salicylate (609). However, research has indicated that, as well as being strain 
dependent, mutational frequencies vary within the class of quinolone agents (610, 
611). Also, the exposure concentration appears to impact the generation of 
mutants, with polarised antibiotic concentrations both demonstrating elevated 
levels of mutation in different organisms (591, 612).  
Stress-induced mutagenesis occurs when damaged DNA is identified by a 
signalling molecule, which initiates a cascade of reactions leading to the de-




stranded DNA acts as the stimulatory element, and is identified by the RecBCD 
enzyme, which activates RecA resulting in LexA cleavage (614). 
The capability of any antimicrobial compound to select resistant, mutant 
progeny is a consideration in its clinical value and dosing practices. Studies have 
demonstrated that selection pressure from exposure to increased 
fluoroquinolone concentrations can lead to increased resistant populations. This 
correlation suggests a link between higher mutation frequencies and exposure 
(615). 
Determination of a compound-dependant, mutation prevention concentration 
potentially minimises resistance development and onward transmission, as well 
as aiding prescribing guidelines. However, since an agent such as moxifloxacin is 
not generally used as a treatment option for CDI, a flaw in the mutation 
prevention contingency may be exposed. Effective treatment of an unrelated 
bacterial infection could potentially lead to the propagation of resistant C. 
difficile populations.  
1.8.6.4 Mutation rate vs mutation frequency 
Mutation frequency and mutation rate have distinctly different definitions, since 
the measureable phenomena they refer to differ in both concept and 
determination. Where mutation rate denotes an estimated probability of the 
number of nucleotide changes over a designated time period, frequency refers to 
acquisition or loss of a specific, quantifiable phenotype, such as resistance to a 
class of antibiotics (589). Since the majority of mutations are likely to occur in 
non-coding DNA regions or result in no expressible differences, the mutation 
rate is not always directly relevant to an evolutionary advantage. Determination 
of an actual frequency of phenotypic expression transformation may be more 
useful when considering clinical impact. Consequently, mutation frequencies 
determined for a designated antibiotic class must only be considered as relevant 
to that specific phenotype. Ultimately, since heterogeneous quinolone 
susceptibilities have been associated with combinations of mutational events in 
gyrA and gyrB regions (616), before even considering other QRDR-independent 
mechanisms, such as enhanced efflux systems, mutation rates are often of lesser 




As all progeny of a mutant cell will carry the same phenotype (disregarding 
reverse mutations at the same nucleotide) standard mutation frequency 
calculations will be wholly dependent on the generation at which the mutation 
occurred. “Mutational jackpots” can arise if a phenotype altering mutation 
transpires in an early generation replication, resulting in an almost entirely 
homogeneous bacterial population reflecting the mutant type (617). In order to 
suppress this potential effect, methodologies have routinely adopted the use of 
multiple biological replicates to generate an average frequency (618, 619). 
1.8.6.5 Mutator strains 
Bacterial strains demonstrating the capacity to mutate at an elevated rate are 
referred to as “mutator” strains and have classically been utilised to aid the 
understanding of DNA error-repair systems (583). Defects in these pathways are 
often reported in mutator strains, resulting in increased mutagenesis (582, 583, 606). 
The MMR system involves the identification of an erroneous nucleotide addition, 
cleavage and correction by DNA polymerase. If any of the mutS, mutL or mutH 
genes involved in the repair process exhibit reduced functionality, then elevated 
mutability (100-1000-fold increase) can been observed (583, 606, 608). Although the 
majority of research into DNA repair systems reflects the E. coli genome, studies 
have identified defective homologues in other genera producing increases in 
mutation rate (620-623). Natural mutator populations amongst E. coli and 
Salmonella isolates have been reported as up to 1% (622, 624), whilst Pseudomonas 
aeruginosa and S. aureus proportions are reported as high as 20% in the 
persistent environment of the lungs of cystic fibrosis patients (623, 625). 
Baquero et al. proposed further delineation of terminology when categorising 
strains of E.coli populations based on their mutation frequencies (582). 
Frequencies in proximity to the modal distribution point (8 x 10-9–4 x 10-8) were 
defined as “normomutable”, with strains with lower and higher mutation 
frequencies termed “hypomutators” and “hypermutators”, respectively.  
Mutators have been demonstrated to confer an early advantage under new 
stress environments (585). However, they are generally accepted to become a 
hindrance when external pressures abate (587, 588). Mutators can lead to 
decreased bacterial fitness through impairment of growth rates, additional 




stable genome is beneficial to a stable population. Constant genetic alteration is 
proposed to maintain the rarity of mutator populations, due to the inevitable 
high proportion of deleterious mutations impacting on strain fitness. This is 
known as Muller’s Ratchet (626). Therefore, it has been suggested that it is 
efficacious for elevated mutation frequencies to be transient in nature and that 
natural populations may lose the mutator phenotype, due to mutational 
reversion or recombination of functioning DNA repair genes (588). SOS repair has 
been implicated as the mechanism involved in transient switching of mutator 
status (627). Transience may negate the deleterious potential of constant 
mutation, enabling survival and stability. 
Research in E. coli suggests an inversely proportional correlation between 
rifampicin resistance and population density, demonstrating reductions in 
density causing a three-fold increase in mutation rate (628). This work has 
highlighted links between the quorum-sensing gene, luxS, and the transitory 
nature of mutation frequencies. 
There is a paucity of research into hypermutability of C. difficile strains. One 
large study interrogated the genomes of 184 PCR ribotype 027 isolates of both 
clinical and in vitro origin documented no evidence of deviations in MMR 
homologues, previously described in other organisms (600). Interestingly, in the 
absence of any classical mutator gene homologues, S. pneumoniae has 
demonstrated 3.4-fold increases in rpoB mutations after ciprofloxacin exposure, 
suggesting the involvement of other unknown mechanisms (618). 
 
1.8.7 Antibiotic resistance and Clostridioides difficile fitness 
The impact of antimicrobial resistance conferring mutations has been 
extensively studied in other organisms, with a particular focus on 
fluoroquinolone substitutions (629-636). However, there is a paucity of data 
investigating their influence in C. difficile.  
Recent work by Kuehne et al. demonstrated the fitness cost of mutations 
imparting fidaxomicin resistance in C. difficile (637). By introducing substitutions 
in the Val-1143 codon of the rpoB gene by allelic exchange, this group observed 




parent strains. This burden upon bacterial fitness could contribute to the 
reasons behind fidaxomicin resistance scarcity in the clinic. Interestingly, 
rifamycin resistance conveying substitutions in other regions of the same gene 
did not impose any burden on fitness in the majority of cases (638). 
Wasels et al. have reported the detrimental effects of the uptake of transferable 
elements, with all isolates receiving a transposon containing the ermB gene 
demonstrating deterioration of growth rates (518). However, crucially, further 
work by the same group reported a lack of fitness cost associated with gyrase 
alterations conveying fluoroquinolone resistance (639). The most common 
chromosomal substitution, Thr82>Ile, demonstrated no impairment to fitness, 
although amino acid replacement of the same codon with valine did indicate a 
significant disadvantage. Although this study focussed on several resistance 
imparting variants, all originated from only one ribotype 012 strain. Therefore, 
more work is necessary to further elucidate the intricacies of the relationship 





Chapter 2 Optimising Clostridioides difficile Germination and 
Recovery Methodologies – The Inhibitory Effect of Glycine 
2.1 Introduction 
Spores are fundamental to C. difficile transmission, but cannot produce the 
toxins necessary for disease. Therefore, germination and subsequent vegetative 
outgrowth are essential to disease aetiology. Consequently, knowledge of 
germination pathways and signalling molecules is important to the optimal 
recovery of this bacteria. C. difficile spore germination mechanisms are gradually 
being elucidated (323, 324, 640), but remain less well defined than that of the model 
organism, B. subtilis. In B. subtilis ger genes act as nutrient germinant receptors 
initiating the germination cascade (343, 641). Since the discovery of an absent 
tricistronic ger receptor operon from the CD630 genome (314), an alternative 
germination mechanism was sought for C. difficile.  
Bile acid components have been strongly implicated in the C. difficile 
germination process, of which taurocholate is the most effective germinant (244, 
315, 316). Notable work by Sorg and Sonenshein revealed a significant increase in 
spore germination in the presence of 0.1% sodium taurocholate, with a 105-fold 
increase observed in broth culture (244). Optimal taurocholate concentrations 
were reported between 0.1-1%, whilst prolonged exposure to low levels 
demonstrated greater germination efficacy than short exposures at higher 
concentrations. They also identified the involvement of glycine, as a germination 
co-factor. By isolating individual nutrient components from the culture media, 
they were able to demonstrate the germination of C. difficile spores in a glycine 
buffer with taurocholate, but not in its absence (244). Further work into the 
influence of physical and chemical factors on C. difficile germination, supported 
this glycine association (331). Other amino acids have also been implicated as 
germination co-factors, with L-alanine, L-histidine and L-serine reported amongst 
compounds increasing the efficiency of C. difficile germination (244, 327, 642). One 
study reported the importance of histidine as a co-germinant, observing 




Nonetheless, germination interactions with bile acid components are more 
complex. The primary bile acid chenodeoxycholate has been demonstrated to 
inhibit C. difficile germination, potentially through direct competition with 
taurocholate for receptor sites (244, 318). Interestingly, primary bile salt analogues 
have demonstrated efficacy as CDI prevention treatments in murine models (643). 
Furthermore, Buffie et al. revealed the concept of a bile acid-mediated CDI 
resistance, highlighting the presence of C. scindens as potentially protective due 
to its bile acid hydrolysing ability (320).  
The most recently proposed model involves bile acid analogues stimulating a 
spore coat-bound pseudoprotease, CspC. This interaction initiates an enzymatic 
cascade comprising a protease, CspB (322), in the activation of a spore lysis 
enzyme, SleC. This reportedly occurs when a small prodomain is cleaved, 
allowing subsequent disruption of the spore cortex. Dipicolinic acid in the spore 
core can then be released in an exchange with water. This process of hydration 
enables the reactivation of spore metabolism and results in vegetative 
outgrowth (323-325). Further additions to the model implicate Ca2+ in the 
activation of CspB (329). Kochan et al. reported an absence of germination during 
in vitro assays deficient in Ca2+, highlighting its involvement in the germination 
mechanism. Co-germinant involvement remains unclear, however, interactions 
between Ca2+, glycine and CspB suggest a co-factor relationship (329). 
Recently, additional characterisation has implicated further genes in C. difficile 
germination, with Fimlaid et al. reporting evidence of the involvement of a GerS 
lipoprotein regulator (307). By observing defective germination and cortex lysis in 
gerS knockout strains they indicated the requirement for GerS in the activation 
of SleC. Furthermore, the gerG gene has been implicated in the incorporation of 
CspA, CspB and CspC into the spore, and thus, the efficacy of germination (644). 
Using strains containing gerG deletions Donnelly et al. highlighted the influence 
of this gene, observing a detrimental effect to both germination efficiency and 
response to germination triggers.  
Recovery of aged spores presents further challenges to C. difficile germination 
investigations. The concept of super dormancy describes bacterial spores with 
attenuated capacities for germination under normal conditions, and has been 




relative notion, where germination environment plays an important role. 
Observations of small proportions of spore populations demonstrating 
superdormancy may represent a risk reducing, non-committal strategy, in case 
the exogenous environment is not tolerable. Spore aging has been related to 
superdormancy in C. difficile, potentially associated with a range of other factors 
linked to longitudinal storage (647). This concept must be considered as a 
potential complicating factor in the attempted recovery of C. difficile spores from 
historical catalogues. 
Optimisation of culture media is essential to the reliable germination and 
recovery of C. difficile, whether for diagnostic or research purposes. Many 
comparisons of culture media, agar and broths, have resulted in a general 
consensus for taurocholate supplementation to increase germination efficiency 
(332, 649-653). Cycloserine-cefoxitin fructose agar (CCFA), cycloserine-cefoxitin egg 
yolk agar with lysozyme (CCEYL) and C. difficile ChromID agars (bioMérieux, 
France) are amongst those widely favoured (332, 342, 654-657). Although 
chromogenic ChromID agar has demonstrated superior sensitivity and recovery 
rates (657-659), deficient detection of ribotype 023 colonies due to an inability to 
hydrolyse esculin indicates a major pitfall with this novel agar (660, 661). A further 
reason for the reluctance to adopt ChromID agar may be because of the high cost 
of these colorimetric plates. The CDRN utilises CCEYL for national surveillance, 
since the addition of lysozyme has been demonstrated to increase the recovery 
rates of environmental samples (342, 363). Enrichment broths, particularly those 
supplemented with germinants have demonstrated beneficial increases in C. 
difficile germination, although a range of broth bases are often used (649, 650, 653).  
While previous studies have indicated the germinant actions of taurocholate and 
co-germinant, glycine (244, 315, 316), inconsistent reports of optimal germination 
concentrations have been proposed (244, 315, 338). A continued search for optimised 
culture approaches is necessary to further define highly sensitive and robust 







By assessing the C. difficile germination potential of two solid agar and two 
anaerobic broth bases, supplemented with a range of known germinant 
compounds at varying concentrations, a model algorithm for spore germination 
and recovery was sought. This was acknowledged as critical to the maximal 
recovery of C. difficile spores from a historical collection of isolates (Chapter 
Three), essential for the further investigation of MDR development in this thesis. 
Without recovery of isolates through optimised germination protocols, 
downstream epidemiological and genomic analyses would not be achievable.  
Whilst the synergistic effects of glycine, as a co-germinant to sodium 
taurocholate, have been demonstrated at low concentrations (331, 642), here 
elevated levels revealed inhibitory effects on C. difficile growth. Further 
examination of this finding was necessary to improve the understanding of this 
concept. This initial chapter attempts to define an optimal combination of solid 
and broth media, in order to maximise the germination and recovery of aged C. 
difficile spores, whilst concurrently investigating inhibition of germination or 






Two solid agar bases and two broth culture media, supplemented with 
contrasting combinations and concentrations of germinant compounds, were 
assessed for C. difficile germination capabilities. Spore and vegetative population 
dynamics were evaluated through culture assays and phase-contrast 
microscopy, with an optimal algorithm sought to facilitate recovery of historical 
C. difficile spores. 
All C. difficile incubations were carried out in an A95 anaerobic workstation 
(Don Whitley Scientific, UK) at 37°C for 48 hours, unless otherwise stated. 
 
2.3.1 Pilot investigations 
2.3.1.1 Germinant exposure pilot 
Pre-reduced 5 mL Schaedlers anaerobic broths (Oxoid, UK) supplemented with 
0.1% sodium taurocholate (MP Biochemicals, USA) and 0.4% glycine (Sigma-
Aldrich, USA) were inoculated with PCR ribotype 027 C. difficile spores (2.5 
x107); (spore preparation and harvesting is described in 2.3.2.2) to achieve a 
broth concentration of 5.2 x105 CFU/mL. Broths were incubated and C. difficile 
vegetative cells were enumerated after 30, 60, 90 & 120 minutes. Enumeration 
was performed through serial dilution (10-7) in pre-reduced, sterile PBS (Oxoid, 
UK) prior to plating of the subsequent dilution series onto Brazier’s agar (LabM, 
UK) supplemented with cycloserine (250 mg/L); (LabM, UK), cefoxitin (8 mg/L); 
(LabM, UK), 2% defibrinated horse blood (E&O Laboratories, UK) lysed with 
Saponin (50 mL/L); (Sigma-Aldrich, USA) and 5 mg/L lysozyme (Sigma-Aldrich, 
USA); (CCEYL). Aliquots of 200 µL were collected at each time point and 
“shocked” in ethanol/water (50% v/v) for spore population enumeration, as 
described previously. Germination differences were assessed based on the 
proportions of spores and vegetative cells. Testing was performed in biological 
triplicate.  
2.3.1.2 Phase-contrast microscopy pilot 
Pre-reduced 5 mL Brain Heart Infusion (BHI) broths (Oxoid, UK) supplemented 
with 0.1% sodium taurocholate and 0.4% glycine were inoculated with 50 µL of 




concentration of 2.3 x105. After 90 minutes incubation, broth aliquots of 125 µL, 
250 µL, 500 µL & 1,000 µL were transferred into 1.5 mL Eppendorf tubes (in 
duplicate) and centrifuged at 12,000 g for one minute. The supernatant was 
decanted and the cell pellets re-suspended in 50 µL of M9 minimal salt media, 
before transferring onto a glass slide (26mm x 26mm). Slides were fixed on a 
heat plate at 50°C for 30 minutes, prior to the addition of 70 µL of molten 
Wilkins Chalgren anaerobe agar (Oxoid, UK) and a glass coverslip. Fixed slides 
were dried at 50°C for a further period of 30 minutes. 
Outcomes were assessed based on an ability to clearly identify entities on a 
single plane of view, whilst ensuring sufficient, countable numbers (10-100) to 
allow accurate quantification. C. difficile spores appeared oval in shape with a 
thick, dark outer coat. Ca2+DPA in dormant spores, presented an inner white 
glow or phase-bright spore core, whilst germinating, phase-dark spores 




Figure 4: Phase-contrast microscopy image of alternative C. difficile forms. A 
– vegetative cell (containing fore-spore), B – phase-dark spore, C - phase-bright 
spore. Image recorded using a Leica DM2000 phase-contrast microscope (100x Hi 







2.3.2 Optimising growth media for spore germination 
The efficacy of ten solid agar and nutrient broth formulations were investigated 
for their potential germination capabilities on C. difficile spores. Total viable 
counts and spore counts, in addition to phase-contrast microscopy techniques 
were performed to facilitate the determination of germination response 
amongst different PCR ribotypes; (Figure 5). 
 
2.3.2.1 Test isolates 
Single isolates of C. difficile from five PCR ribotypes; 001, 015, 020, 027 and 078, 
were assessed for germination response to all test media. These were library 
strains assigned by the CDRN, Leeds, UK. Further data is available via the 
National Centre for Biotechnology Information BioProject database (NCBI), 
http://www.ncbi.nlm.nih.gov/bioproject/248340.    
 
2.3.2.2 Spore preparation and harvesting  
All strains were inoculated onto single CCEYL agar plates and cultured for 48 
hours, before sub-culture onto a further eight CCEYL agars. Growth from each 
CCEYL plate was inoculated onto a further ten Columbia Blood Agar (CBA) plates 
(E&O Laboratories, UK) by spread plating technique and cultured, anaerobically 
for 10-14 days. After incubation, cultured plates were removed from the 
anaerobic cabinet, checked for purity and exposed to aerobic conditions for a 
minimum two hour period. Subsequent sporulated growth was removed from 
the plates with a dry swab and emulsified into ethanol/water (50% v/v), at a 
rate of 20 plates of growth per millilitre of ethanol (209, 662).  
Spore preparations were enumerated before use, through a serial dilution 
plating method, standardised via ethanol dilution to a cell density of ~6 x 105 
CFU/mL and stored at ambient temperature in sealed universal tubes. 
 
2.3.2.3 Solid media comparisons 
Laboratory produced agar plates of ten solid growth media combinations were 




egg yolk agar (CCEY) were used as base media, with each also supplemented 
with a series of germinant compounds; (Table 1). Egg yolk was omitted from 
CCEY agar to provide a direct comparison to the media used by the CDRN. 
Standardised C. difficile spore preparations were serially diluted with sterile PBS 
in 96-well microtitre trays (10-7). Twenty microlitres of each dilution was 
inoculated onto quartered agar plates and spread. Inoculated plates were 
incubated and individual colonies were counted. 
 
Identifier Base Media Supplements 
BHI 
BHI + Agar 
Technical 
No.3 (15 g/L) 
None 
BHI(L) Lysozyme (5 mg/L) 
BHI+0.1% 0.1% taurocholate + 0.4% glycine 
BHI+1% 1% taurocholate + 4% glycine 
BHI+1% (0.8%) 1% taurocholate + 0.8% glycine 
CCEY 




CCEYL Lysozyme (5 mg/L) 
CCEY+0.1% 0.1% taurocholate + 0.4% glycine 
CCEY+1% 1% taurocholate + 4% glycine 
CCEY+1% (0.8%) 1% taurocholate + 0.8% glycine 
Table 1: Constituents of solid agar media used in C. difficile spore 
germination experiments. Taurocholate and glycine added prior to autoclaving, 
lysozyme was added subsequently. BHI – brain heart infusion, CCEY – cycloserine-
cefoxitin egg yolk. 
 
2.3.2.4 Broth media comparisons 
Eight broth culture media combinations were compared for germination 
efficacy; (Figure 5). Schaedlers anaerobic broth and BHI broths were tested as 
base media, without the addition of Agar Technical No.3 (Oxoid, UK) to the 
either broth. A series of broths supplemented with differing germinant 
combinations were tested; (Table 2). Wassermann tubes containing 5 mL of pre-
reduced broth were inoculated with 50 µL of fresh (<2 days old) C. difficile spore 
preparation and allowed to germinate for 90 minutes; as determined by a 
previous exposure experiment (2.3.1.2). Broths were serially diluted as 




quartered CCEYL. Individual colony forming units were counted, post 
incubation. 
After 90 minute germinant exposure, two 500 µL aliquots of each broth were 
transferred into 1.5 mL Eppendorf tubes; one for phase-contrast microscopy 
(see 2.3.2.5) and one shocked with 500 µL ethanol/water (50% v/v) for spore 
population determination. Ethanol shocks were mixed and left at ambient 
temperature for a minimum of one hour, prior to serial dilution to 10-4 and 
plating as previously (2.3.1.1).  
All broths were tested in duplicate, with triplicate serial dilutions. Repeat testing 
of the PCR ribotype 001 and 078 spore preparations was performed after a six 
week period to identify any temporal differences. 
 






SCH(L) Lysozyme (5 mg/L) 
SCH+0.1% 0.1% taurocholate + 0.4% glycine 




BHI(L) Lysozyme (5 mg/L) 
BHI+0.1% 0.1% taurocholate + 0.4% glycine 
BHI+1% 1% taurocholate + 4% glycine 
Table 2: Constituents of broth media used in C. difficile spore germination 
experiments. Taurocholate and glycine added prior to autoclaving, lysozyme was 
added subsequently. BHI – brain heart infusion, SCH – Schaedlers anaerobic broth. 
 
 
2.3.2.5 Phase-contrast microscopy 
As part of the broth media comparison investigation, C. difficile spores were 
processed for phase-contrast microscopy after 0 and 90 minutes incubation. 
Cultured broth aliquots of 500 µL were centrifuged at 12,000 g for one minute, 
and slides were prepared as previously described (2.3.1.2). Ten fields of view 
were imaged for each slide, using a Leica DM2000 phase-contrast microscope 
(100x Hi Plan objective) and an OptikaTM Vision Pro Digital USB Camera, Italy. 




phase-dark spores, with proportionate data evaluated; (Figure 5). All test were 
performed in triplicate. 
2.3.2.6 Statistical analysis 
Statistical analyses were performed with IBM SPSS Statistics v.21.0.0.1. The 
spore recovery on solid agar data was compared using a one-way ANOVA with 
Tukey comparison, after logarithmic transformation. Individual PCR ribotype 
and broth germination data were compared using a non-parametric Kruskal-
Wallis test, with Dunn’s post hoc testing. P values <0.05 were classed as 







Figure 5: Flow diagram of germination investigation methodologies. CCEYL – cycloserine-cefoxitin Brazier’s agar supplemented with 5 
mg/L lysozyme, PBS – phosphate-buffered saline. 
5x C. difficile 
PCR ribotype 
isolates 
10 x solid media variations 
Serial dilution in 
PBS 
8 x enrichment broth variations 
Serial dilution in PBS 
Plated in triplicate onto optimal media - CCEYL 
Optimal media 


















2.3.3 Susceptibility testing 
2.3.3.1 Agar incorporation testing 
A panel of the same five C. difficile isolates (ribotypes 001, 015, 020, 027 and 078) 
tested in the germination assays (2.3.2.1) was utilised to determine any 
antimicrobial effects of the supplementing germinant concentrations. All strains 
were tested for detrimental effects on both vegetative and spore forms of C. 
difficile. Glycine and sodium taurocholate were tested both independently and in 
combination using an agar incorporation minimum inhibitory concentration 
method, as previously described (187, 480). Briefly, concentration ranges were 
selected to correspond with broth supplementation (Table 3), with compounds 
dissolved and diluted in sterile water to achieve a doubling dilution series. 
Supplementary solutions of 5 g/L increments were tested to further delineate the 
MIC, where necessary. Two millilitres of each concentration of test compound 
solution was added to 18 mL of molten agar, mixed, set and dried at 37°C for 20 
minutes. Vegetative cell response was investigated using isolates cultured on CBA 
for 48 hours, prior to inoculation into 4 mL Schaedlers anaerobic broth and 
further culture for 24 hours. Broth cultures were diluted 1 in 10 with pre-reduced 
saline (Oxoid, UK), before a 1 µL inoculation (~1 x 104 CFU) of the compound-
incorporated agars using a multi-point inoculator (Denley Hydraulics, UK). Spore 
response was investigated using a standardised inoculum of each spore 
preparation (~1x107 CFU/mL) directly onto the agar series. Susceptibilities were 
tested on both Wilkins Chalgren and Brazier’s CCEY agar, supplemented with 2% 
lysed, defibrinated horse blood. Due to the insolubility of glycine in high 
concentrations, testing of >30 g/L was carried out with supplementation directly 
into individual agar aliquots, prior to autoclaving. Inhibition of growth was 
assessed after anaerobic incubation, with the MICs defined as the lowest 
concentration at which growth was markedly inhibited. All test compound 






Compound Concentration Range (g/L) 
glycine 1.25 – 40 
sodium taurocholate 0.3 – 10 
glycine & (sodium taurocholate) 1.25 (0.3) – 40 (10) 
Table 3: Test compound concentration ranges for minimum inhibitory 
concentration determination. Compounds were tested in duplicate at doubling 
concentrations. 
 
2.3.4 Germination inhibition assay (PCR ribotypes 015 and 020) 
Two C. difficile strains, PCR ribotype 015 and 020 (2.3.2.1), were utilised to test 
the effects of increasing glycine and sodium taurocholate concentrations in broth 
culture, on both vegetative and spore populations. As with agar incorporation 
testing (2.4.5), both compounds were tested independently and in combination for 
the same concentration ranges; (Table 3). BHI broths supplemented with doubling 
concentrations of test compound were aliquoted (180 µL) into duplicate wells of a 
Sterilin Microplate U, 96-well tray. Spore preparations of approximately 5 x 106 
CFU were added (20 µL) to the broth-containing wells, in order to achieve a final 
spore concentration of ~5 x 105 CFU, as per CLSI guidelines (663). Vegetative 
inocula were created using 0.5 McFarland preparations of overnight BHI broth 
cultures. These were further diluted by 1 in 100 in fresh broth, prior to the 
addition of 20 µL of culture each test well, achieving a final cell concentration of 
~5 x 105. Test wells were created in duplicate with a further set of biological 
duplicates used to validate the results. Blank, uninoculated wells containing each 
compound concentration were used as negative controls, enabling a normalisation 
process of the absorbance data; (Absorbance readings for uninoculated wells 
containing the equivalent compound concentrations were averaged and 
subtracted from those of test wells). Absorbance measurements at 595nm were 
taken at multiple time points (0, 1.5, 3, 6, 24 & 48 hours) using a Tecan Infinite 




2.4.1 Germinant exposure pilot 
Total viable counts (TVC) were comparable across all time points, while after 90 
minutes of germinant exposure, an approximate 1 log reduction in spore counts 
was observed; (Figure 6). Exposure for longer periods (120 minutes) 
demonstrated no further substantial decrease in spore recovery. Therefore, 
further experimentation progressed with a 90 minute exposure period. 
 
Figure 6: C. difficile spore germination vs exposure time in broth culture. 
Spores were cultured in Schaedlers anaerobic broth, supplemented with 0.1% 
sodium taurocholate and 0.4% glycine. Differences in TVC (total viable counts) and 
spore count were indicative of germination.  
 
2.4.2 Phase-contrast pilot 
Centrifugation of a 500 µL aliquot was deemed to be the optimal volume for clear 
visualisation of broth culture populations by phase-contrast microscopy. Entities 









































determined, whilst background cell debris was minimised; (Figure 4). Greater 
volumes (1,000 µL) produced slides that proved over populated, with reliable 
entity counts obscured by cell debris. Smaller samples (<500 µL) conveyed 
insufficient total spore populations to achieve accurate estimates. 
 
2.4.3 Solid media comparisons 
Four variations of solid media demonstrated equivalent peak levels of C. difficile 
spore recovery;  
 BHI 0.1%: (7.93-8.45 log10CFU/mL, x̅ = 8.16±0.10),  
 BHI 1% (0.8% GLY): (7.80-8.59 log10CFU/mL, x̅ = 8.25±0.08),  
 CCEY: (8.15-8.32 log10CFU/mL, x̅ = 8.20±0.05), 
 CCEYL: (8.15-8.38 log10CFU/mL, x̅ = 8.26±0.08). 
  
No significant differences were observed between the four optimal variations; 
(p>0.05); (Figure 7). Slightly elevated spore recovery rates were observed after 
supplementation of 0.1% taurocholate into BHI (x̅ = 0.88 log10CFU/mL), but this 
was not significant (p>0.05), whilst the equivalent addition into CCEY 
demonstrated a significant decrease in recovery (x̅ = 2.73 log10CFU/mL, p<0.001). 
Increased concentrations of 1% taurocholate (TC) and 4% glycine (GLY) effected 
complete inhibition of spore outgrowth for both media types. Reduction in glycine 
concentration (to 0.8%) with 1% taurocholate exhibited significantly different 
effects on recovery with BHI and CCEY (p<0.001). In CCEY, the addition of 1% TC/ 
0.8% GLY led to a significantly reduced recovery (x̅ = 5.34 log10CFU/mL, p<0.001), 
whilst supplementation into BHI demonstrated no significant effect (p>0.05). The 
addition of lysozyme to either media base produced no significant effect on spore 
recovery (p>0.05). No significant variation in recovery performance was observed 










Figure 7: Comparison of germinant supplemented agar for C. difficile spore 
recovery. Percentage concentrations refer to sodium taurocholate, unless stated. 
BHI – Brain Heart Infusion, SCH – Schaedlers anaerobic broth, L – lysozyme 

















































2.4.4 Broth media comparisons 
2.4.4.1 Agar plate growth counts 
Total viable counts across all broth variations remained consistent within each 
isolate/ribotype tested, only differing between 0.08 and 0.48 log10CFU/mL; 
(Figure 8). TVC and spore count differences were comparable between all BHI and 
Schaedlers anaerobic broth variations, ranging from 0.08 – 0.64 (x̅ = 0.22 
log10CFU/mL, p>0.05). Supplementation with 5 mg/L lysozyme displayed minimal 
variance in recovery (0.002 – 0.07, x̅ = 0.03 log10CFU/mL, p>0.05). Broths 
containing bile acid germinants showed notably wider distinctions between TVC 
and spore counts, compared to those without (1.60-3.30 log10CFU/mL, x̅ = 2.52 vs 
0.03–1.38 log10CFU/mL, x̅ = 0.42 respectively); (p<0.001). Increased taurocholate 
concentration in both BHI and Schaedlers broths demonstrated a very slight 
decrease in spore recovery, x̅ = 0.11 and 0.21 log10CFU/mL, respectively (p>0.05). 
In BHI only, reduction of glycine concentration (from 4% to 0.8%) indicated 
further slight reductions (x̅ = 0.35 log10CFU/mL) in spore recovery (p>0.05), (data 
not shown). 
PCR ribotype variance was apparent, with ribotype 001 demonstrating the largest 
difference in vegetative population (TVC minus spore count) between cultures, 
with and without germinant supplementation (x̅ = 2.87 and 2.88 log10CFU/mL for 
BHI and Schaedlers broths, respectively, p>0.001). This contrasted to ribotype 
078, which demonstrated far lower differences of x̅ = 1.44 and 1.12 log10CFU/mL 
in BHI and Schaedlers broths. Ribotype 015 displayed the lowest decrease in 
spore population after taurocholate addition, whilst all other ribotypes indicated 
differences within 0.3 log10CFU/mL of the mean difference (x̅ = 2.08 and 2.11 







Figure 8: Germination of five different PCR ribotype (RT) C. difficile strains in broths supplemented with various germinant 
concentrations. Germination efficiency is represented by differences in mean (±SE) total viable counts (TVC) and spore counts. Broths were 
exposed to germinants for 90 minutes. BHI – Brain Heart Infusion broth, SCH – Schaedlers anaerobic broth, L – lysozyme (5mg/L), GLY – glycine, 
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(0.4% GLY)
BHI + 1% TC (4%
GLY)
SCH SCH(L) SCH + 0.1% TC
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2.4.4.2 Phase-contrast microscopy results 
Proportions of entities observed with phase-contrast microscopy were 
comparable across all ribotypes tested, with the exception of ribotype 078; 
(Figure 9). Excluding the data for this ribotype, proportional entity counts at time 
of spore inoculation (zero) revealed phase-bright spore populations ranging 
between 70-91%, (x̅ = 82%), with phase-dark spores and vegetative cells 
comprising of between 2-25%, (x̅ = 11%) and 5-10%, (x̅ = 8%) respectively. 
Visualisation of ribotype 078 at the zero time point revealed proportions of phase-
bright, phase-dark and vegetative cells as 8%, 85% and 7%, respectively. 
Excluding ribotype 078, comparable entity proportion data was observed for both 
base media, varying by 0-5%, (x̅ = 2.4%). Therefore, average proportional changes 
associated with broth supplementation are reported from here in. Phase-contrast 
data correlated with broth germination colony counts, with the same trends 
observed in both assays. Minimal differences were observed between base media 
and supplementation with lysozyme, with an average of 3% of phase-bright 
spores shifting to phase-dark state. As with agar plate enumerations, bile acid and 
co-germinant addition considerably altered the population dynamics, with 0.1% 
taurocholate conferring significant changes from phase-bright to phase-dark 
spores (p<0.0001). Phase-bright spore populations reduced to between 0-10%, 
(x̅ = 3%), a decrease in the range of 62-68%, (x̅ = 65%). Phase-dark spore 
proportions elevated to 48-49%, (x̅ = 48%), an increase ranging between 44-49%, 
(x̅ = 48%). Vegetative cell percentages raised by 13-21%, (x̅ = 18%) to a range 
between 17-41%, (x̅ = 30%). Exposure to an increased concentration of 
taurocholate (1%) resulted in an even greater percentage of phase-dark spores 
(61-88%, [x̅ = 72%]), with phase-bright proportions almost eliminated (0-6%, [x̅ = 
1%]) and an increasing vegetative cell population, (11-38%, [x̅ = 26%]). In both 
BHI and Schaedlers broth assays with ribotypes 020 and 027, phase-bright spores 









Figure 9: Broth germination comparisons of five different PCR ribotype C. difficile strains by entity proportion determination with 
phase-contrast microscopy. Mean proportions (±SE) of entities after 90 minute incubation are displayed. Entities were enumerated in 10x 










































































































































































2.4.4.3 Six week aged spore preparations 
The trend of TVC and spore population differentiation remained comparable 
between fresh and six week aged spores; (Appendix). Findings for BHI and 
Schaedlers broth cultures produced equivalent counts, ranging from -1.24 – 0.97, 
(x̅ = 0.31) log10CFU/mL, p>0.05. The differences between broth cultures with and 
without germinant supplementation remained significant, ranging from 1.60-3.30 
log10CFU/mL, (x̅ = 2.52) and 0.03–1.38 log10CFU/mL, (x̅ = 0.42), respectively); 
(p<0.001). All but two broth variants demonstrated differences between TVC and 
spore populations slightly elevated over fresh spore observations (x̅ = 0.38 
log10CFU/mL); (Table 4). Whilst the reduction in TVC and spore difference was 
minimal in ribotype 001 Schaedlers broths with 0.1% taurocholate (0.28 
log10CFU/mL), the same spore preparation germinated in BHI with 0.1% 
taurocholate exhibited an outlying finding of a 1.24 log10CFU/mL reduction 






  Mean CFU (log10CFU/mL) difference between TVC and spore populations 
  BHI BHI(L) 
BHI + 0.1% TC 
(0.4% GLY) 
BHI + 1% TC 
(4% GLY) SCH SCH(L) 
SCH + 0.1% TC 
(0.4% GLY) 
SCH + 1% TC 
(4% GLY) 
RT001 (Fresh) 0.35 0.42 3.22 3.26 0.43 0.55 3.31 2.83 
RT001 (6 weeks) 0.85 0.80 1.98 3.62 1.39 1.58 3.03 3.14 
Difference 0.50 0.38 -1.24 0.36 0.96 1.03 -0.28 0.31 
RT078 (Fresh) 1.07 1.03 2.50 2.83 1.38 1.31 3.14 2.99 
RT078 (6 weeks) 1.87 2.00 2.79 3.17 2.00 2.08 3.16 3.19 
Difference 0.80 0.97 0.29 0.33 0.62 0.77 0.02 0.20 
Table 4: Mean CFU differences (log10CFU/mL) between TVC and spore counts for fresh and six week old spore preparations of PCR 
ribotypes 001 and 078. Data represents the mean average of triplicate values. RT – ribotype, BHI – brain heart infusion, SCH – schaedlers 




2.4.5 Susceptibility testing 
2.4.5.1 Agar incorporation testing 
Triplicate testing of five C. difficile PCR ribotypes demonstrated marked inhibition 
of vegetative growth by glycine at 20 g/L concentration (with no colony formation 
at 25 g/L); (Figure 10). Three ribotypes (001, 020 and 078) exhibited noticeably 
inhibited growth at 20 g/L, whilst the other two (015 and 027) demonstrated 
complete inhibition. Results were comparable across both agar types, as well as 
with vegetative and spore forms. Minimal differences were observed between 
vegetative and spore assays, with 86.7% and 80.0% MIC concordance 
demonstrated with Wilkins Chalgren and Brazier’s agar, respectively (Table 5). All 
MIC disparities between vegetative and spore populations were within one 
doubling dilution. No detrimental effect to C. difficile vegetative growth was 
observed in the presence of sodium taurocholate, up to 10 g/L concentration. The 
combination of both compounds in a 4:1 ratio indicated comparable results to 
glycine alone, demonstrating inhibition of growth at 20 g/L glycine: 5 g/L sodium 
taurocholate, although three strains exhibited marginally elevated MICs (<1 
doubling dilution).  
 
Figure 10: Photographic representation of the growth and inhibition response 
of five different C. difficile PCR ribotype strains cultured on Wilkins Chalgren 






Minimum Inhibitory Concentration (g/L) 
GLY veg (spores) TC veg (spores) 











001 20 (25) 25 (25) >10 (>10) >10 (>10) 20 (20) 20 (25) 
015 20 (20) 25 (25) >10 (>10) >10 (>10) 20 (20) 20 (20) 
020 20 (25) 25 (25) >10 (>10) >10 (>10) 20 (20) 20(20) 
027 20 (20) 25 (25) >10 (>10) >10 (>10) 20 (20) 25 (20) 
078 20 (20) 25 (25) >10 (>10) >10 (>10) 20 (20) 20 (25) 
Table 5: Summary table of minimum inhibitory concentrations for glycine 
(GLY) and taurocholate (TC) of five different C. difficile PCR ribotypes, tested in 
both vegetative (veg) and spore forms by agar incorporation method, on two 
agars. * GLY + TC combined in a 4:1 ratio, values displayed refer to GLY 
concentration. 
 
2.4.6 Germination inhibition assay (PCR ribotypes 015 and 020) 
Absorbance readings at 48 hours were consistent (within ~0.1) for all glycine 
concentrations up to 10 g/L, including a glycine-free control broth; (Figure 11A). 
Substantial reductions in absorbance were demonstrated at 20 & 40 g/L 
concentrations (from ~0.8 to 0.02). The combination of glycine and taurocholate 
produced a similar finding; (Figure 11C). Absorbance levels reduced from ~0.8 to 
0.02 between 5 g/L glycine (1.25 g/L taurocholate) and 10 g/L glycine (2.5 g/L 
taurocholate). Parallel analyses of taurocholate concentrations indicated no 
inhibition of growth, but a notable detrimental effect on absorbance was observed 
with the addition of the compound (0.95-0.77, 29% reduction), further decreasing 
to 0.60 (37% reduction) as the concentration increased to 2.5 g/L. Absorbance at 
higher concentrations remain stable at ~0.60. All findings were consistent across 









Figure 11: Germinant compound minimum inhibitory concentrations of PCR 
ribotype 015 and 020 C. difficile spores, as measured by absorbance at 595nm 
after 48 hour incubation. A –glycine, B – sodium taurocholate, C – glycine and 
sodium taurocholate in 4:1 ratio (sodium taurocholate concentration show in 






Absorbance measurements from multiple time points highlighted a delayed 
outgrowth in broth cultures containing 10 g/L glycine (Figure 13 A-B) compared 
to those with 5 g/L concentration (Figure 12). Whilst absorbance increased in 5 
g/L glycine culture after 24 hours (range 0.29-0.48), 10 g/L broth readings 
remained low (0.015-0.049). However, by 48 hours the absorbance readings of 
both sets of cultures were similar (0.47-0.87 and 0.56-0.76 for 5 and 10 g/L, 
respectively). Whilst 24 hour reads for 10 g/L glycine remained low (0.02-0.07) 
for both PCR ribotypes tested, ribotype 020 exhibited elevated absorbance levels 
at 48 hours (0.76), surpassing the growth of 0-5 g/L cultures (0.46-0.65); (Figure 
13B). However, ribotype 015 demonstrated a considerably decreased absorbance 
level of 0.35 at the same concentration; (Figure 13A).  
Growth curves were similar for all taurocholate concentrations and both 
ribotypes, expanding exponentially from six hours onwards; (Figure 13 C-D). 
Interestingly, 5 g/L (0.74-0.79) and 10 g/L (0.74-0.81) concentrations closely 
matched the final absorbance measurements for cultures without taurocholate 
supplementation (0.85-0.76), whereas lower concentrations peaked between 
0.52-0.60. 
Whilst low concentrations of glycine alone (2.5-5 g/L) reached comparable levels 
at 48 hours as cultures containing no glycine, in combination with taurocholate 






Figure 12: Comparison of absorbance measurements (595nm) from BHI 
broths supplemented with 5 and 10 g/L GLY, inoculated with C. difficile spores 
of two PCR ribotypes (015 and 020). Data was calculated as mean averages (±SE) 






































Figure 13: The effect on absorbance (595nm) of glycine (A and B), sodium taurocholate (C and D) and glycine/taurocholate combined 
(4:1) (E and F) on PCR ribotype 015 (A, C and E) and 020 (B, D and F) C. difficile spore outgrowth over time. Spores were cultured in 
brain heart infusion broths supplemented with doubling concentrations of test compound. Data represents mean averages (±SE) of quadruple 





Many commercially produced agars are available for the culture of C. difficile, 
whilst various non-selective broths exist for enrichment of recovery. However, 
there is no conclusive agreement as to which media provides the greatest 
germination recovery and sensitivity, with different studies favouring CCFA, 
CCEYL (utilised by the CDRN (363)), and ChromID C. difficile agars (333, 342, 658, 659, 664, 
665). Often the recovery targets differ, with fresh, aged and environmental spores 
amongst the variable targets tested. Here we investigated selective (CCEY) and 
non-selective (BHI) solid media and two commonly used broths (BHI (244, 341, 666) 
and Schaedlers anaerobic broth (187, 280, 480)), supplemented with varying additives 
and concentrations in an attempt to identify optimal spore germination and 
recovery. Determination of the most efficient method for spore recovery and 
germination was sought with the intention for use in the optimal recovery of aged 
C. difficile spores from an historical collection of isolates. 
 
2.5.1 Solid media comparisons 
Ten combinations of common solid growth media were tested for their efficacy in 
triggering germination in C. difficile spores. Whilst CCEY exhibited superior 
recovery over BHI alone, when supplemented with 0.1% taurocholate, BHI was 
equivalent to CCEY in demonstrating the greatest levels of recovery. This 
complements evidence from Lister et al., who also established the latter media as 
the most sensitive, when compared to four other selective agars (667). In the 
aforementioned study, CCEY was able to detect levels as low as 102 CFU/mL, 
whereas other media could only detect levels above 104. Although ChromID C. 
difficile agar has been reported as the most effective in recovery by several studies 
(657-659), the high sensitivity reported for CCEY is of greater importance with 
regards to aged isolates, since they are likely to contain diminished spore levels. 
This may also translate to diagnostic applications, where clinical specimens may 
have been exposed to antibiotic treatment prior to sample collection and are liable 
to contain reduced bacterial loads.  
Whilst the primary bile acid, taurocholate, in combination with a co-germinant, 




Sonenshein proposed that germination with taurocholate may be enhanced by a 
semi-solid support, implying an efficacy in solid media (244). We might, therefore 
have expected to see a universal increase in recovery using taurocholate, however, 
this was not the case in CCEY. Supplementation with low concentrations (0.1%) of 
taurocholate demonstrated polarised effects on the recovery of spores with both 
agar bases. Whilst an increased efficacy was observed in BHI, bringing its recovery 
potential in line with unmodified CCEY, a dramatic reduction was demonstrated 
with its addition to CCEY; (Figure 7). It is hypothesised that these diverging 
findings are due to the pre-existing cholate content in CCEY, absent from BHI, 
which provides an existing germination efficiency in this previously optimised 
media.  
Strikingly, enhancement of either media with high concentrations of taurocholate 
(1%) and the equivalent 1:4 ratio of glycine (4%) resulted in complete inhibition 
of vegetative growth. Since reduction of glycine concentration to 0.8% enabled 
spore recovery, comparable to lower concentrations (0.4%) in BHI and to a 
reduced extent in CCEY, this potentially identifies it as the implicating factor in 
inhibition. In order to further elucidate the source of inhibition, additional 
experiments were undertaken to investigate the antimicrobial potential of 
elevated concentrations of both compounds (2.3.3).  
Notably, the addition of lysozyme to either agar type demonstrated no beneficial 
effect to recovery, supporting work by Nerandzic (338), with others even finding 
detrimental effects when assessing 24 hour lysozyme exposed cultures (659). 
However, these data are in contrast with previous work by Wilcox et al., where 
supplementation of CCEY agar with lysozyme was shown to improve recovery of 
C. difficile spores from environmental swabs (342). Nonetheless, the latter 
experiment focussed on the recovery of environmental spores, which are likely 
damaged through desiccation and exposure to external physical and chemical 
stressors, such as heat and detergents. This may potentially precede a state of 
dormancy and therefore a reduced germination rate, presenting a greater 
propensity for enhancement by lysozyme action. Although no beneficial impact on 
germination was demonstrated with the relatively new spores tested in this 
investigation, since lysozyme addition showed no detrimental effect, its use in 




Since ChromID agar also contains taurocholate, it might be expected to be effective 
in spore recovery, however it is expensive, at almost three times the cost of CCEYL 
(658). However, issues have been reported regarding lack of colouration in certain 
genotypes (660, 661) and since the chromogenic nature of the media is not necessary 
for pure recovery applications, CCEY provides a reasonable alternative.  
The findings of this investigation suggest the comparable efficacy of three solid 
media variants, CCEY, CCEYL and BHI supplemented with 0.1% taurocholate and 
0.4% glycine. Whilst any of these formulations would provide optimised spore 
germination, selection of a particular agar must be assessed based on the specific 
purpose. For pure culture recovery, all would suffice, although assessment of the 
costings per plate suggest that the BHI option (19 pence) would be less expensive 
than CCEY (32 pence). Although these calculations are highly estimated, as pricing 
will vary on quantity and supplier etc., an obvious preference can be seen for this 
application. However, if faecal specimens or potentially impure samples are to be 
tested, the additional selection factor of cycloserine and cefoxitin would be 
necessary. Whilst BHI was not tested with the addition of these antibiotics, it 
seems unlikely that this would provide equivalent levels of selectivity, as the 
constituent elements of Brazier’s agar have been optimised for the selection of C. 
difficile.  
 
2.5.2 Broth media comparisons 
Determining a sufficient length of exposure time for the effects of germination to 
be distinguishable was essential. The pilot data described in Figure 6 showed that 
spore counts decreased by almost 1 log between 60 and 90 minutes exposure to 
0.1% taurocholate and 0.4% glycine. This represented the largest single step 
decrease in spore population, whilst TVCs remained stable, indicative of the 
exposure time with the greatest increase in germination. Equally, this remained a 
short enough period to eliminate the potential for vegetative overgrowth to mask 
the data. Therefore, a 90 minute incubation was utilised in all broth comparison 
assays. 
There were no apparent differences in germination efficiency between the 




broths supported previous findings (332, 655, 668), demonstrating significantly 
elevated germination (p<0.001); although increasing the concentration yielded no 
advantage. This directly contradicted work by Heeg et al. who found the majority 
of isolates tested demonstrated a greater germination rate when broths were 
supplemented with 1% taurocholate, as opposed to 0.1% (339). However, one strain 
did exhibit no difference in germination response, suggesting inter-strain 
variation, as demonstrated significantly in the different ribotype 027 isolate 
responses to both primary and secondary bile acids. Inter-strain variation was 
demonstrated here, with as much as a 2 log difference observed between 
ribotypes; (Figure 8). Nonetheless, these disparities were consistent across broth 
variations, potentially suggesting some inconsistency in the initial inocula. 
Recently, Weingarden et al. investigated the germination efficacy of clinically 
relevant bile acid concentrations from CDI patients on C. difficile spores, noting 
PCR ribotype variance (669). Interestingly, two ribotype 078 isolates demonstrating 
more efficient germination responses were shown to contain several amino acid 
substitutions in the cspC receptor gene. The elevated recovery of 078 spores in 
this study supports previous findings, although no genomic analysis has been 
undertaken to correlate CspC mutations. It is possible that these receptor 
polymorphisms may contribute to the increased success of this ribotype in clinical 
settings. Nonetheless, the slight variance observed amongst individual ribotypes 
may be related to slight differences in growth rate, as opposed to germination 
efficiency. Inter-ribotype growth rate differences have previously been reported 
in C. difficile (670), and may contribute to the variances detected in this study. 
Interestingly, in this study, the inhibitory effects of high glycine concentration 
observed in solid media was not replicated in broth investigations. This finding 
may have been a consequence of a larger initial inoculum (50 µL) in the broth 
enrichment experiments, or simply that the spores were unculturable in direct 
contact with high glycine concentrations, only stimulating the initiation of the 
germination process. Consequently, when aliquots of broth were enumerated on 
less inhibitory media, germinating spores were able to outgrow as expected. The 
differences between supplemented and non-supplemented broths may be a result 




Phase-contrast microscopy is a vital tool in the evaluation of germination data 
(671), since it allows a visual assessment of spore response at a cellular level, 
providing support to colony counting data (672). Initial tests showed the density of 
spores within the broths to be insufficient to allow a comprehensive analysis of 
entity population by phase-contrast microscopy. Therefore a small pilot study was 
implemented in order to optimise the protocol to allow the inclusion of this 
method.  
Phase-contrast data from the optimised methodology (Figure 9) proffered strong 
support for the colony count findings, demonstrating high proportions of phase-
bright (dormant) spores in the broths exhibiting comparable TVC and spore 
counts, whilst a predominance of phase-dark (germinating) spores were observed 
in broths containing taurocholate. Dominance of phase-dark spores in conjunction 
with a reduction in phase-bright spores is indicative of germination, since the 
release of Ca2+DPA associated with spore cortex lysis (673) causes a marked 
reduction in a spore’s refractive index (674). These alterations in spores can be 
differentiated effectively by phase-contrast microscopy. 
Comparator investigations of broth germination in six week aged spore 
preparations were implemented to identify any variance between germination 
response of nascent and more established spores; (Table 4). Whilst no major 
differences were identified, a far lengthier aging of spores may be necessary to 
elicit different responses, as outlined by several studies (645, 647, 675). Segev et al. 
reported variable RNA production in fresh B. subtilis spores exposed to diverse 
environments, including polarised temperatures and prolonged dormancy (675), 
whilst Ghosh and colleagues described a decrease in germinant receptors in super 
dormant spores (645). In C. difficile Rodriguez-Palacios identified diverging 
responses of fresh and aged spores to germination via heat shock (647). 
Unfortunately, due to extensive experimental testing with these preparations 
during a series of investigations into C. difficile spore heat response, where no 
benefit was observed with heat shocking (676), insufficient volumes of the 
necessary spore suspensions remained for this further testing. Interestingly, 
differences were amplified in the aged spore investigation for broths without 
supplemented by the classical germinants. This could potentially be due to the 




whereas the germination efficiency of taurocholate broth optimisation may negate 
any discrepancies.  
 
2.5.3 Glycine mediated inhibition 
The inhibitory effects of glycine, along with other amino acids, has been 
documented since the 1940s (677), with hindrance to bacterial growth reported in 
multiple genera, irrespective of Gram status (678-681). Hishinuma et al. identified 
substantial variation in the inhibitory action of high concentrations, 
demonstrating a spectrum of responses from sensitive through to resistant. 
Although described in other clostridia (678, 682), to our knowledge this is the first 
report in the literature linking glycine with inhibition of C. difficile outgrowth. The 
findings of this study, that glycine in high concentrations (>2%) entirely inhibits 
bacterial growth, coincide strikingly with other studies demonstrating complete 
inhibition at 2% concentrations, in C. acetylbutylicum, L. lactis and Helicobacter 
pylori (678, 679, 681). Interestingly, Hishinuma et al. reported minimal disruption at 
0.5% glycine, similar to the concentration achieving the best recovery in this study 
(0.4%) (678). 
One study reported that C. difficile germination significantly reduced in slightly 
acidic conditions (pH 5.56-6.32) (331). Since glycine buffers to pH 6.0, high 
concentrations of this compound could bring the pH environment within this 
range, potentially inhibiting germination. Nonetheless, since the inhibitory effect 
of glycine was observed in both vegetative and spore assays, it seems more likely 
that the inhibition is related to vegetative cell reproduction, as opposed to a 
germination. As glycine is considered a co-germinant for C. difficile, this may not 
be unexpected. Glycine, the simplest amino acid, is a protein precursor 
metabolised from serine (683). One of its primary functions in bacteria, is as 
constituent part of the peptidoglycan cell wall, where it forms pentaglycine cross 
linkages to bridge tetrapeptides, as part of the transpeptidase reaction of cell wall 
biosynthesis (684). One putative explanation for glycine mediated inhibition of C. 
difficile is the substitution of alanine isomers with glycine, in residue positions 1 
and 4 of the peptidoglycan subunits, as demonstrated in other organisms (678, 685). 
Incorporation of these deficient tetrapeptide precursors into the cell wall 




withstand the pressure of cell turgidity and eventual cell lysis; (Figure 14). The 
observed reversibility of glycine inhibition with the addition a L-alanine by 
Hishinuma et al. strongly supports this hypothesised mechanism in other bacteria 
(678). Nonetheless, a recent study has highlighted the novel structure of C. difficile 
peptidoglycan, reporting a prevalence of 3-3 cross bridging, compared to the 
typical 4-3 linking (686). Therefore, the relationship between glycine and C. difficile 
peptidoglycan formation may potentially differ. An additional explanation 
suggested by Minami et al. involves the interaction of glycine and 
carboxypeptidase enzymes, essential to cell wall biosynthesis (679). Since glycine 
has been demonstrated to inhibit this enzymatic process, it is plausible that cell 
disruption is effected by this interaction. A more simplistic explanation could 
involve the greater glycine concentrations leading to a hypertonic environment 
and the potential loss of water into the highly concentrated media. Nonetheless, 
this explanation does not account for the lack of inhibition at relatively high 
glycine concentrations below 2% or the decrease in recovery in CCEYL plates with 
0.4% glycine supplementation; (Figure 7). Equally, the aforementioned 
reversibility demonstrated by Hishinuma contradicts this hypothesis, suggesting 






Figure 14: Representation of deficient peptidoglycan formation caused by 
alanine substitutions with glycine in peptide subunits. (A)- Glycine replacement 
of L-alanine in position 1. (B) – Glycine replacement of D-alanine in position 4. 
 
 
The delayed outgrowth observed in cultures containing 1% glycine compared to 
0.5% (Figure 12) potentially indicates an inhibitory concentration boundary. Since 
the final absorbance measurements mask this development, the growth curve 
assays were crucial in elucidating these findings. Here, the actual MIC is likely to 
fall between these concentrations and the exponential outgrowth observed cannot 
occur until the glycine concentration is reduced to below the MIC. It can be 
speculated that glycine within the nutrient broth is being metabolised between 
the six and 24 hour period, after which the concentration becomes tolerable to log 
phase growth. The absence of differentiation between final absorbance readings at 
48 hours may be a result of a prolonged culture, offering the slow starting cultures 
an opportunity to catch up. Interestingly, inhibition at high glycine concentrations 
was demonstrated by micro broth assay, but not at larger volumes during 
enrichment broth germination comparisons; (Figure 8). As previously discussed, 
this may potentially be due to difference in exposure length and the additional 





2.5.4 Response to high levels of taurocholate  
Since previous studies found minimal detrimental effects of taurocholate (244, 687), 
it may be as expected that these data demonstrated no absolute inhibition of C. 
difficile vegetative growth at high concentrations (<=10 g/L); (Table 5). However, 
as observed spectrophotometrically, a reduced absorbance, reflective of 
diminished cell density, was identified with supplementation of concentrations 
above 0.6 g/L; (Figure 11). Although cultures remained viable, the decreased 
absorbance connotes demonstrable impairment. Taurocholate mediated 
inhibition in C. difficile vegetative growth has been reported, with crude 
formulations reducing viable counts by a factor of 3 x 103 compared to pure 
compound (315). This work suggested potential impurities in the preparation, 
including the known inhibitor, deoxycholate (244). However, unlike in the present 
study, Wilson et al. found no detrimental impact of pure taurocholate preparations 
(315). Due to the vast expense in the formulation of taurocholate, it is not 
inconceivable that there may be an element of impurity in the compound used in 
this study. Other organisms have exhibited impairment in the presence of 
taurocholate, with Tannock et al. observing a reduction in lactobacilli viability 
with exposure (688). They discovered high levels of cholic acid accumulating in 
cultures, due to the deconjugation of the primary bile acid by bile salt hydrolases. 
Whilst it seems self-defeating for C. difficile to produce these enzymes, 
homologues have been identified in its genome, as well as in other clostridia (689, 
690). Although Darkoh et al. observed no complete inhibition with taurocholate, 
they demonstrated some inter-strain variability in response. It may be plausible 
that expression of these bile salt hydrolase encoding genes is repressed in C. 
difficile, until unnecessarily high concentrations of primary bile acids are 
encountered. Nevertheless, this did not appear to impact on the germination and 
recovery of spores in more voluminous broths and could represent an artefact of 
the micro broth assay. 
 
2.5.5 Study limitations 
An obvious limitation of this study was the focus of germination testing on only 
two bases each, for both solid (BHI and CCEY) and broth (BHI and Schaedlers 




those tested here represented the commonly used options within our research 
group, inclusive of the CCEYL media type utilised by the national reference centre. 
The focus of these investigations remained on the impact of the addition of 
varying bile acid and co-germinant concentrations. 
One drawback of this investigation surrounds the application of these findings to 
the actual test specimens, which the experimental design was determined for. 
Whilst it was never feasible to replicate spores between 32 and 38 years old, the 
spores tested in the germination assays were only aged by six weeks. Since, 
variation has been identified amongst spores of diverse ages (645, 647), further aging 
may have enabled closer comparisons to the ultimate application. However, 
minimal differences were observed after six week aging. 
Although five prevalent disease causing ribotypes were tested for germination 
responses, multiple isolates from within each type would have further 
substantiated findings, as well as potentially revealing some inter-ribotype 
variability, as previously detected (339, 669). Nonetheless, the experimental 
protocols, particularly the broth methods, were considerably time and labour 
intensive and the addition of multiple strain variables would have proved too 
costly. 
Another possibility for future testing would be to use highly pure taurocholate, 
since the preparation tested was classified as >97% pure, and variation in purity 
has previously been associated with disparity of germination efficacies (341), 
testing of highly pure compound may have provided additional confidence in the 
results.  
Heat activation and ethanol pre-treatments were not considered as part of this 
investigation, as they were beyond the scope of this work and would have 
detracted from the main focus of this research. Nevertheless, some of these 
hypotheses were investigated within our research group, with no beneficial effect 
to germination of heat treatment observed (Pickering et al. 2018, publication 
under review). 
With regards to the discovery of the inhibitory impact of glycine, only five isolates 
were assessed. Whilst determination of susceptibilities of a larger panel of isolates 




variation, the results served to identify the source of the inhibition in C. difficile 
and create an awareness of the burden of high concentrations in solid media. 
 
2.6 Conclusion 
Based on the common laboratory media tested, these data suggested an optimal, 
two-step algorithm for C. difficile germination and recovery. This would involve an 
initial enrichment protocol with either BHI or Schaedlers broth supplemented 
with 0.1% taurocholate and 0.4% glycine, followed by recovery on a standard 
Brazier’s CCEY agar plate. Nonetheless, the spore recovery environment should be 
considered and the addition of lysozyme to the solid media may yield benefits for 
spores exposed to high levels of environmental stress (342). This also correlates 
with the media currently in use by the CDRN (363).  
Supplementation with greater concentrations demonstrated no advantage to 
spore germination and is therefore deemed an unnecessary expense, particularly 
in high throughput diagnostic lines. Whilst, lysozyme exhibited no beneficial 
effects on fresh spore recovery. 
These findings are the first reports of glycine mediated inhibition in C. difficile, 
with concentrations greater than 2% proving inhibitory. Whilst the detrimental 





Chapter 3 Phenotypic Characterisation and Typing of Historical 
Clostridioides difficile Strains 
3.1 Introduction 
Phenotypic characterisation and bacterial typing are highly important to the 
surveillance of epidemiological trends in CDI. Identification of the circulating 
strain types in a given setting facilitates the monitoring of endemicity and 
transmission of epidemic strains (257, 371, 376, 691). While a range of typing 
techniques are available, standardisation is essential to the production of a 
coherent epidemiological picture across multiple time points and geographic 
locations (358-361, 367). The introduction of a national typing service in the UK, the 
CDRN (363), enabled C. difficile strain distribution and prevalence to be 
longitudinally monitored and epidemiological shifts tracked, through the use of 
PCR ribotyping (367). Unfortunately, there are few studies providing typing data 
using this high resolution technique for C. difficile isolates from the early 1980s 
(381, 496, 692-694). This poses challenges when comparing historical and modern 
prevalence data. Whilst the CDRN data is able to highlight decreasing rates of 
ribotype 027 infection and the emergence of ribotypes 005 and 023, it can only 
provide data back to 2008. Prior to the launch of the CDRN, an isolate collection 
existed at the Anaerobe Reference Unit, University Hospital of Wales, Cardiff, UK 
dating back to 1993 (367). This collection was used as a typing service for England 
and Wales for the purpose of outbreak investigation. Whilst the collection at 
Cardiff was invaluable in the formation of the CDRN, the strains described in this 
chapter pre-date these isolates, often by more than a decade. Reports of these 
earlier isolates reveal a dominance by ribotype 001 and 106 isolates, with John 
and Brazier discovering 55% of all isolates tested representing the former strain 
type (692). This correlated with data from outbreaks, caused by clindamycin-
resistant ribotype 001 strains in the USA (97). C. difficile populations have 
fluctuated frequently, whether due to the introduction of epidemic strains, 
change in antibiotic usage and infection control behaviours or clonal expansion 
of resistant strains (363, 417). Analysis of CDRN data revealed considerable 




correlated with the reduction of high risk antibiotic use, as well as with infection 
control behavioural changes brought about by the introduction of mandatory 
reporting (384). As outlined by one pan-European surveillance study of isolates 
from 2014, ribotype prevalence was often region/country dependent (188). 
Whilst hyper-virulent ribotype 027 remained the predominant type across 
Europe, UK distribution demonstrated greater heterogeneity, reporting a 
predominance of ribotypes 014, 106, 015, 020, 078 and 002 (188). In support of 
these data, other large European studies discovered associations between 
ribotype diversity, incidence of epidemic strains and antimicrobial resistance 
(118, 154, 695). 
Further to strain typing, the elucidation of antimicrobial resistance patterns 
gives valuable information, revealing correlations between antibiotic use and 
reductions in susceptibilities (91, 97, 103, 115). These are of importance to the 
potential prediction of clinical response and risk of disease onset. Antibiotic 
susceptibility data from the late 1980s and 1990s is more readily available than 
ribotyping data. The available data from C. difficile studies temporally tracking 
susceptibilities, generally reveals increases in resistance over time (381, 521, 693), 
presumably due to prolonged antibiotic exposure. A study of 179 Scottish 
isolates revealed MXF resistance increases, with reported rates of 0, 3.3 and 
10.2% resistance in 1979-86, 1987-95 and 1996-04, respectively (381).  
However, it is not always the case that resistance levels are reported to increase 
over time. Whilst, reductions in susceptibility to modern agents were observed 
in an analysis by Taori et al., decreases in resistance associated with older 
compounds, clindamycin and tetracycline, correlated with declines in their use. 
Metronidazole and vancomycin susceptibilities are commonly reported to 
remain stable, with minimal resistance development (521, 696). Conversely, Barbut 
et al. demonstrated reductions in the number of isolates resistant to 
clindamycin, tetracycline, erythromycin, rifampicin and chloramphenicol 
between 1991 and 1997 (696). This serves to highlight the relevance of type 
prevalence to resistance levels, since decreases in the aforementioned study 





Recent large scale, retrospective surveillance across >7,000 inpatients indicated 
C. difficile as the most frequently reported MDR pathogen (508). Since C. difficile is 
the primary cause of antibiotic-associated diarrhoea, resistance to multiple 
agents is of high importance, as it may result in elevated risk of disease 
acquisition through increased pathogen survival to antimicrobial exposure for 
alternative infections (387, 697, 698). Determination of the development of MDR, by 
assessing prevalence pre and post introduction of antimicrobial compounds is 
important to the understanding and management of these organisms. High 
prevalence of MDR in C. difficile has been reported amongst recent surveillance, 
with one study reporting a rate as high as 55% (444). Common ribotypes 
associated with multiple resistance were 001, 012, 017, 018, 027, 078, 106 and 
356, where reduced susceptibilities to erythromycin, clindamycin, moxifloxacin 
and rifampicin constituted the majority of instances (188, 444). Contrasted with 
historical data discovering only 7.8% MDR amongst 179 UK isolates, tetracycline 
resistance was elevated and moxifloxacin resistance minimal (381). Whilst 
determination is highly dependent on the panel of agents tested, knowledge of 
any MDR acquisition is central to understanding CDI therapeutics and 
antimicrobial stewardship.  
Ultimately, knowledge of C. difficile epidemiology and resistance progression 
over time provides an opportunity to respond quickly to emerging resistance 
and outbreak situations. Equally, lessons can be learnt from putative mistakes 
from the past, and prescribing behaviours optimised. In this chapter an 
historical collection of isolates was interrogated and assessed regarding 
ribotype distribution and phenotypic response to a panel of antimicrobial 
agents. Understanding toxin status may also help to uncover cases of 
asymptomatic carriage or instances of alternative enteric disease, wrongly 
attributed to C. difficile. Comparisons to modern UK isolates enabled an 







Considering the relationship between the introduction of new antibiotic agents 
and the progression of antimicrobial resistance in C. difficile is essential to 
understanding the development of MDR strains. Investigations in this chapter 
sought to recover and characterise C. difficile isolates from the early 1980s (pre-
dating isolates stored in existing national collections) to establish strain 
distribution and susceptibility profiles, prior to the addition of modern 
generation antibiotics to the formulary. This baseline comparative data could be 
used to further the understanding of the expansion of certain PCR ribotypes and 
their propensities for acquisition and development of multiple antimicrobial 





3.3.1 Isolation of C. difficile from an historical strain collection 
3.3.1.1 Historical C. difficile collection properties 
An historical collection of ~2000 clostridia spp. isolates was established by 
Professor Peter Borriello and retained at Public Health England laboratories, 
Colindale, UK. Strains were collected (September 1980 – September 1986) as 
part of a first national diagnostic service and were originally seeded into cooked 
meat broth at point of isolation. Log books were retained with the specimens, 
containing basic demographic data. Prof. Borriello gave his specific consent and 
encouragement for his isolate collection to be studied in Leeds. 
3.3.1.2 Sample selection 
Upon transfer of this collection to the Healthcare-Associated Infection Research 
group in Leeds, UK, specimens were paired with clinical data where possible. 
Due to the large volume of retained material, an initial cohort selection process 
was implemented. Specimens with the following demographics were removed 
from selection: not specifically identified as C. difficile, of non-human origin, cell 
cytotoxicity negative and/or an absence of original C. difficile positive 
confirmation. Of the retained isolates, 1,253 were matched to specific laboratory 
records, constituting 476 patients. These provided the final sample selection to 
be subjected to recovery and isolation methods.  
3.3.1.3 C. difficile recovery and isolation 
Historical samples were subjected to multiple recovery methodologies in order 
to isolate the maximum number of strains for further analysis; (Figure 15). The 
progression of methodological approaches was based on assessments of 
recovery rates and the contemporaneous findings of the spore germination 
optimisation investigations from the previous chapter. Where patients were 
associated with multiple specimens, testing was ceased after initial C. difficile 
isolation (unless tested for repeat isolation confirmations). All incubations were 
carried out in an A95 anaerobic workstation at 37°C for 48 hours, unless stated.  
3.3.1.3.1 Direct plating method (n=270) 
Historical specimens (cooked meat broths) were vortexed for ten seconds, prior 




were too dry or viscous to pipette, an arbitrary inoculum of a one millilitre loop 
full of material was transferred to the agar. Inocula were streaked in order to 
isolate individual colonies, prior to incubation. Where positive growth was 
observed, individual colonies were sub-cultured to CBA and re-incubated. Where 
multiple colony morphologies were present, each type was sub-cultured to CBA 
for further differentiation by PCR ribotyping (3.3.2.1). C. difficile colonies were 
identified through their grey, feathery appearance and characteristic horse-
manure odour, or by Matrix-Assisted Laser-desorption Identification – Time of 
Flight Mass Spectrometry (MALDI-TOF); (Bruker Daltonik, Germany); see 
3.3.1.4. Recovery batches were controlled using a positive growth control plate, 
consisting of 10 µL of PCR ribotype 001 spore suspension, created as previously 
described (699), streaked onto CCEYL agar. A CCEYL plate streaked with a sterile 
loop acted as a negative control. A CCEYL settle plate was left on the bench 
during culture preparations, representing an environmental control. All control 
agars were incubated alongside test cultures. Recovered C. difficile isolates were 
assigned a unique laboratory identification number (e.g. JV01) and retained in 
duplicate (-20°C), in 1 mL aliquots of 17% glycerol nutrient broth. 
3.3.1.3.2 Broth enrichment (n=20) 
Schaedlers anaerobic broth was prepared according to the manufacturer’s 
instructions and supplemented with lysozyme (5 mg/L) post autoclaving. 
Twenty millilitre aliquots were pre-reduced overnight in an anaerobic 
atmosphere to remove any oxygen. Original cooked meat broth specimens were 
vortexed for ten seconds with 1 mL transferred into a sterile universal, 
containing 1 mL of ethanol/water (50% v/v). Samples were shaken for five 
seconds and left for one hour at ambient temperature (alcohol shock). A 1 mL 
aliquot of the alcohol-shocked sample was transferred into the pre-reduced 
Schaedlers broth and shaken for ten seconds, prior to incubation. CCEYL plates 
were inoculated with 100 µL of the broth cultures, streaked for individual 
colonies and incubated. A pre-reduced Schaedlers broth inoculated with 10 µL C. 
difficile spore suspension acted as a positive experimental control. An 
uninoculated broth was incubated alongside test samples, as a negative growth 




test plates for the duration of testing, acted as an environmental control. All 
control plates were incubated as previously described; (3.3.1.3.1). 
3.3.1.3.3 Broth enrichment with multiple germinants (n=739) 
The method was as described in 3.3.1.3.2 (excluding the ethanol shock stage), 
with the addition of either 4 g/L (0.4%) glycine and 1 g/L (0.1%) sodium 
taurocholate; or 40 (4%) and 10 g/L (1%) to the Schaedlers broth, prior to 
autoclaving. Positive and negative controls were as previously described 
(3.3.1.3.2). 
3.3.1.3.4 Broth enrichment – whole sample method (n=389) 
Schaedlers broth was prepared at double the manufacturer’s strength 
recommendation and were supplemented with the same concentration 
combinations of glycine and sodium taurocholate as previously; (3.3.1.3.3). 
(Broth enrichments using spore germinants were evaluated in Chapter Two. 
Based on the conclusions of this work regarding the potential inhibitory effects 
of high concentrations of glycine, a modified version of this method was also 
performed with glycine supplemented at 4 g/L in conjunction with 10 g/L 
taurocholate). The entire original cooked meat broth specimen (~20 mL) was 
added to a 100 mL flask containing 20 mL broth and agitated prior to incubation. 
Enriched cultures were plated and incubated as previously described; 
(3.3.1.3.2). Positive and negative controls were created as previously (3.3.1.3.2), 







Figure 15: Germination and recovery methods for C. difficile recovery from the historical collection (1980-86). Individual samples were 
subjected to multiple recovery methods. Specimens were not tested if C. difficile was isolated from another sample associated with the same patient. n 
sizes for each methodology are totals from multiple test batches. GLY – glycine, TC – taurocholate.
Positive C. difficile cultures 
isolated and frozen in glycerol 
broth in duplicate, for further 
testing 
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3.3.1.4 Confirmation of C. difficile identification by MALDI-TOF 
MALDI-TOF was performed for the rapid identification and confirmation of C. 
difficile. Principally, a UV-absorbing matrix assists the ionisation of biomolecules 
by laser excitation and subsequent separation based on charge. Electropherogram 
peaks determine standardised molecular weight fragments that can be compared 
against a database on known profiles (700). Identification was carried out using 
single colonies of fresh growth (24-48 hours) from non-selective agar (CBA). 
Colonies were emulsified onto a clean MALDI-TOF plate, overlaid with 1 µL of 
matrix, air dried and analysed on a MALDI Biotyper (Bruker Daltonik, Germany). 
Tests with a “score-value” of >2.0 were accepted as species designation, whilst a 
value >1.7, confirms the genus only. Specimens with scores less than this cut-off 
were re-tested to acquire an organism classification. 
 
3.3.2 C. difficile strain characterisation 
Recovered C. difficile isolates were subjected to an array of phenotypic and 
genotypic typing methods in order to elucidate individual strain characteristics; 
(Figure 17). 
3.3.2.1 PCR ribotyping 
C. difficile isolates were genotyped by the CDRN; based on the methods of Stubbs 
et al. (367), with the addition of capillary electrophoresis. The CDRN is the UK’s 
national typing service for C. difficile, consisting of eight regional laboratories, 
including a reference centre in Leeds, UK. Providing surveillance for the 
mandatory reporting of this pathogen, the CDRN currently tests over 8,000 
specimens per year (363). Briefly, single colonies from non-selective agar (CBA) 
were emulsified in sterile water (McFarland 0.5) and loaded into an extraction 
block for automated DNA extraction by a QIAxtractor (Qiagen, Germany). Extracts 
were digested and specific 16S rRNA regions amplified by PCR. Subsequent 
amplicons were separated by fragment length via capillary electrophoresis (ABI 
Genetic Analyser 3130xl; Applied Biosystems, USA) and peak data assigned by 
GeneMapper software v4.1 (Applied Biosystems, USA). Electropherograms were 
compared against the CDRN database using BioNumerics software (701) (Applied-




3.3.2.2 Inferred multi-locus sequence type 
Next generation sequence read data (FASTQ format) was obtained as described in 
Chapter Four and was used to generate an inferred MLST sequence type for one 
strain (JV59), due to its novel ribotype determination. EnteroBase Clostridiodes 
v1.1.2 (702) was used to assemble raw Illumina reads and determine MLST 
sequence type, based on the seven housekeeping loci described by Griffiths et al 
(375).  
3.3.2.3 Determination of C. difficile toxin status by cell-cytotoxicity assay 
Forty-eight hour growth of C. difficile colonies on CCEYL agar was transferred into 
4 mL pre-reduced BHI broth and incubated. After pipette mixing, a 1 mL aliquot of 
each broth culture was transferred into sterile Eppendorf tubes and sedimented 
by centrifugation for 10 minutes at 12,000 g. Vero cell cultures (African Green 
Monkey Kidney cells; Sigma-Aldrich, USA) were diluted (2:18 mL) in Dulbecco’s 
modified eagle’s medium supplemented with 10% new born calf serum (Gibco, 
Life Technologies, USA), 1% antibiotic/antimycotic solution (Sigma-Aldrich, USA) 
and 1% ʟ-glutamine (Sigma-Aldrich, USA). 180 µL was aliquoted into 96-well 
microtitre trays (Sigma-Aldrich, USA) and incubated at 37°C for 48 hours in a 5% 
CO2 cabinet (Panasonic, Japan). All preparation and passage of Vero cell lines was 
carried out in a laminar flow hood (Holten LaminAir; Holten, USA). Confluency of 
Vero cell monolayers were confirmed via inverted microscopy (Leica DM IL, 
Germany). For each test sample, two wells were inoculated with 20 µL of test 
supernatant, before dilution (1:10) in two further wells. The addition of 20 µL of 
Clostridium sordellii anti-toxin to one set of wells, acted as a neutralising control. 
Inoculated trays were incubated in 5% CO2 at 37°C. Cells were examined after 24 
hours and results were confirmed 48 hours post inoculation. Positive results were 
assigned with the identification of >50% rounding of Vero cells and neutralisation 
(no cytopathic effect) in the corresponding antitoxin well, indicating the presence 





Figure 16: Vero cell response to cytopathic effect of C. difficile toxin as viewed 
under inverted microscopy. A - Confluent growth of living Vero cell monolayer. B – 
Cell rounding with deterioration of the cell monolayer. 
 
3.3.3 Agar incorporated minimum inhibitory concentration testing 
Wilkins Chalgren based agar incorporated susceptibility testing of the historical C. 
difficile isolates was performed in accordance with previous studies (187, 188). A 
panel of 16 comparator antimicrobials; vancomycin (VAN), metronidazole (MTZ), 
rifampicin (RIF), fidaxomicin (FDX), moxifloxacin (MXF), clindamycin (CLI), 
imipenem (IPM), chloramphenicol (CHL), tigecycline (TGC), linezolid (LZD), 
ciprofloxacin (CIP), piperacillin/tazobactam (TZP), ceftriaxone (CRO), amoxicillin 
(AMX), tetracycline (TET) and erythromycin (ERY) was investigated. Briefly, 
antibiotic dilution series were created (Table 7), with 2 mL of each added to 18 
mL molten Wilkins Chalgren anaerobe agar and mixed. Wilkins Chalgren agar was 
used at a concentration higher than the manufacturer’s recommendation, with 
10% more agar powder, to account for the additional diluent from the antibiotic 
solutions. Overnight Schaedlers broth cultures were diluted (1:10) in sterile saline 
and added to an inoculation block. A multi-point inoculator was used to transfer 1 
µL of diluted cultures (~1 x 104 CFU) onto antibiotic-incorporated agar of 
doubling concentrations, which were subsequently incubated anaerobically for 48 
hours. Minimum inhibitory concentrations were defined as the lowest 
concentration at which growth was markedly inhibited. All antibiotic 
concentrations were tested in duplicate. The panel of antimicrobial compounds 
were selected to span a range of antibiotic classes, including the standard 
treatment options for C. difficile. Control strains were tested across all batches to 












C. difficile ATCC 700057 Anaerobic, 37, 48 CCEYL 
C. difficile E4 (PCR Ribotype 010) Anaerobic, 37, 48 CCEYL 
Bacteroides fragilis ATCC 25285 Anaerobic, 37, 48 CBA 
Staphylococcus aureus ATCC 29213 Aerobic, 37, 24 CBA 
Enterococcus faecalis ATCC 29212 Aerobic, 37, 24 CBA 
Table 6: List of control strains for susceptibility testing. CCEYL – cycloserine-
cefoxitin egg yolk agar with lysozyme, CBA – Columbia blood agar, ATCC – American 

























H2O dilution to 
achieve working 
stock solution 
Vancomycin Acros Organics Glycopeptide 0.125-32 Water Water 6400mg/L 32 5 mL 1 in 10 (640 mg/L) 
Metronidazole Fluka Biochemika Nitroimidazole 0.125-32 DMSO Water 6400mg/L 32 5 mL 1 in 10 (640 mg/L) 
Rifampicin Sigma-Aldrich Rifamycin 0.001-16 DMSO Water 3200mg/L 16 5 mL 1 in 10 (320 mg/L) 
Fidaxomicin Astellas Pharma Macrolide 0.002-4 DMSO 
10% 
DMSO 








Lincosamides 0.125-64 Water Water 12800mg/L 32 2.5 mL 1 in 10 (1280 mg/L) 
Imipenem 





Water 12800mg/L 32 2.5 mL 1 in 10 (1280 mg/L) 
Chloramphenicol Sigma-Aldrich Chloramphenicol 1-256 Ethanol Water 51200mg/L 256 5 mL 1 in 10 (5120 mg/L) 
Tigecycline Pfizer Tetracycline 0.03-1 Water Water 800mg/L 4 20 mL 1 in 10 (80 mg/L) 
Linezolid SYNkinase Oxazolidinone 0.25-16 DMSO Water 3200mg/L 16 5 mL 1 in 10 (320 mg/L) 
Ciprofloxacin Fluka Biochemika Fluoroquinolone 1-64 DMSO Water 12800mg/L 32 2.5 mL 1 in 10 (1280 mg/L) 
Piperacillin/ 
Sandoz Beta-lactam 0.25-64 Ethanol Water 12800mg/L 64 5 mL 1 in 10 (12800 mg/L) 
Tazobactam (8:1) 
Ceftriaxone Sigma-Aldrich Cephalosporin 4-64 Water Water 12800mg/L 64 5 mL 1 in 10 (1280 mg/L) 
Amoxicillin Sigma-Aldrich Beta-lactam 0.125-16 DMSO Water 3200mg/L 16 5 mL 1 in 10 (320 mg/L) 




Macrolide 4-256 Ethanol Water 51200mg/L 128 2.5 mL 1 in 10 (5120 mg/L) 
121 
 
3.3.4 Multi-Locus Variable number tandem repeat Analysis 
Multi-locus variable number tandem repeat analysis was carried out using the 
enhanced fingerprinting service of the CDRN (371). MLVA utilises polymorphisms in 
the number of tandem repeating sequences across several well characterised loci. 
PCR amplification of these regions allow charge separation of fragment 
size/repeat length and subsequent profile comparison. Briefly, 2 µL of DNA extract 
from the PCR ribotyping process was added to a 96-well PCR plate containing 18 
µL amplification mix (10 µL HotstarTaq Plus Mastermix, 0.5 µL of two 
oligonucleotide forward and reverse primer pairs, 1.2 µL MgCl2, 5.8 µL water); 
(Qiagen). The plate was foil sealed and amplified through 35 PCR cycles with a 
Veriti™ thermal cycler (Applied Biosystems, USA). Amplimer fragments were 
separated via capillary electrophoresis (ABI Genetic Analyser 3130x) and peak 
size identified in GeneMapper software v4.1. Fragment sizes were recalculated to 
represent numbers of tandem-repeats and compared via dendrogram in the 





Figure 17: Identification, phenotypic and genotypic characterisation 
workflow.  
Orange arrows represent workflow, blue arrows additional confirmatory steps. 




3.3.5 Statistical analysis 
Statistical analyses were performed with IBM SPSS Statistics v.21.0.0.1. MICs for 
each test antimicrobial were compared using a two-tailed Mann-Whitney test. P 
values <0.0002 were classed as extremely significant, whilst p values <0.01 were 
highly significant and p<0.015 were defined as significant. 






3.4.1 Isolation and recovery of C. difficile 
In addition to clinical C. difficile isolates, a large proportion of specimens consisted 
of other clostridial species and multiple replicates from the same patients, 
together with several zoonotic and environmental isolates. Specimens were 
received in an array of conditions, with many in a state of putrefaction or 
overgrown with fungal growth; (Figure 18). Several laboratory note books 
accompanied the isolates, although correlation of data and sample proved difficult, 
due to fading and missing labels or an apparent absence of any demographic data. 
To the best of our knowledge these specimens remained untouched, post isolation 
and were stored at ambient temperature.  
 
 
Figure 18: Photographic representation of the variable states of the historical 
isolates. From left to right; complete putrefaction, through to visible 
fungal/bacterial growth and desiccation. 
 
From 1,253 unique specimens, associated with 476 patients, a total of 89 C. 
difficile isolates were cultured. Fourteen strains were discounted as repeat 
isolations of the same PCR ribotype from samples connected with the same 
patients. Therefore, 75 distinct strains were identified from 64 different patients 
and progressed for phenotypic and molecular characterisation. A total of 117 
124 
 
specimens were not tested due to the recovery of C. difficile from previous samples 
associated with the same patient.  
Recovery with direct plating and ethanol shock methods was low, 5% and 1.2% 
respectively, whilst simple enrichment broth did not increase the yield (5%). 
Supplementation of broths with germinants in low concentrations generated a 
slight increase in strain recovery (8%), whilst testing of whole sample volumes 
offered no enhancement in yield (6.5%). A gradual improvement in recovery 
numbers was observed with broths containing an elevated taurocholate 








Figure 19: Total yields of historical (1980-86) C. difficile obtained from individual germination and recovery methods. Individual 
samples were subjected to multiple recovery methods. Test numbers include isolates recovered in duplicate from the same sample by different 
isolation methodologies. n sizes for each methodology are totals from multiple test batches. GLY – glycine, TC – taurocholate. 
Positive cultures isolated 
and frozen in glycerol broth 
in duplicate, for further 
testing 
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3.4.2 PCR ribotype and toxin status 
Twenty-six known and one previously unobserved PCR ribotype were detected. 
Ribotype prevalence was dominated by strains 015 and 020, which equated to 
21.3% and 17.3% of the total, respectively. Ribotype 001 was isolated on six 
occasions, whilst a further nine ribotypes were recovered in multiple instances; 
two (n=4), three (n=3) and four (n=2). Single instances of fifteen other ribotypes 
were observed; (Table 8).  
Hyper-virulent ribotype 027 was recovered on three occasions from specimens 
dating back to 1981, 1983 and 1986. Two instances of the binary toxin producing 
078 strain were observed, in addition to noted MDR ribotypes 012 (n=4) and 017 
(n=3). One strain matched with no previous ribotyping profiles and was 
subsequently designated the nomenclature, PCR ribotype 862 by the CDRN. 
Isolates were recovered from specimens dated between 1980 and 1986 with the 
majority originating from between 1981 and 1983; (95%). C. difficile was isolated 
from a total of 64 patients, with six patients linked to multiple ribotypes; five 
exhibited two strains, whilst one harboured seven (001, 014, 015, 027, 041, 078 
and 200).  
The majority of strains demonstrated cell cytotoxicity (96%), with only three 
ribotypes (4%) identified as toxin negative via CCNA; 010, 033 and novel ribotype 
862. 
 
3.4.2.1 Inferred MLST typing 












Original Specimen  
Collection Dates 
 
015 16 21.3 + 1981 - 1984 
 020 13 17.3 + 1980 - 1983 
 
001 6 8.0 + 1981 - 1983 
 012 4 5.3 + 1981 - 1982 
 
014 4 5.3 + 1981 - 1983 
 027 3 4.0 + 1981; 1983; 1986 
 
002 3 4.0 + 1981; 1981; 1983 
 017 3 4.0 + 1981; 1982; 1982 
 
078 2 2.7 + 1981; 1983 
 070 2 2.7 + 1980; 1983 
 
200 2 2.7 + 1981; 1982 
 061 2 2.7 + 1983; 1983 
 
220 1 1.3 + 1982 
 056 1 1.3 + 1983 
 
103 1 1.3 + 1983 
 137 1 1.3 + 1983 
 
041 1 1.3 + 1981 
 626 1 1.3 + 1983 
 
341 1 1.3 + 1983 
 032 1 1.3 + 1981 
 
862 1 1.3 - 1983 
 619 1 1.3 + 1983 
 
033 1 1.3 - 1983 
 242 1 1.3 + 1981 
 
003 1 1.3 + 1986 
 023 1 1.3 + 1983 
 
010 1 1.3 - 1982 
Total 27 75 100.0     
Table 8: PCR ribotype prevalence and cell cytotoxicity status amongst UK 
historical C. difficile isolate collection (1980-86).  





3.4.3 Antimicrobial susceptibilities of UK C. difficile isolates (1980-
1986) 
The distribution of MICs by compound is shown in Table 10, whilst statistical 
analyses for each antimicrobial agent are displayed in Table 9. Individual isolate 
susceptibility patterns are reported in the appendix. 
3.4.3.1 Antimicrobial resistance breakpoint analysis 
Breakpoints were defined based on the U.S. Clinical & Laboratory Standards 
Institute (CLSI) (499) and European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) (703) figures; or from previous surveillance reports (201, 225, 444, 480, 
704) where no data for C. difficile existed. These are outlined in Table 11.  
All isolates were sensitive to both FDX and MTZ, with the majority also sensitive to 
VAN (94.7%). Four isolates (5.3%) demonstrated intermediate resistance to VAN 
at 4 mg/L, with two of these identified as PCR ribotype 001. MXF susceptibilities 
were bimodal, seven isolates (9.3%) exhibited resistance (16-32 mg/L) with the 
remainder susceptible (≤2 mg/L). Less than half of isolates (44.0%) were 
susceptible to CLI (≤2 mg/L). CIP resistance (>8 mg/L) was universal, and 
evidence of resistance was established in IPM (1.3%), CHL (5.3%), LZD (5.3%), 
CRO (12.0%), TET (9.3%) and ERY (16.0%); (Figure 20). No isolates revealed 
resistance to TGC, AMX, RIF or TZP; (Table 11).  
Five (71.4%) of the MXF resistant isolates were PCR ribotype 001 (n=2) or 027 
(n=3), with single instances of ribotype 041 and 200 demonstrating the phenotype 
(Table 12). PCR ribotypes 012, 015 and 078 were the only strains to demonstrate 
resistance to TET or LZD. The two most prevalent PCR ribotypes 020 and 015 
were susceptible to most agents, only indicating resistance to CIP and CLI, in 




Figure 20: Percentage of historical C. difficile isolates (1980-86) resistant 
(including intermediate resistance) to a panel of 16 antimicrobials. 
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-
moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-
tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-






Historic UK Isolates  









VAN 0.5 1 0.704 0.25 - 4 
MTZ 0.125 0.25 0.171 0.06 – 1 
RIF 0.001 0.002 0.001 0.001 – 1 
FDX 0.03 0.06 0.028 0.004 – 0.125 
MXF 1 2 1.617 0.125 – 32 
CLI 4 32 4.000 0.125 – >64 
IPM 4 8 4.553 2 – 16 
CHL 4 8 4.902 2 – 64 
TGC 0.03 0.06 0.035 0.03 – 0.125 
LZD 2 2 1.725 1 – 16 
CIP 16 32 22.00 16 – >64 
TZP (n=42) 8 8 6.672 4 – 16 
CRO 32 64 27.60 16 – 64 
AMX 1 2 0.920 0.5 – 2 
TET 0.06 0.125 0.104 0.015 – >32 
ERY <4 >256 7.926 <4 – >256 
Table 9: Antimicrobial susceptibility data analysis from 75 PCR ribotype UK C. 
difficile (1980-1986) isolates.  
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-
moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-
tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-











Number of C. difficile isolates with minimum inhibitory concentration (MIC) mg/L 
0.001 0.002 0.004 0.008 0.016 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >256 
VAN 
        
2 44 23 2 4 
     MTZ 
      
4 45 19 2 5 
       RIF 48 26 
        
1 
       FDX 
  
3 7 19 20 20 6 
          MXF 






  CLI 
       
2 2 1 8 22 12 13 6 2 7 *¹ 
 IPM 
           
11 40 23 1 
   CHL 
           
4 57 9 1 1 3 
 TGC 
     
62 10 3 
          LZD 




   CIP 
             
1 44 23 7 *² 
 TZP (n=42) 
            
14 25 3 
   CRO 
            
1 
 
22 43 9 
 AMX 
         
20 44 11 
      TET 
    
6 10 27 25 




  ERY 






Table 10: Distribution of historical (1980-86) C. difficile isolate MICs by antimicrobial compound.   
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-
chloramphenicol, TGC-tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, TET-
tetracycline, ERY-erythromycin. *¹ 6 isolates >64, *² all isolates >64, *³ 2 isolates >32, *4 all isolates <4. Line graphs denote the distribution of 














Compound     S     I    R 
VAN¹ ≤2 4 ≥8 71 (94.7%) 4 (5.3%) 0 
MTZ¹ ≤2 4 ≥8 75 (100%) 0 0 
RIF¹ ≤0.004 0.008-16 ≥16 74 (98.7%) 1 (1.3%) 0 
FDX¹ ≤0.5 1 * 75 (100%) 0 - 
MXF¹ ≤2 4 ≥8 68 (90.7%) 0 7 (9.3%) 
CLI¹ ≤2 4 ≥8 35 (46.7%) 12 (16.0%) 28 (37.3%) 
IPM¹ ≤4 8 ≥16 51 (68.0%) 23 (30.7%) 1 (1.3%) 
CHL¹ ≤8 16 ≥32 70 (93.3%) 1 (1.3%) 4 (5.3%) 
TGC¹ ≤0.125 0.25 * 75 (100%) 0 - 
LZD² ≤2 4 ≥8 71 (94.7%) 0 4 (5.3%) 
CIP3, 4 ≤2 4 ≥8 0 0 75 (100%) 
TZP3, 4 (n=42) ≤32 64 ≥128 42 (100%) 0 0 
CRO² ≤16 32 ≥64 23 (30.6%) 43 (57.4%) 9 (12.0%) 
AMX³ ≤2 4 ≥8 75 (100%) 0 0 
TET5 ≤0.5 1 ≥4 68 (90.7%) 0 7 (9.3%) 
ERY5 ≤0.25 0.5 ≥2 63 (84.0%) 0 12 (16.0%) 
Table 11: Breakpoint analysis of UK C. difficile isolates (1980-1986) against a panel of 16 antibiotics.  
Breakpoints as defined by ¹ Freeman et al. (2015a) based on the U.S. Clinical & Laboratory Standards Institute (CLSI) and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST); or existing publications: ² Freeman et al. (2015b); ³ Pirs et al. (2013); 4 Dong et al. (2013); 5 
Spigaglia et al. (2011). * No resistant breakpoint defined. VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-
moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-
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VAN 100 - 100 - 66.7 33.3 100 - 100 - 100 - 100 - 100 - 100 - 50.0 50.0 94.7 5.3 
MTZ 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 
RIF 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 94.1 5.9 
FDX 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 
MXF 100 - 100 - 67.0 33.0 100 - 100 - - 100 100 - 100 - 100 - 50.0 50.0 94.7 5.3 
CLI 43.7 56.3 38.5 61.5 16.7 83.3 25.0 75.0 75.0 25.0 66.7 33.3 - 100 66.7 33.3 - 100 50.0 50.0 68.4 31.6 
IPM 68.8 31.2 92.3 7.7 66.7 33.3 50.0 50.0 100 - - 100 100 - - 100 50.0 50.0 - 100 73.7 26.3 
CHL 93.7 6.3 100 - 100 - 75.0 25.0 100 - 100 - 100 - 100 - - 100 100 - 94.7 5.3 
TGC 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 
LZD 93.7 6.3 100 - 100 - 75.0 25.0 100 - 100 - 100 - 100 - - 100 100 - 100 - 
CIP - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 
TZP (n=42) 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 
CRO - 100 53.8 46.2 16.7 83.3 - 100 100 - - 100 - 100 66.7 33.3 100 - - 100 36.8 63.2 
AMX 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 
TET 93.7 6.3 100 - 100 - - 100 100 - 100 - 100 - 100 - - 100 100 - 100 - 
ERY 100 - 100 - 66.7 33.3 50.0 50.0 75.0 25.0 - 100 100 - 66.7 33.3 100 - 50.0 50.0 84.2 15.8 
Table 12: Antimicrobial resistance breakpoints of 75 historical (1980-86) C. difficile isolates by PCR ribotype.  
Breakpoint defined as in Table 11. S – Sensitive, R – Resistant (inclusive of intermediate resistance). VAN-vancomycin, MTZ-metronidazole, RIF-
rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-tigecycline, LZD-linezolid, CIP-
ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, TET-tetracycline, ERY-erythromycin. 
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3.4.3.2 Multidrug resistance classification 
Seventeen isolates (22.7%) demonstrated resistance to three or more 
antimicrobial agents, with half of these only classified as MDR due to CIP 
resistance. Eight isolates (10.7%) were resistant to three antibiotics, four (5.3%) 
to four and five (6.7%) to five compounds. Ten different combinations of 
antimicrobial resistance were demonstrated in the cohort, with three different 
antimicrobial permutations predominating; (TET, CLI, CIP, LZD & CHL; CLI, CIP, 
ERY, MXF & CRO; CIP and CLI, CIP & ERY); (Table 13). Combined ERY and CLI 
resistance was apparent in eight (47.1%) MDR isolates (10.7% of total), whilst 
LZD, CLI and CHL resistance was demonstrated in four (23.5%; 5.3% of total). No 
ERY resistance was associated with any of the latter isolates. 
PCR ribotypes 012, 027 and 078 constituted 23.4% (n=4), 17.6% (n=3) and 11.8% 
(n=2) of all MDR strains, respectively. This represented all recovery instances of 
these PCR ribotypes. Single instances of ribotypes 001 and 017 were also resistant 
to multiple agents. Isolates from these five PCR ribotypes, comprised 64.7% of the 
total MDR population. Both ribotype 078 isolates displayed the same resistance 
pattern, demonstrating MICs above the breakpoints of CLI, CHL, LZD, CIP and TET, 
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  014 (1) 1 
         017 (1) 
   
1 
      010 (1) 1 
         015 (1)         1  
Total (17) 3 1 1 1 1 1 1 3 4 1 
Table 13: Characteristics of the multi-resistant isolates isolated from (1980-1986).  
CLI - clindamycin, CIP – ciprofloxacin, MXF – moxifloxacin, CHL – chloramphenicol, LZD – linezolid, IPM – imipenem, CRO – ceftriaxone, TET – 
tetracycline, ERY – erythromycin. Breakpoints as defined in Table 11. PCR – polymerase chain reaction.  
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3.4.4 Further investigation of PCR ribotype 027 isolates from the 
historical collection by MLVA 
The three recovered ribotype 027 isolates all displayed very similar susceptibility 
profiles, demonstrating resistance to five antimicrobials (Table 14). However, each 
isolate proved distinguishable from each other by MLVA, as well as from 633 
comparator ribotype 027 strains, dating back to 2010. 
    
 
Figure 21: BioNumerics output for a MLVA comparison of the historical isolates 
and the entire CDRN reference database for PCR ribotype 027.  
The highlighted data profile denotes isolate JV02. All other “JV02” data refers to 
strains recovered during re-isolation experiments from different specimens 
associated with the same patient. A6, B7, C6, E7, F3, G8 & H9 refer to primed, 
amplified sequences; the number designated refers to the number of tandem repeats 
at a specific locus. MLVA data is primarily used for cluster analysis, so comparing 




















Minimum Inhibitory Concentration (mg/L) 
JV ID RT VAN MTZ RIF FDX MXF CLI IPM CHL TIG LZD CIP TZP CRO AMX TET ERY 
JV02 027 0.5 1 0.002 0.06 32 8 8 4 0.03 1 >64 16 64 1 0.125 >256 
JV73 027 0.5 1 0.001 0.06 16 2 8 4 0.06 1 >64 nt 64 2 0.125 >256 
JV67 027 0.5 1 0.001 0.06 16 2 16 4 0.06 2 >64 nt 64 2 0.125 >256 
JV14 078 0.5 0.125 0.001 0.004 1 >64 4 64 0.06 16 16 nt 16 0.5 4 <4 
JV22 078 1 0.125 0.002 0.03 2 >64 8 64 0.06 16 16 nt 16 0.5 8 <4 
Table 14: Susceptibilities of historical PCR ribotype 027 and 078 isolates against 16 comparator antimicrobials. 
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-
chloramphenicol, TGC-tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, TET-




3.5.1 Isolation and recovery of C. difficile 
Due to the absence of improvement in recovery with increased taurocholate 
concentrations determined by the previous germination efficiency work (Chapter 
Two), and the high expense of taurocholate, lower concentrations (0.1%) were 
favoured for the attempted recovery of the majority of specimens. Furthermore, no 
recovery advantage was observed with their supplementation in solid agar. 
Therefore, a decision was made to proceed using Schaedlers anaerobic broth with 
0.1% taurocholate/0.4% glycine and CCEYL agar plates for the majority of 
recovery efforts from the historical catalogue. Although CCEY with and without 
lysozyme addition demonstrated comparable spore recovery, due to its association 
with improved recovery of stressed, environmental spores (342), it was used here 
for maximum recovery of potentially damaged, aged spores.  
Initial recovery attempts with 1% taurocholate demonstrated slightly elevated 
yields compared to 0.1% taurocholate broth supplementation (13.3% vs 8.0%). 
However, this may have been biased by repeat testing of the same specimens, 
where samples not recovered by one method were retested with another. 
Therefore, the sample recovery probability of subsequent tests was likely 
diminished and would impact on an observed recovery rate. It is hypothesized 
that, since the viability of spores in the specimens was unknown, there is a 
possibility that many samples tested did not contain any surviving spores. Thus, a 
reliable comparison of recovery methods for application with this specific 
collection is not necessarily achievable. Recreating problematic sample recovery is 
difficult and it is possible that many of these specimens did not contain any 
recoverable material prior to testing. Pilot testing using actual specimens 
produced inconsistent results (data not shown), highlighting the potential for low 
bacterial loads and stochastic variation. Therefore, caution must be taken when 
considering the findings from these recovery attempts, as it is likely that they do 
not necessarily translate to isolation from more consistent collections. 
Although C. difficile was eventually isolated from 15.8% of patient cases, the 
attrition rate of this collection was high, with overall recovery attempts from each 
of the multiple patient specimens demonstrating an approximate seven percent 
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success rate. No single approach demonstrated superiority over the rest, but based 
on the conclusions from Chapter Two, use of enrichment broths supplemented 
with low-level germinants was considered the most efficient method for the 
recovery of depleted levels of potentially “super-dormant” spores (645). Assessing 
all specimens with multiple recovery methodologies would be preferable to 
determine an optimal protocol, but was not feasible due to cost and time 
limitations. Since the aim was the recovery of as many strains as possible for 
further analyses, this was deemed unnecessary for the purposes of this study. 
Whilst, one research study suggested that pre-heating spores with sub-lethal 
temperatures facilitated the reactivation of dormant spores (647), a small pilot study 
performed here, as preliminary work to historical strain recovery (data not 
shown) demonstrated no advantage of this treatment on recovery from the 
historical collection. This was later supported by the findings from our group’s 
work on heat exposure and germination (676), which indicated only detrimental 
effects at temperatures above 70°C. Consequently, heat pre-treatment was 
excluded from the recovery protocols. 
 
3.5.2 PCR ribotype and toxin status 
Strikingly, the prevalence of PCR ribotypes recovered from isolates originating 
between 1980-1986 corresponded closely with the most prevalent types isolated 
in 2015 by the CDRN (363). Each of the ten most common ribotypes recovered from 
the historical collection (Table 8) appeared in the equivalent top 15 list of modern 
circulating strains, whilst six (027, 001, 014, 002, 020 and 015) feature highly in 
European prevalence (118, 154, 385, 394). Although the historical collection is clearly 
dominated by ribotypes 015 and 020, the CDRN data reflects a more even 
apportioning of the most prevalent strains, with ribotypes 078 and 002 
constituting a greater share. The considerable discrepancy in sample size is one 
explanation for these disparities; (n=75 vs n=7609). Nonetheless, the recovery of 
ribotype 002 isolates from the historical collection was not surprising, as this type 
has demonstrated a transitionary epidemiology over the last 40 years. Ribotype 
002 prevalence in the late twentieth century has been reported as high as 15% of 
CDI cases (381). Decreasing in prominence in the wake of ribotype 027’s success 
(384), 002 is once again a prevalent ribotype (363, 705). Currently reported as the 
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primary cause of community-onset CDI (706, 707), ribotype 002 accounts for 13.5% of 
all UK cases (275). Interestingly, these correlate less with known CDI risk factors, 
such as age and antibiotic exposure (708). Emergent ribotypes 005 and 023 are not 
represented in the historic collection, further indicating their rise in prevalence in 
modern CDI epidemiological surveillance. Nonetheless, since the original sources 
of the historical specimens are not specifically known, the collection may be 
subject to geographic or sampling bias.  
Epidemiological comparisons can be made with a study of 69 Scottish isolates from 
1979-1986, which demonstrated dominance by ribotypes 002, 014 and 012, 
constituting 30% of all strains (381). These ribotypes were prevalent in the 
historical isolates recovered here, representing 15% of the total. Interestingly, in 
contrast to the present study, only single instances of ribotypes 015 and 001 were 
identified, whilst no ribotype 020 strains were reported. These ribotypes 
constituted a high proportion of isolates recovered in this study, which suggests 
potential bias attributed to localised outbreaks. 
While the majority of isolates recovered represent those predominating in modern 
surveillance, single instances of uncommon PCR ribotypes were observed, 
including 137, 242, 341, 619 and 626, as well as the novel ribotype 862. These 
strains may have been superseded by ribotypes with more efficient growth, 
germination and virulence pathways, promoting their superior aetiological 
potential. This is demonstrated in CDRN surveillance reports; where particular 
strains proliferate, the occurrences of others diminish (363). 
Further investigation of the previously unassigned ribotype 862, toxin negative 
isolate, JV59, assigned it to ST-337, part of the obscure clade C-II (2). This strain 
type is uncommon and generally associated with environmental samples (2), 
although it has been identified in one clinical report (709). Representing a novel 
toxinotype (XXXII), this sequence type harbours a unique genetic organisation of 
the PaLoc, featuring an absence of the tcdA gene and several SNPs in the tcdB gene 
(709). This rare finding in a clinical specimen may suggest an inefficiency associated 
with this atypical genetic assembly. Although this sequence type purportedly 
exhibits functional clostridial toxin B genes, isolate JV59 repeatedly demonstrated 
negative cytotoxicity results. This casts doubt as to whether this strain was the 
aetiology of the patient’s symptoms or was purely colonising asymptomatically. 
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Although separated by approximately 35 years, the historical typing data revealed 
distinct similarities in populations with modern surveillance studies. While 
epidemiological investigations showed significant fluctuations in the prevalence of 
epidemic strains across several years (384, 417), these data suggest that there may be 
a homeostatic base line of strain distributions that is reverted to, as outbreaks of 
endemic or epidemic nosocomial strains subside.  
Conversely, historical strain recovery could potentially represent the ribotypes 
that are the “fittest” for long term dormancy and survival, as opposed to the actual 
epidemiological spread of the time. Previously reported ribotype variability in 
spore tolerance to external stressors such as heat, pH and organic solvents (710, 711), 
in addition to differing sporulation and germination efficiencies (712) could 
potentially explain the recovery of ribotypes that reflect the current 
epidemiological composition. Nonetheless, since the recovery rate of this historical 
catalogue was low, an accurate distribution cannot be assumed, making holistic 
assessment more challenging.  
Toxigenic strain dominance was as expected (96%), since specimens originated 
from patients with suspected CDI. However, the recovery of three non-toxigenic 
strains suggests that these patients were asymptomatically colonised by the 
isolated C. difficile strains and their diarrhoea was attributable to other 
undiagnosed aetiologies. Equally they may have been concomitantly colonised by a 
toxigenic strain, as has been previously described (713, 714). Although the latter 
explanation cannot be substantiated by the recovery results (i.e. no toxigenic 
strains were recovered from the patients from whom non-toxigenic strains were 
isolated), the high attrition rate of this isolate catalogue potentially masks this 
discovery. Interestingly, two less common, binary toxin gene carrying strains, 023 
and 033 were both isolated in single instances. 
3.5.2.1 Hyper-virulent PCR ribotype 027 recovery 
The hyper-virulent PCR ribotype 027 has been associated with numerous 
international outbreaks, particularly at the beginning of the twenty-first century 
(78, 112, 383). Persisting as one of the most prevalent C. difficile strain types across 
Europe (215), ribotype 027 remains of prominent interest to researchers. The 
earliest example of a ribotype 027 strain recorded in the literature is CD196, an 
isolate recovered in France in 1985 (289). Two of the ribotype 027 isolates 
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recovered from this historical collection, JV02 and JV73, were originally isolated 
from clinical specimens dating back to 1981 and 1983, respectively. Therefore, if 
the findings are true, these potentially represent the earliest PCR ribotype 027 
isolates reported to date. As these isolates may be of significance in the 
understanding of outbreak development associated with this ribotype, further 
confidence was sought to ensure the findings were accurate.  
Firstly, repeat attempts were made to consistently re-isolate the same strains from 
the original specimen tubes, as well as from other specimens associated with that 
patient (untouched in these investigations). Ribotype 027 strains were isolated on 
three occasions and compared to the original finding using MLVA. All subsequent 
strains recovered proved indistinguishable by this method (data not shown). For 
additional confidence in the findings, MLVA was also used to ensure that these 
historical 027 strains were distinct from 633 other 027 isolates analysed by the 
CDRN enhanced fingerprinting service, including the most commonly used 
laboratory control strain. No exact profile matches were observed for any of the 
historical isolates, indicating no direct links to any of the 633 strains processed for 
MLVA by the reference laboratory over the last eight years. Whilst both isolates 
JV67 and JV73 demonstrated distinctly different profiles from any other (>10 
SNPs), all strains recovered from different specimens associated with the same 
patient, were indistinguishable (≤2 SNPs). One closely related strain from 2010 
demonstrated a profile only 2 SNPs divergent from JV02 (Figure 21). While this 
would officially be classified as indistinguishable, since one of these 
polymorphisms was identified in the often highly conserved, G8 loci (376) the 
relatedness of these isolates maybe further questioned. Equally, when considering 
the demographic data, since this closest profile was generated in 2010, years 
before the historical collection even entered our laboratory is strongly suggestive 
of a distinction between the isolates. Similarly, it was highly unlikely that the 
related reference isolate had been cultured over the past ten years, remaining only 
in frozen storage. Whilst sufficient measures were imposed to restrict the 
possibilities of contamination, we cannot vouch for the period between specimen 
collection and receipt at our laboratory. Although this does not provide a definitive 
result, as MLVA is only directly appropriate for cluster analysis, it gives further 
confidence that the isolates recovered were not contaminants from this laboratory.  
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Interestingly, all three isolates exhibited MXF resistance (Table 14), where none 
had been previously reported in isolates dating prior to its introduction (112). 
Whilst this finding may be unexpected, if we consider the alternative hypothesis of 
contamination with a modern strain, it may seem more likely that all 
“questionable” strains would be genetically identical. Contaminating three 
individual specimens with distinct strains of the same ribotype seems highly 
unlikely. Since all 027 isolates were demonstrated as distinguishable from each 
other, this further refutes the theory of contamination.  
3.5.2.2 Recovery of multiple ribotypes 
Infection by multiple strains of C. difficile has been previously described, with rates 
reported as high as 7-16% of CDI cases (713, 715-718). In accordance with this rate, 
these data demonstrated that 9.3% of patients from which C. difficile was 
recovered were colonised with multiple strains. These may potentially occur due 
to recurrent infections and contact with heavily contaminated nosocomial 
environments. 
The recovery of seven different strains from one patient presented a rare and 
interesting discovery. Nonetheless, one recent study reported a severely ill patient 
as suffering from eight relapse/reinfection episodes of CDI across a 13 month 
period (719). In this patient ten phenotypically diverse strains of six PCR ribotypes 
were recovered, with one instance of a mixed infection with three concurrent 
types. This case closely reflects the known circumstances of the patient harbouring 
multiple strains from the historical collection. There is a paucity of clinical data 
associated with any of the historical strains, but this patient was documented as 
suffering from chronic diarrhoea for a period of 18 months, treated with several 
antimicrobials. With this combination of antibiotic therapies and prolonged 
hospital stay, colonisation with multiple strains and development of multiple 
symptomatic recurrences is possible. This may be plausible, since the risk of 
secondary and tertiary reinfections has been demonstrated to become significantly 
compounded with each recurrent CDI episode (720). However, caution must be 
taken when directly comparing these rates with previous reports, as recovery 
issues in this study will have a high impact on the data. Although strict anti-
contamination procedures were employed during the recent recoveries, the 
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possibility of contamination events occurring prior to receipt of the specimens to 
our laboratory cannot be disregarded. 
3.5.3 Antimicrobial susceptibilities of UK C. difficile isolates (1980-
1986) 
As expected, there was no evidence in this data set of resistance to the primary 
treatment drugs, MTZ and VAN. Equally, no resistance to the relatively recently 
licensed, FDX was observed. Since MTZ resistance was only first reported in 1981 
(535) and is still scarce in contemporary surveillance studies (188, 385), the absence of 
reduced susceptibility to this agent was as anticipated. Similarly, no historical 
isolates exhibited resistance to VAN, with four strains demonstrating intermediate 
levels of reduced susceptibility. Nonetheless, VAN resistance remains rare in 
contemporary studies, with a large scale European surveillance study reporting 
resistance in only 0.87% of isolates (188). 
RIF and FDX were the most active compounds, demonstrating geometric mean 
MICs of <0.001 and 0.028 mg/L, respectively. Whilst FDX resistance is scarce (118, 
721), an estimated 11% of modern C. difficile isolates display resistance to RIF (498). 
However, large proportions of this resistance has been identified as highly 
concentrated in specific geographical regions, such as Italy or Czech Republic, 
where high levels of rifamycin consumption are reported (188).  
As a fourth generation fluoroquinolone, MXF was not introduced until 1999, with 
resistance to the compound observed in C. difficile soon after (443). Although 
resistance to this compound was demonstrated in the pre-MXF, historical isolates, 
resistance to previous generations of quinolones have been demonstrated to 
impart cross-resistance due to identical target sites (438, 722). Nevertheless, all 
isolates indicated CIP resistance, but only seven translated this mechanism to a 
MXF resistant phenotype. Two out of six ribotype 001 isolates were MXF resistant, 
which was not too dissimilar to the findings of study of Scottish historical isolates 
by Taori et al. (50%) (381), suggesting that even in their infancy fluoroquinolones 
and associated resistance was potentially contributory to CDI onset. Whilst the 
striking observation of CIP resistance across all test isolates is not uncommon (198, 
723, 724), these strains pre-dated the introduction of this antimicrobial (1987). This 
could potentially indicate the development of cross-resistance due to exposure to 
earlier compounds with similar structures, such as nalidixic acid. However, this 
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drug had minimal use as a treatment for urinary tract infections (725) and therefore 
extensive selection seems improbable. A more plausible explanation would be that 
the majority of C. difficile genomes exhibit an intrinsic resistance to this agent. 
Further discussion of this finding is presented in Chapter Four, where the data is 
discussed in the context of the potential genetic mechanisms. 
Resistance to ERY, CLI and MXF amongst more recent isolates has been reported as 
49%, 65% and 40%, respectively (524). These far surpass the levels in this historical 
collection, which demonstrated 16%, 37.3% and 9% of isolates as resistant. The 
historical resistance rates support work by Ackermann et al. (521), who determined 
very similar resistance levels in ERY (18%) and CLI (30%) amongst isolates from 
1986-95. They also demonstrated slightly lower findings in MXF (2%), which is 
probably exaggeratedly elevated in the historical collection by the inclusion of 
three fluoroquinolone resistant ribotype 027 strains. Nevertheless, Ackermann’s 
research indicated a gradual decrease in susceptibility to each of these agents over 
three isolate groups, delineated by date. 
MIC90 data from the Scottish cohort (1979-86) analysed by Taori et al. 
demonstrated comparable results with the historical strains for MTZ, CRO and 
MXF (381). Conversely, VAN, CLI and TET MICs were elevated above the present 
study. Adding further confidence to the findings, a study of Australian isolates from 
between 1979 and 1989 revealed similar susceptibilities to those observed in the 
present investigation (726). However, the number of isolates independently 
resistant to CLI and TET were elevated above the present study; (CLI) 100% vs 
37.3% and (TET) 22% vs 9.3%. Interestingly they found no evidence of MXF 
resistance. Nevertheless, the predominance (68%) of toxinotype 0 and the small 
number of isolates tested for antimicrobial susceptibilities (n=9) may have 
contributed to this variance. 
One of the earliest reports of in vitro susceptibilities of clinical C. difficile strains, 
described resistance levels of ERY, CLI and TET in pre-1980 strains, as 7%, 14% 
and 9% respectively (727). These correlate well with the findings of this historical 
collection, where resistance proportions are slightly higher (Table 11), perhaps 
due to differences in the age demographics between the cohorts. Furthermore the 
work by Dzink and Bartlett studied isolates from the USA, and although no 
ribotyping data was provided, we know from other surveillance that 
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epidemiological differences are apparent. This may further contribute to the 
variance in antimicrobial susceptibilities. Nonetheless, these resistance rates are 
greatly reduced in comparison to those of modern collections across the world, 
where ERY and CLI resistance is reported as high as 100% and 82.7%, respectively 
(214, 394, 728). 
3.5.3.1 Comparison of UK C. difficile antimicrobial susceptibility data 
between (1980-1986) and (2012-2016) 
In order to assess the progression of antimicrobial susceptibilities from the early 
1980s until the present day, the susceptibility data for 416 UK isolates from the 
ClosER surveillance study (2012-2016) was used as a modern comparator set.  
Significant increases in geometric mean MICs between the historical and modern 
isolate collections were observed. All treatment compounds, MET, VAN and FDX, 
exhibited significant differences across the two panels (p<0.0001, p<0.0002 and 
p<0.0001 respectively). CDI pre-disposing agents, MXF and CLI demonstrated 
highly significant differences (p=0.0025 & p=0.0053; Table 15). All other test 
compounds also exhibited statistically significant increases in MIC; (Table 15). 
These clear statistical differences between the two time periods indicated the 
development of antimicrobial resistance in C. difficile across all classes.  
All test compounds demonstrated an MIC50 increase of one doubling dilution from 
the historical (1980-1986) to the modern collections (2012-2016), with the 
exception of IPM and CHL; (Table 15). Since MIC50 is an indicator of the 
fundamental activity of an antibiotic on the total C. difficile population, this reflects 
a general trend for reduction in susceptibility to most antimicrobial classes. Due to 
the potential selection pressure exerted by these compounds over long exposure 
periods (approximately 35 years), these findings were not unexpected.  
Although, these data are of value as a whole, the biasing impact of the genotypic 









Historic UK Isolates  
(1980-1986) n=75 
ClosER Study UK Isolates  
(2012-2016) n=416 
 Susceptibility Variance  
(Historic » ClosER)     




















𝒙          
(mg/L) 
VAN 0.5 1 0.704 1 2 0.839 p<0.0002 +0.5 (1) +1 (1) +0.135 
MTZ 0.125 0.25 0.171 0.25 0.5 0.283 p <0.0001 +0.125 (1) +0.25 (1) +0.112 
RIF 0.001 0.002 0.001 0.002 0.004 0.002 p <0.0001 +0.001 (1) +0.002 (1) +0.001 
FDX 0.03 0.06 0.028 0.06 0.125 0.050 p <0.0001 +0.03 (1) +0.06 (1) +0.022 
MXF 1 2 1.617 2 8 2.021 p =0.0025 +1 (1) +6 (2) +0.404 
CLI 4 32 4.000 8 16 4.880 p =0.0053 +4 (1) -16 (1) +0.880 
IPM 4 8 4.553 4 8 3.940 p =0.0133 0 0 -0.612 
CHL 4 8 4.902 4 8 5.462 p <0.0001 0 0 +0.560 
TGC 0.03 0.06 0.035 0.06 0.06 0.050 p <0.0001 +0.03 (1) 0 +0.015 
LZD 2 2 1.725 nt nt nt - - - - 
CIP 16 32 20.022 nt nt nt - - - - 
TZP (n=42) 8 8 6.672 nt nt nt - - - - 
CRO 32 64 27.601 nt nt nt - - - - 
AMX 1 2 0.920 nt nt nt - - - - 
TET 0.06 0.125 0.104 nt nt nt - - - - 
ERY <4 >256 16 nt nt nt - - - - 
Table 15: Comparison of UK C. difficile antimicrobial susceptibility data from 1980-1986 and 2012-2016. VAN-vancomycin, MTZ-
metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-tigecycline, 
LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, TET-tetracycline, ERY-erythromycin. 
Geometric means are calculated to 3 decimal places. nt - not tested. * Significance based on two-tailed Mann Whitney analysis. – p<0.0002 
extremely significant, p<0.006 very significant, p<0.02 significant.
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3.5.3.1.1 Assessing comparator data set similarity 
Examination of ribotype distribution across the historical and modern comparator 
groups demonstrated an imbalance; (Figure 22). Since reduced susceptibility is 
often strongly correlated with PCR ribotype (188, 444, 729), considerations of bias were 
essential for the evaluation of the data. In order to eliminate any potential bias, 
comparator cohorts were matched by ribotype. Ultimately, 59 isolates were 
selected for analysis, in conjunction with ribotype-matched modern comparators; 
(Table 16).  
 
 
Figure 22: Proportional prevalence of PCR ribotypes UK historical (1980-
1986); n=75 and modern (2012-2016); n=416 comparator groups. 
 
3.5.3.1.2 Analysis of PCR ribotype-matched susceptibility data 
Elimination of ribotype bias only strengthened the trend seen prior to genotypic 
balancing, further demonstrating reduced susceptibilities across all antibiotic 
classes over a 35 year period. 
MIC90 represents the level of susceptibility of the resistant bacterial population and 
can therefore be utilised as a valuable tool in describing the potential clinical 






























direct clinical relevance, i.e. therapeutic and CDI predisposing agents (20, 99, 103). An 
increased MTZ MIC90 of two doubling dilutions potentially demonstrated the 
impact of the reliance on this nitroimidazole as the primary treatment compound 
for over 50 years. This perhaps highlights the impact of selective pressure 
gradually driving a reduction in susceptibility. The largest increase in resistance 
over time was observed with MXF, revealing a three-fold doubling dilution 
increase in MIC90. In conjunction with a significant increase in geometric mean 
MIC, this serves to highlight the relevance of modern fluoroquinolones in C. difficile 
outbreaks and evolution (99, 417, 562). He et al. used whole genome and phylogenetic 
analyses to identify strong links between fluoroquinolone resistance and the 
dissemination of the hyper-virulent, 027 strain (562), which has elicited several 
outbreaks since 2003 (34). Rapid clonal expansion of highly fluoroquinolone 
resistant strains, such as ribotype 027, likely accounts for the major increase in 
resistance to MXF, a compound that was only introduced into the formulary in 
1999.  
The temporal differences in C. difficile susceptibilities observed in the present 
study were also identified in the study of Australian isolates by Mackin et al. (726). 
Slight increases in MICs of the primary treatment agents, VAN and MTZ, and a 
substantial increase in MXF MIC were observed over a period of several decades.  
Conversely, with the exception of fluoroquinolone resistance, Hecht et al. observed 
no significant differences between MICs of a collection of 64 isolates from 1983-
1998 and those collected from 2000-2004 (478). Unfortunately the study does not 
delineate the temporal groups any further, as the fifteen year span of the older 
catalogue may well contribute to this perceived lack of resistance development. 
Nevertheless, when assessing variations in susceptibility data, we must reflect 
upon the methodology. Agar incorporation is considered the gold standard method 
for MIC determination in C. difficile (500, 730, 731), but is subject to inter-experimental 
variability due to non-exact endpoints. At the higher end of a testing range, a 
difference in MIC (e.g. 16 to 64 mg/L) is more likely to be a true reflection of 
reduced susceptibility; in contrast, at the lower end of a testing range it is much 
more difficult to determine this with confidence. An increase in MIC from 0.002 to 









Historic UK Isolates  
(1980-1986) n=59 
ClosER Study UK Isolates 
(2012-2016) n=59 
Susceptibility Variance (Historic » ClosER)    



















VAN 0.5 1 0.703 1 1 0.754 +0.5 (1) 0 +0.051 
MTZ 0.125 0.25 0.173 0.25 1 0.291 +0.125 (1) +0.75 (2) +0.118 
RIF 0.001 0.002 0.001 0.002 0.002 0.002 +0.001 (1) 0 0 
FDX 0.03 0.0795 0.031 0.03 0.06 0.036 0 -0.0195 (1) +0.005 
MXF 1 2 1.638 2 16 2.845 +1 (1) +14 (3) +1.207 
CLI 4 16 3.518 8 32 6.034 +4 (1) +16 (1) +2.516 
IPM 4 8 4.394 4 8 4.606 0 0 +0.211 
CHL 4 8 5.000 8 8 5.624 +4 (1) 0 +0.623 
TGC 0.03 0.06 0.035 0.06 0.06 0.047 +0.03 (1) 0 +0.012 
Table 16: Comparison of antimicrobial susceptibility data from 59 PCR ribotype-paired, UK C. difficile from 1980-1986 and 2012-
2016.  
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-




3.5.3.1.3 Temporal comparisons of additional antimicrobial agents 
The panel of agents were selected for testing in order to provide an overview of 
the antimicrobial activity of a broad spectrum of classes. Although there is no 
direct comparative data from the ClosER study for several of these compounds, the 
breakpoint analyses offer useful information into the understanding of MDR in the 
historical collection.  
Several contemporary data sets, obtained using the same methodologies, were 
available for comparison with these additional antibiotic classes. Although the 
majority of modern surveillance data is generated from international C. difficile 
cohorts, research by Freeman and colleagues indicated MIC data for a selection of 
UK isolates (732). In their study ceftriaxone MICs were demonstrated to be one 
doubling dilution higher than those from the historical collection presented here, 
with resistant proportions reported as five times higher (12% historical and 60% 
modern). LZD resistance was also reported in higher proportions (5.3% and 
13.7%, across the historical and modern strains, respectively) with an increase of 
three doubling dilutions in MIC90. These may suggest a possible increase in clonal 
spread or horizontal gene transfer of resistance determinants.  
Data for LZD and ERY resistance may link the presence of MDR determinants, such 
as the cfr or mar genes, with these phenotypes (528). Similarly, the presence of TET 
resistance may suggest the existence of mobile genetic elements, such as 
transposons harbouring TET resistance determinants. TET resistance was 
observed in 9.3% of historical isolates, far lower than the rate reported by a study 
of Scottish isolates from 1979-86 by Taori et al., where this rate reduced to 
comparable levels over the next ten years (381). Interestingly, in the present 
investigation, resistance to TET did not translate to decreased susceptibility to 
TGC, a modern tetracycline derivative. This supports the findings in other 
organisms (733, 734), although one recent study identified the potential for multiple 
tet gene mutations to confer resistance to all tetracycline compounds (735). This 
was hypothesized to be due to a decreased selectivity of efflux proteins, allowing 
TGC expulsion. TET resistance levels were as high as 42% in Chinese isolates, 
compared to only 9.3% in the historical UK isolates (201). Although ribotype 
prevalence and geographic isolation will affect these comparisons, they remain 




All isolates from the historical collection demonstrated sensitivity to AMX and 
TZP. This correlates with several studies indicating total AMX and TZP 
susceptibility (197, 407, 736). In correlation with the historical isolates, almost all 
strains in two Japanese studies demonstrated CIP resistance (198, 724).  
3.5.3.1.4 Temporal susceptibility comparison by individual PCR ribotype 
The relatively small number of isolates recovered from the historical collection 
meant that an in-depth comparison of antimicrobial susceptibilities by individual 
ribotype was not feasible and is unlikely to reflect genuine trends. Nonetheless, 
some evaluations have been proffered for ribotypes 015 and 020, where isolate 
numbers were sufficient. MIC90 figures for the majority of agents, including MTZ 
and VAN (Appendix), demonstrated a doubling dilution increase in the modern 
ribotype 020 strains, with CLI levels rising from 16 to 32 mg/L. Since CLI MICs 
ranged between 2 and 16 mg/L in this ribotype alone, we may be identifying 
differences between lineages with or without previous exposures to the antibiotic. 
More notably, MXF MIC90 figures increased by two doubling dilutions, reflecting 
the same trend as analysis of the entire catalogue. The effects are less pronounced 
in ribotype 015 comparisons, where MTZ and CLI MIC90 figures doubled, although 
this is within the range of error for the agar incorporation susceptibility testing 
method.  
 
3.5.4 Multidrug resistance investigation 
The data from this study demonstrated a MDR rate of 22.7%. This is similar to the 
MDR rate reported in a previous large scale European surveillance study by 
Spigaglia et al. (26%) (444), but considerably lower than reported recently in a 
North American study by Peng et al. (59.7%) (214). Many factors have the potential 
to influence the rates of MDR in any given surveillance study. Of these factors it is 
important to note geographical differences in strain prevalence and antimicrobial 
prescribing that may have an effect on MDR rates in distinct study populations. 
The prevalence of particular ribotypes within a collection will influence overall 
rates of MDR. This may be a feature in the study by Spigaglia et al., where no 
instances of the commonly reported MDR ribotype 027 were isolated, potentially 




crucial. In the US surveillance study by Peng and colleagues, the susceptibility 
testing panel comprised of almost twice as many antibiotics as those in the study 
by Spigaglia et al. Ampicillin and cefoxitin contributed greatly to MDR 
determinations in the former study; compounds that were not even tested against 
the European isolates. This factor may have also inflated the MDR rate of the 
collection tested in the present investigation, as susceptibilities to a large number 
of antimicrobial agents were assessed.  
3.5.4.1 PCR ribotype prevalence of MDR strains 
Forty-one percent of the PCR ribotypes recovered displayed a MDR phenotype, 
largely constituting ribotypes 012, 027 and 078; (23.4%, 17.6% and 11.8%, 
respectively). These correlated with data reported in the ClosER surveillance 
study by Freeman et al. (188). Interestingly, the ClosER study discovered the high 
prevalence of MDR in ribotypes 001 and 017, which were also identified in single 
MDR instances in the historical collection. Nonetheless, the majority of ribotype 
001 and 017 isolates in the collection presented in this thesis did not exhibit a 
multiple resistant phenotype. These may represent distinct lineages of these 
strain types, isolated prior to their evolution into modern MDR genotypes. As a 
direct temporal comparison, an historic collection of Scottish isolates 
demonstrated dominance by ribotypes 012 and 001, representing 43% and 29% 
of the total MDR strains, respectively (381). 
Phylogenetic analysis estimates that the ribotype 017 clone did not reach Europe 
until 1986 (580). However, the 017 isolates in the historical collection originated 
from specimens dating 1981 and 1982. Therefore, these isolates may indicate the 
international dissemination of this ribotype earlier than previously believed. The 
lack of a multi-resistant phenotype in the majority of these strains, potentially 
suggests an independent, parallel evolution, where multiple resistance-conferring 
determinants were yet to be acquired. 
3.5.4.2 Multidrug resistance patterns 
In the historical collection, nearly half (47.1%, n=8) of the MDR strains exhibited a 
combination of ERY, CLI and fluoroquinolone resistance; (Table 13). This finding 
was in concordance with a recent large scale review (498), which indicated this 
combination as the most prevalent (comprising of almost 30% of all MDR 




(724), further highlighting the potential for geographic variance in resistance 
element distributions. Resistance to ERY and CLI are often reported in tandem, 
frequently amongst ribotype 001 isolates (521, 693, 705). One comparative study of 
strains from 1990 and 2008 by Ilchmann et al. demonstrated significant increases 
in this concomitant phenotype, from 37% to 87% of isolates respectively 
(p<0.001) (693). Interestingly, European surveillance by Spigaglia et al. 
demonstrated that all modern MDR isolates were characterised by a combined 
ERY and CLI resistance phenotype (444). The presence of the ermB gene has been 
identified as the most common MLSB resistance-conferring determinant in C. 
difficile (444, 489, 518), suggesting a proficiency in the dissemination or selection of 
this gene over time. Where the historical collection demonstrated consistent co-
resistance of MXF and ERY, the majority (71%) also exhibited CLI resistance. This 
pattern is strongly reflective of Ackermann’s C. difficile collection incorporating 
strains from 1986-1995 (521). 
Research by Spigaglia and colleagues revealed that by far the most dominant MDR 
phenotype was the combination of ERY, CLI, MXF and RIF; with this permutation 
dominated by ribotype 001 (444). Although only one historical ribotype 001 isolate 
was designated as MDR, the pattern of resistance matched the one outlined by 
Spigaglia et al., with the exception of RIF resistance. Large proportions of modern 
MDR isolates exhibit resistance to RIF (737-740), with the increase in prevalence of 
this phenotype across Italy and eastern Europe linked to the extensive use of 
rifamycins in these countries over the last twenty years (498). This offers a potential 
explanation as to why no evidence of rifamycin resistance was observed amongst 
the historical collection, whereas it contributes substantially to modern MDR 
rates. Many of the recently emerging ribotypes, such as 176 and 356 are closely 
related to pre-existing MDR types such as 027 (739) and 018 respectively (740). They 
may not be expected in an historical collection and their increasing presence in 
more recent epidemiological studies could partly explain the increase in MDR over 
time.  
Each of the four ribotype 012 and three 027 isolates exhibited differing 
combinations of resistance, demonstrating the potential for these ribotypes to 
develop resistance to varying classes of antibiotics. A similar pattern is reflected in 




five different resistance combinations (444). Differences in fitness cost may impact 
upon resistance acquisition and survival, as individual isolates respond to specific 
antimicrobial exposures. Wasels and colleagues demonstrated no detrimental 
effect of fluoroquinolone resistance mutations on the in vitro fitness of C. difficile 
(639), while other transposable elements, such as macrolide-lincosamide-
streptogramin B resistance determinants presented a fitness burden (518). 
Interestingly, a recent observational study of CDI control interventions 
highlighted a greater decline in CDI cases associated with fluoroquinolone strains 
when use of the antibiotic class was restricted (387). This notable research by 
Dingle et al. indicated that resistance to key antimicrobial classes may potentially 
be as important to strain proliferation as multiple resistances. 
Four strains displayed phenotypic resistance to CLI, CHL and LZD. This 
combination of class resistance has been linked to a transposable cfr homologue 
reported in C. difficile by Marin and colleagues (528). Whole genome sequencing 
analysis of all historical strains is presented in Chapter Four, providing a valuable 






This study highlights some of the difficulties faced when investigating historical 
culture collections. Whilst recovery was achieved from a proportion of the aged 
specimens, approximately 85% of patient strains either remained dormant under 
exposure to conventional germination methods, or more likely, had perished 
leaving no viable bacterial cells to recover.  
The observation of striking similarities between ribotype prevalence amongst the 
historical isolates and modern epidemiology prompted two potential 
explanations: 
1) Ribotype distribution in the UK has a tendency to revert to a state of 
equilibrium, when outbreaks subside,  
Or  
2) The prevailing ribotypes are the fittest for long-term survival and recovery.  
Through continued surveillance of this important nosocomial pathogen, emerging 
ribotypes external to this stable distribution, can be monitored carefully as 
potential epidemic strains.  
This investigation has also potentially identified two of the earliest isolates of PCR 
ribotype 027 C. difficile, dating back to 1981. Due to the originality of these 
findings, MLVA was utilised to check for contamination events amongst other 
laboratory strains, ultimately demonstrating that the historical isolates were 
distinguishable from 633 other ribotype 027 lab strains. Phylogenetic analyses of 
the historical collection is further discussed in Chapter Four. 
Significant increases in antimicrobial resistance were observed between the 
historical collection (1980-86) and ClosER isolates (2012-2016). Geometric mean 
MICs were increased in the modern strains for all but one of the antimicrobial 
comparators (IPM). Susceptibility to the therapeutic agents (MET, VAN, FDX) 
demonstrated marginal decreases, but resistance was not observed. Reductions in 
high-level CLI resistance may indicate the success of the management of this 
known risk antibiotic, but increased resistance in other classes remains a concern. 
On average lower rates of MDR were observed in the historical collection in 




ribotypes 001, 012, 027 and 078 detected (118, 381, 444). A combination of ERY, CLI 
and fluoroquinolone resistance was the most frequently observed resistance 
pattern. This is reflective of previous studies, indicating the involvement of MDR 
conferring genes, such as ermB. This serves to emphasise the extent of MDR 
development and highlights the need for antimicrobial stewardship.  
MXF resistance was observed in the historical strains, long before the introduction 
of the compound, further strengthening the argument for co-selection of 
resistance mutations with earlier generation compounds (741, 742). As expected, due 
to the current widespread resistance to fluoroquinolones (118, 498), MXF resistance 
increased considerably, with MIC90 data revealing a three-fold doubling increase. 
Intriguingly, the three ribotype 027 isolates recovered from 1981-86 
demonstrated MXF resistance. These strains represent evidence of resistance in 
this hyper-virulent ribotype, prior to existing reports in the literature (34, 112, 289, 
562), and may contribute to the understanding of the evolution of this epidemic 
strain type. Nonetheless, caution must be taken, with further investigations 




Chapter 4 Genomic Interrogation and Phylogenetic Analysis of 
Historical Clostridioides difficile (1980-86) 
4.1 Introduction 
The acquisition of an historical collection of C. difficile isolates has provided an 
opportunity to generate valuable baseline data, from which we can assess strain 
dissemination and antimicrobial resistance development. Whilst phenotypic 
investigations present important information on bacterial susceptibility, they 
cannot provide information on the mechanistic foundation of resistance. Modern 
molecular techniques offer the opportunity to elucidate the genetic machineries 
behind antibiotic resistance and enables epidemiologists to monitor how 
determinants disseminate.  
The advent of NGS has enabled the rapid, inexpensive acquisition of large 
quantities of genomic data. Unlike Sanger sequencing (743), where DNA is 
synthesised with chain-terminating di-dNTPs and sequenced in a separate stage 
of the process, NGS enables sequencing by synthesis on a massively parallel 
scale (744). Here adaptor-ligated DNA is indexed and hybridised to 
oligonucleotides fixed to a glass flow cell. Clustering occurs through a process of 
bridge amplification, where fixed template strands are complemented by DNA 
polymerase before being washed away, allowing the nascent strand to form a 
bridge by binding to a second oligo on the flow cell. Polymerase then generates a 
copy of the original template bound to the flow cell, before the process is 
repeated to generate millions of copies through clonal amplification. Sequencing 
of these clusters occurs with the addition of fluorescently labelled nucleotides, 
which are excited after each nucleotide addition. The differences in signal 
emission determines the nucleotide incorporation at each step (745). This method 
produces millions of read sequences, which require complex in silico assembly. 
Sequencers will produce terabytes of output data for individual base calls. In 
order to assess the accuracy of each of these determinations the base calls are 
each associated with a quality score, known as a Phred score. This data is 




sequencer peak parameters, such as resolution and shape, and represent the 
probability of a correct call (746).  
Reliable genome assembly and variant calling from NGS data requires a complex 
pipeline of computational processes for quality control, adapter trimming, 
sequence alignment, mapping to a reference genome, indel re-alignment, PCR 
duplicate removal and variant analysis (747). Adding to the challenge of 
computational assembly, there are multiple options for analysis tool selection at 
any given stage of the algorithm (748). The majority of practices involve 
executable, UNIX command line based frameworks without a graphical user 
interface (GUI), making initial access for beginners particularly difficult. 
Nonetheless, some GUI based frameworks are available (749). Taverna (750) and 
Galaxy (751) are two such web-based interfaces, which can be utilised in 
conjunction with cloud processing, negating the requirement for vast amounts of 
local processing power. Standalone NGS handling software such as CLC 
genomics workbench are available and provide a more user friendly, guided 
analysis, although licenses are highly expensive, limiting their availability (752). 
There are many assembly and alignment tools available that can be categorised 
into two main approaches, string and de Bruijn graph based methods (748). 
Burrows-Wheeler transformation is an example of the former, where tools such 
as BWA (Burrows-Wheeler Aligner) (753) and Stampy (754) rely on a reversible, 
text-based transformation of reads, using cyclical rotation and subsequent 
sorting to dramatically reduce required processing power. The de Bruijn graph 
method is based on linking overlapping k-mers to generate all potential 
pathways through a sequence. Software tools such as Velvet (755) enable the 
simplification of these pathways, reducing computational memory 
requirements. Whilst no single tool represents the gold standard across all 
metrics, Hatem and colleagues identified BWA as the best application for longer 
read lengths, as produced with Illumina NGS chemistry (756). 
Variant calling is typically the fundamental goal for NGS, with different tools 
available for this task, including the Genome Analysis Tool Kit (GATK) (757) and 
SAM tools (758). Differentiating true SNPs from sequencing artefacts is the most 
challenging part of the process, therefore the greater the read depth (number of 




Whilst the GATK attempts to define optimal pipelines for sequence data analysis 
(757), each research group implements pipelines tailored to their specific needs. 
Analysis of the C. difficile genome is no different, with the use of Stampy for 
mapping, Velvet for de novo assembly and SAM tools for SNP calling seemingly 
preferred in recent, large scale studies (257, 565, 760, 761). Nonetheless, 
bioinformatics expertise is required to access these pipelines, hence, the most 
accessible platform, CLC genomics workbench, was utilised here. 
In the pursuit of resistance elements, searchable resistance determinant 
databases (762, 763) were interrogated with the historical genomes and loci of 
widely reported resistance-conferring chromosomal mutations were aligned 
(764). Polymorphisms in the DNA gyrase genes, gyrA and gyrB have been 
extensively described in C. difficile (438, 443-445), with the substitutions in the QRDR 
commonly associated with fluoroquinolone resistance (439, 442, 765). The most 
common amino acid substitution in gyrA is that of Thr82>Ile (438, 443-445) and has 
been strongly associated with the epidemic ribotype 027 (112, 766). Conferring 
high levels of resistance to modern generation fluoroquinolones, this mutation 
reduces the antibiotic binding capacity of the gyrase enzyme, resulting in a 
continuation of unhindered DNA synthesis (440). These genetic regions were 
examined to ascertain the levels of these polymorphisms in isolates from the 
early 1980s. 
The dissemination of antimicrobial resistance determinants often occurs 
through the horizontal transfer of mobile elements. Common MDR genes 
involved in methyltransferase activity, ribosomal protection and efflux have all 
been reported in C. difficile, as associated with transposable elements (444, 488, 489, 
528). The main TET resistance encoding element, tetM, has been observed 
primarily on Tn916 transposons (487, 488), whilst carriage on a Tn5397-like 
determinant has also been reported (489). Methylation of key residues of 
ribosomal subunits can sterically block antibiotic binding, enabling DNA 
synthesis to proceed as usual. ErmB and Cfr are two such enzymes with this 
capability and have been implicated in concurrent resistance in C. difficile to 
ERY, CLI and the PhLOPSA group of antimicrobials (97, 489, 511, 528). Seventeen 
different genetic arrangements of the ermB gene have been described in C. 




increase in the frequency of ermB detection amongst C. difficile isolates was 
observed between 1991-98, correlating with increased use of CLI in the 
experimental setting (510). Rates among modern strains have been reported as 
high as 28% amongst European isolates, with confluent ERY and CLI resistance 
observed (444). Frequencies of cfr determinants have been reported as around 
10% (530), with Marin et al. identifying the gene in seven out of nine LZD resistant 
isolates (528). 
Determination of the prevalence of resistance determinants amongst historical 
isolates may help to reveal the involvement of these elements in resistance 
progression over the last 35 years. Identification of the frequencies of resistance 
genes could further allude to reasons for proliferation amongst specific 
ribotypes. In this chapter, NGS was performed on all historical isolates, with 
genomic data interrogated for resistance-conferring chromosomal mutations 
and transposable determinants. Findings were correlated with susceptibility 
phenotypes and evaluated for potential clinical impact. Furthermore, 
phylogenetic analysis of the historical isolates and modern comparators was 
performed to assess the evolution of common ribotypes. 
 
4.2 Rationale 
The determination of genetic aetiology for antimicrobial resistance phenotypes 
is essential to the understanding of MDR progression. NGS technologies, 
combined with a plethora of genomic analysis tools were utilised to facilitate a 
greater awareness of resistance mechanisms and prevalence in the historical 
collection. By enabling comparisons to modern studies, this data would allow 
epidemiological differences between two temporally distinct bacterial 
collections to be identified and evaluated for their influence on MDR 
development. Phylogenetic analyses were performed to further contribute to the 
understanding of C. difficile evolution and how the presence of resistant 






4.3.1 Antimicrobial resistance determinant detection 
4.3.1.1 Genomic sequencing 
4.3.1.1.1 Culture and DNA extraction 
Growth from 24 hour C. difficile CBA culture was emulsified in pharmacy grade 
water, achieving a 0.5 McFarland suspension. Emulsifications were transferred 
to a deep-well extraction block and DNA extracted with QIAamp Fast DNA Kit 
chemistry (Qiagen) on a QIAxtractor, with extended lysis stages (2 x 10 
minutes).  
Double-stranded DNA (dDNA) was quantified via a PicoGreen fluorescence 
assay. Briefly, DNA extracts were diluted 1:50 in a Nunclon 96 Flat Bottom Black 
Tray (Thermo Fisher Scientific, USA) and mixed with 0.5% PicoGreen (Life 
Technologies, USA) in TE Buffer (Sigma-Aldrich, USA). This was followed by a 
ten minute incubation at ambient temperature. Fluorescence was excited at 
585nm and measured at 535nm, using a Tecan infinite F200 pro. Absorbance 
readings were converted to dDNA quantifications via a calibration curve of 
lambda DNA (Sigma-Aldrich). A cut-off of 1 µg/µL dDNA was implemented 
before proceeding with library preparation.  
Quality control and sample transposition were assured by PCR ribotyping of four 
DNA extracts from disparate plate locations and cross referenced back to the 
original determination. 
4.3.1.1.2 Library preparation and next generation sequencing 
Library preparation and sequencing was performed by the University of Leeds 
Next Generation Sequencing Facility using the NEBNext® Ultra™ DNA Library 
Prep Kit for Illumina®; (New England Biolabs, USA).  
Briefly, dDNA was quantified with the Quant-iT™ High-Sensitivity dsDNA Assay 
Kit (Thermo Fisher Scientific) and a FLUOstar Omega Microplate Reader (BMG 
Labtech, UK) to enable an optimal 200 ng of gDNA to be sheared via sonication 
in a Covaris E220 Focused Ultrasonicator (Covaris, USA). Optimal DNA 
fragmentation was assessed with an Agilent Technologies 2200 Tapestation 




a two stage incubation with end prep enzyme mix; 30 minutes at 20°C, followed 
by 30 minutes at 65°C. NEBNext adapters were ligated to the end-repaired 
fragments during a 15 minute incubation at 20°C, followed by cleavage of the 
adapter hairpin at the uracil base by incubation with the USER® (Uracil-Specific 
Excision Reagent) Enzyme (New England Biolabs) at 37°C for a further 15 
minutes. This process created the Y-shaped adapters necessary for primer 
annealing and binding to the complementary oligonucleotide sequences on the 
flow cell. A magnetic bead clean up (AxyPrep Mag PCR clean-up; Axygen, USA) 
with two 80% ethanol washes removed excess reagents and unbound adapters. 
Adapter-ligated fragments were indexed and enriched with unique 6bp primer 
indexes, through eight PCR cycles. Post-PCR samples were subjected to a further 
magnetic clean up step to remove any primer dimers and an additional 
Tapestation check to assess the enriched fragment spread. Indexed libraries 
were quantified as previously (4.3.1.1.1), allowing equal concentrations of 
sample DNA to be pooled for cluster generation on the Illumina cBot Cluster 
Generation System (Illumina, USA). Clonally amplified DNA, hybridised to the 
flow cell, was sequenced on a HiSeq 3000 Sequencing System (Illumina, USA) 
through sequencing by synthesis.  
4.3.1.1.3 Bioinformatic assembly 
Raw read data files were processed through a bioinformatics pipeline, using CLC 
Genomics Workbench (Qiagen) (752). Briefly, forward and reverse reads were 
compiled into single files by the software, before processed through a trimming 
protocol. Here poor quality reads (cut-off 0.05) were annotated to be ignored in 
downstream analyses. De novo assembly was achieved via a de Bruijn graph 
method (755) with minimum contig length set at 200. Multiple contig files were 
generated and output in FASTA format. 
 
4.3.1.2 Genome annotation and resistance gene identification 
Identification of resistance determinants was accomplished with a multiple step 
algorithm; (Figure 23). Coding DNA sequences (CDS) of all sets of contig 
assemblies were annotated using the Rapid Annotation using Subsystem 
Technology (RAST) web server based service, accessible at 




annotations were output in both GenBank (an annotated sequence format for 
use with the National Center for Biotechnology Information (NCBI)) and a fully 
searchable, tab delimited format (.csv).  
RAST outputs were interrogated for resistance genes, putatively implicated in C. 
difficile; (Table 17). Nucleotide sequences of known resistance-conferring, 
mutable genes; DNA-directed RNA polymerase beta subunit (rpoB), Large 
ribosomal subunit proteins (L3, L4 and L22), DNA gyrase subunit A (gyrA) and B 
(gyrB) were extracted from RAST output files and converted into a FASTA 
format using a programmable script coded by the author in the R programming 
language; (Appendix). Sequences were then compared with CD630 genes (314) 
through multiple sequence alignment, using Clustal Omega 1.2.4 (764). 
Assembled contig sequences were interrogated for antibiotic resistance genes 
using both the Comprehensive Antibiotic Research Database’s (CARD) 
Resistance Gene Identifier (RGI) (762) and ResFinder 3.0 (763). RGI search 
parameters were set to include perfect, strict and loose hits, with the latter 
allowing for novel resistance determinant and distant homologue searches. All 
“perfect” and “strict” hits were further investigated for their relevance to C. 
difficile. Results from CARD and ResFinder were cross referenced to ensure 
maximal identifying coverage, any discrepancies were re-run as confirmation. 
Contigs were also searched by PlasmidFinder 1.3 (Center for genomic 
epidemiology) (770) to identify plasmid-borne genes originating from the 
Enterobacteriaceae family and enterococcus, streptococcus and staphylococcus 
genera. 
Where the aforementioned software did not identify certain targeted resistance 
determinants, amino acid sequences of selected putative MDR genes (Table 17) 
were obtained from the necessary publications. These were then BLAST 
(v.2.2.26) (771) searched against the individual genomes using the RAST SEED 
Viewer (v.2.0). The cfr, CD2068 and qnr-like sequences used for comparisons 
were obtained from accession numbers KM359438.1, YP_001088582.1 and 
CAJ69589.1; respectively. The marR gene from CD630 was compared to all 




Determinant Mechanism and Putative Phenotype Reference 
lmrA Bacterial homologue of human MDR efflux 
pump, MDR1, functional in E. coli. 
 
Van Veen et al. (1996) 
(772) 




Chesneau et al. (2005) 
(773) 
msrA ABC-F subfamily involved in ribosomal 
protection from macrolide and streptogramin 
resistance. 
 
Reynolds et al. (2003) 
(774) 
efrA ABC transporter involved in MDR efflux, 
including fluoroquinolones. 
 
Lee et al. (2003) (775) 
cfr rRNA methyltransferase encoded by cfr causes 
methylation of position A2503 of the 23S rRNA 
gene. CHL, LZD, CLI and ERY resistance. 
 
Marin et al. (2015) (528), 
Candela et al. (2017) (530) 
qnr-like  Pentapeptide repeat proteins protect DNA 
gyrase from quinolone activity. 
 
Rodríguez-Martínez et al. 
(2008) (776) 
CD2068 Homologue of cmpA, an ABC transporter 
involved in MDR efflux, including 
fluoroquinolones. 
 
Ngernsombat et al. 
(2009) (777) 
cme Efflux pump homologue of norA. Resistance to 
ethidium bromide, safranin O, and ERY. 
 
Lebel et al. (2004) (546) 
marR Repressor gene for efflux. Resistance to CHL, 
cephalosporins, rifamycins, tetracyclines, 
fluoroquinolones and penicillins. 
 
Leeds et al. (2014) (213) 
cdeA MATE family Na+-coupled efflux pump. 
Responsible for ethidium bromide and acriflavin 
resistance, as well as putative fluoroquinolone 
resistance. 
 
Dridi et al. (2004) (509) 
Table 17: List of putative resistance genes with potential involvement in C. 
difficile resistance, used for historical genome interrogation. MDR – 
multidrug resistance, MATE - multidrug and toxic compound extrusion, CHL – 






Figure 23: Work flow for sequence analysis and interrogation. CARD RGI – the 
Comprehensive Antibiotic Research Database and Resistance Gene Identifier 
software (762), RAST - Rapid Annotation using Subsystem Technology (767), 
ResFinder 3.0 (763) (Center for Genomic Epidemiology), Clustal Omega multiple 






4.3.1.3 Mobile element determination 
Transposon identification was sought in order to correlate resistance 
determinant configurations with published data. The sequences of Tn5397 and 
Tn916-like transposons from C. difficile genomes CD630 and M120; accession 
numbers AM180355.1 and FN665653.1; respectively, were obtained from the 
NCBI website. The cfr gene encoding element, Tn6218 was acquired from 
accession number KM359438.1. Sequences were aligned to the genomes of the 
historical collection using NCBI BLAST. 
 
4.3.1.4 Investigative responses to genotyping data 
4.3.1.4.1 Efflux pump inhibition 
The impact of efflux mechanisms on antimicrobial susceptibility was 
investigated for all isolates demonstrating ERY resistance in the absence of ermB 
genes, as well as those resistant to MXF. The agar incorporation method used 
previously (Chapter Three), was adapted to allow integration of known efflux 
inhibitors; the plant alkaloid, reserpine (Sigma, UK) (778) and proton motive force 
inhibitor, Carbonyl Cyanide 3-Chlorophenylhydrazone (CCCP); (Sigma, UK) (779). 
Briefly, both efflux inhibitors were dissolved in 5 mL dimethyl sulfoxide and 
further diluted in sterile water to create 250 mg/L and 800 mg/L solutions, for 
CCCP and reserpine respectively. CIP, MXF and ERY dilution series were each 
tested independently and in the presence of reserpine and CCCP to compare the 
effect of these compounds on antimicrobial susceptibilities. Wilkins Chalgren 
anaerobe agar was used with reserpine assays and Brazier’s (supplemented 
with 2% lysed horse blood) with CCCP. Two millilitres of antimicrobial solution, 
plus equal volumes of efflux pump inhibitor were added to 16 mL of agar base 
(prepared with a 20% reduction in water content, to accommodate the addition 
of efflux pump inhibitors). For the control series, where no inhibitor solution 
was added, agar was supplemented with 2 mL sterile water. As previously, 
plates were dried and multipoint inoculated with MXF resistant and ERY 
resistant, ermB negative isolates. In line with other research, a four-fold change 





4.3.1.4.2 Further antimicrobial susceptibility testing 
Streptomycin susceptibility was assessed with the agar incorporation method, 
as previously described; (Chapter Three). Streptomycin (Sigma, UK) was 
dissolved in sterile water and tested in doubling concentrations, ranging 
between 256 and 2,048 mg/L. Isolates harbouring the putative streptomycin 
resistance gene, aadE (JV73 and JV74) were tested alongside nine aadE negative 
isolates. 
Isolate JV60, encompassing an EF-Tu homologue of a mutated elongation factor 
relating to resistance to the kirromycin class of antibiotics, was not tested for 
phenotypic resistance to this class. Equally, JV73 was not tested for a kanamycin 
resistant phenotype, related to the presence of the AAC(6')-Ie-APH(2'') gene, 
since it has been demonstrated to have minimal Gram positive and anaerobic 
activity (780, 781).    
 
4.3.2 Phylogenetic analysis 
NGS data from the historical isolates of seven common PCR ribotypes; 001, 002, 
014, 015, 020, 027 and 078, encompassing three different clades, was further 
processed through a phylogenetic analysis pipeline. Sequences were analysed, 
grouped by PCR ribotype. Additional comparator sequences from these 
ribotypes were included from the EUCLID study (154), (552 sequences from a 
pan-European survey [2012-2013]) and He et al. (562) (149 ribotype 027 
sequences [1985-2010]).  
Sequence data was processed by Dr David Eyre (Nuffield Department of 
Medicine, University of Oxford, John Radcliffe Hospital, Oxford) using a 
bioinformatics pipeline established for the analysis of bacterial genomic data (257, 
782). Briefly, Illumina HiSeq sequencing data was mapped to the C. difficile 630 
reference genome (314), with the exception of ribotype 027 (clade 2) isolates, 
which were mapped to CD196 (579) to enable comparisons of the novel genetic 
elements exhibited by this ribotype. Mapping was performed with Stampy (754), 
variants were identified using SAMtools mpileup (758) and filtered requiring a 
read consensus of >75% and a minimum coverage of five reads. Maximum 




data adapted with ClonalFrameML (784) to exclude regions of recombination. The 
author analysed the resulting trees using the Interactive Tree of Life (v.4.2) (785). 
Prediction intervals were calculated based on SNP and year differences to 
nearest neighbouring taxa on the maximum likelihood trees. RStudio v.1.1.383 
(786) was used to calculate prediction intervals based on Poisson distribution of 
the estimated molecular clock (0.74 per genome, per year), using the formula:  
ppois (SNP difference, years difference*0.74). 
E.g. for 25 actual SNP differences between two genomes 31 years divergent, the 






4.4.1 Antimicrobial resistance determinant detection 
4.4.1.1 Bioinformatic assembly 
All historical isolate NGS read data assembled into multiple contig files 
successfully. The average assembly size was 4,371,170bp, consisting of 494 
contigs with N50 and L50 figures of 128,249 and 26, respectively. Individual 
genome assembly statistics are reported in the Appendix. 
4.4.1.2 Transferable genetic elements 
Twenty different antibiotic resistance encoding genetic elements were identified 
amongst the genomes of the historical C. difficile isolate collection. Sixteen of 
these were detected by a combination of the CARD-RGI and ResFinder 3.0 
databases. Eighteen (24.0%) historical strains revealed mobile genetic elements, 
by this algorithm. Four additional resistance gene homologues were identified 
via BLAST comparisons.   
TET resistance gene, tetM was identified in seven (9.3%) strains, all of which 
demonstrated a TET resistant phenotype. These strains represented three PCR 
ribotypes; 012 (n=4), 078 (n=2) and 015 (n=1); (Figure 24). All tetM genes 
clustered into two phylogenetically distinct groups; (Figure 25). In all ribotype 
012 genomes, tetM was contained on the Tn5397 transposon, matched with 
100% coverage and sequence identity. All other genomes harbouring the TET 
resistance determinant carried it on a Tn916-like mobile element, 
demonstrating 100% coverage and 97% identity with that contained on the C. 
difficile M120 genome. One isolate, JV32, harboured an additional tetA(P) gene in 
conjunction with tetM, displaying a TET MIC of >32 mg/L. No other strains 
exhibited reduced susceptibility to TET; (Table 18).  
MLSB resistance determinant, ermB, was detected in six (8.0%) genomes, 
reflecting ribotypes 014 (n=3), 012 (n=2) and 010 (n=1); (Figure 24). All ermB 
gene sequences clustered by ribotype; (Figure 25). Three isolates (50.0%) 
demonstrated a combined CLI and ERY resistant phenotype, whilst one (16.7%) 
exhibited resistance to CLI only and two (33.3%) were fully susceptible to 
members of the MLSB class. Eight (10.7%) strains displayed an ERY resistant 




reduced susceptibility to CLI in the absence of the ermB determinant; (Table 18; 
Figure 26). 
Four genomes (5.3%) revealed the presence of a collection of VAN resistance 
determinants (vanRG, vanSG, vanUG, vanYG, vanG, vanXYG, vanWG and vanTG), 
correlating precisely with all intermediate VAN resistant (4 mg/L) phenotypes. 
Although representing three ribotype variants, all four of these strains were co-
recovered from a single patient at multiple time points. Sixty-four remaining 
strains exhibited CARD-RGI matches of 77.9% similarity to VAN resistance 
regulator gene, vanRG, with single instances of vanSD and vanSG genes also 
discovered. None of these strains conferred a reduced susceptibility to VAN; 
(Table 18). 
 
Figure 24: Distribution of resistance determinants and phenotypes identified 
in historical C. difficile genomes (1980-86) by PCR ribotype. Inner circles refer 
to susceptibility phenotype proportions to relevant agents; ermB – erythromycin 
and clindamycin, tetM – tetracycline, cfr – clindamycin, chloramphenicol and 
linezolid, Van operon – vancomycin, aadE – streptomycin, Thr82>Ile in gyrA – 




All four LZD resistant isolates, JV14, JV17, JV22 and JV30 demonstrated coding 
sequences with 100% identity to the cfr gene, previously identified in C. difficile 
(528). All cfr genes were located on Tn6218 transposons, correlating with 
concurrent CHL and CLI resistance. 
The genomes of strains JV73 and JV74 demonstrated perfect matches to 
streptomycin resistance determinant, aadE, with the former also revealing an 
AAC(6')-Ie-APH(2'') complex associated with kanamycin resistance. Upon further 
testing both of these isolates exhibited streptomycin resistance (>2,048 mg/L), 
whilst all but one aadE negative strain indicated MICs of <512 mg/L. Isolate 
JV47 revealed a streptomycin MIC of >2,048 mg/L in the absence of the aadE 
determinant; (Appendix). 
The putative ABC transporter, CD2068 was detected in 85.3% of historical 
isolates, with BLAST comparisons revealing identities >98%. The remaining 
eleven isolates only demonstrated 30-31% homology and consisted of ribotypes 
015 (n=6), 020 (n=3), 341 (n=1) and 862 (n=1). All isolates revealed >99% 
identity with qnr-like putative pentapeptide repeat-containing protein, with the 
exception of JV59 which revealed 91% homology. Isolate JV60, ribotype 619, 
exhibited a sequence similarity (80.6%) with a streptomyces derived elongation 
factor, EF-Tu, implicated in natural kirromycin resistance.  
All genomes revealed 100% identity with the cme gene from C. difficile strain H3, 
whether demonstrating an ERY resistant phenotype or not. The multidrug efflux 
gene, cdeA was universally observed in all historical genomes. Conversely, MDR 
determinants msrA, lmrA, vgaB and efrA, present in other organisms were not 







Figure 25: Phylogenetic analysis of ribotype (RT) clustering of ermB (top) 
and tetM genes (bottom) identified in the historical (1980-86) C. difficile 
collection. Genes were aligned with Clustal Omega and visualised by the 
Interactive Tree of Life. 
 
4.4.1.3 Mutational resistance 
Fifty-six (74.7%) genomes revealed amino acid substitutions in known mutable 
resistance-conferring genes (gyrA, gyrB and rpoB); (Table 18).  
Seven strains (9.3%), including all three ribotype 027 isolates exhibited the 
common Thr82>Ile polymorphism in the gyrA gene. All MXF resistant 
phenotypes (16-32 mg/L) correlated with this mutation. Two of six ribotype 001 
strains shared these characteristics, along with each ribotype 041 and 200 
isolate; (Figure 24). Epidemic ribotype 027 strains also exhibited two further 
gyrA mutations; Leu406>Ile and Asp468>Asn, which have not previously been 
reported as linked with fluoroquinolone resistance. Across the entire collection, 
only two other non-synonymous mutations were determined in gyrA; 
Lys413>Asn (n=3) and Asp205>Glu (n=1), although only the ubiquitous CIP 
resistant phenotype was displayed in these strains; (Table 18).  
Eight variant gyrB polymorphisms were identified amongst the strain collection, 
with fifty (66.7%) genomes revealing at least one non-synonymous mutation in 







fluoroquinolone resistance were discovered, five mutant variants were 
determined. The two most prevalent were Val130>Ile and Ile139>Arg, revealed 
in 29.3% and 25.3% of historical genomes, respectively. Ribotype 078 strains all 
exhibited three gyrB mutations; Gln160>His, Ser366>Val and Phe375>Leu, 
whilst all ribotype 017 isolates displayed the Ser366>Ala mutation alone. Single 
instances of Ile266>Val and Glu523>Gly substitutions were identified in 
ribotypes 061 and 137, respectively; (Table 18). None of these substitutions 
correlated with reduced susceptibility to MXF. 
Analysis of the RNA polymerase β sub unit encoding gene, rpoB, revealed six 
non-synonymous mutant genotypes; Ile750>Met (10.7%), Ile750>Val (8.0%), 
Ile750>Glu (1.3%), Pro1113>Ser (1.3%), Val1033>Gly (1.3%) and concomitant 
Glu1037>Gln, Asn1207>Ala, Ala1208>Thr and Asp1232>Glu mutations, 
representing all ribotype 027 strains. Newly assigned ribotype 862 strain, JV59, 
the only isolate exhibiting reduced susceptibility to rifampicin, demonstrated 16 
non-synonymous mutations in the rpoB gene; (Table 19), however, none had 
been previously linked to a resistant phenotype. 
No non-synonymous mutations were observed in the majority of historical 
genomes when compared to the marR transcriptional regulator sequence of 
CD630. Sequence identity was 99% for all isolates except JV59, which had 











Non-synonymous mutations  Phenotypic 
Resistance Ω gyrA gyrB rpoB 
JV01 012 tetM, ermB, 
cdeA 
      CLI, CIP, CRO, 
TET, ERY 
JV02 027 cdeA Thr82Ile,           






MXF, CLI, IPM(I), 
CIP, CRO, ERY 
JV03 015 cdeA   Val130Ile   CLI, CIP, CRO(I) 
JV04 001 cdeA    CLI, CIP, CRO(I) 
JV05 020 cdeA   Ile139Arg   CLI(I), CIP, 
CRO(I) 
JV06 020 cdeA  Ile139Arg  CIP, CRO(I) 
JV07 015 cdeA   Val130Ile   CLI(I), CIP, 
CRO(I) 
JV08 220 cdeA  Ile139Arg Ile750Val, 
Pro1133Ser 
CLI, CIP, CRO(I) 
JV09 015 cdeA   Val130Ile   CLI(I), CIP, 
CRO(I) 
JV10 015 cdeA  Val130Ile  CLI(I), CIP, 
CRO(I) 
JV11 015 cdeA   Val130Ile   CLI, CIP, CRO(I) 
JV12 020 cdeA  Ile139Arg  CLI, CIP 
JV13 020 cdeA   Ile139Arg   CLI(I), CIP, 
CRO(I) 
JV14 078 cfr, tetM, cdeA Lys413Asn Gln160His, 
Ser366Val, 
Phe375Leu 
Ile750Met CLI, CHL, LZD, 
CIP, TET 
JV15 020 cdeA   Ile139Arg   CLI, CIP, CRO(I) 
JV16 056 cdeA    CIP 
JV17 015 cfr, tetM, cdeA Lys413Asn Gln160His, 
Ser366Val, 
Phe375Leu 
Ile750Met CHL, CLI, CIP, 
LZD, CRO(I), TET 
JV18 103 cdeA    CLI, CIP, CRO(I) 
JV19 137 cdeA   Val130Ile, 
Glu523Gly 
  CLI, CIP, CRO(I) 





Thr82Ile   VAN(I), MXF, CLI, 
CIP, CRO(I), ERY 
JV22 078 cfr, tetM, cdeA Lys413Asn Gln160His, 
Ser366Val, 
Phe375Leu 
Ile750Met CLI, IPM(I), CHL, 
LZD, CIP, TET 





Thr82Ile   VAN(I), MXF, CLI, 
CIP, CRO, ERY 





 Thr82Ile,           
Leu406Ile,      
Asp468Asn 
    VAN(I), MXF, CLI, 
IPM(I), CIP, CRO, 
ERY 










Non-synonymous mutations  Phenotypic 
Resistance Ω gyrA gyrB rpoB 
JV26 015 cdeA   Val130Ile   CLI, IPM(I), CIP, 
CRO(I) 
JV27 020 cdeA  Ile139Arg  CLI, CIP 
JV28 001 cdeA       CLI, CIP 
JV29 002 cdeA    CLI(I), CIP, 
CRO(I) 
JV30 012 cfr, tetM, ermB, 
cdeA 
      CLI, CHL, LZD, 
CIP, CRO(I), TET 
JV31 002 cdeA    CLI, CIP, CRO(I) 
JV32 012 tetM, tetAP, 
cdeA 
      CLI, IPM(I), CIP, 
CRO, TET 
JV33 014 ermB, cdeA  Ile139Arg  CIP 





Thr82Ile     VAN(I), MXF, CLI 
(I), IPM(I), CIP, 
CRO(I), ERY 
JV35 020 cdeA  Ile139Arg Ile750Val CLI, CIP 
JV36 015 cdeA   Val130Ile   CLI, CIP, CRO(I) 
JV37 001 cdeA  Val130Ile  CLI, CIP, CRO(I) 
JV38 626 cdeA   Val130Ile   CLI(I), CIP, 
CRO(I) 
JV39 341 vanYG, cdeA  Val130Ile  CIP 
JV40 014 ermB, cdeA   Ile139Arg   CIP 
JV41 002 cdeA    CLI, CIP, CRO(I) 
JV42 015 cdeA   Val130Ile   CLI(I), CIP, 
CRO(I) 
JV43 015 cdeA  Val130Ile  CIP, CRO(I) 
JV44 020 cdeA   Ile139Arg   CIP 
JV45 015 cdeA  Val130Ile  CIP, CRO(I) 
JV46 061 cdeA   Val130Ile, 
Ile266Val 
Val1033Gly IPM(I), CIP, CRO 
JV47 012 tetM, cdeA    IPM(I), CIP, 
CRO(I), TET, ERY 
JV48 020 cdeA   Ile139Arg   CIP 
JV49 032 cdeA    CIP 
JV50 017 cdeA   Ser366Ala Ile750Met CLI(I), IPM(I), 
CIP, CRO, ERY 
JV51 020 cdeA  Ile139Arg Ile750Val IPM(I), CIP, 
CRO(I) 
JV52 020 cdeA   Ile139Arg Ile750Val CLI(I), CIP 
JV53 020 cdeA  Ile139Arg Ile750Val CLI(I), CIP 
JV54 015 cdeA   Val130Ile   CIP, CRO(I) 
JV55 015 cdeA  Val130Ile  IPM(I), CIP, 
CRO(I) 
JV56 017 cdeA   Ser366Ala Ile750Met IPM(I), CIP 











Non-synonymous mutations  Phenotypic 
Resistance Ω gyrA gyrB rpoB 
JV58 017 cdeA   Ser366Ala Ile750Met IPM(I), CIP 
JV59 862 cdeA 
See Table 19 
RIF(I), IPM(I), 
CIP, CRO(I) 
JV60 619 S. cinnamoneus 
EF-Tu, cdeA 
      CIP, CRO(I) 
JV61 015 cdeA  Val130Ile  IPM(I), CIP, 
CRO(I) 
JV62 015 cdeA   Val130Ile   IPM(I), CIP, 
CRO(I) 
JV63 001 cdeA  Val130Ile  IPM(I), CIP, 
CRO(I) 
JV64 020 cdeA   Ile139Arg   CIP, CRO(I) 




JV66 015 cdeA   Val130Ile   IPM(I), CIP, 
CRO(I) 
JV67 027 cdeA Thr82Ile,           






MXF, IPM, CIP, 
ERY 
JV68 242 cdeA   Ser366Ala Ile750Met CIP 
JV69 014 cdeA  Ile139Arg  CIP 
JV70 003 cdeA   Ile139Arg Ile750Val CIP, CRO(I) 
JV71 070 cdeA    CIP, CRO(I) 
JV72 023 cdeA Asp205Glu     CIP, CRO(I) 
JV73 027 aadE, AAC(6')-
Ie-APH(2''), 
cdeA, ant(6)-Ia 
Thr82Ile,           






MXF, IPM(I), CIP, 
CRO, ERY 
JV74 010 ermB, aadE, 
cdeA 
      CLI, IPM(I), 
CHL(I), CIP, ERY 
JV75 061 cdeA    IPM(I), CIP, CRO 
JV76 070 cdeA       IPM(I), CIP 
Table 18: Summary of resistant determinants and phenotypes for 75 
historical C. difficile strains (1980-1986). * Resistance genes were identified 
either by the Comprehensive Antibiotic Research Database (CARD) Resistance Gene 
Identifier (RGI) (762) and/or ResFinder 3.0 (763). The cfr gene was identified through 
BLAST comparisons. Ω Breakpoints as defined previously, based on the U.S. Clinical 
& Laboratory Standards Institute (CLSI) and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST); or existing publications. VAN-
vancomycin, RIF-rifampicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, 
CHL-chloramphenicol, CIP-ciprofloxacin, CRO-ceftriaxone, TET-tetracycline, ERY-






Figure 26: Heat map of antimicrobial resistance genes and phenotypes 
observed in the historical collection. Breakpoints as defined previously, based on 
CLSI and EUCAST definitions, or existing publications. VAN-vancomycin, MTZ-
metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-
clindamycin, IPM-imipenem, CHL-chloramphenicol, TGC-tigecycline, LZD-linezolid, 
CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, 




4.4.1.4 Distinctive genome, JV59 
Isolate JV59 demonstrated a high number of non-synonymous mutations in the 
phenotypically important gyrA (n=12), gyrB (n=8) and rpoB (n=16) genes; (Table 
19). Whilst intermediate resistance to RIF was identified in this strain, the 
gyrase alterations conferred no reduction of susceptibility to MXF.  
Non-synonymous mutations 
gyrA gyrB rpoB 
Asn4>Lys Val130>Leu Thr227>Ser 
Val194>Ile Ile139>Val Glu291>Gln 
Leu406>Gln Ile348>Leu Asp312>Glu 
Glu410>Asp Ser366>Ala* Ala316>Asp 
Lys413>Asn Ser416>Ala Asp350>Asn 
Asp444>Glu Val563>Ala Ser575>Ala 
Ser478>Ala Glu581>Asp Glu603>Asp 
Val546>Ile Glu587>Asp Asn744>Ser 








    Val951>Ile 
  
Glu1019>Asp 
    Ser1038>Thr 
    Asp1232>Glu 
Table 19: Table of non-synonymous substitutions identified in the JV59 
genome in genes known for conferring resistant phenotypes. * Previously 
reported in a moxifloxacin sensitive C. difficile strain (198). 
 
4.4.1.5 Resistance gene identification software comparison 
Resistance genes (>90% identity) were identified by both CARD-RGI and 
ResFinder 3.0 in 92% (46/51) of cases. Both identification systems overlooked 
determinants recognised by the other. ResFinder failed to identify resistance 
elements in three instances (5.9%), including failing to detect the presence of an 
ermB gene in JV01, even though it was highlighted with 99.15% identity by the 
CARD algorithm. Individual VAN resistance element, vanYG was not reported by 
ResFinder in isolate JV39, vanWG was missed in JV34. CARD-RGI could not detect 
resistance determinants on two occasions (3.9%), with the lack of identification 




abundant cdeA gene or any vanRG, vanSG or vanSD genes with lesser similarity 
(77.9%).  
Neither software was able to identify the presence of the cfr gene, whilst the 
RAST service assigned the annotation “Ribosomal RNA Large Subunit 
Methyltransferase N” to coding DNA sequences in all isolates regardless of 
whether they encoded for Cfr or RlmN proteins. No plasmids were identified by 
the PlasmidFinder 1.3 algorithm. 
 
4.4.2 Phylogenetic analysis 
Isolates recovered from the historical catalogue generally formed clusters with 
at least one other strain from the same collection (Figure 27 - Figure 33), 
reflecting the original sampling frame. The estimated number of SNPs from the 
closest “modern” isolate (2012-13) was commonly identified as >13. In keeping 
with the age differences between the historical isolates and comparator 
sequences (~30 years) and the estimated rate of C. difficile evolution (~0.74 
SNPs per genome, per year), the majority of sequences (69%) fit within a 95% 
prediction interval of Poisson distributions. 
Analyses of two PCR ribotypes provided exceptions to these findings. The three 
ribotype 027 isolates did not cluster together and the historical isolates, JV73 
and JV67 were only eight and two SNPs different from genomes recovered in 
2008 and 2006; respectively; (Figure 27). The Poisson probability distribution of 
these events were calculated as 4.51 x 10-5 and 3.93 x 10-3, for JV73 and JV67 
respectively. Isolate JV02 demonstrated closest relatedness to another UK 
isolate from 2008, 13 SNP differences, but within the prediction interval; 
(p=0.07). Furthermore, the three ribotype 027 genomes demonstrated multiple 
non-conserved regions between each isolate. Isolates JV14 and JV22, 
representing PCR ribotype 078, demonstrated identical genomes, representing 
six SNP differences from an Irish strain from 2013; (Figure 29). Prediction 
intervals for six SNPs in isolates of this presumed age were outside of the 95% 









                   
Figure 27: Phylogenetic tree representation of "historical" ribotype 027 isolates amongst >350 comparator 027 strains from 1985-
2013, acquired from the published He et al. (562) and the EUCLID studies (154). Maximum likelihood trees were estimated as previously (257), 









Figure 28: Phylogenetic tree representation of "historical" ribotype 001 isolates amongst comparator 001 strains from 2013, 






Figure 29: Phylogenetic tree representation of "historical" ribotype 078 
isolates amongst comparator 078 strains from 2013, acquired from the 
EUCLID study (154). Maximum likelihood trees were estimated as previously (257), and 









Figure 30: Phylogenetic tree representation of "historical" ribotype 002 isolates amongst comparator 002 strains from 2013, 






Figure 31: Phylogenetic tree representation of "historical" ribotype 014 
isolates amongst comparator 014 strains from 2013, acquired from the 
EUCLID study (154). Maximum likelihood trees were estimated as previously (257), and 







Figure 32: Phylogenetic tree representation of "historical" ribotype 015 
isolates amongst comparator 015 strains from 2013, acquired from the 
EUCLID study (154). Maximum likelihood trees were estimated as previously (257), and 








Figure 33: Phylogenetic tree representation of "historical" ribotype 020 isolates amongst comparator 020 strains from 2013, 






4.5.1 Antimicrobial resistance determinant detection 
Whilst the C. difficile core genome is comprised of approximately 1,000 genes, the 
pan genome consists of nearly 10,000 (573). This demonstration of genomic 
plasticity highlights the potential for resistant determinant acquisition through 
mobile genetic elements. The historical collection harboured twenty resistance 
conferring genes with the potential to spread amongst the gut microbiome, along 
with multiple mutational elements. As these strains are exposed to antibiotics, a 
selection process may result in concentration of MDR C. difficile, causing greater 
clinical challenges. 
4.5.1.1 Macrolide-lincosamide-streptogramin-B resistance 
Methylation of ribosomal RNA is widely accepted as the most prevalent 
mechanism of resistance to the MLSB classes of antimicrobials, with the ERY 
resistance methylation genes predominant in resistant C. difficile (444, 498). Whilst 
up to 86.7% of modern isolates have demonstrated the presence of the ermB gene 
(521, 728), only eight percent of this historical collection harboured the determinant. 
This disparity is potentially attributable to the temporal differences between the 
strain catalogues, since more comparable frequencies (15%) were reported in C. 
difficile from 1987-1998 (510). This North American study by Tang-Feldman et al. 
demonstrating an elevated occurrence rate was observed over a period spanning a 
decade and was primarily associated with increased CLI use and subsequent 
selection (510). This increase in resistant genotype prevalence over time may be as 
expected, since the frequency and heterogeneity of genetic arrangements 
previously reported in ermB determinants suggests high levels of transposition 
and genetic exchange amongst C. difficile and other species (489, 496, 511, 512).  
Reflective of previous publications (510, 521, 787), resistance to both ERY and CLI in 
the ermB positive isolates was not absolute, with a minority of strains containing 
the determinant, but displaying CLI sensitivity. Here, two strains remained 
lincosamide sensitive, whilst harbouring this resistance-conferring element. This 
could potentially be explained in terms of an inducible MLSB phenotype, often 
reported in Gram positive bacteria (788, 789). Isolates demonstrating contrasting 




inducer. This inducible phenotype could have important clinical implications in 
instances where MLSB therapy is used.  
 
 
Analysis of the upstream regions of the ermB gene was performed to establish any 
sequence differences that may be inhibiting methyltransferase expression (Figure 
34). ERY sensitive isolate JV30 exhibited an additional repeating region on the 
leader peptide sequence. Since mutations in erm leader peptide regions have been 
reported to reduce the efficacy of expression induction (790), this sequence 
polymorphism has the potential to cause the sensitive phenotype observed here. 
During an un-induced state the Shine-Dalgarno sequence of the ermB gene is 
concealed within a hairpin structure in the mRNA, resulting in inhibited 
Figure 34: Schematic representation of the configuration of regulatory 
sequences upstream from the ermB gene of historical C. difficile genomes. 
Thick blue lines represent identical nucleotides to the consensus sequence, whilst 




translation. In the presence of an ERY inducer molecule the ribosome stalls during 
leader peptide translation, exposing the ermB Shine-Dalgarno sequence for 
translation (791). Therefore, sequence mutation in this region may impact on RNA 
secondary structure and expression inducibility, ultimately affecting susceptibility 
phenotype. Furthermore, the transcriptional regulator is truncated in this genome 
and may impact the transcription of the methyltransferase.  
These data cannot explain the exact mechanisms behind the apparent lack of ermB 
expression in isolates JV33 and JV40. Since these sequences are comparable with 
those of ERY resistant isolates (JV01/JV25), they may require a pre-incubation 
with sub-MIC ERY in order to induce expression. Alternatively, there could be a 
potentially distant, trans-acting element silencing the gene. Whilst the sequences 
237bp upstream of the transcriptional regulator are different between resistant 
and sensitive isolates, these regions may be too distant to impact ermB expression. 
Interestingly, isolate JV74 demonstrated an absence of leader peptide or Shine-
Dalgarno sequence, but still an ERY resistant phenotype. This may be explained in 
terms of a substantial deletion of upstream sequence resulting in a lack of ermB 
Shine-Dalgarno obstruction and subsequent over expression of the ermB gene 
(791). This would suggest that resistance in this strain was constitutive as opposed 
to inducible. 
Additional determinants have been demonstrated to confer this susceptibility 
pattern in other genera, with an msrA gene responsible for resistance in 
streptococci (789). The mechanism of msrA-like proteins has recently been 
attributed to one of ribosomal protection, as opposed to efflux, clarifying long 
standing controversy in this area (792). Although not previously reported in C. 
difficile, this protection protein has selective activity for 14 and 15-membered ring 
macrolides, and is therefore incapable of inhibiting lincosamide activity, thus 
generating phenotypic differentiation. Nonetheless, this study was unable to 
identify any close msrA homologues amongst the historical collection. Further 
unidentified determinants responsible for this phenotype could potentially 
demonstrate similar ribosomal protection mechanisms. 
Since ermB presence usually confers ERY resistance (444, 510, 521), the unexpected 
finding of two strains (JV33 and JV40) harbouring the gene, but not indicating the 




due to expression complexities associated with promotor or regulator sequences 
or even a mutation within the ermB gene, leading to loss of functionality. The 
latter notion has been previously reported in an ermB positive, ERY sensitive C. 
difficile strain (793). Nonetheless, although three different ermB gene sequences 
were observed (Appendix), these did not correlate with the resistant phenotypes 
and cannot explain the differences detected. Further investigations would be 
required to determine the mechanism behind these discrepancies.  
Similarly, since ten strains tested in this study exhibited an ERY resistant 
phenotype without the presence of the classic ermB gene, further elements 
conferring a reduced susceptibility must be conveying influence. Similar to one 
large study of MDR C. difficile strains, where 17% of isolates exhibited ERY 
resistance in the absence of an ermB determinant (444), this collection revealed 
12% with the same genotype/phenotype combination. Additional efflux 
transporters (794, 795) or target modifications in rRNA domains (513, 796) could 
provide ulterior mechanisms for macrolide resistance, although no non-
synonymous mutations were discovered in the L22 or 23S large subunits of rRNA 
in either this or Spigaglia’s study (444). The latter research study also concluded 
that all nine ermB negative strains referred for supplementary MIC testing were 
unaffected by efflux inhibitors, CCCP and reserpine. Correspondingly, CCCP and 
reserpine testing revealed no demonstrable effect on ERY MICs in these historical 
strains, suggesting the presence of further, undetermined elements relevant to the 
macrolide resistance mechanism. No proximal homologues to mefA or mefE 
determinants were detected amongst the historical collection, with all CARD-RGI 
outputs revealing <35% similarity.  
4.5.1.2 Oxazolidinone resistance determinants 
LZD resistance amongst C. difficile is uncommon (797-799), although higher 
prevalence has been demonstrated in ribotype 001 and 027 isolates (225). Whilst it 
is not a typical treatment option for CDI, as with many broad spectrum 
antimicrobials, resistance to this oxazolidinone has the potential to induce 
disease. This protein synthesis inhibitor targets the 23S ribosomal RNA unit, with 
resistance conferred via alteration of the central loop domain V (800). In C. difficile 
the predominant resistance aetiology is the presence of the cfr gene and the 




in all four LZD resistant isolates doubtlessly conferred the phenotype in these 
strains, all of which revealed concurrent CHL and CLI resistance, as previously 
associated with this multiple resistance determinant (225, 528). Interestingly, two of 
these isolates represented the 078 ribotype, in support of the work by Marin et al. 
who identified the cfr gene on a Tn6218 transposon amongst ribotypes 017 and 
078 (528). In support of this data the same transposable element harboured the cfr 
gene in all LZD historical genomes. Curiously, the RAST annotation service proved 
unable to distinguish between the Cfr and RlmN methyltransferases, since both 
methylate the A2503 position, assigning CDSs in all isolates as a generic “rRNA 
methyltransferase”. However, the latter methylates at C-2, as opposed to the C-8 
position directed by the cfr gene, and crucially is not associated with reduced 
antimicrobial susceptibility (801). 
Whilst, the presence of the cfr gene is the primary source of LZD resistance in C. 
difficile, point mutations in ribosomal proteins have also been linked to 
oxazolidinone resistance in its absence (528, 802, 803). Here, investigations of three 
previously implicated ribosomal proteins, L3, L4 and the 23S subunit revealed 
several non-synonymous substitutions. Though mutations in the 23S ribosomal 
subunit are the most prevalently reported resistance-conferring element in other 
species (800, 804), with the Gly2576>Thr substitution strongly implicated, none were 
discovered during an in vitro passage experiment with C. difficile (805). Nonetheless, 
further regions of the central loop domain, crucial to drug-ribosome interactions 
have been discovered, including the substitutions Gly2032>Ala and Gly2447>Thr 
(E. coli numbering) (806). In the genomes investigated in this thesis, 12 isolates 
revealed three variant amino acid substitutions at the Ile750 codon (Table 18), in 
the proximity of the aforementioned point mutations. Intriguingly, all LZD 
resistant isolates exhibited a methionine replacement at this position, providing 
further credence to the notion that these point substitutions may effect the 
tertiary structure of the LZD active site. Interestingly, replacement of the aliphatic 
isoleucine at the same codon with either valine or glutamic acid did not correlate 
with a resistant phenotype. Since valine has very similar properties to isoleucine, 
this exchange may not convey as significant structural changes as the sulphur-
containing methionine. Nevertheless, five isolates demonstrated the Ile750>Met 
point mutation in the absence of a resistant phenotype, potentially suggesting that 




Examination of the L3 ribosomal protein gene revealed only one non-synonymous 
substitution amongst all historical genomes. Identified in the highly distinct 
genome of isolate JV59, an Ile205>Val mutation did not correlate with LZD 
resistance. However, SNPs were detected in the L4 protein in concurrence with 
reduced susceptibility; (Appendix). Resistant isolates JV14, JV17 and JV22 
exhibited Gly71>Asp and Val163>Ile point mutations, which although is distal to 
the drug binding site, has been linked to reduced susceptibility to LZD (805). The 
former substitution has been associated with resistance in C. perfringens (807), 
whilst a proximal Lys68>Asn mutation has been implicated in C. difficile (805). 
Although the finding of this substitution correlated with LZD resistance in these 
isolates, JV30 exhibited a lower level of resistance (8 mg/L), in the absence of any 
L4 gene variations. Whilst it seems more plausible that the presence of the cfr 
gene is likely the primary aetiology of the phenotype, these substitutions may be 
contributory. Non-synonymous amino acid replacement at the Val-163 codon was 
deemed as less plausible as an influential factor in the reduction of LZD 
susceptibility, as JV65 harboured modification at this position, independent of 
resistance.  
The rate of cfr prevalence amongst this historical collection was lower than 
reported in modern collections, 5.3% vs 10% (530). Although CLI use is currently 
subject to greater restriction (68, 103), this increase may be attributed to the 
introduction of LZD in the interim period (808), resulting in increased selection of 
this gene. The identification of the cfr gene amongst an isolate collection from the 
1980’s suggests that this determinant may have contributed to C. difficile 
outbreaks in a period of elevated CLI use. 
4.5.1.3 Tetracycline resistance determinants 
All TET resistance discovered in this historical catalogue was correlated with the 
primary determinant in C. difficile, tetM (486, 488). The importance of this element 
was supported by the absence of any TET sensitive isolates harbouring the gene. 
The 9.3% prevalence rate of tetM in this collection corresponds closely with the 
13.0% resistance rates amongst UK isolates from 1979-86 (381). Although TET 
resistance rates in the UK have reduced since this period (381, 394), European 
frequencies were reported as high as 17.1% in MDR isolates (444). In support of 




ribotypes 012 and 078. These two ribotypes have historically contained resistance 
determining transposable elements, with the Tn5397 and Tn916-like transposons 
found in 012 and 078, respectively (488). These findings are reflected unerringly in 
the historical genomes interrogated in this thesis. This complete coverage of 
particular strain types is indicative of resistant elements proving advantageous, 
leading to retention and subsequent clonal expansion. Interestingly, a recent 
report from Dingle et al. revealed the presence of the tetM gene in 76.9% of 
ribotype 078 isolates (809), identifying the determinant in pre-1990 strains, but 
describing major clonal expansion from 2000 onwards. The research postulated 
that the most plausible explanation for this, in the wake of reduced clinical use, 
was agricultural prescribing and zoonotic transmission. 
The presence of an additional TET resistance element, tetA(P), in conjunction with 
tetM in isolate JV32, correlated with a >32 mg/L TET MIC. This MFS efflux 
determinant featuring 12 transmembrane domains, is ubiquitous amongst C. 
perfringens (810) and has previously been reported in 19% of zoonotic C. difficile 
isolates (576). The minimal clinical data associated with this specimen documents 
“profuse diarrhoea following tetracycline”. Coupled with the susceptibility findings 
this potentially indicates that, whilst tetA(P) imparts no independent resistant 
phenotype (576), these two elements combined may demonstrate an exacerbating 
effect. Nonetheless, tetM mediated TET resistance in C. difficile has been linked to 
a diverse range of resistant phenotypes (811), with gene configuration contributory 
to this. 
4.5.1.4 Fluoroquinolone resistance determinants 
The QRDR has been outlined as a region of mutational hotspots, relevant to 
fluoroquinolone resistance development (438). The majority of substitutional 
determinants are reported in these short regions of the gyrA and gyrB genes (765, 
812-814) and the examination of historical genomes from this study revealed 
comparable findings. All MXF resistance detected in the historical collection 
correlated with the common Thr82>Ile substitution. Associated with high-level 
resistance (16-32 mg/L), the majority of strains carrying this genotype 
represented ribotypes 001 and 027. In addition to this mutation, all three 027 
isolates carried the same two, non-synonymous substitutions, Leu406>Ile and 




independently associated with a resistant phenotype, they cannot be dismissed as 
contributory factors based on this data set. Similarly, the two further non-
synonymous substitutions identified in gyrA of the collection did not convey MXF 
resistance.  
While the isolates displaying MXF resistance are well characterised with the 
Thr82>Ile mutation, the rationalisation for the ubiquitous CIP resistance was not 
clear. While there are several known mechanisms of fluoroquinolone resistance in 
bacteria, unfortunately, the data presented in this study cannot provide sufficient 
information to identify a mechanism for the putatively intrinsic CIP resistance 
observed here. Whilst evidence for the involvement of putative efflux or gyrase 
protective homologues, such as CD2068 (777) or qnr-like genes (815, 816) is 
undermined by lack of absolute correlation between genotype and phenotype, all 
extra-QRDR mutations revealed a non-existent relationship with CIP resistance. 
Therefore, further unidentified mechanisms are likely connected, whether that be 
efflux or mutational inhibition. Although C. difficile does not contain any close parC 
homologues, the role of the topoisomerase IV must be performed by an alternative 
enzyme, as it is crucial to DNA synthesis. Therefore, there may be an unidentified 
enzyme of similar function, with a lower affinity to CIP, which potentially inhibits 
its action. Discussion of the evidence available from this investigation, including 
the reasoning why they are unlikely to be the cause of CIP resistance, is presented 
below. 
Multiple sequence alignments of two putative fluoroquinolone resistance 
determinants, a qnr-like, pentapeptide protein and an ABC transporter, CD2068 
was performed to further investigate a potential mechanism for the apparent, 
intrinsic CIP resistance observed here. CD2068 has been associated with 
upregulation in the presence of CIP and the impact on fluoroquinolone 
susceptibility has been reported in C. difficile (777). Demonstrating 63% identity 
with the CpmA transporter observed in other clostridia (817), this putative MDR 
efflux determinant exhibited >98% identity in the majority of historical genomes. 
Since this ATP-activated element has demonstrated membrane translocation of 
several antimicrobial classes, including fluoroquinolones (777), it has the potential 
to be associated with the CIP resistance observed in these strains. However, it 




this gene and therefore, it is likely that the CIP resistance cannot be attributable to 
this determinant. Interestingly, the presence of this CD2068-like gene with low 
homology seemed confined to specific ribotypes (015 and 020, particularly). 
Coupled with its low homology determination in single instances of two rare, 
distinctive ribotypes (341 and 862), it appears to represent an element associated 
with clonal divergence.  
Further genomic analysis revealed the presence of homologues (>99%) to the 
DNA gyrase protecting, qnr-like element (815, 816). However, this C. difficile element 
only demonstrates a low homology to the E. coli gene responsible for a 
pentapeptide repeating protein, which inhibits the quinolone molecule from 
binding to the gyrase active site. Whilst close homologues to the C. difficile element 
discovered in other clostridia conferred a reduction in susceptibility to CIP, when 
transformed in to an E. coli strain, the CD qnr-like protein demonstrated minimal 
effect on CIP MIC (776) and is therefore unlikely to be the cause of intrinsic 
resistance. 
Corroborating other findings (814), 74.7% of all test isolate genomes demonstrated 
no QRDR mutations. Two QRDR-independent polymorphisms in the gyrB gene, 
Val130>Ile and Ile139>Arg, were highly prevalent amongst MXF sensitive isolates, 
signifying that they convey no resistant phenotype. This finding is in support of 
previous work indicating these mutations in sensitive isolates (814). Nonetheless, it 
cannot be dismissed that they contribute to the steric hindrance of antimicrobial 
binding, as codon 139 represents a side chain area of the protein, likely imparting 
a greater conformational change (814). Many of these silent mutations in the gyrB 
gene were observed as highly ribotype-specific, with Val-130 intrinsically linked 
to ribotypes 001 and 015, and Ile-139 to the closely related 014 and 020 strains. 
Equally, the previously reported Ser366>Ala was localised to ribotype 017 and 
242 genomes (198). These findings reflect the study by MacAogain et al. who 
identified similar ribotype traits, suggesting homoplasic variations (814). This 
apparent parallel evolution of analogous substitutions highlighted the potential 
for consistent, high-level mutability in this important resistance determining 
region. Due to the lack of correlation between these polymorphisms located 





Assessment of the highly distinct genome of isolate JV59, revealed a plethora of 
amino acid substitutions in the DNA gyrase genes; (Table 19). All gyrA 
substitutions were located outside of the QRDR, whilst only the Ser-366 and Ser-
416 codons of gyrB demonstrated SNPs inside the central region. Both of these 
non-synonymous mutations have been reported to confer no resistance to 
fluoroquinolones (198, 814), as observed in the phenotypic analysis of this isolate. 
Therefore, although harbouring a highly variant set of gyrase genes from the rest 
of the collection, these variations appear to represent the distinct phylogeny of 
this ribotype 862 isolate, rather than an adaptive response to antimicrobial 
pressure. While they do not appear deleterious in nature, this ribotype has not 
previously been reported and it is therefore likely that elements of its genetic 
organisation may have contributed to its inability to compete with other, more 
successful ribotypes in clinical environments. 
4.5.1.5 Vancomycin resistance determinants 
Whilst VAN resistance is common in other genera, such as staphylococci and 
enterococci, it is relatively rare in C. difficile (108, 188, 818, 819). Nonetheless, reduced 
susceptibility has been reported amongst clinical isolates, particularly in the 
context of outbreak situations (199, 200, 820). Interestingly, whilst no resistance was 
detected in this historical collection, reduced susceptibility was observed in four 
strains isolated from temporally distinct specimens, associated with the same 
patient. The potential for horizontal gene transfer between these concomitant 
strains may well have been high, and as one of these isolates represented ribotype 
001, a type occasionally associated with reduced susceptibility to VAN (188), this 
may have been the source of transmission.  
The identification of eight van genes in each intermediate resistant isolate 
supported the suggestions that this operon only encodes for low-level resistance 
(467, 821). The vanG-like cluster identified by Sebaihia (314), consists of five open 
reading frames, vanR, vanS, vanG, vanXY and vanT, whilst regulatory genes vanUG, 
vanRG and vanSG complete the operon (821). In this data set, the presence of all 
eight genes correlated with an intermediate resistant phenotype, whilst the 
independent detection of homologues appeared to confer no influence on VAN 
resistance. Interestingly, it has been reported that although the vanG complex was 




Ammam et al. were able to confirm the functionality of the genes, with identifiable 
modified peptidoglycan precursors, but could not explain the lack of cell wall 
uptake. One explanation was proffered, suggesting a lack of elimination of 
unmodified peptidoglycan building blocks and subsequent competitive inhibition. 
Whilst this seems plausible, the revelation that the C. difficile cell wall is 
synthesised in a novel configuration may contribute to the deficient cell wall 
modification (686). Nevertheless, the clinical implications of these genes appears 
minimal, as the faecal concentrations of VAN are reportedly far superior to the 
resistant breakpoint (520-2,200 mg/L) (822). 
4.5.1.6 Further resistance determinants 
The identification of an EF-Tu, elongation factor homologue in isolate JV60 may be 
indicative of resistance to the kirromycin class, as demonstrated in streptomyces 
(823). This class of protein synthesis inhibitors act to block the disassociation of the 
elongation factor and ribosome, preventing formation of essential peptide 
bonding (824). Minimal data is available regarding C. difficile susceptibilities to this 
class, although Clabots et al. were able to demonstrate MICs in the range of 0.06-
0.5 mg/L for a panel of strains exposed to efrotomycin, a member of the 
kirromycin class (825). However, the resistance phenotype of isolate JV60 was not 
able to be tested for this class, as the compounds are highly expensive and the 
clinical relevance deemed minimal. Equally, the determination of isolate JV73, 
possessing the kanamycin resistance determining complex, AAC(6')-Ie-APH(2''), 
was not further investigated, as kanamycin has been demonstrated to have 
minimal activity in anaerobic bacteria (780, 781). Nonetheless, this transposable 
resistance element (826), further demonstrates the ability of C. difficile to assimilate 
a range of resistance conferring elements. The AAC(6')-Ie-APH(2'') gene may also 
contribute to multiple resistances; by encoding for a multifunctional enzyme, 
combining sequential acetylation and phosphorylation (827). The enzyme can 
reduce electrostatic and steric interactions, decreasing the binding affinity of 
several aminoglycosides to the rRNA target (828). 
Both strains JV73 and JV74 harboured the aadE gene, a resistance determinant for 
streptomycin (829). Generally, there is an absence of activity of aminoglycosides 
against anaerobic bacteria; however Pirs et al. demonstrated only 81% 




breakpoints were defined as high as 1,000 mg/L, elevated considerably above 
potential gut concentrations achieved by the drug (830, 831). Here, both isolates 
harbouring the resistance determinant demonstrated high levels of resistance to 
streptomycin, whilst the majority of aadE negative comparators were sensitive to 
the drug (<512 mg/L). Nevertheless, since one isolate demonstrated resistance in 
the absence of the gene, it suggests that additional determinants are involved. 
Whilst streptomycin resistance in C. difficile is of lesser importance, as it is not 
deemed as a classic risk factor (832), in particular patient cohorts such as those with 
paediatric cancers, aminoglycoside administration has been correlated with an 
increased CDI risk (833). The presence of these determinants also further 
highlighted the potential for horizontal gene transfer across the bacterial 
kingdom. 
The presence of chromosomal efflux gene, cdeA, in all isolates supported previous 
findings of high prevalence amongst C. difficile (834). Whilst this MATE protein 
encoding homologue was initially considered a putative cause for the ubiquitous 
CIP resistance, in this study the presence of sodium ion gradient based expulsion 
inhibitor, reserpine, revealed no effect on susceptibilities. Equally in the primary 
study by Dridi et al., native C. difficile promotors did not sufficiently respond to CIP 
exposure to elicit resistance (509). These outcomes corroborated to suggest further 
unidentified elements as the source of the underlying CIP resistance, for instance 
modified promotors or additional efflux determinants. 
4.5.1.7 Multidrug resistant strains 
Of the MDR strains identified in the historical collection, 76.5% exhibited 
transposable resistance-conferring elements, predominantly tetM, ermB and cfr. 
Chromosomal mutations in the gyrA gene were contributory in 41.2% of isolates 
demonstrating an MDR phenotype. Whilst fluoroquinolone resistance 
substitutions have been reported as highly influential in the success of ribotype 
027, this data suggests that mobile elements may offer a substantial contribution 
to the spread of MDR strains. Since for genetic transposition to occur, no 
antimicrobial pressure is necessary, the opportunity for this event to transpire is 
more widespread. Nonetheless, evidence eluded to in Chapter Six of this thesis 
indicates that once acquired, resistance to fluoroquinolones seemingly causes no 




subsequent generations. The retention of such elements, combined with 
transposable multi-agent resistance determinants, may ultimately result in an 
untenable position, where many antibiotic classes become ineffective against this 
prevalent pathogen.  
Interestingly, two MDR isolates did not demonstrate any of the well-defined 
resistance conferring determinants identified in this investigation. This suggests 
the contributions of unknown or yet to be fully understood factors, such as the 
multi-compound extrusion system, CdeA, ubiquitous in this collection. Equally, 
whilst genes encoding DNA gyrase and RNA polymerase elements were examined 
for amino acid substitutions, alterations in other chromosomal regions, yet to be 
implicated in antimicrobial resistance, may well be responsible. 
 
4.5.2 Phylogenetic analysis 
Phylogenetic analyses were utilised to corroborate the notion that the isolates 
recovered from the historical collection genuinely originated from the early 
1980s. Harnessing the knowledge of the C. difficile molecular clock (257, 569), the 
majority of these genomes were assessed for age authenticity, based on their 
relatedness to modern genomes in evolutionary tree analyses. Since this type of 
analysis presents no absolute answer, only probability of relatedness, the 
investigation proved complex. Where distant relationships were ascertained, with 
divisions of thousands of SNPs separating genomes (Figure 28), an evolutionary 
distinction could be assumed. However, the majority of instances were not so 
definitive. 
The unusual discovery of MXF resistant ribotype 027 isolates, pre-dating the 
addition of the agent to the formulary, raised questions regarding the accuracy 
and reliability of the isolates’ presumed ages. Whilst this may have developed due 
to exposure to earlier quinolones, such as nalidixic acid, phylogenetic analysis was 
performed to elucidate ancestral relationships of “historical” isolates, in order to 
identify how these strains related to modern C. difficile populations. Seven 
ribotypes were investigated to establish evolutionary relationships in distinct 
clades. These genomes consisted of many of the most prevalent ribotypes, both in 
the historical collection and also amongst modern epidemiology. The comparator 




years ago. Unfortunately, such historical comparators were not available for other 
ribotypes at the time of analysis. Nonetheless, in some instances considerable 
genomic distinction from modern genomes provided convincing conclusions; 
(Figure 28 and Figure 33). 
Whilst spatial clustering and root proximity on phylogenetic trees offer valuable 
evidence into genomic ancestry, the magnitude of SNP deviations from the closest 
modern relation may provide an additional measure of confidence in the true age 
of an isolate. Prediction intervals were calculated to represent a probabilistic 
lower limit of evolution, based on current C. difficile molecular clock estimations 
(0.74 SNPs per genome, per year) (257, 569). In this context they refer to the 
probability of an observed number of SNPs or fewer occurring in the number of 
years separating a genome from its nearest neighbour on the phylogenetic tree. It 
was observed that 69% of genomes from the historical collection correlated with a 
95% prediction interval; (Figure 35). This inspired confidence in the age 
demographics of these historical isolates, potentially supporting the accuracy of 
proposed evolutionary rates. Nonetheless, this analysis also casts some doubt on 
the validity of the genomes observed outside of the expected range. Since 
molecular clock data only provide estimations, it may be conceivable that a small 









Figure 35: Prediction intervals representing the probabilities of the observed number of single nucleotide polymorphisms (SNPs) or 
fewer occurring in the time period separating neighbouring taxa, based on Poisson distribution of C. difficile molecular clock 
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Unexpectedly, the three “historical” ribotype 027 isolates clustered amongst the 
modern genomes of recent EUCLID strains. Combined with the presence of 
fluoroquinolone resistance, prior to previously reported acquisition time scales 
(562), these isolates did not necessarily fit the anticipated characteristics of early 
ribotype 027 strains. Whilst the closest relative of isolate JV02 (putatively from 
1981) was an isolate from Glasgow from 2008, the prediction interval probability 
(based on 0.74 SNPs per genome, per year (257)) for 13 or fewer SNPs occurring 
over 27 years was p=0.07. This observed SNP difference would fall into the 
expected range (95% prediction interval) of the Poisson distribution of the 
molecular clock (Figure 35), alluding to the finding of a true historical isolate. 
Nonetheless, the other two isolates JV67 and JV73 were only eight and two SNPs 
divergent, respectively. Based on the current understanding of the molecular 
clock, the latter finding would conflict with the notion that it was greater than 25 
years older than comparator genomes. However, further analysis of branches 
comprising older isolates (back to 1985) indicated the assimilation of some 
modern strains, denoting close ancestries. If we consider the branches close to the 
root of the phylogram (Figure 36), it can be observed that isolates >20 years apart 
reveal only ~8 SNPs difference. Equally, isolates separated even further by time 
have shown zero SNP differences between genomes from 1991 to 2007 and 1993 
to 2004. These findings would also lie outside of the 95% prediction interval 
estimations. This evidence is highly suggestive of a greater complexity to temporal 
analyses based on phylogeny. Assuming that this sequence data (acquired from 
highly cited publications) is reliable, a relationship is portrayed where additional 
considerations may be necessary when investigating the dating of C. difficile 
genomes, other than clustering and SNP differentiation. The extent of evolutionary 
dormancy experienced by a strain, whilst existing in a quiescent spore form is one 
potential explanation. 
The striking observation of two clusters of identical genomes, spanning 11 and 16 
years, appeared to contradict the current understanding of C. difficile evolution. 
Further investigation into these isolates revealed another possible intriguing 
explanation for these seemingly erroneous findings. All isolates clustered with 
zero SNP differences (highlighted in green in Figure 36) originated from Arizona, 
with one isolate putatively deriving from 1991 clustered amongst strains from 




revealed the presence of ribotype 027 in retail meats purchased in Arizona (835). 
However, a follow up publication from the same research group (836), used MLVA 
to demonstrate that many of these isolates were indistinguishable from each 
other, with all data strongly suggestive of specimen contamination with a 
laboratory strain. This seems increasingly likely to have been with the identical 
1991 isolate, prior to whole genome sequencing. These data serve to highlight the 
caution required during interpretation of external data sets. 
The convoluted nature of the individual C. difficile PCR ribotype evolutionary trees 
may be partially explained by the sporulation of this bacteria (837). Since genetic 
replication does not occur when bacteria exist in the quiescent spore form, 
evolution has been reported as far slower in spore-forming organisms (838, 839). 
With no way of knowing how long a particular strain has existed in spore form, it 
proves difficult to confidently establish temporal, evolutionary links. Whilst it may 
be assumed that the isolates from the historical collection existed in spore form 
for over 30 years, the proportion of time, so-called “modern” strains have 
remained in this state is practically incalculable. We know C. difficile is harboured 
as spores, asymptomatically in both humans and animals (8) and can potentially 
exist for prolonged periods in the environment (840). This unknown period of 
quiescence contributes to the difficulty of aging through phylogenetic analysis. 
While on the face of it, the “historical” ribotype 027 strains demonstrated <10 
SNPs difference to genomes from 2013, we cannot be certain as to the number of 
generations the “closely related” strains have passed through in comparison to 
others. Longitudinal studies could provide further information as to the impact of 







Figure 36: Expanded phylogenetic tree of ribotype 027 genomes from 1985-
2009, acquired from the published He et al. study (562). Red circles highlight 
branches of closely related strains originating between up to 20 years apart. Green 
circles highlight taxa clusters consisting of temporally distant genomes, identified as 
zero SNPs different. Maximum likelihood trees were estimated as previously (257), and 
generated with the Interactive Tree of Life (785).  
Collapsed branch 





The close relatedness to a neighbouring isolate from 2013 of the two ribotype 078 
genomes isolated from the historical collection does not fit within even the lowest 
ranges of molecular clock estimations for this distinct ribotype (575). It is still 
reasonable to consider the potential involvement of evolutionary dormancy 
during unknown periods of existence in spore form. Whilst it must only be 
considered as conjecture, there may be an exacerbated evolutionary stasis effect 
linked with ribotype 078, due to its association with zoonotic carriage. This could 
potentially result in an extended existence in spore form, whilst carried 
asymptomatically amongst animals.   
Analysis of the phylogenetic tress for all ribotypes, with the exception of 027, 
demonstrated clustering of the genomes from this collection, as maybe expected. 
However, the 027 phylogram presented a different picture, with isolates spread 
out amongst genomes of all ages. This finding is supported by the identification of 
groups of older isolates amongst more modern genomes in the existing data. 
Where older strains are branched closely with more modern genomes, the in silico 
fluoroquinolone susceptibility statuses correlated; sensitive with sensitive and 
resistant with resistant. This was also true for the three 027 strains recovered 
from the historical collection. However, the resistance identified in these isolates 
potentially exhibits a deviation from the expected molecular clock behaviour, 
indicating the possible complicating role of spore quiescence. Furthermore, these 
findings may suggest the earlier emergence of fluoroquinolone resistance in 
regions outside of North America, as previously documented (562). One potentially 
occurring in the UK (relating to JV02/JV67) and one emerging from Western 
Europe (relating to JV73). Whilst gyrase genes are highly mutable, it is plausible 
that resistant mutants may have arisen from multiple locations. The phylogenetic 
analyses performed here potentially support this hypothesis. 
The analysis of PCR ribotype 027 isolates provided a substantial insight as to the 
relatedness and common ancestry of the strains isolated from the historical 
collection, due to the considerable temporal span of the genomes available. 
However, this is not the case for other ribotypes. Due to a distinct lack of pre-
twenty-first century genomes for non-027 ribotypes, the database inadequacies 
pose difficulties to the accurate estimations of chronology. Nonetheless, where 




Interestingly, all ribotype 014 isolates clustered towards the root tree, sufficiently 
distant from modern genomes. Three distinct phylogenetic tree branches were 
observed, this was in support of previous findings indicating three different 
sequence types within this ribotype (576). 
The outcome of these phylogenetic analyses potentially casts some doubt on the 
reliability of aged isolate collections. Whilst appropriately controlled collections 
with suitable restrictions may be considered dependable, without the knowledge 
of a collection’s access and handling history, no matter how well anti-
contamination procedures are obeyed, queries regarding the age of isolates 
cannot be answered with absolute certainty. Though measures were 
implemented, such as the use of negative controls and bench top settle plates, the 
risk of single cell contamination cannot be eradicated entirely. Conversely, the 
recovery of rare ribotypes, highly unlikely to be circulating in the laboratory 
environment and the recovery of identical strains in previously untouched 





NGS provides an excess of data for subsequent analysis. While genomic 
interrogations enable the identification of genotypic resistance determinants, a 
multitude of tools are available to generate further genetic links including those 
regarding ancestry and evolution. Here, we observed a diverse range of bacterial 
resistance determinants, with reduced prevalence from contemporary isolates. 
Whilst not all resistant phenotypes can be explained by the current level of 
understanding, the acquisition of NGS data will allow future retrospective 
analyses for the further elucidation of resistance mechanisms. The data presented 
here indicated that resistance progression has developed over the past 35 years, 
with horizontal gene transfer and antibiotic exposure the probable driving forces.  
Whilst the majority of phylogenetic analyses conform to current molecular clock 
estimations, several isolates were observed outside this range. Though we may 
question the reliability of isolations from historical collections, there remains a 




Chapter 5 The Impact of Clostridioides difficile Mutation 
Frequencies on Fluoroquinolone Resistance 
5.1 Introduction 
Fluoroquinolone resistance is often considered as an important feature of major 
C. difficile outbreaks, particularly those associated with ribotype 027 (34, 112). 
Differing strain propensities for spontaneous mutation may contribute to 
evolutionary survival and a subsequent favoured clonal spread of certain 
ribotypes, particularly those harbouring mutational resistance determinants.  
The process of DNA replication is not infallible, on occasion DNA polymerase 
enzymes make mistakes when pairing nucleotide bases (582). Whilst DNA repair 
systems have evolved to correct mismatches, errors result in spontaneous 
mutations that become permanent additions to the daughter cell’s genome (583). 
Evolutionary principles assume that spontaneous bacterial mutations generally 
occur at frequencies between 10-10 and 10-9 per genome, per generation (584), 
whilst precise frequencies are highly species dependant (585). Where a consistent 
genome is favoured in a stable environment, the stochastic nature of 
spontaneous mutations benefit the bacteria when exposed to external stressors 
(613, 841). Elevated potential for mutagenesis offers possible survival opportunities 
through the acquisition of favourable, resistance conferring genotypes. A 
comparatively increased capability of one strain type to mutate at important 
antimicrobial resistance determining regions more readily than another, 
potentially contributes to successful dissemination of the more mutable type. 
Mutation frequencies have been demonstrated to vary amongst organisms, 
ranging between 1x10-9 and 7x10-3 (232, 590, 608, 611, 842, 843). Equally, varying 
fluoroquinolone mutation frequencies have been observed between individual 
compounds within the class (610, 611) and under differing selection concentrations 
(591, 612). In C. difficile, fluoroquinolone resistant mutants are reportedly 
generated at rates as high as 2.4 × 10−5 for levofloxacin and 6.6 × 10−5 for MXF 
(812). Nonetheless, there is a paucity of data separating C. difficile mutation 




further contributory factor to the distribution of ribotypes, particularly the 
widespread success of ribotype 027 in clinical environments. 
C. difficile genomes reveal highly conserved methyl-directed mismatch repair 
genes (573, 600), and whilst there is minimal data available regarding the C. difficile 
specific mechanism, mutS and mutL knockouts in Clostridium acetobutylicum 
resulted in elevated mutagenesis (599). An assessment of the influence of these 
genes, in relation to C. difficile mutation frequency, may help to identify possible 
explanations for variable mutability and link to any association with ribotype 
prevalence. 
Ultimately, an elevated capacity to mutate crucial fluoroquinolone resistance 
genes potentially confers an evolutionary advantage, allowing progeny to 
survive exposure to such agents. Subsequent capacity for clonal expansion of 
resistant strains may contribute to endemicity and epidemic potential. Here, 
bacterial mutagenesis of fluoroquinolone resistance determining regions is 
investigated in a range of C. difficile ribotypes to examine the influence of 
mutability differences on C. difficile propagation. 
 
5.2 Rationale 
In this chapter, the mutability potential of seven prominent PCR ribotypes was 
explored through increasing mutational assays and fluoroquinolone selection. C. 
difficile mutation frequency assays were implemented to ascertain whether 
particular PCR ribotypes or individual isolates demonstrated differing 








5.3.1 C. difficile mutation frequency determination 
5.3.1.1 Test isolates 
C. difficile isolates (n=44) from seven of the most prevalent disease-causing PCR 
ribotypes (001, 012, 015, 017, 020, 027, and 078) (118, 385) were acquired from 
the historical collection (1981-83) investigated in Chapter Three; (n=18) and the 
modern ClosER; (n=26). All isolates selected for mutability testing demonstrated 
susceptibility to MXF (≤2 mg/L), with the exception of resistant strain CD4362, 
which displayed an MIC of 32 mg/L. MICs of all original test isolates were 
confirmed via retesting through an agar incorporation susceptibility testing 
method, as outline in Chapter Three. ClosER strain identifiers were generated 
with a prefix of CD to the last four digits of original reference number (e.g. 









CD3904 2015 Ӧrebro, Sweden 1 
CD3891 2015 Ӧrebro, Sweden 2 
CD9609 2016 St Antoine, France 1 
CD9946 2016 Glasgow, UK 1 
CD3809 2012 Dublin, Rep. Ireland 1 
CD3051 2013 AGES, Austria 1 
CD3079 2013 Ӧrebro, Sweden 1 
Table 20: Demographics of seven moxifloxacin susceptible PCR ribotype 027 
isolates investigated in the mutation frequency assays. MXF – moxifloxacin, 
MIC – minimum inhibitory concentration. 
 
5.3.1.2 Mutation frequency calculations 
Mutation frequencies were calculated with an adaptation of the method 
described by O’Neill et al. (619); (Figure 37). Briefly, Brazier’s media enhanced 
with 2% lysed, defibrinated horse blood was supplemented with MXF to create 
4, 8 and 16 mg/L incorporated agars. Plates were dried at 37°C for 25 minutes 




distinct colonies. Ten to fifteen colonies of overnight growth were emulsified 
into 5 mL pre-reduced BHI broths and cultured for six hours. Total C. difficile 
populations were enumerated via serial dilution in pre-reduced PBS and plated 
onto Brazier’s agar. Mutations were selected through inoculation of 100 µL of 
neat broth culture onto each of ten MXF-incorporated (4x MIC) agar plates and 
spread. All plates were incubated anaerobically at 37°C for 48 hours, prior to 
enumeration by direct colony counting. For each ribotype 027 isolate test, three 
colonies were picked off from the MXF selective plates and transferred into 
Schaedlers anaerobic broth for MXF MIC determination. Mutant isolate pickoffs 
of other ribotypes were tested intermittently to ensure the antibiotic 
concentration in the agar was accurate. An agar incorporation testing 
methodology was used as described in Chapter Three. 
Individual assays were controlled using C. difficile isolates (obtained through 
pilot investigations) with MXF MICs of 0.5x and 2x the antibiotic concentration 
of the test agars. Control strains were streaked onto the same MXF 
supplemented Brazier’s agar used in the assays. Test data was confirmed only if 
the 0.5x MIC, positive control demonstrated visible growth, whilst growth of the 
2x MIC, negative control was inhibited after 48 hour culture.  
 
Mutation frequencies were determined asː 
TVCmut (CFU/mL)  
TVC (CFU/mL) 
 
Where TVCmut was the total colony counts from all ten MXF-incorporated agars, 
TVC is the total viable count from non-selective Brazier’s agar, per millilitre. 
Mutation frequencies were reported as a mean average of a minimum of three 









Figure 37: Flow diagram of mutation frequency determination 
methodologies. TVC – total viable count, MIC – minimum inhibitory 
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5.3.1.3 Experimental design  
Mutation frequencies were determined at 4x MIC for the entire panel of isolates. 
An expanded selection of ribotype 027 strains were subjected to repeat assays at 
4x MIC, in addition to further testing at 4, 8 and 16 mg/L MXF concentrations. 
Mutant isolates were assessed for MXF MIC by agar incorporation and retained, 
frozen (-20°C) in glycerol broth for further molecular analysis. Mutation 
frequency assays were repeated in triplicate for all primary experiments, whilst 
ribotype 027 isolates were subjected to a minimum of six replicates. 
Mutant strains generated from the primary experiments were further exposed 
to frequency testing under increased MXF concentrations. Six 4 mg/L MXF MIC 
ribotype 027 mutants were tested with exposures of 8 and 16 mg/L MXF, and 
three 32 mg/L MXF MIC 027 mutants (including one MXF resistant 027 isolate, 






Figure 38: Experimental design of mutation frequency investigations. Orange 
arrows refer to parent isolate testing, green arrows refer to reduced moxifloxacin 
(MXF) susceptibility mutant testing. MIC – minimum inhibitory concentration. 
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5.3.1.4 Next generation sequencing and single nucleotide polymorphism 
identification 
All seven PCR ribotype 027 parent isolates, one strain with pre-existing MXF 
resistance (CD4362) were processed for NGS as previously; (Chapter Four). 
Sequencing was performed by the University of Leeds, Next Generation 
Sequencing facility, whilst de novo assembly was performed as before.  
Genomes were annotated using RAST (767) and SNP differences in DNA gyrase 
genes, as well as in seven genes related the DNA repair and SOS response (Table 
21) were identified through multiple sequence alignment using Clustal Omega 
(764).  
 
Gene of Interest Function 
mutS (601) DNA mismatch repair 
MutS related protein gene DNA mismatch repair  
mutL(601) DNA mismatch repair 
lexA (598) SOS-response repressor protease  
recA (598) DNA recombination and repair 
recX (844) RecA Regulator  
hfq (602, 845) RNA-binding protein  
Table 21: List of C. difficile genes putatively related to mutability, compared 
for sequence homology.  
 
5.3.1.5 Statistical analyses 
All statistical tests were performed using IBM SPSS Statistics v.21.0.0.1. Mutation 
frequency data was analysed using Kruskal-Wallis and the Dunn-Bonferroni 
multiple comparison post hoc test. Differences were deemed significant at 





5.4.1 C. difficile mutation frequency determination  
5.4.1.1 Mutation frequencies with 4x MXF MIC selection 
Considerable inter and intra ribotype variation of mutation frequencies 
associated with fluoroquinolone resistance were observed (3.77 x 10-9 – 5.91 x 
10-6, x̅ = 4.15 x 10-7); (Figure 39). The highest frequency was detected in 
ribotype 027 isolate, CD3904. Five isolates (CD0128, JV05, CD3904, CD9609 and 
CD0222) constituting four out of the seven ribotypes tested (012, 020, 027 (n=2) 
and 078), exhibited markedly elevated mutation frequencies (5.83 x 10-7 – 5.91 x 
10-6). Ribotype 027 demonstrated two isolates with mutation frequencies 
greater than 1 x 10-6 (CD3904 and CD9609). Highly polarised frequencies were 
observed in these four ribotypes, with 020 and 027 strains demonstrating the 
largest divergence; 3.38 x 10-9 – 4.58 x 10-6 and 7.23 x 10-9 – 5.91 x 10-6, 
respectively.  
Mutation frequencies for ten isolates were assigned as “below the lower limit of 
detection”, as no resistant colonies were detected. These included all but one 
ribotype 017 isolate (CD3771) and were designated low average frequencies of  
x̅ = 5.10 x 10-9. Mean average mutation frequencies indicated 027 as the most 
mutable ribotype when exposed to four-fold MXF MIC pressure (x̅ = 1.48 x 10-6); 
(Table 22). No direct correlation was observed between mutation frequency and 










Figure 39: Mean (±SE) mutation frequencies of C. difficile isolates from seven PCR ribotypes exposed to 4x MIC moxifloxacin (MXF) 
pressure. Lower limit of detection (LLOD) calculated as 1 / (mean total viable counts/mL). No error bars are displayed where the frequency 
























































































































































































































































Mutation Frequency - Moxifloxacin Selection         
(4 x MIC) 
Mean (?̅?) Minimum Maximum 
001 4.95 x 10-8 3.79 x 10-9 1.41 x 10-7 
012 1.07 x 10-7 3.00 x 10-9 5.83 x 10-7 
015 2.55 x 10-8 <3.72 x 10-9 * 9.17 x 10-8 
017 5.10 x 10-9 <3.05 x 10-9 * <1.37 x 10-8 * 
020 7.82 x 10-7 <3.38 x 10-9 * 4.58 x 10-6 
027 1.48 x 10-6 7.04 x 10-9 5.91 x 10-6 
078 3.88 x 10-7 7.24 x 10-9 2.25 x 10-6 
Table 22: Mutation frequency determinations by PCR ribotype. All ribotype data 
consisted of six isolates each, except 027 (n=5). * frequency allocated as the lower limit 
of detection, where no resistant colonies were identified. 
 
 
Categorising mutation frequency data by PCR ribotype further demonstrated the 
high levels of variation; (Figure 40). Multiple comparison analyses using the Dunn-
Bonferroni test revealed significant differences between ribotypes 017 and 001 
(p=0.008), 015 (p=0.038) and 078 (p=0.025), whilst highly significant differences 
were observed in comparison to ribotype 027; (p<0.001). Further differences were 




PCR Ribotype (p=) 
  













) 001   1.000 1.000 *0.008 1.000 0.869 1.000 
012 1.000   1.000 1.000 1.000 *0.007 1.000 
015 1.000 1.000   *0.038 1.000 0.885 1.000 
017 *0.008 1.000 *0.038   0.079 ***<0.001 *0.025 
020 1.000 1.000 1.000 0.079   0.495 1.000 
027 0.869 *0.007 0.885 ***<0.001 0.495   1.000 
078 1.000 1.000 1.000 *0.025 1.000 1.000   
Table 23: Chequerboard of P values for PCR ribotype mutation frequency 
pairwise comparisons. Values were determined by the Kruskal-Wallis and by Dunn-






Figure 40: Mean average (±SE) moxifloxacin (MXF) selected mutation 
frequencies by PCR ribotype (RT). All RT groups n=6, except RT027 (n=5). * - 
significant, *** - extremely significant by Dunn-Bonferroni test. 
 
 
Fluoroquinolone pressure selected a diverse range of mutant, MXF resistant 
phenotypes, with MICs ranging between 4 mg/L and 64 mg/L; (Table 24). Isolates 
from ribotypes 001 and 078 generated only highly resistant mutants (>32 mg/L), 
while the remainder, including ribotype 027 strains, produced a series of 
susceptibility phenotypes from 4 mg/L upwards. Not all ribotype 027 isolates 
generated resistant mutants >8 mg/L, with one (CD9946) adapting minimally to 
























































Mutant MXF MICs (mg/L) 
P/O 1 P/O 2 P/O 3 
001 JV28 1 32 32 64 
  CD0160 1 32 32 32 
  CD4032 1 4 4 4 
012 CD0099 1 4 8 32 
  CD0079 1 8 16 32 
  JV30 2 32 32 32 
  JV32 2 32 32 32 
  CD0127 1 8 8 16 
015 JV03 1 32 32 32 
  JV07 1 8 8 8 
  JV09 1 16 16 16 
  JV10 2 4 8 8 
  JV11 2 8 8 8 
  JV26 1 8 8 8 
020 JV05 1 32 32 32 
  JV06 1 8 8 8 
  JV27 1 4 4 4 
027 CD3904 1 4 32 32 
  CD3891 2 4 32 32 
  CD9609 1 4 8 32 
  CD3051 1 4 8 8 
  CD9946 1 4 4 4 
  CD3809 1 4 16 16 
  CD3079 1 8 16 32 
078 CD0223 1 32 32 32 
  CD0222 1 32 32 64 
  CD4112 2 32 32 32 
Table 24: Cross section of minimum inhibitory concentrations of C. difficile 
mutants generated with 4 mg/L MXF pressure. The minimum inhibitory 
concentrations (MIC) for three pick-offs (P/O) represent colonies from different 





5.4.2 PCR ribotype 027 mutability 
5.4.2.1 PCR ribotype 027 mutation frequencies at 4x MIC 
The observation of elevated mutation frequencies, combined with the broad 
distribution of mutational propensities detected in ribotype 027 isolates (Table 22), 
advocated a more in depth focus on this clinically important strain type. Two 
additional susceptible strains were identified from the ClosER study (188), allowing 
further analysis of a total of seven European, clinical isolates. 
Additional ribotype 027 isolates, CD3051 and CD3079 demonstrated comparably 
low mutation frequencies of 3.02 x 10-8 and 2.93 x 10-8, respectively; (Figure 41). 
Frequencies appear to be of almost bimodal distribution, with delineation into two 
approximate groups of either high (>10-7) and low (<10-9) mutability. Again, no 
apparent relationship was observed between fluoroquinolone mutation response 
and isolate age or origin. The three isolates originating from the same institution, 
Ӧrebro University Hospital in Sweden, revealed demonstrably different responses, 
particularly those from the same year of isolation (CD3904 and CD3891). 
 
 
Figure 41: Mean (±SE) mutation frequencies of seven PCR ribotype 027 isolates 
with 4x MIC moxifloxacin (MXF) selection. Data represent a minimum of three 
replicate tests. Lower limit of detection (LLOD) calculated as 1 / (mean total viable 





























































































5.4.2.2 PCR ribotype 027 mutation frequencies at fixed MXF concentrations 
Since the lowest frequency determined was associated with that of the only isolate 
with an initial MXF MIC of 2 mg/L (CD3891), all 027 strains were examined for their 
response to a fixed MXF concentration of 4 mg/L. To further ensure robust findings, 
six biological replicates were tested for each isolate, with minimal effect observed 
on the majority of the data. Reducing the selectivity of the agar for isolate CD3891 
from 8 mg/L to 4 mg/L dramatically altered the mutation frequency, from 7.04 x 10-
9 to 2.11 x 10-6; (Figure 42). Isolate CD3904 demonstrated a mutation frequency that 




Figure 42: Mean (±SE) mutation frequencies of seven PCR ribotype 027 isolates 
selected under 4 mg/L moxifloxacin (MXF) pressure. Lower limit of detection 
(LLOD) calculated as 1 / (mean total viable counts/mL). No error bars are displayed 
































































































Mutation frequencies determined at elevated MXF concentrations (8 mg/L and 16 
mg/L) demonstrated a substantially reduced capability for ribotype 027 isolates to 
adapt and generate resistant colonies; (Table 25). Mean mutability decreased from 
2.12 x 10-6 (4 mg/L) to 4.25 x 10-9 (8 mg/L), with no colony growth detected under 
16 mg/L MXF pressure. This resulted in a frequency designation of below the lower 
limit of detection; <3.69 x 10-9. Only four isolates exhibited colony formation on 8 
mg/L MXF agar, albeit in a vastly reduced capacity; (Table 25). No correlation was 
observed between mutation frequency in the 4 and 8 mg/L assays. CD3891 
demonstrated the highest mutation frequencies at 8 mg/L (7.04 x 10-9), whilst the 
two other isolates exhibiting high frequencies to 4 mg/L (<10-6), CD3904 and 
CD9609, revealed no recordable growth. 
 
Strain 
Mutation Frequency  
Moxifloxacin Selection (n=) 
4 mg/L 8 mg/L 16 mg/L 
CD3904 5.91 x 10-6 (6) <3.35 x 10-9* <3.35 x 10-9* 
CD3891 2.11 x 10-6 7.04 x 10-9 (6) <3.14 x 10-9* 
CD9609 2.73 x 10-6 (6) <4.01 x 10-9* <4.01 x 10-9* 
CD9946 3.77 x 10-8 (6) <3.24 x 10-9* <3.24 x 10-9* 
CD3809 3.91 x 10-7 (6) 4.14 x 10-9 <4.14 x 10-9* 
CD3051 3.02 x 10-8 (6) 4.17 x 10-9 <4.17 x 10-9* 
CD3079 2.93 x 10-8 (6) 3.77 x 10-9 <3.77 x 10-9* 
Table 25: Comparison of mutation frequencies of seven PCR ribotype 027 strains 
selected under 4, 8 and 16 mg/L moxifloxacin pressure. n = 3 unless stated. Where 
no resistant colonies were identified frequencies are defined as <, with values referring 
to the lower limit of detection. 
 
 
5.4.2.3 Molecular analysis of PCR ribotype 027 isolates investigated in 
mutation frequency assays 
With the exception of one isolate, all MXF sensitive ribotype 027 strains investigated 
in this chapter demonstrated one hundred percent homology for all DNA gyrase, 
mismatch repair and SOS response genes. The exception was CD9946, 




ribotype, exhibiting a host of synonymous and non-synonymous mutations; (Table 
27). Two non-synonymous amino acid substitutions were observed in gyrA, 
Ile406>Leu and Asn468>Asp, with no impact on the fluoroquinolone susceptibility 
phenotype. Both of these variants were exclusively present in the genomes of the 
ribotype 027 isolates (n=3) from the historical collection; (Chapter Four). One gyrB 
modification, Val130>Ile, represented a commonly observed polymorphism 
amongst the historical strains (n=29/75), with no perceived consequence to 
resistance phenotype. Resistant isolate (32 mg/L) CD4362 harboured the common 
Thr82>Ile substitution. Sequencing of single mutant colonies for each isolate 
revealed individual instances of Thr82>Ile and Asp71>Tyr mutations in gyrA and 










Mutant Strain Amino 
Acid Substitution 
gyrA gyrB 
CD3904 1 32 Thr82>Ile - 
CD3891 2 32 Thr82>Ile - 
CD9609 1 32 Thr82>Ile - 
CD9946 1 4 - Gly429>Val 
CD3809 1 16 Asp71>Tyr - 
CD3051 1 4 - Gln434>Lys 
CD3079 1 32 Thr82>Ile - 
Table 26: Characteristics of C. difficile ribotype 027 mutant strains generated 
during mutation frequency investigations (4x MIC). Parent and mutant progeny 
moxifloxacin (MXF) minimum inhibitory concentrations (MICs) and mutant strain 
amino acid substitutions are displayed. 
 
Single non-synonymous mutations in each of the mutS, mutL and lexA genes were 
observed in the CD9946 genome, whilst five were identified in the mutS related 
protein; (Table 27). This isolate did not demonstrate an extreme level of mutation 
compared to the other isolates with no deviance in these genes, therefore no 
correlation could be determined between these SNPs and mutation frequency. No 








Isolate CD9946 gyrA gyrB mutS 
mutS related 
protein, family 1 
mutL lexA recA recX hfq 
Non-synonymous 
substitutions 
Ile406 >Leu, Val130 >Ile Met5>Ile Phe42>Leu, Asp379>Gly Thr9>Ile None None None 
Asn468 >Asp     Asn191>Asp,           
      Ser266>Ala,           
      Ile377>Val377,           




3 5 7 4 11 2 0 0 0 
Table 27: Single nucleotide polymorphisms in the DNA gyrase, mismatch repair and SOS response genes of PCR ribotype 027 isolate 




5.4.2.4 Mutation frequencies of primary mutant strains under exposure to 
fixed MXF concentrations 
Secondary culture and selection with increased fluoroquinolone concentrations (8 
mg/L and 16 mg/L) resulted in all primary mutants (MXF MIC 4 mg/L) producing 
subsequent populations exhibiting higher levels of MXF resistance; (Figure 43). 
Mean average mutation frequencies were 1.24 x 10-5 and 1.71 x 10-8, for 8 mg/L and 
16 mg/L respectively. Isolates CD3809 and CD3051 demonstrated strikingly raised 
frequencies under 8 mg/L exposure (3.61 x 10-5 and 3.81 x 10-5; respectively). 
Isolates CD3904 and CD3891 expressed a slightly elevated proclivity for mutability 
when exposed to higher MXF concentrations (16 mg/L); (4.73 x 10-8 vs 2.50 x 10-8 
and 2.76 x 10-8 vs 1.47 x 10-8; respectively). No 4 mg/L mutants were generated 
from isolate CD3079 to enable further testing. 
 
 
Figure 43: Mean (±SE) mutation frequencies of six PCR ribotype 027 mutants (4 
mg/L MXF MIC) selected under 8 and 16 mg/L moxifloxacin (MXF) pressure. 
Lower limit of detection (LLOD) calculated as 1 / (mean total viable counts/mL). No 
















































































































Further testing of two mutant strains with 32 mg/L MICs (from CD9609 and 
CD3079) generated during initial 027 mutation frequency assays demonstrated 
distinctly different responses when assessed with further elevated MXF 
concentrations; (Appendix). No colonies were generated by CD9609 mutant at 
either raised concentration, therefore, mutation frequencies were determined as 
<2.81 x 10-9. Conversely, the CD3079 mutant responded at a frequency of 2.65 x 10-5 
under 32 mg/L pressure and 6.08 x 10-9 at 64 mg/L. Isolate CD4362, exhibiting pre-
existing MXF resistance (32 mg/L MIC), was observed to mutate at 4.67 x 10-5 and 
5.71 x 10-8, under 32 and 64 mg/L MXF pressure; respectively. MXF MICs for all 
subsequent mutant colonies were determined as 128 mg/L. 
 
5.4.2.5 Minimum inhibitory concentrations of secondary mutant strains 
produced during stepped exposure investigations 
All but one 4 mg/L MXF MIC mutant generated in mutation frequency experiments  
demonstrated further increases in MIC after secondary assay and selection with 
elevated MXF pressure; (Table 28). A mutant isolate generated from CD9946 did not 
produce any further stepwise when selected with increased fluoroquinolone 
concentrations.  
In four isolates, 8 mg/L MXF exposure selected for mutants with MICs of up to 16 
mg/L, however, one strain (CD3891 4 mg/L mutant) was able to generate mutant 
colonies with MICs of 32 mg/L. Three out of six 4 mg/L mutants tested produced 
colonies with MICs of 32 mg/L, under 8 or 16 mg/L selection. Two mutant strains 
(CD3904 and CD3051) generated a homogeneous response under 8 mg/L selection, 
with all progeny revealing consistent MICs. The remainder produced a 
heterogeneous reaction, with differing MICs observed between colonies; (Table 28). 
A CD3051 mutant was the only strain unable to grow on 16 mg/L MXF agar, while 
able to produce colonies at 8 mg/L. Of the two mutants demonstrating initial step 
mutant MICs of 32 mg/L, only one (CD3079) was able to withstand up to 64 mg/L 
MXF pressure, generating mutants with a corresponding MIC. 
Concurrent testing of an original MXF resistant strain, CD4362, highlighted a 
potential to produce further resistant phenotypes, capable of surviving up to 128 














Secondary Mutant MXF MIC 
(mg/L) 
P/O 1 P/O 2 P/O 3 
CD3904 4 8 16 16 16 
    16 16 32 - 
CD3891 4 8 32 - - 
    16 32 16 - 
CD9609 4 8 16 8 - 
    16 32 16 16 
CD9946 4 8 No mutants 
    16 No mutants  
CD3809 4 8 8 16 - 
    16 16 16 - 
CD3051 4 8 8 8 8 
    16 No mutants   
CD3051 32 32 No mutants 
    64 No mutants  
CD3079 32 32 32 32 32 
    64 64 64 64 
CD4362 32 32 32 32 64 
    64 128 128 128 
Table 28: Minimum inhibitory concentrations of second-step mutants of C. 
difficile selected with further exposure of first-step mutant 027 isolates to 8, 16, 
32 or 64 mg/L moxifloxacin (MXF) pressure. Where available, three colonies from 
each strain and each MXF concentration were tested for MXF MIC. “-” refers to no 





5.5.1 C. difficile mutation frequency determination 
The importance of fluoroquinolone resistance and its impact on CDI rates has 
recently been highlighted (387). Therefore, investigating the propensities for 
individual C. difficile isolates to develop MXF resistance in vitro may be crucial to the 
further understanding of the proliferation of the organism. Here, an interrogation of 
a panel of isolates consisting of historical and modern strains highlighted potential 
strain and ribotype specific variance in fluoroquinolone resistance conferring 
mutation frequencies. Whilst these data indicated interesting findings, further 
exposure of this strain collection to mutability assays with additional antibiotics is 
necessary to corroborate the results. The use of a compound such as rifampicin, 
where mutability could be assessed independently from DNA gyrase gene 
mutations, is essential to confirm the observed mutational differences. By 
establishing comparable levels of mutability in other areas of the genome, this data 
could potentially validate the hypothesis of variable mutation frequencies, as 
opposed to alternative explanations such as hetero-resistance. Therefore, these 
findings are discussed in provisional context. 
The most striking observation from the mutation frequency screening experiment 
was the variation of both inter and intra ribotype mutability demonstrated; (Figure 
39). While the mean average spontaneous mutation frequency at four times MIC 
selection, a common approach successfully applied by others (232, 608, 610, 611, 619), was 
determined as 4.15 x 10-7, the range was expansive: 3.77 x 10-9 – 5.91 x 10-6. This 
range reflects the results of fluoroquinolone resistance mutability research in other 
organisms (590, 608, 610, 611, 842, 843), although much of this relates to earlier generations 
of quinolones, such as CIP. One such study identified CIP-induced mutations in E. 
coli, with a closely comparable range of 1 x10-9 to 1.5 x 10-6 (608).  
Although there is a paucity of data for MXF-resistance mutation frequencies in C. 
difficile, Locher et al. demonstrated this agent as generating higher levels of 
spontaneous mutation compared to other antimicrobials, including LZD and VAN 
(232). Nevertheless, the average observed frequency here is greater than that 
reported in C. difficile by Locher et al. (~2 x 10-8) (232), but lower than previously 
described by Spigaglia and colleagues, where levels of mutation amongst five 




(812). Nonetheless, the disparities in variance between the findings of the present 
study and other published data may be explained by the greater number of strains 
tested in this investigation. Equally, in selected instances Spigaglia’s findings 
represented colony formation from only two-fold MIC selection, as opposed to four-
fold exposure tested here. Though findings of the present study determined 
mutation frequencies based on the ability of a colony to demonstrate an increase in 
MIC, the study by Spigaglia et al. searched for gyrA or gyrB mutations in three colony 
pick offs before allocating a mutation frequency (812). Whilst this may seem more 
appropriate, this approach neglects to consider alternative resistance aetiologies. 
DNA gyrase alterations are often associated with high-level resistance (443, 812) and 
ignoring slight reductions in susceptibility could overlook important intermediatory 
steps, potentially caused by alternative mechanisms, such as efflux. The slight 
decreases in susceptibility may act as a precursor step to high-level resistance 
mutations and consequently may be considered as potentially significant to the 
dissemination of fluoroquinolone resistance. Hence, the methodology for measuring 
mutation frequency selected here, of using a defined MIC multiple concentration 
with secondary susceptibility confirmation, may produce a more comparable and 
clinically representative data set. Although gyrase substitutions were identified for 
ribotype 027 mutant isolates, the majority of other strains were unable to be 
genotyped due to the high expense of sequencing several colonies of multiple 
isolates. Interestingly, Spigaglia only observed the classic Thr82>Ile substitution in 
spontaneous mutants generated by levofloxacin pressure and not MXF (812). 
However, since only five isolates were tested, this finding may denote an 
unrepresentative test panel.  
Whilst mutation frequencies for ten isolates were determined as below the lower 
limit of detection, further bacterial concentration steps via centrifugation would 
have potentially enabled the recovery and enumeration of resistant mutants with 
greater precision. However, since the inter strain divergence between mutation 
frequencies was clearly apparent and an excessive amount of work would have been 
required to repeat ten tests, in triplicate, this was not performed. 
A major factor to consider when assessing mutation frequencies is the amount of 
antimicrobial selection pressure to expose test isolates to, as spontaneous mutation 




susceptible isolates will vary in MIC, standardisation of experimental approach is 
critical. Consequently, testing at multiples of original MICs is often implemented as 
best practice (232, 608, 610, 611, 619). Studies have revealed elevated mutation frequencies 
at four times MIC (608, 610, 611), whilst imposing sufficient selection pressure on a 
population to identify genuine mutational response. Greater fold increases appear to 
reduce bacterial capacity to mutate, since large step increases in concentration 
prove more efficient in inhibiting growth (608, 842). A study by Spence and Towner 
observed marked reductions in mutation frequency of Acinetobacter baumannii 
exposed to MXF at concentrations between four and eight-fold MIC. This is equally 
reflected here, where data from focussed experimentation with ribotype 027 
isolates showed distinct reductions at 8 mg/L and 16 mg/L; (Table 25). 
Although all the primary test strains were MXF susceptible (< 2 mg/L), the initial 
MICs were inconsistent, defined as either 1 mg/L or 2 mg/L; (Appendix). Therefore 
the use of a multiple of MIC concentration resulted in antimicrobial pressures 
infused in the agars of 4 mg/L and 8 mg/L. This disparity in testing protocol 
potentially resulted in some of the inter strain variation observed, with discrepant 
conclusions determined for those strains tested at higher concentrations. Seventeen 
isolates (42%) demonstrated an initial 2 mg/L susceptibility phenotype, with a 
noticeably reduced mean mutation frequency of 6.40 x 10-9 compared to 7.05 x 10-7 
for all 1 mg/L MIC isolates. Nonetheless, in order to include a larger number of 
isolates in frequency testing, a stringent parameter was necessary to enable cross 
comparisons of all isolates. During focussed ribotype 027 investigations, CD3891 
demonstrated conspicuously low mutation frequencies at four times MIC (Figure 
41), but when tested at the same concentrations as comparator strains (4 mg/L MXF 
pressure), mutability was considerably raised; (Figure 42). These approaches 
generated highly divergent results. Nonetheless, the latter approach may have 
resulted in test concentrations too close (only one doubling dilution increase) to the 
original MIC for a requirement of mutation to survive the fluoroquinolone pressure. 
Since MIC data is generally regarded as somewhat approximated, this may have 
been the case.  
Interestingly, mutant colonies produced by isolates within all ribotype groups; (with 
the exception of ribotype 078), exhibited a broad spectrum of susceptibilities (from 




for further susceptibility testing, had MICs greater than 32 mg/L. Whilst this 
ribotype is not frequently associated with MXF resistance, reduced susceptibility is 
not uncommon (188, 480, 846), and MDR does occur (188, 846). This was observed in both 
078 isolates from this historical collection; (Chapter Three). 
Whilst the data from this mutation frequency investigation demonstrated putative 
mutability variance between individual bacterial strains, one alternative explanation 
to the differences observed could be the existence of hetero-resistance amongst 
strain populations. The presence of minority sub-populations of highly resistant 
bacteria, concealed in standard MIC determination methodologies (847), may have 
contributed to the variance observed in this data set. Evidence of hetero-resistance 
had been reported in C. difficile, primarily associated with MTZ (452), but has also 
been demonstrated with fluoroquinolones in other species (848, 849). The 
epidemiological and clinical relevance of this somewhat ambiguous phenomenom 
has the potential to be vast. If ribotype 027 has a greater propensity to demonstrate 
hetero-resistance to MXF than other strains, this could prove contributory to the 
progression of fluoroquinolone resistance in this epidemic strain type. 
 
5.5.2 PCR ribotype 027 mutability 
Large differences in mutation frequencies were observed across the examined 
isolates, but the significantly higher rates observed in general for ribotype 027 
strains (compared with those for ribotypes 012 and 017 [Figure 40]) were of 
particular interest. Given these results and the clinical importance of C. difficile 
ribotype 027, focussed investigation of these strains was undertaken. Since ribotype 
027 is a prominent, outbreak causing ribotype (34, 112), and is commonly associated 
with fluoroquinolone resistance (562), this ribotype was of particular interest for 
further examination. Observations of two potentially hypermutable strains (CD3904 
and CD9609), the highest mean average mutation frequency (Table 25) and a broad 
diversity of mutation frequencies between the isolates (7.23 x 10-9 - 5.91 x 10-6), 
further underlined ribotype 027 as being of particular of interest.  
5.5.2.1.1 Phenotypic analyses 
The variability of MXF-selected mutation frequency observed across all ribotypes, 




reflective of the potential for strain survival and population maintenance through 
clonal expansion. As it may be reasonably assumed that highly mutable strains are 
more likely to mutate in clinical situations, survival and onward transmission of 
these strains may prove advantageous. Dong et al. reported correlations between 
high fluoroquinolone mutation frequencies in S. aureus and greater progeny 
resistance (850). The data set acquired here largely supports this notion, with the 
three isolates indicating the highest mutational ability all producing mutants with 
≥32 mg/L MIC. In contrast, three out of four ribotype 027 isolates demonstrating the 
lowest mutability (CD9946, CD3809 and CD3051) all failed to generate resistant 
mutants with MICs >16 mg/L conferred by the Thr82>Ile substitution. This may be 
reflective of an amino acid substitution dependent bacterial fitness impact (639), with 
a potential for bacteria containing intermediate resistance conferring SNPs to be 
less fit than others. This hypothesis is partially supported by further investigations 
into bacterial fitness in Chapter Six. 
Fluoroquinolone resistance is an almost universal characteristic of ribotype 027, 
with very few sensitive isolates reported (118, 851). This was reflected in the difficulty 
in obtaining such strains for this investigation. Since sensitive isolates are rare, that 
would suggest that although mutability may vary, these strains may either develop 
and retain resistance to this class of antimicrobials or be quickly superseded by 
other more clinically adapted bacteria. The successful dissemination of this ribotype 
may have originated from a propensity for high-level mutagenesis under pressure 
from these antibiotics. Interestingly, three of the seven strains originated from 
Swedish institutions, which are reportedly amongst the lowest consumers of 
fluoroquinolones in Europe (852). Equally, one further sensitive strain was isolated 
from the United Kingdom, where antibiotic stewardship programs are more 
established than other countries (853, 854). This goes to further the argument for 
regulated prescribing regimens as a measure to reduce resistance. 
Based on the data produced in this study, the four-fold MIC approach to mutability 
testing appeared to generate optimal findings. Colony forming units were readily 
countable (<200 CFU) and a diverse, measurable response was observed across all 
strains. Increased MXF pressure, particularly at 16 mg/L often inhibited all 




limit of detection”. This may therefore be considered as the mutation prevention 
concentration for these isolates (855, 856).  
Secondary mutation investigations were undertaken in order to assess the 
subsequent mutability of progeny with reduced susceptibilities. Whilst no clear 
trend was observed, all isolates, with the exception of CD9946 revealed the 
propensity to generate highly MXF resistant (>32 mg/L) mutants; (Table 28). 
Resistance acquisition through incremental steps has been previously reported (812), 
and is deemed crucial for bacteria to reach a level of reduced fluoroquinolone 
susceptibility necessary to gain an adaptive advantage in clinical environments. 
Although clinical levels are generally likely to surpass these test concentrations (857), 
the tapering effect of antimicrobial concentrations post treatment may allow for 
mutational response to survive antimicrobial pressure. This may confer C. difficile 
strains a temporal advantage over commensal gut flora and therefore a proliferation 
opportunity. Interestingly, pre-existent MXF resistant isolate CD4362 demonstrated 
the propensity to develop further resistance up to 128 mg/L. The gyrA sequencing 
of this highly resistant mutant revealed the common Thr82>Ile mutations in 
addition to an Ala118>Ser substitution, reported in other strains with MXF 
MICs >64 mg/L (766). This elevated level of resistance becomes of greater clinical 
concern when considered in relation to the faecal concentrations achieved by MXF 
treatment. Edlund et al. reported concentrations in the faeces to reach a peak of 65.7 
mg/L (857). Although faecal concentrations may be lower than true intestinal levels, 
this figure remains well below the tolerable level of these high-level mutants. 
Resistance to this extent could potentially result in increased CDI cases, where 
fluoroquinolone use is putatively involved as a predisposing factor. Since no fitness 
cost has been associated with this phenotype (639), resistant substitutions can be 
retained for clonal expansion.  
5.5.2.1.2 Genomic analyses 
In order to ascertain the source of the extensive variation in mutation frequencies 
amongst isolates of the same PCR ribotype, several mechanisms with demonstrable 
effects on mutability in other organisms were investigated (583, 593, 594, 606, 627). 
Unfortunately, since all but one strain demonstrated full homology of mismatch 
repair and SOS response genes, no correlations could be identified. The variation in 




repair and response genes tested here. As there are likely to be many more ancillary 
genes involved in these processes (593, 841), differences in alternative loci may be 
relevant to mutation frequency variance. 
Intruigingly, isolate CD9946 represented a highly distincitive genome in comparison 
to the other strains examined, with multiple synonymous and non-synonymous 
mutations exhibited in these genes. Interestingly, the single amino acid substitution 
detected in the mutS gene, Met5>Ile, represented a start codon alteration. 
Modification of start codons have previously been reported to impact on the 
efficiency of translation, with a reduced binding affinity of tRNA hypothesised as the 
primary cause (858-860). Nevertheless, the substitution in the mutS start codon did not 
appear to have any detrimental effect on the strain’s mutability in response to 
fluoroquinolone stress and may not have affected translation of this gene. Further 
protein expression analyses would help to elucidate the validity of this theory (861). 
Also, the threonine substitution at codon nine of the lexA gene does not occur near 
the binding site of the LexA protein (598), and it is therefore improbable that this 
would impact the efficacy of the translated protein; reflected in the relatively low 
mutation frequency (3.23 x 10-8) observed in this isolate. Similar observations were 
made with the mutL gene, as the only non-synonymous alteration occurred at Asp-
379, outside of the distinct domains recently associated with mutS interactions in in 
silico docking simulations (862). The eighteen silent mutations detected across the 
mutS and mutL genes of CD9946 are more likely to represent the evolutionary 
distinction between this relatively distant genome, than convey any discernible 
influence on the mismatch repair system of this isolate.   
Nonetheless, isolate CD9946 was conspicuous by its muted response to resistance 
development (no resistant mutants were generated in step-wise experiments) and 
genomic analysis indicated a distinctly distant genotype in comparison to the other 
ribotype 027 strains examined; (Table 27). It is not unreasonable to suggest that a 
plethora of SNP differences in this genome may contribute to influence the efficacy 
of DNA repair response. 
Molecular analysis of the DNA gyrase genes was performed to establish any variance 
in baseline characteristics at these loci, potentially influencing antimicrobial 
mutagenesis. As expected, no gyrA or gyrB polymorphisms were observed in the 




were detected in strains CD9946, two in gyrA and one in gyrB; (Table 27). These 
amino acid substitutions, although variant from the majority of genomes examined, 
were detected in other fluoroquinolone susceptible isolates; (Chapter Four). 
Interestingly, the Ile406>Leu and Asn468>Asp modifications observed were evident 
in all of the ribotype 027 genomes investigated from the historical collection. 
Although the historical strains demonstrated fluoroquinolone resistance, this was 
associated with the characteristic Thr82>Ile mutation. Therefore, it is conceivable 
that the gyrase polymorphisms possessed by this MXF sensitive isolate are artefacts 
of archaic horizontal gene transfer, characterising this PCR ribotype (563). The valine 
substitution at codon 130 of the gyrB gene also appears to transmit minimal 
influence on fluoroquinolone resistance, as it has been detected in the genomes of 
22 MXF sensitive C. difficile isolates from the historical collection (Chapter Four) and 
in no resistant strains. Therefore, this difference appears to be of evolutionary 
origin, as opposed to driven by quinolone exposures. 
These findings further verify the reports of a high-level of gene conservation in C. 
difficile mutS, and mutL homologues (573, 600), thus indicating the presence of an 
alternative source of mutation variability in these strains. The mechanisms relevant 
to the diverse mutability observed here, are likely to be more complex, potentially 
epigenetic in nature. 
 
5.6 Conclusions 
The high proportion of CDI cases associated with ribotype 027 strains resistant to 
modern fluoroquinolones (34, 118) is a major clinical concern. Provisional evidence 
reported in this chapter suggests that a greater propensity for mutagenesis, 
effecting resistance to these antimicrobials, may contribute to the wide distribution 
of these polymorphisms. Increased mutability potential may have provided an 
advantage to these strains with regards to fluoroquinolone survival and resistance 
acquisition (863). The rarity of fluoroquinolone sensitive ribotype 027 isolates (118) 
suggests that resistance may develop more readily in these strains and be retained 
in the absence of any bacterial fitness cost (639). Whilst, subsequent clonal expansion 
has enabled this ribotype to reach epidemic levels, other lineages demonstrating 




mutability variance in these isolates does not appear to be directly related to the 
common DNA SOS and mismatch repair genes, mutS, mutL, recA or lexA, and further 




Chapter 6 The Impact of Fluoroquinolone Resistance-Conferring 
Mutations on In Vitro Bacterial Fitness  
6.1 Introduction 
Fluoroquinolones have been associated with CDI as a predisposing risk factor (92, 
99) and have been strongly implicated in major international outbreaks of PCR 
ribotype 027 (34, 92). A recent retrospective analysis reported correlations 
between a reduction in fluoroquinolone prescribing and CDI caused by 
fluoroquinolone resistant strains (387). However, the potential for C. difficile 
strains to retain the resistant phenotype in the absence of antimicrobial 
pressure remains unclear. The fitness associated with these resistant 
determinants may be a factor in the maintenance of fluoroquinolone resistance 
in this important nosocomial pathogen. 
The impact of resistance determinants may not always be constrained to an 
antibiotic susceptibility phenotype. Several reports have linked resistance-
conferring amino acid substitutions to a demonstrable burden on bacterial 
fitness (518, 585, 629, 864). Whilst typically related to a reduction in growth rates, the 
effects on the functionality of crucial pathways, such as sporulation and toxin 
production in C. difficile can also be appropriate measures of fitness. 
Investigations of fluoroquinolone resistance mutations have demonstrated 
diverse responses across a host of bacterial species (630, 633, 634), with some more 
detrimental to fitness than others. Both transferable elements and chromosomal 
mutations have been correlated with fitness disadvantages in C. difficile, with 
ermB (518) and rpoB (637), respectively. However, the relationship is not always 
straightforward; rifamycin resistance-conferring mutations in different locations 
on the rpoB gene have demonstrated minimal effect on C. difficile fitness (638). 
Similarly, Wasels et al. observed no impairment with the common 
fluoroquinolone resistance, Thr82>Ile mutation in isogenic mutants created via 
allelic exchange, whilst the rarer valine substitution at the same codon imposed 




We investigated the impact of gyrA and gyrB mutations on C. difficile PCR 
ribotype 027 fitness, through growth rate analysis and, for the first time, using a 
competitive co-culture assay.  
6.2 Rationale 
In this chapter, the bacterial fitness impact of common fluoroquinolone 
resistance-conferring substitutions was determined in vitro. A collection of MXF 
susceptible 027 parent strains and their resistant progeny were investigated for 
differences in growth rate, toxin production and competitive co-culture 
response. Continuous co-culture modelling was performed with one strain 
pairing, to further test the effects of the Thr82>Ile mutation in a bacterial 
turnover environment, more reflective of clinical situations. Whilst previous 
findings in ribotype 012 have indicated an absence of a fitness burden 
associated with the majority of resistance mutations (639), equivalent discoveries 








6.3.1 Test isolates 
Seven MXF susceptible (1-2 mg/L) PCR ribotype 027 strains (parent) and seven 
corresponding MXF resistant mutants (Table 26), generated through previous 
mutation frequency assays (Chapter Five), were subjected to in vitro fitness 
investigations. Bacterial responses were evaluated for both parent and mutant 













Mutant Strain Amino 
Acid Substitution 
gyrA gyrB 
CD3904 1 CD3904 Mut 32 Thr82>Ile - 
CD3891 2 CD3891 Mut 32 Thr82>Ile - 
CD9609 1 CD9609 Mut 32 Thr82>Ile - 
CD9946 1 CD9946 Mut 4 - Gly429>Val 
CD3809 1 CD3809 Mut 16 Asp71>Tyr - 
CD3051 1 CD3051 Mut 4 - Gln434>Lys 
CD3079 1 CD3079 Mut 32 Thr82>Ile - 
Table 29: Characteristics of C. difficile ribotype 027 strains tested during 
bacterial fitness investigations. Parent and mutant progeny moxifloxacin (MXF) 
minimum inhibitory concentrations (MICs) and mutant strain amino acid 
substitutions are indicated. 
 
6.3.1.1 Test isolate variant detection 
Genomes were sequenced, annotated and interrogated for fluoroquinolone 
related resistance mechanisms, using RAST (767), CARD RGI (762) and ResFinder 
3.0 (763), as previously; (Chapter Four). Variant detection was performed 
between parent and mutant genomes using CLC Genomics Workbench (752); 
(Appendix). Briefly, sequence reads were mapped to the C. difficile R20291 
reference genome and realigned for indel and structural variants, prior to basic 
variant detection and amino acid change determination. SNP differences in 
fluoroquinolone resistance determining genes, gyrA and gyrB were confirmed 




6.3.1.1.1 Sanger sequencing 
Sanger sequencing of the QRDRs of both gyrA and gyrB genes was used to 
confirm SNP identification. As previously described (Chapter Four), DNA was 
extracted from an overnight, single colony emulsion using a QIAxtractor and the 
QIAamp Fast DNA Kit.  
6.3.1.1.1.1 Amplification of gyrA and gyrB regions 
Primer sequences were obtained from previously published literature (438, 812), 
and synthesised by metabion international AG; (Germany). The QRDR sections of 
the DNA gyrase genes were amplified using the primer pairs: gyrAF (5´-
AATGAGTGTTATAGCTGGACG-3´), gyrAR (5´-TCTTTTAACGACTCATCAAAGTT-3´) 
and gyrBF (5´-AGTTGATGAACTGGGGTCTT-3´), gyrBR (5´-
TCAAAATCTTCTCCAATACCA-3´), generating 390bp regions of gyrA and gyrB, 
respectively.  
The PCR reactions consisted of 12.5 µL Dreamtaq green PCR master mix 
(Thermo Fisher Scientific), 0.3 µL forward primer, 0.3 µL reverse primer, 10.9 µL 
PCR water and 1 µL DNA target. PCR amplification was performed using a 2720 
thermal cycler (Applied Biosystems) with an initial denaturation stage of 94°C 
for 15 minutes, followed by 30 cycles of denaturation for 30 seconds at 94°C, 
annealing for 30 seconds at 58°C (gyrA) and 54°C (gyrB) and a 30 second 
extension phase at 72°C. A final extension stage of five minutes at 72°C was 
implemented. PCR clean-up was performed using the QIAquick PCR Purification 
Kit; (Qiagen), as per the manufacturer’s instructions.  
6.3.1.1.1.2 Sanger sequencing of QRDR regions 
Purified PCR product was quantified using a Nanodrop 2000C (Thermo Fisher 
Scientific) and subsequently diluted by 100-fold in sterile water. Sequencing was 
performed by the Leeds Teaching Hospitals Trust, Molecular Microbiology 
Department, using BigDye™ Terminator Kit v.3.1 (Thermo Fisher Scientific) and 
an ABI 3130xl genetic analyser. Sequence data was analysed in comparison with 






6.3.2 In vitro fitness determination for fluoroquinolone resistance 
mutations 
6.3.2.1 Maximal growth rate determination 
Bacterial growth curves were generated for all strains, in order to determine the 
beginning and end of the exponential growth phases. Based on the assay 
outlined by Wasels et al. (518), ten colonies of overnight CBA culture were 
emulsified into 25 mL BHI broth in soda glass universals. Broths were cultured 
anaerobically, whilst shaking on an Orbital Shaker PSU-10i (Grant-Bio, UK) at 
150 rpm, for 18 hours. Optical densities of the bacterial cultures were measured 
with a Genesys 20 spectrophotometer (Thermo Fisher Scientific) and diluted to 
0.5 (±0.05) OD600 with sterile BHI broth. Dilution ratios were recorded and 
recreated under anaerobic conditions, to limit the exposure of the culture to O2. 
Fresh 25 mL BHI broths were inoculated with 1 mL of standardised culture and 
cultured for a further 11 hours, under the same conditions as previously. At 
hourly time points (including zero hour) broths were mixed via multiple 
inversions and 200 µL was transferred to a 96-well microtitre tray. Absorbance 
measurements were taken at 595nm using a Tecan Infinite F200 pro plate 
reader. All absorbance measurements were calculated as the mean averages of 
three independent culture replicates. Growth curves were plotted and the log 
phase was determined as between the initiation and cessation of exponential 




=  𝜶 (𝒕 − 𝒕𝟎) 
Where, ln is natural logarithm, Nt is the absorbance at log phase end point, N0 is 
absorbance at the beginning of the log phase, α is the growth rate constant and t 
is time at log phase end (865, 866).  
 
6.3.2.2 Assessment of toxin production by cytotoxigenic culture 
Clostridial toxin production was measured via toxigenic culture and cell-
cytotoxicity titre assay. Strains were cultured in BHI broth for 48 hours, before 
centrifugation for 10 minutes at 12,000 g. Twenty microlitres of supernatant 
was inoculated into microtitre tray wells containing 180 µL of confluent Vero 




incubated in 5% CO2 for 48 hours. Toxin action was confirmed by neutralisation 
of additional wells with a C. sordellii antitoxin. Toxin titres were recorded, with 
positivity determined at >50% cell rounding, as previously; (Chapter Three). 
 
6.3.2.3 Competitive batch culture 
Independent overnight BHI cultures of parent and mutant strains were 
standardised as previously (6.3.2.1) and combined in equal bacterial 
concentrations (0.5 mL:0.5 mL) into 25 mL BHI broths. Co-cultures were 
incubated, whilst shaking for 24 hours. Population distributions were quantified 
at both zero and 24 hour time points by serial dilution to 10-7 (20 µL:180 µL) in 
peptone water (Oxoid, UK), before plating onto selective and non-selective 
Brazier’s agar. Mutant populations were assessed with MXF-incorporated agar 
(0.25x MIC). After 48 hour anaerobic incubation, colonies were counted and 
mutant populations subtracted from the TVC counts to determine parent 
populations. All strains were tested in both biological and technical triplicate. In 
vitro fitness was calculated as: 
s = ln(CI) / [t x ln(2)] 
Where, s is selection coefficient, CI is competition index and t is number of 
generations (518). 
Number of generations is               log10 Nt - log10 N0 
                     log10 2 
Where, Nt is total population at time point 24 hours and N0 is total population at 
time point zero hours (631). 
 
Competition index is                      R(t1) / S(t1) 
                                  R(t0) / S(t0) 
 
Where R(t0) is the resistant (mutant) population (CFU) at time point zero, R(t1) is 
the resistant population at 24 hours and S is the sensitive (progenitor) 
population (CFU). 
Fitness of the parent strains were set at 1 and the relative fitness of the mutant 





Figure 44: Flow diagram of bacterial fitness determination methodologies. 
Seven PCR ribotype moxifloxacin (MXF) susceptible parent strains (MIC < 2mg/L) 
and resistant progeny were assessed by three fitness determining assays. BHI – 
brain heart infusion, OD – optical density, RT – ribotype. 
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6.3.2.4 Competitive co-culture in a continuous chemostat model 
A continuous competitive co-culture chemostat model was implemented to 
further investigate any associated effects of fluoroquinolone mutation on C. 
difficile fitness. 
6.3.2.4.1 Chemostat model configuration 
A one litre sealed, glass chemostat vessel was autoclave sterilised with BHI 
media in situ. The chemostat was connected to an additional growth media 
supply (BHI) by sterile tubing, fed through a peristaltic pump; (Watson-Marlow 
101 U/R peristaltic pump; Watson-Marlow, UK). BHI was continuously fed into 
the chemostat over the span of the model, at a rate of 42 mL h-1. Expended 
growth media sources were aseptically replaced daily, to ensure a consistent 
supply of nutrients. The pH of the vessel was measured and maintained at 6.8 
(±0.2) using a P200 ChemoTrode (Hamilton, USA), in conjunction with an 
Anglicon Bio Solo 3 pH controller; (Anglicon, UK). Duran bottles containing acid 
(1M HCl) and alkali (1M NaOH) solutions were connected to the chemostat 
vessel through the peristaltic pumps of the controller unit with sterile tubing. 
The chemostat was positioned on an AGE magnetic stirrer (VELP Scientifica, 
Italy), with an integrated magnetic flea continuously mixing the culture at 
approximately 150 rpm. Temperature was maintained at 37°C (±2°C) using a 
silicone beaker heater and the BriskHeat SDS Benchtop Digital Temperature 
Controller; (BriskHeat, USA). To ensure anaerobicity, the vessel was continually 
sparged with N2 from a generator (Parker Balston, USA). The full continuous 
culture model apparatus is presented in Figure 45, whilst the chemostat 









Figure 45: Continuous competitive co-culture chemostat configuration. Red line represents acid flow, blue represents alkali, green 
represents nutrient media flow (BHI) and purple represents waste output.










Figure 46: Continuous co-culture vessel port configuration. A – Sample port, B – 
Growth media input, C – Nitrogen input, D – pH probe, E – Alkali input, F – Acid input, 
G – Inocula input, H – Gas outlet.  
 
6.3.2.4.2 Experimental design 
Equal proportions of the CD3079 parent (1 mg/L MXF MIC) and CD3079 Mut (32 
mg/L MXF MIC) strains were syringe inoculated into the continuous culture model. 
Prior to inoculation, these initial cultures were standardised as previously (6.3.2.3). 
The population balance of the inoculum was measured to ensure that the parent to 
mutant colony ratio was sufficiently balanced (±0.2 OD), before proceeding with the 
experimental run. Population dynamics were tested at the zero time point using the 
previously described viable count method (6.3.2.3). This enabled baseline 
proportions to be established for the assessment of population progression. 
Sampling was achieved aseptically by using a 20 mL syringe to draw a vacuum 
through a sterile glass bijou connected to a sampling tube; (Appendix). Each model 
replicate was run for a period of eight days (192 hours) with samples tested every 
24 hours for population dynamics and further resistance mutations (>32 mg/L and 
>64 mg/L MXF MICs). Fitness of the mutant strain was calculated as previously 












6.3.2.4.3 Population dynamics testing 
Parent and mutant populations were assessed by comparing TVCs and MXF 
breakpoint plate colony counts to differentiate between fluoroquinolone sensitive 
parent and resistant, mutant bacteria. Samples were serially diluted to 10-7 in sterile 
peptone water with 20 µL aliquots inoculated onto both non-selective Brazier’s agar 
(supplemented with 2% lysed horse blood) and breakpoint, Brazier’s agar 
containing 8 mg/L MXF. Colony counts from breakpoint plates were subtracted from 
TVC counts, obtained from the Brazier’s agar, to acquire sensitive parent counts. 
These were compared to resistant mutant counts to assess the population ratios. 
Spore populations were also determined with a one hour ethanol shock (50% v/v) 
prior to dilution and plating on Brazier’s agar, as previously. Additionally, samples 
were inoculated onto further breakpoint plates, containing 32 and 64 mg/L MXF, in 
order to investigate elevated mutational response. All tests were carried out in 
triplicate with mean averages reported. Several colonies from both 32 and 64 mg/L 
MXF plates had their MICs determined, via the agar incorporation method; 
(previously described in Chapter Three). 
  
 
6.3.3 Statistical analyses 
All statistical tests were carried out using IBM SPSS Statistics v.21.0.0.1. Due to the 
skewed data in one of the fitness assay variables, Thr82>Ile containing isolates were 
analysed using a Wilcoxon signed rank test. P values <0.05 were identified as 
significant, whilst p<0.001 as highly significant. Holistic batch co-culture data was 
compared using the same statistical test. 
For continuous competitive co-culture model data, mutant to parent population 
ratios were assessed after normality testing using the Shapiro Wilk test statistic. The 







6.4.1 In vitro fitness determination for fluoroquinolone resistance 
mutations 
6.4.1.1 Parent and mutant isolate characteristics 
Mutant colonies representing the highest MXF MICs generated for each strain tested 
in mutability assays (Chapter Five) were selected for further investigation into the 
effect of fluoroquinolone resistance adaptations on strain fitness; (Table 30). All 
gyrA and gyrB substitutions were confirmed by Sanger sequencing (Appendix), with 
the detected mutations all demonstrating close proximity to the fluoroquinolone 
target region of DNA gyrase; (Figure 47).  
 
Figure 47: Visualisation of the non-synonymous mutation locations on the 
protein structure on the C. difficile 630 DNA gyrase complex interacting nucleic 
acid (orange). Light blue structures represent gyrase subunit A, light green 
represents gyrase subunit B. Atomic spatial depictions denote amino acid 
substitutions; GyrA: red – Thr82>Ile and purple – Asp71>Tyr. GyrB: green – 








6.4.1.2 Maximal growth rate determination 
Based on bacterial growth curves (Figure 48), log phase was estimated to begin at 
the three hour time point, where absorption increased by an average of 176% from 
the previous time point; (in comparison to 137% between to prior two readings). 
The end of log phase was determined as the nine hour time point, since no further 
increase in absorbance was recorded after this point. For the purpose of maximal 
growth rate calculations, the three and nine hour measurements were applied. 
Maximal growth rates of all parent and fluoroquinolone resistant isolates remained 
comparable, ranging between 0.0050-0.0065 OD595 min-1 (x̅ = 0.0060) and 0.0053-
0.0070 OD595 min-1 (x̅ = 0.0061), respectively; (Table 30). Individual parent to 
mutant growth rate comparisons demonstrated no substantial differences, ranging 
between -0.0006 and 0.0007 OD600 min-1 (x̅ = 0.00007). Three mutant strains 
(CD3904, CD9609 and CD9946) exhibited slightly reduced maximal growth rates 
than their progenitor isolates, whilst three demonstrated marginally elevated rates 
(CD3809, CD3051 and CD3079). One parent and mutant strain pairing revealed 
almost the exact same growth rate calculation (CD3891); (Figure 49).  
Analysis of maximal growth rate and mutation frequency revealed a positive 
correlation. Parent isolates demonstrating mutation frequencies greater than 1x10-7 
(Chapter Five) revealed a correlation with marginally elevated maximal growth 
rates (0.0062-0.0065 OD595 min-1), compared to those with lower mutation 












Figure 48: Growth curves of seven PCR ribotype 027 strains and their fluoroquinolone resistant progeny. Vertical dotted lines represent 
the beginning and end of log phase, used to calculate the maximal growth rates. Absorbance measurements represent the mean of triplicate 


















































Figure 49: Mean maximal growth rates (±SE) of seven PCR ribotype 027 parent strains and their fluoroquinolone resistant, mutant 





























6.4.1.3 Assessment of toxin production by cytotoxigenic culture 
 
All parent and mutant strains produced clostridial toxin, negated by C. sordellii anti-
toxin, effective to a titre of 10-4; (Table 30). No differences were observed between 
parent and mutant isolates. 
 
6.4.1.4 Competitive batch culture 
A variation of fitness (w) responses to fluoroquinolone resistance conferring 
mutations were observed, ranging between w=0.80 and 1.24 (x̅ = 1.13), relative to 
parent fitness set at 1; (Figure 50). In six isolates, fluoroquinolone resistant, mutant 
progeny exhibited a fitness advantage when cultured in direct competition with 
parent strains. All mutants containing a Thr82>Ile substitution displayed a 
considerably elevated fitness level, with collective 24 hour mutant to parent ratio 
scores significantly higher than the zero time point scores; p=0.002. Isolate CD9946, 
containing a Gly429>Val substitution, demonstrated the largest fitness benefit 
(w=1.24). Notably, the single fluoroquinolone resistant strain exhibiting the 
Asp71>Tyr mutation (CD3809) demonstrated a distinct burden to fitness, with 
relative fitness defined as w= 0.80. All strain comparisons identified a statistically 
significant variation between the ratios of fluoroquinolone sensitive parents and 








Figure 50: Mean relative fitness (±SE) of fluoroquinolone (FQ) resistant progeny 
compared to parent fitness (set to 1) in competitive co-culture assays. Values are 



































































Cell Cytotoxicity Assay 
Status (+ve titre) 
Parent FQR Mutant Zero Hour 24 Hours Parent FQR Mutant Parent FQR Mutant 
CD3904 5.91 x 10-6 0.0062 0.0059 1.17 0.46 1 1.2224 + (10-4) + (10-4) 
CD3891 2.11 x 10-6 0.0065 0.0065 0.92 0.68 1 1.0815 + (10-4) + (10-4) 
CD9609 2.73 x 10-6 0.0063 0.0057 0.94 0.58 1 1.1925 + (10-4) + (10-4) 
CD9946 3.77 x 10-8 0.0059 0.0053 1.03 0.40 1 1.2459 + (10-4) + (10-4) 
CD3809 3.91 x 10-7 0.0064 0.0070 0.95 1.20 1 0.8036 + (10-4) + (10-4) 
CD3051 3.02 x 10-8 0.0059 0.0066 0.97 0.74 1 1.1777 + (10-4) + (10-4) 
CD3079 2.93 x 10-8 0.0050 0.0057 1.19 0.69 1 1.1512 + (10-4) + (10-4) 
Table 30: Fitness testing of seven PCR ribotype 027 strains and fluoroquinolone resistant (FQR) progeny determined by batch culture. 





6.4.1.5 Competitive co-culture in a continuous chemostat model 
Fluoroquinolone resistant mutant to parent ratios demonstrated a gradual increase 
across the duration of the model, averaging at ?̅? = 1.43, with a peak of 1.80 at 96 
hours; (Figure 51). Mutant to parent population ratios were significantly different 
between the zero (?̅? = 1.16, SD=0.38) and 96 hour time points (?̅? = 2.7, SD=1.9); 
t(8)=-2.294, p=0.025. Proportional disparity was briefly reduced between 120 and 
144 hours, before rising again towards peak levels. Populations of highly MXF 
resistant bacteria peaked after 24 hours, with counts on 32 mg/L and 64 mg/L MXF-
containing agars observed at 7.34 x 104 and 4.44 x 101 log10 CFU/mL, respectively. 
By 72 hours, >32 mg/L mutant counts decreased to stable populations for the 
remainder of the model duration, ranging between 7.89 x 103 and 1.17 x 104 log10 
CFU/mL; (x̅ = 9.54 x 103). Greater than 64 mg/L MXF mutants were undetectable 
between 48 and 96 hours, with sporadic low-level detection identified towards the 
end of the culture model. All colonies obtained from 64 mg/L MXF agars were 
confirmed to have MXF MICs of 128 mg/L. Colonies present on 32 mg/L MXF agars 
from early (days 1-2) and late (days 6-8) stages of each model had MXF MICs of 64 
mg/L. MXF resistant mutant fitness remained relatively consistent throughout the 
duration of the continuous co-culture model (w= 1.11–1.45, ?̅? = 1.25); (Appendix). 
Total C. difficile counts peaked after 24 hours (1.23 x 108 log10 CFU/mL), with the 
population levelling out by 48 hours, remaining stable through to the conclusion of 
the model (x̅ = 7.93 x 107 log10 CFU/mL); (Figure 52). Spore counts demonstrated an 
exponential increase between 24 and 48 hours (4.07 x 103 – 6.32 x 106 log10 
CFU/mL), corresponding to the initial reduction and subsequent stabilisation of 










Figure 51: Progression of mutant (CD3079 Mut) and parent (CD3079) ribotype 027 C. difficile ratios in a continuous co-culture 
chemostat model. The linear trend line (purple) demonstrates the increasing divergence between mutant and parent strain populations. 
Highly resistant populations >32 mg/L and >64 mg/L MXF were documented to track further resistance development. The line of equality 
represents the baseline of equivalent mutant and parent strain proportions, data above this signifies a fitness advantage for the mutant strain. 
Data are presented as mean averages (±SE) of three independent model replicates. * p=0.025, significantly different mutant : parent ratios. Line 
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Figure 52: The progression of total C. difficile and spore populations observed in a continuous co-culture chemostat model. The point 









































6.5.1 In vitro fitness determination for fluoroquinolone resistance 
mutations 
The effect of fluoroquinolone resistance determinants on an organism’s fitness has 
been widely investigated in a host of bacterial species (587, 629, 630, 633, 635). While 
fitness burdens are regularly reported, commonly associated with a decreased 
growth rate (585, 629, 864), beneficial effects of gyrase and topoisomerase mutations 
have also been observed (630, 633, 634). However, there is a dearth of information 
regarding the fitness effect of fluoroquinolone mutations in C. difficile, particularly 
ribotype 027. Fluoroquinolone resistance was a notable characteristic of PCR 
ribotype 027 strains involved in large outbreaks of severe disease around the world 
and fitness impacts may have been a factor in the predominance of this ribotype (99, 
387, 562). In vitro batch culture experiments with C. difficile may yield indicative data, 
whilst chemostat models have been used successfully to predict clinical CDI risk and 
treatment response (117, 125, 867-869). 
6.5.1.1 Competitive batch culture 
The competitive batch culture findings of this investigation demonstrated evidence 
of both benefit and burden to bacterial fitness, with amino acid substitution 
dependent responses observed. Whilst the majority of mutations exhibited a 
significant advantageous effect (p<0.001), intriguingly, an Asp71>Tyr mutation in 
isolate CD3809 demonstrated a distinct fitness burden; (Figure 50). Therefore, these 
data present a complex picture, with mutational site impacting heavily on bacterial 
fitness. 
In this study Thr82>Ile mutations demonstrated no fitness burden on C. difficile, in 
agreement with previous findings in this organism (639) as well as in others (870-872). 
Furthermore, a significant advantage was observed in these mutant isolates in co-
culture experiments. This common fluoroquinolone resistance substitution has been 
identified in isolates associated with major ribotype 027 outbreaks (34, 92), suggesting 
that resistance acquisition without fundamental hindrance to fitness may offer a 
substantial contribution to clonal expansion. A recent retrospective analysis of local 
and national data provided further insight into the influence of fluoroquinolones on 




by fluoroquinolone resistant strains, but no changes in case rates due to susceptible 
strains, in the context of a fluoroquinolone restricted environment. Whilst the 
aforementioned study highlighted the important role of antibiotics in selection and 
maintenance of certain populations, it does not necessarily explain the whole story. 
In a three-year pan-European study of C. difficile PCR ribotypes and resistance, 
Freeman et al. described the continued prevalence of MXF-resistant PCR ribotype 
027 in Cyprus, against a background of decreasing fluoroquinolone use. In contrast, 
the PCR ribotype 027 isolates from Cyprus became progressively less resistant to 
other antimicrobials tested, inferring no detriment to fitness from the presence of 
fluoroquinolone resistance mutations in these isolates (118). This suggests the 
involvement of additional factors. Infection control interventions in the Netherlands, 
without fluoroquinolone restriction, resulted in substantial decreases in ribotype 
027 prevalence in the aftermath of a series of outbreaks, whilst other types 
flourished in its absence (873). The data outlined in this chapter suggest that, for 
Thr82>Ile mutants in particular, retention of a resistant genotype incurs no 
detectable fitness cost, and so may be retained in the absence of antibiotic pressure. 
This may help to explain the continued presence of fluoroquinolone resistant C. 
difficile PCR ribotype 027 in some locations.   
The only available data for C. difficile comes from a study by Wasels et al., who 
observed no fitness cost to the organism, associated with the majority of amino acid 
substitutions investigated (639). However, one in vitro mutant variant of the CD630 
strain (ribotype 012) did demonstrate a statistically significant impairment in co-
culture investigations. Interestingly, the amino acid substitution present was the 
less common Thr82>Val mutation. This could explain the rarity of the mutant 
variant, as strains acquiring the mutation could incur the reduced growth rate and 
suffer from competitive inhibition in clinical environments. Lee et al. reported 
epidemiological shift in Korean hospitals, aligned with this fitness dynamic (724). 
They described a shift from a predominance of ribotype 001 to a broad distribution 
of other ribotypes, representing a change from Thr82>Val to Thr82>Ile. This 
followed the fitness model, since the ousted strain type harboured the substitution 
variant demonstrating the greater fitness burden (639). Nonetheless, there are other 
factors that potentially had a major impact on strain prevalence, including 





In batch culture, one Asp71>Tyr containing mutant demonstrated a burden on 
fitness. Although proximally located to the advantageous mutation, Thr82>Ile, a 
contrasting fitness response was observed. Whilst the mechanisms of these 
polarised responses are not yet understood, there may be a considerable impact on 
the tertiary structure of the gyrase molecule, affecting replication efficacy. Although 
the fitness cost of CD3809 Mut alterations may be attributed to the gyrA Asp71>Tyr 
mutation, as this amino acid substitution was only present in a single instance, 
further isolates featuring the same modifications are required to substantiate this 
hypothesis.  
The mutations in gyrB, conveying low-level resistance, also displayed no fitness 
burden. This correlated with previous findings (639), where mutations at Asp-426, 
generating equally moderate MIC increases (4 mg/L MXF), produced very slight 
(non-significant) fitness advantages. Since these intermediary steps are an 
important stage in evolutionary resistance development, it may be that the absence 
of a fitness cost/slight fitness advantage may shift the population baseline and allow 
further advantegeous mutations to achieve higher levels of resistance. Whilst gyrB 
mutations may appear of less importance, producing only marginal decreases in 
fluoroquinolone susceptibility, they can act as a transitional step up the resistance 
hierarchy. The capacity to incur fluoroquinolone resistance mutations without 
detriment, as shown in the present study, may be a contributory factor to 
widespread dissemination in this ribotype. Research in other genera support this 
notion, with resistance mutations generating the least burden, identified as the most 
clinically prevalent (636). 
Although a definitive cause for this fitness advantage is unknown, Marcusson et al.  
suggested that modifications to the genes involved in the supercoiling process may 
ultimately affect gene expression (635). By eliciting increased gyrase promotor 
activity and the upregulation of other core processes, beneficial adaptations may be 
acquired. Furthermore, D’Ambrozia discovered altered transcriptomes between 
parent and gyrA mutant, Neisseria gonorrhoeae isolates (874), indicating a potential 
for differential expression associated with fluoroquinolone resistance mutation in 
other bacteria. Whilst it remains unclear as to why sterically proximal mutations can 
impart such opposing effects, one hypothesis may be that the change in amino acid 




Though it might be expected that advantageous chromosomal mutations would be 
optimised and preserved through Darwinian evolution, we cannot discount the 
impact of these substitutions on other factors, crucial to the bacterium. 
Interestingly, Hiramatsu et al. suggested that the S. aureus wildtype gyrA gene may 
have offered resistance to natural antibacterials, such as nybomycin, as the 
emergence of mutations conferring resistance to modern fluoroquinolones resulted 
in nybomycin susceptibility (875). This suggests that the retention of a survival 
element (natural antimicrobial resistance), was perhaps more important in archaic 
lineages than the slight fitness advantage arising from an additional Thr82>Ile 
susbstitution.  
The ability to outcompete other strains may have been a factor in the successful 
expansion and maintenance of epidemic ribotype 027 strains. Robinson et al. 
demonstrated a competitive advantage for ribotype 027 versus other non-027 
strains in an in vivo murine model (430), although the precise mechanisms are not 
clear. The authors proffered an explanation of an elevated ability to outcompete 
others for limited nutrients, postulating an increased replication rate of the thyA 
gene, encoding for thymidylate synthase enzyme, as a potential factor in ribotype 
027 fitness (430). Combined with such physiological factors, additional benefits 
conferred by gyrase mutations, however slight, have the potential to compound any 
ecological advantages held by this ribotype. Nonetheless, as no mention of 
fluoroquinolone resistotype was made in the study by Robinson et al., differing 
susceptibilities may have been a contributory factor.  
Since the discovery of both fitness advantages and burdens, amongst a similar 
cohort of isolates is of great interest, an additional presentation of the data was 
produced to further outline the findings; (Figure 53). Inoculation of co-culture 
experiments with carefully balanced proportions of test populations is vital to any 
fitness investigation. However, although optical densities of the individual cultures 
were meticulously measured, with a tolerance of ±0.05 OD600 variability, a 
consistent, precise balance of populations is practically impossible to achieve. Thus, 
in two strains of equal growth rate, a slight imbalance in initial populations would 
only be exacerbated with exponential growth, potentially skewing findings. 
Nonetheless, in this investigation a repeatable fitness effect was observed across the 




strain at the zero time point. This pattern was also reflected whether or not the 
mutation was advantageous or detrimental. The majority of the seven batch 
competition experiments generated atleast one replicate representing a slight 
imbalance favouring parent and one weighted towards mutant populations. For 
example, CD3904 replicates A and C were imbalanced in the favour of the parent 
strain, whilst replicate B exhibited the opposite imbalance. Nevertheless, after 24 
hours growth, all cultures demonstrated the same predominance of mutant isolate 
populations; (Figure 53). For the majority of parent and mutant test pairings, each 
replicate generated comparable final ratios. This observation adds to the robustness 
of the findings, although the result of intentionally varied inocula proportions would 
provide interesting insight towards the ultimate assessment of this hypothesis. 
Whilst these findings are stark, it is not inconceivable that compensatory mutations 
may have occurred during fitness investigations (876). Since genomic analysis was 
not implemented for the end-stage resistant mutants, there is a possiblity that those 
reflecting no fitness burden may have generated compensatory mutations in order 
to redress a fitness imbalance. 
Maximal growth rate calculations revealed minimal differences between parent and 
mutant strains, demonstrating a lack of correlation with co-culture data. This 
suggests that fitness variability may only become apparent in direct competitive 
culture. Equally, no effect was observed on strain cytotoxicity. However, the 
possibility cannot be excluded that a competitive growth advantage could result in 











Figure 53: Representation of mutant to parent ratios within starting inocula (zero hours) and at 24 hours, for three replicate 
competitive co-culture assays. Values >0 represent greater numbers of FQR mutants within the population, whilst <0 represents greater 
numbers of parent strain. FQR – fluoroquinolone resistant. A, B & C represent biological replicates.
















































6.5.1.2 Bacterial fitness of the gyrA Thr82>Ile mutation in a continuous co-
culture chemostat model 
Animal modelling has been extensively used to test in vivo CDI response (877-881), 
however this methodology requires specialist skills and environments to achieve 
reliable results. Whilst batch culture experiments can provide easily obtainable 
insights into bacterial responses, it is not particularly reflective of the bacterial 
turnover occurring in gastrointestinal environments. Continuous culture models 
provide more representative data regarding the dynamics within clinical bacterial 
populations (882). The concept of continual nutrient replenishment and population 
dilution permits a highly controlled environment for adaptive evolutionary analyses 
(882), where strain dynamics and serial adaption under selective pressures can be 
assessed. Onderdonk et al. utilised this method to successfully investigate the 
impact of environmental pressures on C. difficile toxin production (883).  
6.5.1.2.1 Relative fitness of MXF resistant C. difficile isolate CD3079 Mut in a 
continuous co-culture model. 
The balance of mutant and parent population ratios in co-culture represents the 
ideal foundation to measure the effect of genetic mutations, whether advantageous 
or detrimental, on the fitness of an organism. Here the proportion of mutant to 
parent strain populations in the initial inocula were remarkably concordant (0.98 
ratio). Based on this close proximity, the continuous co-culture model demonstrated 
that isolate CD3079 Mut, encompassing amino acid substitution Thr82>Ile in the 
important gyrA gene, revealed a gradual increase in divergence in population from 
its progenitor strain. In support of batch culture findings, these data demonstrated a 
lack of detrimental effect of the aforementioned DNA gyrase mutation on C. difficile 
fitness. Intriguingly, this mutant progeny demonstrated an advantage over its 
parent strain, CD3079. The fitness calculations for this strain generated consistent 
findings throughout the experimental model, regardless of at which time point the 
determination was made; (Appendix). The mean average fitness of the mutant was 
established as w=1.25, which supports the results of the batch culture investigation 
of this strain; (w=1.16). This advantage surpasses the fitness effects observed in C. 
difficile by Wasels et al. (w=0.90-1.09) (639), as well as those reported across a range 
of organisms (w=0.80-1.05) (884). It also correlates closely with the highest relative 




(w=1.26) (638), suggesting that this may be a substantial benefit, in the context of 
other findings. Further confidence in this finding could be attained, since each 
independent experimental model replicate exhibited consistent trends with regards 
to the population ratios; (Appendix). These data all indicate how a slight bacterial 
fitness advantage can quickly become exacerbated in continuous culture, resulting 
in significant growth benefits. 
Nutrient limitation may impact the behaviour and fitness of an organism. When 
assessing the total vegetative and spore populations of each co-culture (Figure 52), 
it is plausible that after 24 hours the availability of nutrients lessened. Total viable 
populations peaked at this stage, prior to a reduction in numbers, whilst spore 
populations expanded extensively just after. This is suggestive of an inhospitable 
environment, triggering sporulation as a survival mechanism. Thereafter, the 
gradual supply of fresh nutrients correlates with population stabilisation. Since 
populations of high-level MXF resistant strains (>32 mg/L) diminished soon after 
the point of putative nutrient limitation, it may also suggest that these bacteria 
become burdened with additional mutations and cannot compete efficiently at high 
levels. The sporadic instances of 128 mg/L MXF resistant mutant detection may be 
explained by the same rationalisation, which would reflect observations of high-
level resistance reversion in previous C. difficile models (117). Intriguingly, the models 
described by Saxton et al. also demonstrated low-level toxin production prior to 
detectable germination, during investigations with MXF and ribotype 027. The 
presence of a minority, resistant sub-population, able to germinate in the presence 
of high MXF concentrations may explain this phenomenon. This concept may also be 
evident in the continuous culture model described here, where early detection of 
highly resistant colonies was observed. 
One interesting observation, apparent in all independent model replicates, was the 
reduction in mutant to parent ratio occurring between 96 and 120 hours, prior to 
returning to a gradual increase after 144 hours; (Figure 51 and Appendix). Since this 
time point correlated with the creation of fresh breakpoint media, one explanation 
for this could be the deterioration of the antibiotic efficacy in the fluoroquinolone-
incorporated agar used to quantify mutant populations. Nonetheless, this does not 
explain the rapid increase observed beyond 144 hours, where relatively fresh 




counts. However, differences at higher concentrations may prove less discernible. 
This period may also align with the formation of biofilm, temporarily impacting the 
planktonic population dynamics, resulting in a decreased mutant to parent ratio. 
 
6.5.2 Study limitations 
Whilst multiple stage chemostat models using faecal emulsions have proven 
effective in modelling CDI responses to a plethora of environmental pressures (117, 
125, 350, 869, 885), they require a complexity of expertise to operate successfully. While 
these may be more reflective of a human intestinal environment, they cannot 
replicate the interactions with an immune response (867). Therefore, whilst this 
model does not reflect the complexity of interactions in vivo, the pure continuous C. 
difficile culture system implemented here, enabled an extension of the batch culture 
investigations into the fitness of fluoroquinolone resistant strains; (6.4.1.3). Further 
development of this chemostat system to accommodate culture in a faecal emulsion 
would closer imitate the clinical environment and the microbial interactions 
between colonic flora, as utilised by Saxton et al. (117). One study has suggested that 
the fitness behaviour of an organism maybe different between in vitro and in vivo 
experiments, suggesting there may be a culture medium specific element to the 
adaption to a fitness burden (886).  
It is also possible that compensatory mutations may have occurred during fitness 
investigations (876). Since genomic analysis was not implemented on the resistant 
mutants detected towards the end of the continuous co-culture model, there is a 
chance that those demonstrating no fitness burden may have acquired 
compensatory mutations in order to redress a fitness imbalance. Instances of gyrB 
mutation reversion have been previously observed in in vitro C. difficile models (117). 
Although the mutants in this investigation were not developed via controlled gene 
insertion (allele exchange), the mutations represent a natural adaptive response and 
may be more clinically representative. Nonetheless, in vivo modelling would provide 







In summary, fluoroquinolone resistance was a feature of PCR ribotype 027-
associated outbreaks of severe disease. This PCR ribotype continues to persist and is 
highly prevalent in some locations (34, 112). This study demonstrates a fitness 
advantage associated with the common Thr82>Ile gyrA mutation, which may have 
afforded this strain an epidemiological advantage. Without hindrance of an 
associated fitness impairment, the potential for clonal expansion is increased. 
Notably, a lack of fitness detriment associated with this phenotype, theoretically 





Chapter 7 Concluding Discussion and Further Work 
7.1 Discussion 
This thesis presents evidence of antimicrobial resistance progression in C. 
difficile, through comparisons of historical and modern isolate collections. 
Potential contributory factors have also been suggested with the demonstration 
of variable mutation frequencies and a fitness benefit associated with common 
fluoroquinolone resistance mutations observed.  
The discovery of MXF resistant isolates from the early 1980s demonstrated the 
potential for the development of cross-resistance between generations of 
fluoroquinolones, as previously reported (438). The isolation of three ribotype 
027 strains from the historical collection, potentially provided two of the earliest 
instances of this epidemic, hyper-virulent ribotype. Originating from 1981 and 
1983, these two isolates pre-dated the CD196 strain recovered from a French 
patient in 1985 (289). While it is likely that this ribotype existed prior to this 
isolation, CDI cases caused by 027 strains may have been rarer due to the 
scarcity of a resistance advantage. The detection of fluoroquinolone resistance in 
this important ribotype, prior to the major clonal expansion of the early 2000s, 
may suggest the presence of genomic differences hampering these strains from 
flourishing where others did. Although outside the scope of this work, 
comparative analysis of SNP locations between these historical isolates and 
modern, resistant strains may reveal distinct regions with the potential to affect 
epidemiological success. 
Whilst it is known that resistance often rapidly follows the introduction of a new 
antibiotic (535), there is a paucity of data comparing C. difficile epidemiology 
across decades, using modern molecular techniques (381, 726). Here we compared 
phenotypic resistance prevalence amongst an historical collection of C. difficile 
isolates originating from the UK between 1980-1986 and modern UK strains 
from a large-scale surveillance study (2012-2016) (118). Comparisons revealed 
significant increases in the geometric mean MICs of all comparator compounds 
(p=0.01-p<0.0001), with the exception of imipenem. Whilst no evidence of 




fidaxomicin) was detected in the historical isolates, all demonstrated slightly 
lower geometric mean MIC, when compared to modern strains; (VAN 0.135, 
MTZ 0.112 and FDX 0.001 mg/L). Interestingly, the MXF MIC90 was two doubling 
dilutions lower in the historical isolates, suggesting a substantial expansion of 
high-level resistance amongst modern strains. This development of high-level 
resistance may substantially increase the risk of CDI onset in colonised patients 
with fluoroquinolone exposures and therefore, generate considerable concern 
for clinicians.  
Ribotype prevalence in the historical catalogue reflected modern epidemiology, 
with the collection dominated by ribotypes 015 and 020. Whilst it cannot be 
ignored that the recovered strains may represent those ribotypes fittest for long 
term survival, distributions potentially indicate a baseline of strain types that is 
reverted to as outbreaks (e.g. ribotype 027 or long-term periods of endemicity, 
such as ribotype 001 in the UK during the 1990s) subside. The presence of the 
rare ribotypes 242, 341, 619, 626 and 862 may indicate that these were more 
common decades ago, but have subsequently become more or less extinct, due 
to competition inhibition by more successful genotypes. Importantly, these data 
cannot account for the interim period between the two collections, as they only 
inform us about two disparate time points. Nonetheless, taken as a whole, the 
data indicate increasing resistance to multiple antimicrobials in C. difficile. 
Next generation sequence data revealed the presence of many resistance 
determining elements in the historical genomes. Although not as prevalent as 
indicated in modern surveillance studies, resistance determinants, such as ermB, 
tetM and cfr were detected in genomes from the 1980s. The discrepancy in 
prevalence between the temporally distinct isolate collections highlighted the 
progression of these elements, potentially through clonal expansion and 
horizontal gene transfer. This escalation in the presence of resistance 
determinants emphasises the concerning progression towards increased 
incidence of multidrug resistance in C. difficile. The situation becomes self-
perpetuating, as the greater the abundance of transposable genes in the gut 
microbial pan-genome, the more opportunities for gene acquisition.  
The phylogenetic investigations performed on these strains highlighted the 




in the assessment of molecular clock data. Whilst contamination of historical 
specimens with modern isolates cannot wholly be dismissed, rigorous measures 
were imposed during the recovery protocols to ensure the risk was minimal. 
Though the phylograms indicated that the majority of isolates fitted within the 
predicted range of SNP differences, molecular clock estimations did not always 
correlate with age distinctions. The dormancy experienced by C. difficile during 
its existence in spore form conceivably contributes to the evolutionary rate. 
However, as this is an almost indeterminable measure, it should be reasonable 
to consider that estimations of molecular clock rates are only guideline 
approximations and outlying findings may be observed. The impact of spore 
quiescence on evolutionary estimations is therefore an area requiring further 
examination. 
Investigations of C. difficile mutability under fluoroquinolone selection revealed 
a diverse range of responses, with ribotype 027 isolates demonstrating the 
highest rates (?̅?=1.48 x 10-6). This discovery revealed the high plasticity of the 
QRDR, particularly amongst the hyper-virulent types and may contribute to the 
success of these strains. Though the mechanism driving these different 
responses is yet to be elucidated, several genes relating to the DNA SOS and 
mismatch repair systems revealed no correlations with mutability phenotypes. 
The cause may lie in, yet undiscovered, complex epigenetic mechanisms. 
The impact of any genetic alteration on bacterial fitness potentially influences 
the survival and evolution of a genotype (585). Here the effects of fluoroquinolone 
resistance mutations on C. difficile growth rates, toxin production and co-culture 
competition were assessed in the epidemic ribotype 027. Three fluoroquinolone 
resistance conferring mutations, both in the gyrA and gyrB genes, indicated no 
burden to fitness, with a significant advantage observed in isolates harbouring 
the common Thr82>Ile substitution (w=1.16, p=0.002). A continuous co-culture 
chemostat model was successfully established for the further evaluation of 
bacterial fitness testing, with repeatable results observed for one Thr82>Ile 
harbouring isolate. The capacity for C. difficile to develop common 
fluoroquinolone resistance mutations without detriment to the core functions of 
the bacteria, revealed the potential for resistance spread through unabated 




proliferate and outgrow sensitive populations in the gut, causing additional 
clinical challenges. From ribotype 027 phylogeny it was observed that the 
majority of ancestral strains were fluoroquinolone sensitive, whilst recent 
lineages are almost entirely resistant. The fitness advantages of resistance 
substitutions, observed in this ribotype, may be a contributing factor in this 
evolutionary direction. Nonetheless, an absence of fitness burden was not a 
universal trait with MXF resistance mutations. A single instance of an Asp71>Tyr 
substitution revealed a substantial detriment in batch culture, highlighting the 
importance of SNP location to bacterial fitness. 
In conjunction with the absence of a fitness burden associated with common 
fluoroquinolone resistance substitutions, clonal expansion of genetic elements 
may result in even more problematic, clinical challenges. Whilst resistance to 
antibiotic treatment options remains uncommon, an assemblage of elements 
providing protection from other antimicrobial classes may generate increased 
occurrences of CDI. Current trends are moving away from managing this 
antibiotic-mediated disease with paradoxical antimicrobial treatments and 
towards alternative therapeutics, such as monoclonal antibody (255), microbial 
transplants (216, 887) and probiotic therapies (245). While, in time, research may 
generate efficacious, novel treatment options, controlled antimicrobial 
stewardship programs remain essential to reduce resistance development 





7.2 Further work 
Whilst the elucidation of the mechanism behind the vegetative cell replication 
inhibition effected by high concentrations of glycine would be of interest, further 
optimisation of additional C. difficile culture based media would have greater 
clinical relevance. A comprehensive assessment of all widely used growth media, 
both agar and broth, would enable the recommendation of a “gold standard” 
recovery method, potentially leading to a reduction in false negative 
determinations of CDI and an improved clinical response. 
Beyond the scope of this thesis, further extensive attempts to recover aged C. 
difficile isolates from the historical collection would be valuable. Further 
investigations of historical C. difficile isolates would be worthwhile in their 
contributions to the knowledge base, however caution must be taken when 
considering the provenance of isolates and any potential contamination issues. 
With regards to the mutation frequency investigations, repeat testing of the 
same panel of isolates with exposures to an agent with an alternative resistance 
mechanism, such as RIF, would corroborate the mutability findings. Assessment 
of C. difficile mutability frequencies when exposed to the commonly used 
ciprofloxacin and levofloxacin, as well as testing of all ribotype groups under 
elevated concentrations, would further clarify the mutational consequences for 
C. difficile. 
In order to confirm the consistency of the fitness responses outlined in this 
thesis, the assays could be repeated with end stage mutants sequenced to ensure 
no additional compensatory mutations had occurred. Equally, corroboration of 
the fitness effects of mutations tested in only single replicates (e.g. Asp71>Tyr) 
could contribute to the significance of the conclusions. 
The introduction of a fluorescent marker, such as green fluorescent protein 
(GFP), into the mutant populations tested in bacterial fitness assays would 
enable the use of flow cytometry to assess small variations in growth 
rates/fitness. Where only slight effects were observed, they could be accurately 
quantified. Nonetheless, assays would require suitable controls to ensure the 




Both batch and continuous co-culture fitness experiments would benefit from 
being performed in faecal slurry, as opposed to pure broth. This would facilitate 
the assessment of fitness response in an environment closer reflecting a clinical 
setting and the effects of bacterial interactions amongst colonic microbial 
populations. Repeat model testing with different strains exhibiting the same 
substitution, as well as others with diverse mutations would all increase the 
robustness of the hypotheses outlined here. Equally, since the continuous 
culture chemostat model has produced consistent results across several 
replicates, this model could be used to test the impact of other resistance 
elements or even to perform fitness assays in other organisms.  
The analyses performed as part of this PhD research are only the tip of the 
iceberg when considering the use of NGS data. Generation of vast amounts of 
genomic information provides a whole host of opportunities for genome mining 
for novel resistance determinants and the identification of genetic relationships 
to phenotyping data. With the ever increasing availability of sequencing 
technologies, this collection of genomic information (directly linked to 
phenotypic resistance determinations) could provide a basis for future 
antimicrobial resistance prediction algorithms. Applications such as machine 
learning (888, 889) have the potential to harvest genomic data sets and produce 
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8.1 Supplementary data for C. difficile germination assays 
 
 
Figure 54: Germination of PCR ribotype 001 (A) and 078 (B) C. difficile aged 
(six weeks) spores in broths supplemented with various germinant 
concentrations.  
Germination efficiency is represented by differences in mean (±SE) total viable 
counts (TVC) and spore counts. Broths were exposed to germinants for 90 minutes. 
BHI – Brain Heart Infusion, SCH – Schaedlers anaerobic broth, L – lysozyme 
(5mg/L), GLY – glycine, TC – sodium taurocholate. Counts are based on triplicate 


































































































8.2 Supplementary data for historical C. difficile isolate characterisation (1980-86)  









VAN MTZ RIF FDX MXF CLI IPM CHL TGC LZD CIP TZP CRO AMX TET ERY 
JV01 03.12.81 012 + 1 0.125 0.001 0.03 2 >64 4 4 0.06 1 32 16 64 2 32 >256 
JV02 31.12.81 027 + 0.5 1 0.002 0.06 32 8 8 4 0.03 1 >64 16 64 1 0.125 >256 
JV03 30.03.82 015 + 0.5 0.06 0.001 0.03 1 8 4 4 0.03 2 32 4 32 1 0.125 <4 
JV04 06.05.82 001 + 1 0.125 0.002 0.015 2 16 4 4 0.03 1 16 4 32 0.5 0.06 <4 
JV05 01.06.82 020 + 0.25 0.06 0.001 0.06 1 4 2 4 0.03 1 32 8 32 0.5 0.06 <4 
JV06 23.08.82 020 + 0.25 0.06 0.001 0.015 1 2 4 4 0.03 1 32 8 32 0.5 0.125 <4 
JV07 23.09.82 015 + 0.5 0.125 0.001 0.06 1 4 4 4 0.03 2 32 4 32 1 0.125 <4 
JV08 13.12.82 220 + 0.5 0.06 0.002 0.06 1 8 2 4 0.03 2 32 8 32 0.5 0.125 <4 
JV09 03.12.81 015 + 1 0.125 0.001 0.015 1 4 4 4 0.03 2 32 8 32 1 0.125 <4 
JV10 09.12.82 015 + 1 0.125 0.001 0.03 1 4 4 4 0.03 2 32 8 32 1 0.125 <4 
JV11 17.11.82 015 + 1 0.25 0.001 0.03 2 16 2 8 0.03 2 32 8 32 1 0.125 <4 
JV12 19.04.82 020 + 0.5 0.25 0.002 0.06 2 16 2 8 0.03 2 16 4 16 1 0.06 <4 
JV13 01.06.82 020 + 0.5 0.25 0.002 0.06 2 4 2 4 0.03 2 32 4 32 0.5 0.06 <4 
JV14 09.12.82 078 + 0.5 0.125 0.001 0.004 1 >64 4 64 0.06 16 16 nt 16 0.5 4 <4 
JV15 28.03.83 020 + 0.5 0.25 0.002 0.06 2 16 2 8 0.03 2 32 8 32 1 0.125 <4 
JV16 03.10.83 056 + 1 0.25 0.002 0.03 2 2 4 8 0.03 2 32 4 16 0.5 0.125 <4 
JV17 01.02.82 015 + 1 0.125 0.001 0.03 2 >64 4 64 0.03 16 32 8 32 1 4 <4 
JV18 09.05.83 103 + 1 0.25 0.002 0.06 2 32 4 8 0.03 2 32 8 32 1 0.125 <4 
JV19 10.09.83 137 + 1 0.25 0.002 0.03 2 16 4 8 0.03 2 32 4 32 0.5 0.125 <4 

















VAN MTZ RIF FDX MXF CLI IPM CHL TGC LZD CIP TZP CRO AMX TET ERY 
JV22 31.12.81 078 + 1 0.125 0.002 0.03 2 >64 8 64 0.06 16 16 nt 16 0.5 8 <4 
JV23 04.12.81 001 + 4 1 0.002 0.008 32 64 4 8 0.03 2 >64 8 64 0.5 0.125 >256 
JV24 04.12.81 200 + 4 0.5 0.001 0.015 16 8 8 4 0.03 1 >64 4 64 1 0.125 >256 
JV25 04.12.81 014 + 1 0.25 0.002 0.06 1 32 4 4 0.03 2 16 8 16 0.5 0.06 16 
JV26 31.12.81 015 + 1 0.125 0.001 0.06 1 8 8 4 0.03 2 32 8 32 1 0.06 <4 
JV27 03.12.81 020 + 0.5 0.25 0.002 0.06 1 8 4 2 0.03 1 32 4 16 0.5 0.03 <4 
JV28 15.07.82 001 + 1 0.25 0.002 0.03 1 16 4 4 0.03 2 32 4 16 0.5 0.06 <4 
JV29 07.01.81 002 + 1 0.125 0.002 0.125 1 4 4 4 0.03 2 16 8 32 1 0.015 <4 
JV30 10.02.81 012 + 2 0.125 0.002 0.125 2 >64 2 32 0.03 8 32 8 32 2 32 <4 
JV31 02.01.81 002 + 1 0.125 0.002 0.03 2 8 4 4 0.03 2 16 8 32 1 0.015 <4 
JV32 10.03.82 012 + 2 0.25 0.002 0.125 2 8 8 8 0.03 2 32 16 32 2 >32 <4 
JV33 10.03.82 014 + 0.5 0.25 0.001 0.06 1 2 2 4 0.03 1 16 4 16 0.5 0.015 <4 
JV34 31.12.81 001 + 4 0.5 0.001 0.03 16 4 8 4 0.03 1 >64 4 32 0.5 0.06 >256 
JV35 11.04.83 020 + 1 0.25 0.002 0.125 2 8 4 4 0.03 2 32 8 16 1 0.125 <4 
JV36 19.04.83 015 + 1 0.25 0.002 0.06 2 8 4 4 0.03 2 16 8 32 1 0.015 <4 
JV37 19.04.83 001 + 1 0.25 0.002 0.06 2 8 4 4 0.03 2 16 8 32 1 0.03 <4 
JV38 06.05.83 626 + 0.5 0.25 0.001 0.06 2 4 4 4 0.03 2 16 8 32 1 0.03 <4 
JV39 15.09.83 341 + 0.5 0.125 0.002 0.06 0.25 1 4 4 0.03 1 32 8 16 1 0.015 <4 
JV40 13.09.83 014 + 0.5 0.125 0.001 0.06 0.125 2 2 2 0.03 1 16 4 4 0.5 0.015 <4 
JV41 03.10.83 002 + 1 0.125 0.002 0.03 2 8 4 4 0.03 2 16 8 32 1 0.06 <4 
JV42 25.11.83 015 + 0.5 0.125 0.001 0.03 2 4 4 4 0.03 2 16 8 32 1 0.06 <4 

















VAN MTZ RIF FDX MXF CLI IPM CHL TGC LZD CIP TZP CRO AMX TET ERY 
JV44 11.04.83 020 + 0.5 0.25 0.002 0.125 2 2 4 8 0.03 1 16 4 16 1 0.06 <4 
JV45 19.04.83 015 + 1 0.125 0.001 0.03 2 1 4 4 0.03 2 16 8 32 1 0.03 <4 
JV46 07.04.83 061 + 0.5 0.125 0.001 0.008 1 1 8 4 0.03 2 16 nt 64 0.5 0.03 <4 
JV47 22.06.81 012 + 1 0.125 0.001 0.015 1 2 8 2 0.06 1 16 nt 32 2 >32 >256 
JV48 13.11.80 020 + 0.5 0.125 0.001 0.008 1 2 4 4 0.06 1 16 nt 16 1 0.03 <4 
JV49 07.02.81 032 + 0.5 0.125 0.001 0.004 1 0.125 4 4 0.03 1 16 nt 16 0.5 0.06 <4 
JV50 15.02.81 017 + 0.5 0.125 0.001 0.03 1 4 8 4 0.03 2 16 nt 64 1 0.06 >256 
JV51 02.03.81 020 + 0.5 0.125 0.001 0.015 1 2 8 4 0.03 2 16 nt 32 1 0.125 <4 
JV52 04.03.81 020 + 0.5 0.125 0.001 0.015 1 4 4 4 0.03 1 16 nt 16 1 0.03 <4 
JV53 10.03.81 020 + 0.5 0.125 0.001 0.015 1 4 4 4 0.06 2 16 nt 16 1 0.06 <4 
JV54 01.02.82 015 + 0.5 0.125 0.001 0.015 1 2 4 4 0.06 2 16 nt 32 2 0.06 <4 
JV55 17.06.82 015 + 0.5 0.125 0.001 0.015 1 0.25 8 4 0.03 1 16 nt 32 1 0.06 <4 
JV56 15.07.82 017 + 0.5 0.125 0.001 0.015 1 0.25 8 4 0.03 2 16 nt 16 1 0.03 <4 
JV57 31.08.82 200 + 0.5 0.125 0.001 0.015 1 2 8 4 0.03 1 16 nt 32 1 0.125 <4 
JV58 23.09.82 017 + 0.5 0.125 0.001 0.015 1 1 8 2 0.03 2 16 nt 16 1 0.06 <4 
JV59 09.03.83 862 - 1 0.125 1 0.015 1 2 8 4 0.125 1 16 nt 32 1 0.03 <4 
JV60 21.03.83 619 + 0.5 0.125 0.001 0.03 1 1 4 4 0.06 1 16 nt 32 2 0.06 <4 
JV61 23.03.83 015 + 0.5 0.125 0.001 0.03 1 2 8 4 0.03 1 16 nt 32 1 0.06 <4 
JV62 14.08.83 015 + 0.5 0.125 0.001 0.015 1 2 8 4 0.03 1 16 nt 32 2 0.06 <4 
JV63 02.08.83 001 + 0.5 0.125 0.001 0.015 1 2 8 4 0.03 1 16 nt 32 1 0.125 <4 
JV64 04.11.83 020 + 0.5 0.125 0.001 0.015 1 2 2 4 0.03 2 16 nt 32 1 0.06 <4 

















VAN MTZ RIF FDX MXF CLI IPM CHL TGC LZD CIP TZP CRO AMX TET ERY 
JV66 20.12.82 015 + 0.5 0.125 0.001 0.015 1 1 8 4 0.125 1 16 nt 32 1 0.125 <4 
JV67 28.01.86 027 + 0.5 1 0.001 0.06 16 2 16 4 0.06 2 >64 nt 64 2 0.125 >256 
JV68 05.01.81 242 + 0.5 0.125 0.001 0.06 2 2 4 4 0.03 2 16 nt 16 1 0.125 <4 
JV69 19.10.81 014 + 0.5 0.125 0.001 0.015 1 2 2 4 0.03 2 16 nt 16 1 0.06 <4 
JV70 06.02.86 003 + 0.5 0.125 0.001 0.03 2 2 4 4 0.03 2 16 nt 32 1 0.06 <4 
JV71 09.09.83 070 + 0.5 0.125 0.001 0.03 2 2 4 4 0.03 2 16 nt 32 1 0.06 <4 
JV72 18.10.83 023 + 0.5 0.125 0.001 0.008 1 0.5 4 4 0.125 1 16 nt 32 2 0.03 <4 
JV73 15.11.83 027 + 0.5 1 0.001 0.06 16 2 8 4 0.06 1 >64 nt 64 2 0.125 >256 
JV74 21.10.82 010 - 0.5 0.125 0.001 0.03 1 >64 8 16 0.03 2 16 nt 16 1 0.125 >256 
JV75 21.03.83 061 + 0.5 0.125 0.001 0.008 1 1 8 4 0.03 2 16 nt 64 1 0.06 <4 
JV76 7.11.80 070 + 0.5 0.25 0.002 0.008 1 0.125 8 4 0.03 2 32 nt 16 2 0.125 <4 
Table 31: Minimum inhibitory concentrations of 16 antimicrobials against a panel of 75 historical C. difficile isolates (1980-1986).  
VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-clindamycin, IPM-imipenem, CHL-
chloramphenicol, TGC-tigecycline, LZD-linezolid, CIP-ciprofloxacin, TZP-piperacillin/tazobactam, CRO-ceftriaxone, AMX-amoxicillin, TET-
tetracycline, ERY-erythromycin. nt – not tested. Red cells indicate resistance, orange cells indicate intermediate resistance based on the U.S. 
Clinical & Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST); or existing 









  PCR Ribotype 015 
 
Historic UK isolates (n=16)                                
(1980-1986) 






















VAN 0.75 1 0.707 1 1 0.755 0.25 0 0.048 
MTZ 0.125 0.25 0.136 0.25 0.5 0.230 0.125 0.25 0.094 
RIF 0.001 0.001 0.001 0.002 0.004 0.002 0.001 0.003 0.001 
FDX 0.03 0.06 0.030 0.06 0.06 0.045 0.03 0 0.015 
MXF 1 2 1.297 2 2 1.614 1 0 0.317 
CLI 4 8 2.954 4 17.6 4.579 0 9.6 1.626 
IPM 4 8 4.757 4 8 4.416 0 0 -0.340 
CHL 4 6.4 4.362 4 8 5.384 0 1.6 1.022 
TIG 0.03 0.048 0.034 0.06 0.06 0.052 0.03 0.012 0.018 
 
 
          PCR Ribotype 020 
 
Historic UK isolates (n=13)                                 
(1980-1986) 






















VAN 0.5 0.5 0.474 0.75 1 0.707 0.25 0.5 0.233 
MTZ 0.125 0.25 0.154 0.25 0.5 0.322 0.625 0.75 0.553 
RIF 0.001 0.002 0.001 0.002 0.004 0.002 0.001 0.002 0.001 
FDX 0.06 0.112 0.034 0.06 0.125 0.052 0 0.013 0.018 
MXF 1 2 1.306 2 8 2.446 1 6 1.141 
CLI 4 14.4 4.219 8 32 10.623 4 17.6 6.404 
IPM 4 4 3.232 4 8 4.537 0 4 1.306 
CHL 4 8 4.450 8 8 6.025 4 0 1.575 
TIG 0.03 0.054 0.033 0.06 0.06 0.055 0.03 0.006 0.021 
Table 32: Comparison of antimicrobial susceptibility data by individual PCR ribotype for the two most prevalent types in the 
historical collection (015 & 020). VAN-vancomycin, MTZ-metronidazole, RIF-rifampicin, FDX-fidaxomicin, MXF-moxifloxacin, CLI-




8.3 Supplementary data for genomic resistance determinant 
identification in historical C. difficile isolates (1980-86) 
 
    Genes Identified (% identity) 
    






95-100%  75-94% 95-100% 75-94% 95% threshold 




JV02 027 cdeA (99.09) vanRG (77.87) - - - 
JV03 015 cdeA (99.32) vanRG (77.87) - - - 
JV04 001 cdeA (99.52) vanRG (77.87) - - - 
JV05 020 cdeA (99.77) vanRG (77.87) - - - 
JV06 020 cdeA (99.77) vanRG (77.87) - - - 
JV07 015 cdeA (99.32) vanRG (77.87) - - - 
JV08 220 cdeA (99.77) vanRG (77.87) - - - 
JV09 015 cdeA (99.32) vanRG (77.87) - - - 
JV10 015 cdeA (99.32) vanRG (77.87) - - - 
JV11 015 cdeA (99.32) vanRG (77.87) - - - 
JV12 020 cdeA (99.77) vanRG (77.87) - - - 
JV13 020 cdeA (99.77) vanRG (77.87) - - - 
JV14 078 cdeA (97.51) - tetM (100) - - 
tetM (90.45)   
JV15 020 cdeA (99.77) vanRG (77.87) - - - 
JV16 056 cdeA (98.87) vanRG (77.87) - - - 
JV17 015 cdeA (97.51) - tetM (100) - - 
tetM (90.45)         
JV18 103 cdeA (99.32) vanRG (77.87) - - - 
JV19 137 cdeA (99.32) vanRG (77.87) - - - 
JV20 041 vanRG (100) - vanRG (100) - - 
vanSG (100) vanSG (100) 
vanYG (100) vanYG (100) 
vanG (100) vanG (100) 
vanXYG (100) vanXYG (100) 
vanTG (99.86) vanTG (99.95) 
vanWG (99.64) vanWG (99.88) 
cdeA (99.32) vanUG (99.56) 
vanUG (98.67)   
JV22 078 cdeA (97.51) - tetM (100) - - 
tetM (90.45)   
JV23 001 vanRG (100) - vanRG (100) - - 
vanSG (100) vanSG (100) 
vanYG (100) vanYG (100) 
vanG (100) vanG (100) 
vanXYG (100) vanXYG (100) 
vanTG (99.86) vanTG (99.95) 
vanWG (99.64) vanWG (99.88) 
cdeA (99.32) vanUG (99.56) 




    Genes Identified (% identity) 
    






95-100%  75-94% 95-100% 75-94% 95% threshold 
JV24 200 vanRG (100) - vanRG (100) - - 
vanSG (100)   vanSG (100)   
vanYG (100)   vanYG (100)   
vanG (100)   vanG (100)   
vanXYG (100)   vanXYG (100)   
vanWG (100)   vanTG (99.95)   
vanTG (99.86)   vanWG (99.88)   
vanUG (98.67)   vanUG (99.56)   
cdeA (98.86)       
JV25 014 cdeA (99.77) vanRG (77.87) ermB (100) - - 
ermB (98.37)   
JV26 015 - vanRG (77.87) - - - 
JV27 020 cdeA (99.77) vanRG (77.87) - - - 
JV28 001 cdeA (99.32) vanRG (77.87) - - - 
JV29 002 cdeA (99.09) vanRG (77.87) - - - 
JV30 012 cdeA (100) vanRG (77.87) ermB (100) - - 
tetM (100) tetM (95.68) 
ermB (97.55)   
JV31 002 cdeA (99.09) vanRG (77.87) - - - 
JV32 012 cdeA (100) vanRG (77.87) tetA(P) (98.81) - - 
tetM (100) tetM (95.68) 
tetA(P) (98.28)   
JV33 014 cdeA (99.77) vanRG (77.87) ermB (100) - - 
ermB (98.37)   
JV34 001 vanRG (100) - vanRG (100) - - 
vanSG (100) vanSG (100) 
vanYG (100) vanYG (100) 
vanG (100) vanG (100) 
vanXYG (100) vanXYG (100) 
vanTG (99.86) vanTG (99.95) 
cdeA (99.32) vanWG (99.88) 
vanUG (98.67) vanUG (99.56) 
JV35 020 cdeA (99.77) vanRG (77.87) - - - 
JV36 015 cdeA (99.32) vanRG (77.87) - - - 
JV37 001 cdeA (99.32) vanRG (77.87) - - - 
JV38 626 cdeA (99.32) vanRG (77.87) - - - 
JV39 341 vanYG (98.82) cdeA (78.05) - - - 
  vanRG (77.87) 
JV40 014 cdeA (99.77) vanRG (77.87) ermB (100) - - 
ermB (98.37)   
JV41 002 cdeA (99.09) vanRG (77.87) - - - 
JV42 015 cdeA (99.32) vanRG (77.87) - - - 
JV43 015 cdeA (99.32) vanRG (77.87) - - - 
JV44 020 cdeA (99.77) vanRG (77.87) - - - 
JV45 015 cdeA (99.32) vanRG (77.87) - - - 
JV46 061 cdeA (99.77) vanRG (77.87) - - - 
JV47 012 cdeA (100) vanRG (77.87) tetM (95.68) - - 
tetM (100)   
JV48 020 cdeA (99.77) vanRG (77.87) - - - 




    Genes Identified (% identity) 
    






95-100%  75-94% 95-100% 75-94% 95% threshold 
JV50 017 cdeA (98.41) vanSG (82.72) - - - 
JV51 020 cdeA (99.77) vanRG (77.87) - - - 
JV52 020 cdeA (99.77) vanRG (77.87) - - - 
JV53 020 cdeA (99.77) vanRG (77.87) - - - 
JV54 015 cdeA (99.32) vanRG (77.87) - - - 
JV55 015 cdeA (99.32) vanRG (77.87) - - - 
JV56 017 cdeA (98.41) vanSD (86.76) - - - 
JV57 200 cdeA (99.32) vanRG (77.87) - - - 
JV58 017 cdeA (98.41) - - - - 
JV59 862 cdeA (93.65) - - - - 





JV61 015 cdeA (99.32) vanRG (77.87) - - - 
JV62 015 cdeA (99.32) vanRG (77.87) - - - 
JV63 001 cdeA (99.32) vanRG (77.87) - - - 
JV64 020 cdeA (99.77) vanRG (77.87) - - - 
JV65 033 cdeA (97.51) - - - - 
JV66 015 cdeA (99.32) vanRG (77.87) - - - 
JV67 027 cdeA (99.09) vanRG (77.87) - - - 
JV68 242 cdeA (98.64) - - - - 
JV69 014 cdeA (99.77) vanRG (77.87) - - - 
JV70 003 cdeA (99.55) vanRG (77.87) - - - 
JV71 070 cdeA (99.55) vanRG (77.87) - - - 















JV74 010 cdeA (100) vanRG (77.87) aadE (100) - - 
ermB (98.78) ermB (100) 
JV75 061 cdeA (99.77) vanRG (77.87) - - - 
JV76 070 cdeA (99.55) vanRG (77.87) - - - 
Table 33: Comparison of resistance determinants identified by CARD RGI - 
Comprehensive Antibiotic Research Database – Resistance Gene Identifier, 
ResFinder 3.0 and PlasmidFinder 1.3.  












L3 ribosomal protein L4 ribosomal protein 
JV14 16 - Gly71 >Asp, Val163>Ile 
JV17 16 - Gly71 >Asp, Val163>Ile 
JV22 16 - Gly71 >Asp, Val163>Ile 
JV59 1 Ile205 >Val Lys98 >Arg 
JV65 2 - Val163 >Ile 
Table 34: List of non-synonymous substitutions in the historical C. difficile 
collection (1980-86).  
LZD – linezolid, MIC – minimum inhibitory concentration. No other non-synonymous 









(R or S) 
Non-synonymous substitutions in ermB 
gene* 
JV01 R/R None 
JV25 R/R 
Ile75>Thr, Arg118>His, Lys152>Gln, Ala191>Val, 
Tyr217>His, Asp242>Asn 
JV30 S/R None 
JV33 S/S 
Ile75>Thr, Arg118>His, Lys152>Gln, Ala191>Val, 
Tyr217>His, Asp242>Asn 
JV40 S/S 
Ile75>Thr, Arg118>His, Lys152>Gln, Ala191>Val, 
Tyr217>His, Asp242>Asn 
JV74 R/R 
Arg118>His, Lys152>Gln, Ala191>Val, Tyr217>His, 
Asp242>Asn 
Table 35: List of non-synonymous substitutions in the ermB gene of six 
historical C. difficile genomes (1980-86).  
* compared to the CD630 gene sequence (Sebaihia et al. (2006)). R - resistant, S - 
sensitive, based on breakpoints defined by Clinical & Laboratory Standards Institute 











JV01 4,294,084 339 159,199 10 
JV02 4,323,376 326 119,501 12 
JV03 4,411,449 236 134,981 10 
JV04 4,201,848 301 199,826 8 
JV05 4,220,432 361 108,331 14 
JV06 4,190,182 257 136,281 10 
JV07 4,420,362 240 143,270 10 
JV08 4,109,750 348 83,868 14 
JV09 4,412,611 244 127,345 11 
JV10 4,416,385 237 149,170 9 
JV11 4,419,205 250 135,359 10 
JV12 4,180,700 254 94,622 13 
JV13 4,242,652 448 122,477 13 
JV14 4,558,737 1290 108,761 15 
JV15 4,173,684 208 133,545 10 
JV16 4,186,391 386 118,189 11 
JV17 4,498,895 1160 99,064 15 
JV18 4,125,058 279 173,858 9 
JV19 4,134,833 260 165,737 10 
JV20 4,278,197 224 134,691 12 
JV22 4,047,675 301 108,712 13 
JV23 4,337,571 385 152,058 10 
JV24 5,911,314 5177 1,540 764 
JV25 4,257,057 240 133,619 11 
JV26 4,414,022 280 127,224 11 
JV27 4,161,753 178 123,869 12 
JV28 4,143,686 162 138,307 9 
JV29 4,229,942 189 135,424 11 
JV30 4,303,203 238 147,813 7 
JV31 4,327,345 448 149,725 10 
JV32 4,316,338 414 185,750 8 
JV33 4,249,241 214 108,373 12 
JV34 4,292,483 230 138,336 10 
JV35 4,187,322 270 149,150 10 
JV36 4,388,508 302 125,447 12 
JV37 4,387,631 314 143,692 10 
JV38 4,439,936 319 129,717 12 
JV39 5,081,435 2569 3,763 302 
JV40 4,273,282 295 95,990 13 
JV41 4,323,529 194 149,777 8 
JV42 4,417,284 256 127,297 11 
JV43 4,681,326 695 23,533 60 










JV45 4,421,752 276 127,319 11 
JV46 4,236,135 324 144,291 10 
JV47 4,360,673 500 139,604 10 
JV48 4,330,455 243 142,950 11 
JV49 4,458,558 400 138,336 8 
JV50 4,313,082 530 131,864 11 
JV51 4,393,504 434 137,734 10 
JV52 4,467,179 636 137,796 9 
JV53 4,468,119 663 142,998 11 
JV54 4,528,290 608 127,237 10 
JV55 4,411,271 508 165,844 9 
JV56 4,411,134 946 156,199 10 
JV57 4,345,760 303 132,351 11 
JV58 4,238,422 473 109,353 14 
JV59 4,742,161 391 201,523 8 
JV60 4,356,689 499 137,783 9 
JV61 4,501,974 730 127,248 12 
JV62 4,451,252 633 132,209 11 
JV63 4,870,482 473 117,650 13 
JV64 4,437,542 423 108,851 13 
JV65 4,073,858 380 94,693 14 
JV66 4,314,602 208 115,267 14 
JV67 4,189,156 240 112,951 12 
JV68 4,224,388 344 104,221 15 
JV69 4,263,571 327 135,900 10 
JV70 4,303,203 238 213,813 7 
JV71 4,301,305 837 135,360 9 
JV72 4,576,657 699 123,632 13 
JV73 4,377,357 750 17,627 78 
JV74 4,283,808 495 135,099 9 
JV75 4,250,749 337 144,291 10 
JV76 4,287,172 671 157,051 10 
Table 36: Assembly statistics for historical C. difficile genomes (1980-86).  
N50 refers to the length of the contiguous sequence representing the 50th percentile 
of the genome length, after size ordering. L50 represents the number of contigs 












JV02 - <256 
JV19 - <256 
JV20 - <256 
JV22 - 512 
JV24 - <256 
JV34 - <256 
JV47 - >2048 
JV50 - 512 
JV67 - 512 
JV73 + >2048 
JV74 + >2048 
Table 37: Streptomycin minimum inhibitory concentrations (MICs) of two C. 




















CD4032 001 ClosER UK 2015  1 
CD3293 001 ClosER UK 2014 1 
CD4067 001 ClosER UK  2015  2 
JV28 001 JV UK 1982 1 
JV37 001 JV UK 1983 2 
CD0160 001 ClosER Czech Rep. 2016 1 
JV01 012 JV UK 1981 2 
JV30 012 JV UK 1982 2 
JV32 012 JV UK 1982 2 
CD0079 012 ClosER UK 2014 1 
CD0127 012 ClosER France 2016  1 
CD0099 012 ClosER France 2016 1 
JV03 015 JV UK 1982 1 
JV07 015 JV UK 1982 1 
JV09 015 JV UK 1981 1 
JV10 015 JV UK 1982 1 
JV11 015 JV UK 1982 2 
JV26 015 JV UK 1981 1 
JV05 020 JV UK 1982 1 
JV06 020 JV UK 1982 1 
JV27 020 JV UK 1981 1 
JV12 020 JV UK 1982 2 
JV13 020 JV UK 1982 2 
JV15 020 JV UK 1983 2 
CD0071 017 ClosER Ireland 2016  2 
CD0095 017 ClosER UK 2015 2 
CD4500 017 ClosER Spain 2015  2 
CD4511 017 ClosER Poland 2015 2 
CD3757 017 ClosER France 2015  2 
CD3771 017 ClosER France 2015 2 
CD3904 027 ClosER Sweden 2015 1 
CD3891 027 ClosER Sweden 2015 2 
CD9609 027 ClosER France 2016 1 
CD9946 027 ClosER UK 2016 1 
CD3809 027 ClosER Rep. Ireland 2012 1 
CD3051 027 ClosER Austria 2013 1 
CD3079 027 ClosER Sweden 2013 1 

















CD4706 078 ClosER UK 2015  1 
CD3998 078 ClosER UK 2015 1 
CD3994 078 ClosER UK 2015  1 
CD4112 078 ClosER UK 2015  2 
CD0222 078 ClosER Germany 2016  1 
CD0223 078 ClosER Germany   2016 1 
 
Table 38: Demographic data for all isolates tested during mutation frequency 
investigations.  
JV prefix and study origin refer to isolates recovered from the historical catalogue 







Figure 55: Mean (±SE) mutation frequencies of two PCR ribotype 027 mutants 
and one resistant isolate (32 mg/L MXF MIC) under 32 and 64 mg/L 
moxifloxacin (MXF) pressure.  
Lower limit of detection (LLOD) calculated as 1 / (mean total viable counts/mL). No 





















CD3051 1 CD3051           
Step Mut 
4 Asp71>Val - 
CD3079 1 CD3079           
Step Mut 
4 Asp71>Val - 





Table 39: Amino acid substitutions in DNA gyrase genes from additional 
















































































8.5 Supplementary data for variant detection using CLC 
genomics workbench 
 
Figure 56: CLC genomics workbench workflow for variant detection and amino 





8.6 Supplementary data for Sanger sequence alignment 
 
Figure 57: Example chromatogram confirming CD3051 Mut gyrB substitution 
Gln434>Lys (CAA>AAA) using CLC Genomics Workbench and Sanger sequence 





8.7 Supplementary data of R programming code for the 
collation of gene sequences from RAST output .xls files into 
a FASTA text format 
This program was written as part of a Biotechnology and Biological Sciences 
Research Council (BBSRC) - Strategic Training Awards for Research Skills 
(STARS), Next Generation Biologists 'Essential computing skills for molecular 
biology' course, with some assistance from the tutors. This simple program in the 
R programming language collates individual DNA sequences of specific genes from 
RAST annotation output files and prefaces them with “> ” as required for the 
FASTA file format. One text file is generated with defined gene sequences for all 
genomes. These output files were used in conjunction with Clustal Omega for 
multiple sequence alignment and SNP identification. Lines of code beginning with 
a “#” are in-code comments to assist in the comprehension of the coding. 
 
CD3051 gyrB 
CD3051 Mut F 
CD3051 Mut R 
 




AllFiles <- Sys.glob("C:/Users/Jon/Desktop/All_RAST_CSV_files/JV*.csv") 
# Defines file location and accesses all .csv files prefaced with JV under “AllFiles” 
variable 
geneOfInterest<-"DNA gyrase subunit A" 
# Defines a variable for gene name that matches the RAST output.  
extractGeneFasta<-function(filename, geneOfInterest){ 
# Defines a function called extractGeneFasta with two inputs 
  data<-read.csv(filename, stringsAsFactors = FALSE) 
# Import data (not as factor class (default for strings), i.e.  import as character 
class) 
   row<-grep(geneOfInterest, data$"function", fixed = TRUE)  
# Extract the row number for the defined gene. Dollar symbol means give a 
column from "data" file 
   sequence<-data[row,"nucleotide_sequence"] 
# Extract the sequence 
     if (length (sequence)!=1)stop("did not find single sequence") 
# This line generates an error in 0 or >1 sequence is found 
    label<-sprintf("> %s",filename)  
    # Prefaces sequence with label (> ). "%s" is a space holder for further text 
   names (sequence)<-label  
  return(sequence) } 
# return sequence with label concatenation 
for (filename in AllFiles){ 
# Acquire output, with sequences appended after each iteration of the loop. 
    result<-extractGeneFasta(filename, geneOfInterest) 
    printResult<- paste(names(result), result[1], sep = "\n") 




















JV04 001 1982 2013 25.3 0.69 
JV23 001 1981 2013 12.7 0.01 
JV28 001 1982 2013 25.3 0.69 
JV34 001 1981 2013 12.7 0.01 
JV37 001 1983 2013 6696.3 1.00 
JV63 001 1983 2013 6229.4 1.00 
JV29 002 1981 2013 12.9 0.01 
JV31 002 1981 2013 12.9 0.01 
JV41 002 1983 2013 14.9 0.04 
JV25 014 1981 2013 18.2 0.13 
JV33 014 1982 2013 18.2 0.16 
JV40 014 1983 2013 18.2 0.20 
JV69 014 1981 2013 14.5 0.02 
JV03 015 1982 2013 20.6 0.29 
JV07 015 1982 2013 20.6 0.29 
JV09 015 1981 2013 19.6 0.18 
JV10 015 1982 2013 20.6 0.29 
JV11 015 1982 2013 20.6 0.29 
JV26 015 1981 2013 20.6 0.24 
JV36 015 1983 2013 13.7 0.02 
JV42 015 1982 2013 19.6 0.22 
JV45 015 1983 2013 19.6 0.27 
JV54 015 1983 2013 19.6 0.27 
JV55 015 1982 2013 21.5 0.37 
JV61 015 1983 2013 4.9 2.17 x 10-06 
JV62 015 1983 2013 4.9 2.00 x 10-06 
JV66 015 1982 2013 4.9 1.00 x 10-06 
JV05 020 1982 2013 91.7 1.00 
JV06 020 1982 2013 91.7 1.00 
JV12 020 1982 2013 92.7 1.00 
JV13 020 1982 2013 92.7 1.00 
JV15 020 1983 2013 91.7 1.00 
JV27 020 1981 2013 91.7 1.00 
JV35 020 1983 2013 23.5 0.60 



















JV48 020 1980 2013 27.8 0.72 
JV51 020 1981 2013 27.8 0.77 
JV52 020 1981 2013 27.8 0.77 
JV53 020 1981 2013 27.8 0.77 
JV64 020 1983 2013 37.7 1.00 
JV02 027 1981 2008 13.1 0.06 
JV67 027 1986 2006 2 3.93 x 10-05 
JV73 027 1983 2008 8 0.01 
JV14 078 1982 2013 5.8 5.69 x 10-06 
JV22 078 1981 2013 5.8 3.13 x 10-06 
Table 40: Comparison of single nucleotide polymorphism (SNP) differences 
between historical isolates analysed phylogenetically and prediction intervals 
based on Poisson distributions of previous C. difficile molecular clock 





8.9 Supplementary data for continuous competitive co-culture 




Figure 58: Continuous culture chemostat model sample port configuration.  
A syringe draws a vacuum, pulling culture into the sample bijou. The tubing was 
clamped and the bijou replaced. Twenty millilitres of sample was run off before 
sample collection, to account for culture accumulation in the tubing. 
Syringe attached 
to draw a vacuum 
Replaceable bijou 






Figure 59: Continuous co-culture vessel configuration. A – Internal 
configuration of chemostat, prior to experimental use. B – Visualisation of the fully 























Figure 60: Relative fitness of moxifloxacin (MXF) resistant ribotype 027 C. difficile mutant compared to sensitive parent strain, 
tracked over the continuous culture model duration.  












































Figure 61: Progression of mutant and parent ribotype 027 C. difficile ratios in a continuous co-culture chemostat model – Run 1.  
The linear trend line (purple) demonstrates the increasing divergence between mutant and parent strain populations. Highly resistant 
populations >32 mg/L and >64 mg/L moxifloxacin (MXF) were documented to track further resistance development. The line of equality 
represents the baseline of equivalent mutant and parent strain proportions, data above this signifies a fitness advantage for the mutant strain. 
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Figure 62: Progression of mutant and parent ribotype 027 C. difficile ratios in a continuous co-culture chemostat model – Run 2.  
The linear trend line (purple) demonstrates the increasing divergence between mutant and parent strain populations. Highly resistant 
populations >32 mg/L and >64 mg/L moxifloxacin (MXF) were documented to track further resistance development. The line of equality 
represents the baseline of equivalent mutant and parent strain proportions, data above this signifies a fitness advantage for the mutant strain. 
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Figure 63: Progression of mutant and parent ribotype 027 C. difficile ratios in a continuous co-culture chemostat model – Run 3.  
The linear trend line (purple) demonstrates the increasing divergence between mutant and parent strain populations. Highly resistant 
populations >32 mg/L and >64 mg/L moxifloxacin (MXF) were documented to track further resistance development. The line of equality 
represents the baseline of equivalent mutant and parent strain proportions, data above this signifies a fitness advantage for the mutant strain. 
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1 24 64 128 
2 24 64 128 
2 24 64 128 
2 168 64 128 
2 192 64 128 
3 120 64 128 
1 48 32 64 
1 144 32 64 
2 48 32 64 
2 192 32 64 
3 48 32 64 
3 144 32 64 
Table 41: Moxifloxacin (MXF) minimum inhibitory concentrations (MICs) of 
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